



DIRECTORATE GENERAL HEALTH SERVICES KHYBER PAKHTUNKHWA

Office Phone No. 091-9210269
DGHS Fax No. 091-9210230
Exchange No. 091-9210187-96

No ~~3387~~ 97 /MCC
Date. 19 / 11 /2025

OFFICE ORDER

In continuation to this office order No. 3343/MCC dated 31/10/2025, the revised Bid Evaluation Report (Technical) of Govt. MCC FY 2025-26 after grievance redressal meeting is hereby approved and shall be published on the official websites of Health department and KP-PPRA, please.

Encl: Bid Evaluation Report (Technical) Govt. MCC FY 2025-26


Director General Health Services Khyber Pakhtunkhwa
(Chairman S&RC Committee Govt. MCC 2025-26)

No & Date Even.

Copy for information to:

1. Chairman Technical & Evaluation Committee Govt. MCC FY 2025-26.
2. Managing Director KP-PPRA, Govt. of Khyber Pakhtunkhwa, Peshawar with the request to hoist the approved Bid Evaluation Report (Technical) on the authority website.
3. Deputy Director IT, Health Department, Govt. of Khyber Pakhtunkhwa, to hoist/upload the approved Bid Evaluation Report (Technical) for the medicines/drugs, surgical disposables, medical devices and non-drug items Govt. MCC FY 2025-26, on the official website (www.healthkp.gov.pk).
4. Database Administrator, Directorate General Health Services, Khyber Pakhtunkhwa, to hoist/upload the approved Bid Evaluation Report (Technical) for the medicines/drugs, surgical disposables, medical devices and non-drug items Govt. MCC FY 2025-26, on the official website (www.dghskp.gov.pk).
5. PS to Principal Secretary to Chief Minister, Govt. of Khyber Pakhtunkhwa Peshawar.
6. PS to Advisor to Chief Minister on Health, Govt. of Khyber Pakhtunkhwa Peshawar.
7. PS to Director General National Accountability Bureau Khyber Pakhtunkhwa.
8. PS to Secretary Health, Govt. of Khyber Pakhtunkhwa Peshawar.
9. PS to Special Secretary Health, Govt. of Khyber Pakhtunkhwa Peshawar.
10. PA to DG DC&PS, Khyber Pakhtunkhwa.
11. All participant bidders of Govt. MCC Tender FY 2025-26.


Director General Health Services Khyber Pakhtunkhwa
(Chairman S&RC Committee Govt. MCC 2025-26)

NOTE:

The participant firms/bidders at Serial No; 12, 41, 61, 64, 67, 70, 72, 73, 77, 79, 82, 83, 93, 95, 102, 100, 107, 109,110, 111, 123, 126, 127, 128, 129, 135, 138, 139, 143, 144, 148, 149, 160, 161 & 162 are provisionally accepted for further evaluation subject to provision of undertakings for clarification.

The procuring enty reserves the right to rectify any inadvertent clerical or typographical errors or omissions, if identified with in due course of time, and shall be rectified accordingly.

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																						
Name of the firm					3N-LIFEMED PHARMACEUTICALS PVT LTD LAHORE																	
S.No	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	Technical Evaluation Matrix							Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score													
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm) Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023/24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s. Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, Human Resource as per testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non availability shall lead to disqualification of the section/s or firm).	Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid away bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.					
	Ref. No. of item in MCC	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70		
	112	Activated Charcoal	Powder	Lifemed Activated Charcoal	0	5	0	2	5	5	5	5	27	0	0	0	0	10	10	37		
weifang	651	Hemodialysis concentrate	Part-A solution 4L, Part-B Powder 504g	Lifemed Bicarb concentrate	0	5	0	2	5	5	5	5	27	5	5	0	0	10	20	47		
	905	Sodium Hypochloride	500ml	Lifemed Hypochlorite 10%	0	5	0	2	5	5	5	5	27	0	0	0	0	10	10	37		

GRC Decision

The firm failed to submit Professional Tax certificate in the bid, as mandatory criterion under mandatory bid form 1, (6) (V) of the Bid Solicitation Documents (BSDs) of Govt. MCC FY 2025-26, hence Not Recommended.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																															
Name of Firm																															
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score			
					Documents Based Factory Score												Product Evaluation Parameters														
					Factory Evaluation Visit Score												Product Technical Parameters														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26					
				Valid ISO 18001:45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan - (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firm having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41-100 positions 3 marks.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Weighing, Assay Analysis of raw material, in-process material and finished products for the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 at least. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Ishikawa Accelerated and Real Time)(as in Schedule B of DRAP)	Raw material, In-process and Finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts)	Adherence to GMP guidelines, (as in Schedule-B of DRAP) (as evaluated at the time of inspection).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).	Non-availability or non-functionality of the	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO (Website) and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In case where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in volume 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Made or Health Canada or by regulatory authority/body of SRA's country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).	Stability studies of quoted items duly attested by the Q.C (incharge of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 82 Tender approvals- 01 mark 94 Tender approvals- 02 marks 96 Tender approvals- 03 marks	Availability of quoted item/s in Pakistan market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 11-30% market share = 1 mark 31-50% market share = 2 marks 50% and above market share = 5 marks	37	70						
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	31	5	5	5	5	3	4	5	5	37	70					
1	64	Paracetamol + Orphenadrine	Tab.450 mg/25 mg	Shwarzol 450mg/25mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51					
2	67	Paracetamol+ Tr amadol	Tab.325mg/37.5 mg	Caffin Plus 325mg/37.5mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	0	0	0	0	5	5	0	5	36					
3	69	Flizandine	Tab.4mg	Terradex 4 mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51					
4	70	Tramadol HCl	Inj. 50 mg/ml, 2ml	Caffin 100mg/ 2ml Injection	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
5	164	Cetirizine	Tab. 10 mg	Righ 10mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	22	53					
6	165	Cetirizine	Syp. 5 mg/5 ml 60 ml	Righ Oral Syrup 120 ml Solution	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	3	18	49					
7	171	Montelukast	Tab. 10 mg	Lucast 10mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
8	202	Azithromycin	Tab. / Cap. 250 mg 12s or	Aziamax 250 mg Capsules	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	2	21	52					
9	203	Azithromycin	Tab. / Cap. 500 mg 6s	Aziamax 500 mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	2	21	52					
10	205	Azithromycin	Dry Sussp. 200 mg/5ml 15ml	Aziamax 200 mg/5ml Dry Syrup 15ml	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	5	5	2	21	52					
11	205	Azithromycin	Dry Sussp. 200 mg/5ml 25ml	Aziamax 200 mg/5ml Dry Syrup 25ml	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
12	209	Cefaclor	Oral Drops 50mg /ml 15 ml	Cefclor 50mg Drops	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	5	0	4	5	3	27	58					
13	211	Cefaclor	Susp. 125mg/ 5ml 60 ml	Cefclor 125mg Suspension	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	5	0	4	5	3	27	58					
14	212	Cefaclor	Susp. 250 mg /5ml 60 ml	Cefclor 250mg Suspension	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	5	0	4	5	3	27	58					
15	217	Cefixime	Cap. 400 mg 5s	Cefixone 400mg Capsules	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
16	218	Cefixime	Dry Sussp. 100 mg/5ml 30ml	Cefixone 100mg/5ml Suspension	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
17	219	Cefixime	Dry Sussp. 200 mg/5ml 30ml	Cefixone 200mg/5ml Suspension	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
18	243	Ciprofloxacin	Tab. 250 mg 10s	Axio 250 mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
19	244	Ciprofloxacin	Tab. 500 mg 10s	Axio 500 mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
20	383	Iron Hydroxide poly maltose sample	Tab. 100 mg	Rubifer 400mg Chewable Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51					
21	384	Iron Hydroxide poly maltose sample	Syp. 50 mg/5ml	Rubifer 50 mg Syrup 120ml	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51					
22	385	Iron Hydroxide poly maltose sample	Oral Drops 50 mg/ml 15 ml	Rubifer Drops	0	2	3	5	5	6	2	2	2	2	2	31	0	0	0	0	0	4	5	1	10	41					
23	387	Iron Sucrose	Inj. 20 mg/ml 5 ml	Rubifer 100mg/5ml Inj. 5ml	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51					
24	388	Mecobalamin	Inj. 500 mcg 1ml	Mecobal 500mcg/1ml Injection	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	15	46					
25	399	Tranexamic Acid	Cap. 500 mg	Marena 500mg Capsules	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51					
26	401	Tranexamic Acid	Inj. 500 mg 5 ml	Marena 500mg Injection	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51					
27	412	Amikodipine Bicyclate	Tab. 5 mg	Norvasc 5mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	2	21	52					
28	413	Amikodipine Bicyclate	Tab. 10 mg	Norvasc 10mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	2	21	52					
29	414	Amikodipine + Valartan	Tab. 5mg+80 mg	Norvasc-V 5/80 mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	5	5	0	15	46					
30	415	Amikodipine + Valartan	Tab. 5mg+160 mg	Norvasc-V 5/160 mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	5	5	0	15	46					
31	416	Amikodipine + Valartan	Tab. 10 mg+160 mg	Norvasc-V 10/160 mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	5	5	0	15	46					
32	517	Famotidine	Tab. 40 mg	Nacid 40 mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51					
33	528	Esomeprazole	Cap. 40mg	Acid Nex 40mg Capsules	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
34	529	Ondansetron	Tab. 8 mg	Zofan 8 mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
35	530	Ondansetron	Inj. 2 mg/ml 4 ml	Zofan 8 mg Injection	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
36	533	Phloroglucinol + Trimechyl Phloroglucinol	Tab. 80 mg + 80 mg	Audacteran Plus 80mg/80mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	0	0	0	0	4	5	2	11	42					
37	534	Phloroglucinol + Trimechyl Phloroglucinol	Inj. 40 mg + 0.04mg 4 ml	Audacteran Plus 0.04mg/40mg Injection	0	2	3	5	5	6	2	2	2	2	2	31	0	0	0	0	0	4	5	2	11	42					
38	550	Empagliflozin	Tab. 10 mg	Triglit 10mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					
39	551	Empagliflozin	Tab. 25 mg	Triglit 25mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50					

40	555	Glimepiride	Tab. 1mg	Glucoserm 1mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51
41	556	Glimepiride	Tab. 2mg	Glucoserm 2mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51
42	557	Glimepiride	Tab. 3mg	Glucoserm 3mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51
43	558	Glimepiride	Tab. 6mg	Glucoserm 6mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51
44	583	Staglipitin + Metformin	Tab. 50 mg/500 mg	Glylaklet 50/500 Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	0	0	0	0	4	5	0	9	40
45	584	Staglipitin + Metformin	Tab. 50mg /1000 mg	Glylaklet 50/1000 Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	0	0	0	0	4	5	0	9	40
46	694	Sulfenacin Succinate	Tab. 10mg	Urgesin 10mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51
47	711	Chlorzpine	Tab. 25mg	Chazet 25 mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	5	0	4	5	2	26	57
48	712	Chlorzpine	Tab. 100 mg	Chazet 100 mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	5	0	4	5	2	26	57
49	723	Eucalakopum	Tab. 10 mg	Eul Dep 10 mg Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50
50	752	Pregabalin	Cap. 75mg	Lyrlica 75mg Capsules	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50
51	753	Pregabalin	Cap. 150 mg	Lyrlica 150 mg Capsules	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50
52	759	Risperidone	Tab. 2mg	Xiton 2mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51
53	760	Risperidone	Tab. 4 mg	Xiton 4mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51
54	806	Ketotifen	Tab. 1 mg	Zafafen 1mg Tablet	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	5	30	51
55	807	Ketotifen	Syp. 0.2 mg/ml 60ml	Zafafen 0.2mg/ml Syrup 60ml	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	5	24	55
56	910	Ostein Mineral Complex + Vitamin D	Syp. 250mg+400IU 5ml 120ml	Ososte D 250mg/400 IU Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	3	22	53
57	911	Cholecalciferol (Vitamin D3)	80/ Oral Inj. 200000 IU 3ml	800mg/4000IU Tablets	0	2	3	5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	3	22	53

					Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																	
Name of the firm					AKRAM BROTHERS LAHORE																	
S. No.	Product General Parameter				Technical Evaluation Matrix																	
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation									Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20			
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC. (Certificate duly attasted by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only.(verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.						
	Ref. No. of	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70			
Kollsut International, USA	1300	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	4/0	KOLGUT CHROME CATGUT CHROMIC	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43			
Kollsut International, USA	1301	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	3/0	KOLGUT CHROME CATGUT CHROMIC	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43			
Kollsut International, USA	1302	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	2/0	KOLGUT CHROME CATGUT CHROMIC	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43			
Kollsut International, USA	1303	26mm, 1/2 circle round bodied taper point needle, strand length 70cm	2/0	KOLGUT CHROME CATGUT CHROMIC	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43			
Kollsut International, USA	1304	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	0	KOLGUT CHROME CATGUT CHROMIC	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43			
Kollsut International, USA	1305	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	0	KOLGUT CHROME CATGUT CHROMIC	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43			
Kollsut International, USA	1306	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	1	KOLGUT CHROME CATGUT CHROMIC	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43			
Kollsut International, USA	1307	30mm, 3/8 circle round bodied taper point needle, strand length 70cm	1	KOLGUT CHROME CATGUT CHROMIC	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43			
Kollsut International, USA	1308	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	2	KOLGUT CHROME CATGUT CHROMIC	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43			
Foosin, China	1309	17mm, 1/2 circle round bodied taper point needle, strand length 75cm	4/0	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Foosin, China	1310	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	3/0	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Foosin, China	1311	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	3/0	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Foosin, China	1312	26mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm	3/0	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Foosin, China	1313	17mm, 1/2 circle round bodied taper point needle, Strand length 75cm	3/0	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Foosin, China	1314	31mm, 1/2 circle round bodied, taper point needle, Strand length 75cm	2/0	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Foosin, China	1315	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	2/0	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Foosin, China	1316	31mm, 1/2 circle round bodied taper point needle, Strand length 75cm	0	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Foosin, China	1317	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			

Foosin, China	1318	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1319	40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	1	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1320	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	2	WEGO Black Braided Silk	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1325	11mm, 3/8 circle reverse cutting needle,Strand length 45 cm	5/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 914	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1326	13mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm	5/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 915	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1327	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm	5/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 916	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1328	16mm, 3/8 circle conventional or curved cutting needle, strand length 75cm	4/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 917	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1329	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	4/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 918	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1330	19mm, 3/8 circle reverse cutting needle,strand length 75cm	4/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 919	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1331	22mm, 1/2 circle round bodied taper point,strand length 70 cm	4/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 920	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1332	16mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	3/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 921	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1333	19mm, 3/8 circle reverse cutting needle,Strand length 75cm	3/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 922	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1334	22mm, 1/2 circle round bodied taper point,strand length 70 cm	3/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 923	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1335	26mm, 1/2 circle round bodied taper point,Strand length 70 cm	3/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 924	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1336	26mm, 1/2 circle round bodied taper point,strand length 70 cm	2/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 925	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1337	31mm, 1/2 circle round bodied taper point,Strand length 70 cm	2/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 926	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1338	36mm, 1/2 circle round body taper cutneedle, strand length 90 cm	2/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 927	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1339	45mm, 1/2 circle round bodied taper cutneedle, strand length 75 cm	2/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 928	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1340	36mm, 1/2 circle round bodied taper cut needle, strand length 90 cm	0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 929	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1341	40mm, 1/2 circle round bodied taper point,strand length 90 cm	0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 930	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1342	40mm, 1/2 circle round bodied taper point,strand length 70 cm	1	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 931	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1343	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm	1	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 932	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1344	40mm, 1/2 circle round bodied taper point,strand length 90 cm	2	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 933	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1345	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm	2	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 934	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1346	17mm, 1/2 circle round bodied taper point needle, Strand length 70cm	5/0	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1347	17mm, 1/2 circle round bodied needle,Strand length 75cm	4/0	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1348	22mm, 1/2 circle round bodied taper point needle, Strand length 75cm	4/0	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1349	22mm, 1/2 circle round bodied taper point,strand length 75 cm	3/0	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1350	25mm, 1/2 circle round bodied taper point,strand length 75 cm	2/0	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1351	30mm, 1/2 circle round bodied taper point,strand length 75 cm	2/0	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1352	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	0	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1353	30mm, 1/2 circle round bodied taper point needle, strand length 75 cm	1	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56

Foosin, China	1354	40mm, 1/2 circle round bodled taper point needle, strand length 75 cm	1	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1355	40mm, 1/2 circle round bodled taper point needle, strand length 75 cm	2	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1356	48mm, 1/2 circle round bodled taper point needle, strand length 75 cm	2	WEGO PGA POLYGLYCOLIC ACID	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1366	13mm, 1/2 circle round bodled taper point double armed needle, strand length 60cm	5/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1367	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	5/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1368	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	4/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1369	26mm, 1/2 circle round bodled taper point double armed needle, strand length 90cm	4/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1370	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	3/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1371	26mm, 1/2 circle round bodled taper point double armed needle, strand length 75cm	3/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1372	30 mm, 1/2 circle round bodled taper point double armed needle, strand length 90cm	3/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1373	26mm, 1/2 circle round bodled taper point needle, strand length 75cm	2/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1374	26mm, 3/8 circle reverse cutting needle, strand length 45cm	2/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1375	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	2/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1376	26mm, 1/2 circle round bodled taper cut double armed needle, strand length 75cm	2/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1377	30mm, 1/2 circle round bodled taper point needle, strand length 75cm	2/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1378	55mm, straight cutting needle, strand length 75cm	2/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1379	60mm, straight cutting needle, strand length 75cm	2/0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1380	40mm, 1/2 circle round bodled taper point needle, strand length 75cm	0	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1381	40mm, 1/2 circle round bodled taper point needle, strand length 75cm	1	WEGO PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1383	48mm, 1/2 circle round bodled taper point, strand length 150cm	1	Wego Polyamide/Nylon	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1384	26mm, 1/2 circle round bodled taper point double needle, strand length 100cm	3/0	WEGO POLYESTER	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1385	17mm, 1/2 circle round bodled taper cut double needle, strand length 75cm	2/0	WEGO POLYESTER	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1386	26mm, 1/2 circle round bodled taper cut double needle, strand length 75cm	2/0	WEGO POLYESTER	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1387	26mm, 1/2 circle round bodled taper point double needle, strand length 90cm	2/0	WEGO POLYESTER	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1392	13mm, 1/2 circle round bodled taper point double armed needle, strand length 75cm	5/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1393	13mm, 1/2 circle round bodled taper point needle, strand length 75cm	5/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1394	17mm, 1/2 circle round bodled taper point double needle, strand length 75cm	5/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1395	17mm, 3/8 circle round bodled taper point double armed needle, strand length 75cm	5/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1396	19mm, 3/8 circle round bodled taper point double armed needle, strand length 75cm	5/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1397	17mm, 1/2 circle round bodled taper point needle, strand length 75cm	4/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1398	17mm, 1/2 circle round bodled taper point double armed, strand length 75cm	4/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1399	20mm, 1/2 circle round bodled taper point needle, strand length 70cm	4/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46

Foosin, China	1400	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	4/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1401	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	3/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1402	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	3/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1403	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	3/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1404	26mm, 1/2 circle round bodied taper point needle, strand length 70cm	2/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1405	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1406	36mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1407	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1408	40mm, 1/2 circle round bodied taper point needle, strand length 150cm.	0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1409	40mm, 1/2 circle round bodied taper point needle, Strand length 70cm	0	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1410	36mm, 1/2 circle round bodied taper point needle, strand length 75cm	1	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1411	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1	WEGO PDO POLYDIAXANONE	3	5	0	5	5	6	24	0	0	0	2	10	10	22	46
Foosin, China	1412	6 mm, 3/8 circle micro point spatula double needle, strand length 30cm	10/0	WEGO NYLON	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Foosin, China	1413	6.2mm, 3/8 circle micro point spatula double needle, strand length 30cm	10/0	WEGO NYLON	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																	
	Name of the firm				Akram Brothers Non Drug Items FY 2025-26																	
						Technical Evaluation Matrix																
						Principal's and Importer's Evaluation Parameters										Product Technical Evaluation					Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score										
							1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
		S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical	
							3	5	5	5	6	6	30	5	5	5	3	6	16	40	70	
Foosin, China	1321	7mm, 1/2 circle, micro-point spatula needle, strand length 45cm	7/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910		3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
Foosin, China	1322	8mm, 1/4 circle spatulated needle, strand length 45cm	6/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 911		3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
Foosin, China	1323	11mm, 3/8 circle reverse cutting needle, strand length 45 cm	6/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 912		3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
Foosin, China	1324	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm	6/0	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 913		3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
Foosin, China	1357	8mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	12/0	WEGO PROLENE		3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
Foosin, China	1358	8mm, 3/8 circle round bodied taper point double armed needle, strand length 60 cm	11/0	WEGO PROLENE		3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26															
Name of the firm					AKRAM BROTHER LAHORE															
					Technical Evaluation Matrix															
					Principal's and Importer's Evaluation Parameters						Product Technical Evaluation								Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation												
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	C.E. mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical	
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70	
Foosin, China	1414	48mm, 1/2 circle round bodied taper cut point needle, strand length 45cm	5	WEGO STAINLESS STEEL	0	0	0	5	6	6	17	0	0	0	0	2	16	18	35	
Foosin, China	1415	48mm, 1/2 circle round bodied taper cut point needle, strand length 45cm	4	WEGO STAINLESS STEEL	0	0	0	5	6	6	17	5	5	0	0	2	16	28	45	
Foosin, China	1416	Polypropylene	30cm x 30cm	WEGO PROLENE POLYPROPYLENE MESH SIZE	0	0	0	5	6	6	17	5	5	0	0	2	16	28	45	
Foosin, China	1417	Polypropylene	15cm x 15cm	WEGO PROLENE POLYPROPYLENE MESH SIZE	0	0	0	5	6	6	17	5	5	0	0	2	16	28	45	
Foosin, China	1418	Polypropylene	15cm x 6cm	WEGO PROLENE POLYPROPYLENE MESH SIZE	0	0	0	5	6	6	17	5	5	0	0	2	16	28	45	
Foosin, China	1419	Polypropylene	6cm x 11cm	WEGO PROLENE POLYPROPYLENE MESH SIZE	0	0	0	5	6	6	17	5	5	0	0	2	16	28	45	

Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																			
Name of the firm					AL-HAMD ENTERPRISES KARACHI														
					Technical Evaluation Matrix														
					Principal's and Importer's Evaluation Parameters														
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score	Product Technical Evaluation						Product Evaluated Score	Total Technical Score
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant sections by the US-FDA or WHO or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA countries (duly attested by senior executive of the firm). In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC. Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. (In case of non-provision of matching GD the marks for GD will not be awarded).	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. Certificates on company's	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union. (Verification link shall be provided), and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US FDA (510 K) / US free sale certificate of the quoted products Certificates with same brand name shall be considered. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Product Evaluated Score	Total Technical Score
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	6	6	30	5	5	5	3	6	16	40	70
Suzhou Colorway, China	1047	Disposable sterile latex surgical gloves (poweder free)	6.5, 7.0, 7.5, 8.0, 8.5	Surgitex	3	5	0	5	6	6	25	5	5	0	0	4	16	30	55
Suzhou Colorway, China	1048	Disposable sterile latex surgical gloves (powederd)	6.5, 7.0, 7.5, 8.0, 8.6	Surgitex	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53
Zhejiang Kekang, China	1296	Zinc oxide adhesive Plaster (Cloth Tape)	2.5 cm x 5m	Kohlcan	3	5	0	5	6	6	25	5	5	0	0	0	16	26	51
Zhejiang Kekang, China	1297	Zinc oxide adhesive Plaster (Cloth Tape)	5 cm x 5m	Kohlcan	3	5	0	5	6	6	25	5	5	0	0	0	16	26	51
Zhejiang Kekang, China	1298	Zinc oxide adhesive Plaster (Cloth Tape)	7.5 cm x 5m	Kohlcan	3	5	0	5	6	6	25	5	5	0	0	0	16	26	51
Zhejiang Kekang, China	1299	Zinc oxide adhesive Plaster (Cloth Tape)	10 cm x 5m	Kohlcan	3	5	0	5	6	6	25	5	5	0	0	0	16	26	51

Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																					
Name of the firm					AL-HAMD ENTERPRISES KARACHI																
S. No.	Product General Parameter				Technical Evaluation Matrix															Product Evaluated Score	Total Technical Score
					Principal's and Importer's Evaluation Parameters						Product Technical Evaluation										
					Principal Manufacturer Evaluation			Importer's Evaluation													
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20		
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm). In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals-01 mark 04 Tender approvals-02 marks 06 Tender approvals-03 marks 08 Tender approvals-04 marks 10 or more 1 tender approvals-05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (\$10 K)/ US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.					
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70		
Zhejiang Kekang, China	917	Adhesive tape (paper)	1"x5 yard	Kohican	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54		
Zhejiang Kekang, China	918	Adhesive tape (paper)	2"x5yard	Kohican	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54		
Zhejiang Kekang, China	919	Adhesive tape (paper)	3"x5yard	Kohican	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54		
Zhejiang Kekang, China	920	Adhesive tape (paper)	4"x5yard	Kohican	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54		
Farcomake, Egypt	1116	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G	Inpharven	3	5	0	5	5	6	24	5	5	0	2	DTL Substandard	10	22	46		
Farcomake, Egypt	1118	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G	Inpharven	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56		
Farcomake, Egypt	1120	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)			3	5	0	5	5	6	24	5	5	0	2	DTL Substandard	10	22	46		
Farcomake, Egypt	1123	I.V Cannula (Sterile having wings with heparin stopper inside sterilized blister packing. The cannula should be radioopaque, as well as latex, pyrogen, and PVC free)	24G	Farcoathe	3	5	0	5	5	6	24	5	5	0	2	DTL Substandard	10	22	46		

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																						
Name of Firm																						
S. No.	Product General Information				ALLIED DISTRIBUTOR, KARACHI																Product Evaluated Score	Total Technical Score
					Principal's and Importer's Evaluation Parameters					Suppliers Technical Score	Product Technical Evaluation											
					Principal Manufacturer Evaluation						Product Technical Parameters											
	1	2	3	4	5	6	7	8	9	13	14	15	16	17	18	19	20	21	22	23		
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided	Valid accreditation of manufacturing unit or its relevant sectors by the USFDA or WHO or official accreditation body for regulatory products in the case of SRA countries (duly attested by senior executive of the firm)	Valid calibration certificates for equipment / instruments used in the Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm)	Bioavailability / Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-similar certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral (i.e. greater than 100ml up to 5L, product validation report (as per WHO/USFDA/USP guidelines) shall be submitted, and / or Proof of inventors / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item(s) from Pakistan Customs, coupled with valid airway bill or Bill of Lading of the quoted item(s), not older than 24 months on the cut-off date for submission of bids. In case of purchases through third party importers a valid Test/Link/DNA/ Clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of finished quoted item(s) from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA/ PMDA / Swiss Meds or Health Canada or by regulatory authority/body of SRA country (ies). Trail of principal manufacturer shall be established from the respective QID, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for QID, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NT/td submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. 2 mark for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item(s), as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product) 3. Type of Glass material for Oral Syringe/ Suspensions must be USP Type 1 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).	Stability studies of quoted item(s) duly attested by the Q/C incharge of the firm). Availability of quoted item(s) in Pakistan market as per recent most data of IMS/IOVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IOVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals-01 mark 04 Tender approvals-02 marks 06 Tender approvals-03 marks 08 Tender approvals-04 marks 10 or more Tender approvals-05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.						
	Ref. No. of Item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	2	5	5	30	5	5	5	5	6	4	5	5	40	70		
Piramal, USA	19	Isoflurane	Liq. for Inh.100ml	Restane	0	0	0	5	5	24	0	5	5	5	2	4	5	0	26	50		
Piramal, USA	32	Sevoflurane	Liq. for Inh. 250 ml	Sojourn	0	0	0	5	5	24	0	5	5	5	4	4	5	0	28	52		
Dankook, Korea	28	Propofol	inj. 10 mg/ml, 20ml	Pofol	0	2	0	5	5	26	0	5	5	5	0	4	5	0	24	50		

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																						
Name of Firm		Allmed Laboratories Karachi																				
S. No.	Product General Information				Technical Evaluation Matrix																	
					Principal's and Importer's Evaluation Parameters									Product Technical Evaluation								
					Principal Manufacturer Evaluation					Importer's Evaluation				Suppliers Technical Score	Product Technical Parameters							
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
	Valid WHO (HSEI) certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm				Valid WHO (HSEI) certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm	Valid WHO (HSEI) certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm	Valid accreditation of manufacturing unit or its relevant entities by the WHO or WHO-recognized bodies for regulatory body in the case of IMA's countries duly attested by senior executive of the firm	Valid calibration certificates for equipment / instruments used in the facility for measuring, weighing, Assay/ Analysis of raw material, process material and finished products for the manufacturing of the quoted products	Valid calibration certificates for equipment / instruments used in the facility for measuring, weighing, Assay/ Analysis of raw material, process material and finished products for the manufacturing of the quoted products	Availability of validated SOPs, recovery of the total impact of the quoted items during last one year certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC's expert's	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)	Substance to which storage procedure (GDP) for storage of finished goods, Finished and effective, Non-sterilizing & Validation System and effective cold chain (Pharmaceuticals)
	Online verification link shall be provided				Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided
	Source	Ref. No. of Item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	2	5	5	4	5	5	30	5	5	5	6	4	5	5	40
	Pharmaceutical Denmark	286	Item	100 mg/ml	Manufacturer	0	0	0	5	5	4	5	5	24	0	5	5	0	0	5	0	20

[illegible]

Demopho rius Cyprus						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																	
	Name of the firm					ALPHA 6 Pvt Ltd, ISLAMABAD																	
						Technical Evaluation Matrix																	
						Principal's and Importer's Evaluation Parameters						Product Technical Evaluation										Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation														
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19			
	S. No.	Ref. No. of Item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	C.E.mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical			
						3	5	5	5	6	6	30	5	5	5	3	6	16	40	70			
	1	944	Blood Transfusion Sets	sterile and pyrogen free, minimum 125cm tube length, blister pack	Demotek	0	5	0	5	6	6	22	0	0	0	0	0	16	16	38			

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																						
Name of Firm				Amros Pharmaceuticals, Karachi																																		
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters										Total Product Evaluated Score	Total Technical Score										
					Documents Based Factory Score												Factory Evaluation Visit Score												Product Evaluation Parameters									
																													Product Technical Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26												
					Valid ISO 18001:2000 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered) Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions shall be awarded 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificate for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm)	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 at latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all laboratories. Adherence to cGMP guidelines, as per the schedule-II of DRAP (as evaluated at the time of inspection by the MCC experts)	Raw material, In-process and Finished goods, stored in the schedule-II of DRAP (as evaluated at the time of inspection by the MCC experts)	Non-compliance to cGMP guidelines shall lead to disqualification of the firm.	Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection.	Non-availability or non-functionality of the HVAC system and/or testing and/or disqualification of the section/s or firm.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs, (As evaluated by the MCC experts at the time of inspection).	Non-availability or non-functionality of the HVAC system and/or testing and/or disqualification of the section / firm.	33	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website For biologicals, bio-similarity studies shall be provided for award of marks in this parameter, and / or In case of Large volume parenteral (i.e., greater than 100ml up to 5L, product validation report as per WHO/US-FDA/USP guidelines) shall be submitted, and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the biogequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid away bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of Large volume parenteral (i.e., greater than 100ml up to 5L, product validation report as per WHO/US-FDA/USP guidelines) shall be submitted, and / or Proof of inventor / innovator product from relevant body shall be provided where the firm claims that the biogequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (CD) provided in column 18, duly attested by the senior executive of the firm. Moreover, in case of product/ingredient item having multiple APIs, the marks for GDS, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In case of Non-provision of matching CD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Made or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form(s) (Form of undertaking to accompany an application for License to import Drugs)	Valid WHO prequalification and / or Valid product registration in SRA countries) and / or Valid free sale certificate issued by regulatory body of the SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capable Sheath, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Oral/Inj. Specimens must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 3. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Class 2 marks will be awarded. c. For products where USP Type 2 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Document duly attested by the Senior executive of the firm)	Stability studies of quoted items duly attested by the Q.C. (exchange of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tendering date Govt. Hospitals, Health related Govt. projects and or ICJ accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: (Tender approval means award of contract) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entity and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity (purchasing agency/ies), etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted items in Pakistan market as per recent most data of IMS/QVIA Health not older than twelve (12 months). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tendering date Govt. Hospitals, Health related Govt. projects and or ICJ accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: (Tender approval means award of contract) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entity and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity (purchasing agency/ies), etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.												
C.No.	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70												
1	279	Lincomycin	Cup. 500mg	Amrin	0	0	0	0	5	2	The visit of this firm was rescheduled on 19th September 2026 as per request of the firm due to their scheduled inspection visit by the Nigerian National Agency For Food And Drug Administration And Control (NAFDAC) Drug Evaluation And Research (DER) Directorate (15th to 18th September 2025). The inspection team of MCC observed the following at the time of inspection: Non Adherence to Good Storage Practices & cGMP: 1. The material placed in the Raw Material Store (RMS) Quarantine was un-labelled (no status of the material was reflected). 2. There was no rejection area in the RMS. 3. Food grade olive oil was present in the RMS quarantine without any label. The RMS in charge conveyed that the said olive oil is used in the artemether injection as a vehicle. The inspection team inquired about the documentation such as COA, Monograph details, Invoice/GD for the said olive oil but they failed to provide the same. The use of food grade olive oil in parenteral without quality documentation specially COA, Monographs, violates the current Good Manufacturing Practices (cGMP) potentially leading to product instability and patient harm. 4. There was no thermometer & hygrometer and no record of its documentation was present in the RMS at the time of inspection. 5. In RMS refrigerator, the temperature at the time of inspection was 12.5 °C instead of 2-8 °C. 6. In Finish Good Store, no temperature and humidity device and no log-record sheet was found at the time of inspection. 7. In RMS, a dispensed batch of amoxicillin+clavulanic acid was present in the dispensed cupboard, at the time of inspection, which was dispensed on 11-09-2025 as per the label without any environment control (temperature/humidity) till the day of inspection that is 19-09-2025. 8. Loose doors, cracks in the walls near HVAC outlets were observed at multiple locations that was compromising the air differential, ultimately leading to the compromised HVAC system. In view of the above, the firm is Not-Recommended.					7	0	0	0	0	0	7	0	5	5	0	0	4	5	0	9	16						
2	185	Amoxycillin	Dry Sup. 250mg/5ml, 60ml	Amfux-DS	0	0	0	0	5	2						7	0	5	5	0	0	5	0	19	26													
3	182	Amoxycillin	Dry Sup. 125mg/5ml, 60ml	Amfux	0	0	0	0	5	2						7	0	5	5	0	0	4	5	0	19	26												
4	192	Amoxicillin + Clavulanic Acid	Dry Sup. 250 mg + 62.5mg / 5ml	Clav-D	0	0	0	0	5	2						7	0	5	5	0	0	4	5	0	19	26												
5	190	Amoxicillin + Clavulanic Acid	Dry Sup. 125 mg +31.25mg / 5ml	Clav	0	0	0	0	5	2						7	0	5	5	0	0	4	5	0	19	26												
6	41	Diclofenac Sodium (IM/IV for Injection)	Inj. 25mg/ml, 3ml	Amrofe	0	0	0	0	5	2						7	0	5	5	0	0	4	5	0	19	26												
7	547	Dexamethasone	Inj. 4mg/ml, 1ml	Dexamethasone	0	0	0	0	5	2						7	0	5	5	5	0	4	5	0	24	31												
8	174	Phenitamine Malate	Inj. 22.75mg/ml, 2ml	Amrovi	0	0	0	0	5	2						7	0	5	5	5	0	4	5	0	24	31												
9	230	Ceftriaxone	Inj. 500mg/vial	Rilexone	0	0	0	0	5	2						7	0	5	5	0	0	2	0	0	12	19												
10	231	Ceftriaxone	Inj. 1g/vial	Rilexone	0	0	0	0	5	2						7	0	5	5	0	0	2	5	0	17	24												
11	232	Ceftriaxone	Inj. 2g/vial	Rilexone	0	0	0	0	5	2						7	0	5	5	0	2	0	0	0	12	19												
12	222	Ceftriaxone	Inj. 250mg/vial	Amtrax	0	0	0	0	5	2						7	0	0	0	0	2	0	0	0	2	9												
13	223	Ceftriaxone	Inj. 500mg/vial	Amtrax	0	0	0	0	5	2						7	0	0	0	0	2	0	0	0	2	9												
14	224	Ceftriaxone	Inj. 1g/vial	Amtrax	0	0	0	0	5	2						7	0	0	0	0	0	2	0	0	2	9												

GRC Decision
The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																							
Name of the firm					AMSONS VACCINES, ISLAMABAD																		
S.No	Product General Information				Factory Technical Evaluation Parameter									Factory Evaluated Score	Technical Evaluation Matrix							Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score						Product technical Evaluation Parameters								
					1	2	3	4	5	6	7	8	9		10	11	12	13	14	15	16		
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (As evaluated at the time of inspection by the MCC experts). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC experts at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC. (Certificate Duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 2 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Physical examination of the quoted items by the MCC experts. Rejection of the quoted items by the MCC experts shall lead to disqualification of the said items.					
S.NO	Ref. No. of item in	Generic Name of Item	Size & Gauge of Medical Device	Trade Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70		
1	1013	Disposable Auto Disable Syringe (Blister packing) sterile	0.5ml	Apple K1 0.5ml	3	5	5	6	3	3	2	2	29	5	5	0	2	10	10	32	61		
2	1014	Disposable Auto Disable Syringe (Blister packing) sterile	1ml	Apple K1 1ml	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	30	59		
3	1015	Disposable Auto Disable Syringe (Blister packing) sterile	2ml	Apple K1 2ml	3	5	5	6	3	3	2	2	29	5	5	0	2	10	10	32	61		
4	1016	Disposable Auto Disable Syringe (Blister packing) sterile	3 ml	Apple K1 3ml	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	30	59		
5	1017	Disposable Auto Disable Syringe (Blister packing) sterile	5 ml	Apple K1 5ml	3	5	5	6	3	3	2	2	29	5	5	0	2	10	10	32	61		
6	1021	Disposable Syringe Ordinary (Blister packing) sterile	10ml	Apple K1 10ml	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	30	59		

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																										
Name of Firm				AMSONS VACCINES, ISLAMABAD																						
S. No.	Product General Information				Technical Evaluation Matrix																Product Evaluation Parameters				Total Product Evaluation Score	Total Technical Score
					Factory Technical Evaluation Parameters																					
					Documents Based Factory Score								Factory Evaluation Visit Score								Total Factory Evaluation Score					
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
Ref. No. of Firm	Generic Name of Firm	Design/Trade name with strength	Trade Name	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of	Valid WHO 100% 100% certificate of
1	243	Cephalexin	TAB. 250 mg. 500	Glaxo	2	2	3	5	5	4	2	2	2	2	2	20	5	5	5	5	3	4	5	5	27	70
2	244	Cephalexin	TAB. 500 mg. 500	Glaxo	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	49
3	247	Cephalexin	TAB. 250 mg. 500	Glaxo	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	49
4	248	Cephalexin	TAB. 500 mg. 500	Glaxo	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	49
5	278	Paracetamol + Folic Acid	TAB. 325mg + 0.5mg	Indus	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	0	0	4	5	2	21	51
6	412	Acetaminophen	TAB. 5 mg	Amgen	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	49
7	542	Zinc Sulphate	TAB. 20 mg	Glaxo	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	50
8	543	Zinc Sulphate	Sol. 20 mg/5ml 60 ml	Glaxo	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	50
9	563	Bifidobacterium	mg 100 mg/10ml	Glaxo	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	5	0	4	5	2	27	57
10	564	Bifidobacterium	mg 200 mg/10ml	Glaxo	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	5	0	4	5	2	27	57
11	623	Stable Vitamin Antioxidant	mg 10 ml	Pharmaceutical Antioxidant	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	49
12	626	Tranexamic Acid	mg 0.5 ml	Amgen	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	0	0	4	5	1	24	54
13	613	Pyridoxine HCl	TAB. 50 mg	Amgen	2	2	3	5	5	4	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	49

				Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																									
Name of the firm					ANWAR & SONS, ISLAMABD																								
S. No.	Product General Parameter				Technical Evaluation Matrix																	Product Evaluated Score	Total Technical Score						
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation																	
					Principal Manufacturer Evaluation			Importer's Evaluation																Suppliers Technical Score					
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20										
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item's during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item's. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attasted by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification n of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.													
	Ref. No.	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70										
SMI, Belgium	1309	17mm, 1/2 circle round bodied taper point needle, strand length 75cm 4/0	4/0	Silk	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1310	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm 3/0	3/0	Silk	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1311	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm 3/0	3/0	Silk	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1312	26mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm 3/0	3/0	Silk	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1315	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm 2/0	2/0	Silk	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1316	31mm, 1/2 circle round bodied taper point needle, Strand length 75cm 0	0	Silk	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1318	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm 1	1	Silk	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1321	7mm, 1/2 circle, micropoint spatula needle, strand length 45cm 7/0	7/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1322	8mm, 1/4 circle spatulated needle, strand length 45cm 6/0	6/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1324	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm 6/0	6/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1327	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm 5/0	5/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1331	22mm, 1/2 circle round bodied taper point, strand length 70 cm 4/0	4/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1334	22mm, 1/2 circle round bodied taper point, strand length 70 cm 3/0	3/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1335	26mm, 1/2 circle round bodied taper point, Strand length 70 cm 3/0	3/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1336	26mm, 1/2 circle round bodied taper point, strand length 70 cm 2/0	2/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1337	31mm, 1/2 circle round bodied taper point, strand length 70 cm 2/0	2/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1341	40mm, 1/2 circle round bodied taper point, strand length 90 cm 0	0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1342	40mm, 1/2 circle round bodied taper point, strand length 70 cm 1	1	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1345	45mm, 1/2 circle round bodied taper point, strand length 75 cm 2	2	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1351	30mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0	Surgicryl PGA	0	5	0				5	0	0	0	4	10	10	24	29										
SMI, Belgium	1354	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm 1	1	Surgicryl PGA	0	5	0				5	0	0	0	4	10	10	24	29										
SMI, Belgium	1362	12mm, 3/8 circle reverse cutting needle, strand length 60cm 6/0	6/0	Polypropylene	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1364	13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm 6/0	6/0	Polypropylene	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1365	16mm, 3/8 circle curved cutting needle, strand length 90cm 6/0	6/0	Polypropylene	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1367	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 6/0	5/0	Polypropylene	0	5	0				5	5	5	0	4	10	10	34	39										
SMI, Belgium	1368	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 4/0	4/0	Polypropylene	0	5	0				5	5	5	0	4	10	10	34	39										

SMI, Belgium	1369	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm 4/0	4/0	Polypropylene	0	5	0	2. BIOHEALTH MEDICAL CHINA Embassy attested original Free sale certificate and EC/cGMP wer not present at the time of inspection. Hence, the FIRM IS NOT RECOMMENDED for the award of marks as specified for physical inspection in the relevant pro-forma for items of BIOHEALTH MEDICAL CHINA.	5	5	5	0	4	10	10	34	39
SMI, Belgium	1370	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 3/0	3/0	Polypropylene	0	5	0		5	5	5	0	4	10	10	34	39
SMI, Belgium	1371	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm 3/0	3/0	Polypropylene	0	5	0		5	5	5	0	4	10	10	34	39
SMI, Belgium	1374	26mm, 3/8 circle reverse cutting needle, strand length 45cm 2/0	2/0	Polypropylene	0	5	0		5	5	5	0	4	10	10	34	39
SMI, Belgium	1377	30mm, 1/2 circle round bodied taper point needle, strand length 75cm 2/0	2/0	Polypropylene	0	5	0		5	5	5	0	4	10	10	34	39
SMI, Belgium	1379	60mm, straight cutting needle, strand length 75cm 2/0	2/0	Polypropylene	0	5	0		5	5	5	0	4	10	10	34	39
SMI, Belgium	1380	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 0	0	Polypropylene	0	5	0		5	5	5	0	4	10	10	34	39
SMI, Belgium	1381	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 1	1	Polypropylene	0	5	0		5	5	5	0	4	10	10	34	39
SMI, Belgium	1389	13mm, 1/2 circle round bodied taper point needle, strand length 45cm 6/0	6/0	PDO	0	5	0		5	0	0	0	4	10	10	24	29
SMI, Belgium	1393	13mm, 1/2 circle round bodied taper point needle, strand length 75cm 5/0	5/0	PDO	0	5	0		5	0	0	0	4	10	10	24	29
SMI, Belgium	1399	20mm, 1/2 circle round bodied taper point needle, strand length 70cm 4/0	4/0	PDO	0	5	0		5	0	0	0	4	10	10	24	29
SMI, Belgium	1400	26mm, 1/2 circle round bodied taper point needle, strand length 75cm 4/0	4/0	PDO	0	5	0		5	0	0	0	4	10	10	24	29
SMI, Belgium	1402	26mm, 1/2 circle round bodied taper point needle, strand length 75cm 3/0	3/0	PDO	0	5	0		5	0	0	0	4	10	10	24	29
SMI, Belgium	1405	30mm, 1/2 circle round bodied taper point needle, strand length 75cm 2/0	2/0	PDO	0	5	0		5	0	0	0	4	10	10	24	29
SMI, Belgium	1409	40mm, 1/2 circle round bodied taper point needle, Strand length 70cm 0	0	PDO	0	5	0		5	0	0	0	4	10	10	24	29
SMI, Belgium	1411	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 1	1	PDO	0	5	0		5	0	0	0	4	10	10	24	29
SMI, Belgium	1412	6 mm, 3/8 circle micro point spatula double needle, strand length 30cm 10/0	10/0	Nylon	0	5	0		5	0	0	0	4	10	10	24	29
SMI, Belgium	1413	6.2mm, 3/8 circle micro point spatula double needle, strand length 30cm 10/0	10/0	Nylon	0	5	0		5	0	0	0	4	10	10	24	29
BioHeath Medical, China	1416	Polypropylene 30cm x 30cm	30x30cm	ProHeal Surgical Mesh	0	5	0	2. BIOHEALTH MEDICAL CHINA Embassy attested original Free sale certificate and EC/cGMP wer not present at the time of inspection. Hence, the FIRM IS NOT RECOMMENDED for the award of marks as specified for physical inspection in the relevant pro-forma for items of BIOHEALTH MEDICAL CHINA.	5	5	0	0	4	10	10	29	34
BioHeath Medical, China	1417	Polypropylene 15cm x 15cm	15x15cm	ProHeal Surgical Mesh	0	5	0		5	5	0	0	2	10	10	27	32
BioHeath Medical, China	1419	Polypropylene 6cm x 11cm	6x11cm	ProHeal Surgical Mesh	0	5	0		5	5	0	0	2	10	10	27	32

					Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																									
Name of the firm					ANWAR & SONS, ISLAMABD																									
S. No.	Product General Parameter				Principal's and Importer's Evaluation Parameters							Technical Evaluation Matrix										Product Evaluated Score	Total Technical Score							
					Principal Manufacturer Evaluation			Importer's Evaluation				Suppliers Technical Score	Product Technical Evaluation																	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20											
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attasted by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only.(verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.															
	Ref. No.	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70											
SMI, Belgium	1309	17mm, 1/2 circle round bodied taper point needle, strand length 75cm 4/0	4/0	Silk	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1310	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm 3/0	3/0	Silk	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1311	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm 3/0	3/0	Silk	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1312	26mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm 3/0	3/0	Silk	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1315	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm 2/0	2/0	Silk	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1316	31mm, 1/2 circle round bodied taper point needle, Strand length 75cm 0	0	Silk	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1318	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm 1	1	Silk	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1321	7mm, 1/2 circle, micropoint spatula needle, strand length 45cm 7/0	7/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1322	8mm, 1/4 circle spatulated needle, strand length 45cm 6/0	6/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1324	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm 6/0	6/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1327	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm 5/0	5/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1331	22mm, 1/2 circle round bodied taper point, strand length 70 cm 4/0	4/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1334	22mm, 1/2 circle round bodied taper point, strand length 70 cm 3/0	3/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1335	26mm, 1/2 circle round bodied taper point, Strand length 70 cm 3/0	3/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1336	26mm, 1/2 circle round bodied taper point, strand length 70 cm 2/0	2/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1337	31mm, 1/2 circle round bodied taper point, strand length 70 cm 2/0	2/0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1341	40mm, 1/2 circle round bodied taper point, strand length 90 cm 0	0	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1342	40mm, 1/2 circle round bodied taper point, strand length 70 cm 1	1	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1345	45mm, 1/2 circle round bodied taper point, strand length 75 cm 2	2	Surgicryl 910	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1351	30mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0	Surgicryl PGA	0	5	0				5	0	0	0	4	10	10	24	29											
SMI, Belgium	1354	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm 1	1	Surgicryl PGA	0	5	0				5	0	0	0	4	10	10	24	29											
SMI, Belgium	1362	12mm, 3/8 circle reverse cutting needle, strand length 60cm 6/0	6/0	Polypropylene	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1364	13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm 6/0	6/0	Polypropylene	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1365	16mm, 3/8 circle curved cutting needle, strand length 90cm 6/0	6/0	Polypropylene	0	5	0				5	5	5	0	4	10	10	34	39											
SMI, Belgium	1367	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 5/0	5/0	Polypropylene	0	5	0				5	5	5	0	4	10	10	34	39											

SMI BELGIUM :Embassy attested original Free Sale Certificate was not available at the time of inspection. Hence, the FIRM IS NOT RECOMMENDED for the award of marks as specified for physical inspection in the relevant pro-forma for items of SMI

SMI BELGIUM :Embassy attested original Free Sale Certificate was not available at the time of inspection. Hence, the FIRM IS NOT RECOMMENDED for the award of marks as specified for physical inspection in the relevant pro-forma for items of SMI

SMI, Belgium	1368	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 4/0	4/0	Polypropylene	0	5	0
SMI, Belgium	1369	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm 4/0	4/0	Polypropylene	0	5	0
SMI, Belgium	1370	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 3/0	3/0	Polypropylene	0	5	0
SMI, Belgium	1371	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm 3/0	3/0	Polypropylene	0	5	0
SMI, Belgium	1374	26mm, 3/8 circle reverse cutting needle, strand length 45cm 2/0	2/0	Polypropylene	0	5	0
SMI, Belgium	1377	30mm, 1/2 circle round bodied taper point needle, strand length 75cm 2/0	2/0	Polypropylene	0	5	0
SMI, Belgium	1379	60mm, straight cutting needle, strand length 75cm 2/0	2/0	Polypropylene	0	5	0
SMI, Belgium	1380	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 0	0	Polypropylene	0	5	0
SMI, Belgium	1381	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 1	1	Polypropylene	0	5	0
SMI, Belgium	1389	13mm, 1/2 circle round bodied taper point needle, strand length 45cm 6/0	6/0	PDO	0	5	0
SMI, Belgium	1393	13mm, 1/2 circle round bodied taper point needle, strand length 75cm 5/0	5/0	PDO	0	5	0
SMI, Belgium	1399	20mm, 1/2 circle round bodied taper point needle, strand length 70cm 4/0	4/0	PDO	0	5	0
SMI, Belgium	1400	26mm, 1/2 circle round bodied taper point needle, strand length 75cm 4/0	4/0	PDO	0	5	0
SMI, Belgium	1402	26mm, 1/2 circle round bodied taper point needle, strand length 75cm 3/0	3/0	PDO	0	5	0
SMI, Belgium	1405	30mm, 1/2 circle round bodied taper point needle, strand length 75cm 2/0	2/0	PDO	0	5	0
SMI, Belgium	1409	40mm, 1/2 circle round bodied taper point needle, Strand length 70cm 0	0	PDO	0	5	0
SMI, Belgium	1411	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 1	1	PDO	0	5	0
SMI, Belgium	1412	6 mm, 3/8 circle micro point spatula double needle, strand length 30cm 10/0	10/0	Nylon	0	5	0
SMI, Belgium	1413	6.2mm, 3/8 circle micro point spatula double needle, strand length 30cm 10/0	10/0	Nylon	0	5	0
BioHealth Medical, China	1416	Polypropylene 30cm x 30cm	30x30cm	Pro-Heal Surgical Mesh	0	5	0
BioHealth Medical, China	1417	Polypropylene 15cm x 15cm	15x15cm	Pro-Heal Surgical Mesh	0	5	0
BioHealth Medical, China	1419	Polypropylene 6cm x 11cm	6x11cm	Pro-Heal Surgical Mesh	0	5	0

BELGIUM.

2. BIOHEALTH MEDICAL CHINA
Embassy attested original Free sale certificate and EC/cGMP wer not present at the time of inspection.
Hence, the FIRM IS NOT RECOMMENDED for the award of marks as specified for physical inspection in the relevant pro-forma for items of BIOHEALTH MEDICAL CHINA.

5	5	5	0	4	10	10	34	39
5	5	5	0	4	10	10	34	39
5	5	5	0	4	10	10	34	39
5	5	5	0	4	10	10	34	39
5	5	5	0	4	10	10	34	39
5	5	5	0	4	10	10	34	39
5	5	5	0	4	10	10	34	39
5	5	5	0	4	10	10	34	39
5	5	5	0	4	10	10	34	39
5	5	5	0	4	10	10	34	39
5	0	0	0	4	10	10	24	29
5	0	0	0	4	10	10	24	29
5	0	0	0	4	10	10	24	29
5	0	0	0	4	10	10	24	29
5	0	0	0	4	10	10	24	29
5	0	0	0	4	10	10	24	29
5	0	0	0	4	10	10	24	29
5	0	0	0	4	10	10	24	29
5	0	0	0	4	10	10	24	29
5	5	0	0	4	10	10	29	34
5	5	0	0	2	10	10	27	32
5	5	0	0	2	10	10	27	32

GRC Decision

The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																		
Name of the firm					ANWAR & SONS, ISLAMABD																		
					Technical Evaluation Matrix																		
					Principal's and Importer's Evaluation Parameters										Suppliers Technical Score	Product Technical Evaluation						Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19				
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good Storage	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality control certificate issued by	Physical examination	Evaluated	Technical				
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70				
	Mascia Brunelli, Italy	915	Absorbable Haemostatic Gelatine Sponges	Different Sizes	Cutanplast	0	5	0	5	6	6	22	5	5	0	1	2	16	29	51			
	SUMI, Poland	1010	Disposable Endotracheal Tube with Cuff 7mm	7mm	Tracheal tube	0	5	0	5	6	6	22	5	0	0	1	2	16	24	46			
	SUMI, Poland	1011	Disposable Endotracheal Tube with Cuff 7.5mm	7.5mm	Tracheal tube	0	5	0	5	6	6	22	5	0	0	1	2	16	24	46			
	Ningbo Advan Electrical Co Ltd, China	1204	Skin Stapler Straight	35 W	Disposable Skin Stapler	0	5	0	Embassy attested original Free sale certificate was not present at the time of inspection. Furthermore, EC declaration of conformity produced before inspection team was also not embassy attested. Hence, the FIRM IS NOT RECOMMENDED			5	5	5	0	0	2	16	28	33			
	SMI, Belgium	1222	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel) 10	10	Surgical Blades	0	5	0				5	0	0	0	1	2	16	19	24			
	SMI, Belgium	1223	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel) 11	11	Surgical Blades	0	5	0				5	0	0	0	1	2	16	19	24			

					Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																		
Firm Name					AQIB TRADING COMPANY PVT LTD PESHAWAR																		
S. No.	Product General Parameter				Principal's and Importer's Evaluation Parameters							Technical Evaluation Matrix										Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation				Suppliers Technical Score	Product Technical Evaluation										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20				
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (\$10 K)/ US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.						
	Ref. No. of	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70				
Jiangxi Hongda Medical Equipment Group Ltd. China	1016	Auto Disable Syringe (Blister packing) sterile	3ml	AT-INGE	3	5	0	5	5	6	24	5	5	0	4	10	10	34	58				
Jiangxi Hongda Medical Equipment Group Ltd. China	1017	Auto Disable Syringe (Blister packing) sterile	5ml	AT-INGE	3	5	0	5	5	6	24	5	5	0	4	10	10	34	58				
Jiangxi Hongda Medical Equipment Group Ltd. China	1019	Disposable Insulin Syringe Ordinary sterile	1ml	AT-SULIN	3	5	0	5	5	6	24	5	5	0	4	10	10	34	58				
Jiangxi Hongda Medical Equipment Group Ltd. China	1020	Disposable Syringe Ordinary (Blister packing) sterile	1ml	AT-INGE	3	5	0	5	5	6	24	5	5	0	4	10	10	34	58				
Jiangxi Hongda Medical Equipment Group Ltd. China	1021	Disposable Syringe Ordinary (Blister packing) sterile	10ml	AT-INGE	3	5	0	5	5	6	24	5	5	0	4	10	10	34	58				
Jiangxi Hongda Medical Equipment Group Ltd. China	1022	Disposable Syringe Ordinary (Blister packing) sterile	20ml	AT-INGE	3	5	0	5	5	6	24	5	5	0	4	10	10	34	58				
Jiangxi Hongda Medical Equipment Group Ltd. China	1023	Disposable Syringe Ordinary (Blister packing) sterile	50ml	AT-INGE	3	5	0	5	5	6	24	5	5	0	4	10	10	34	58				
Jiangxi Hongda Medical Equipment Group Ltd. China	1024	Disposable Syringe Ordinary (Blister packing) sterile	60ml	AT-INGE	3	5	0	5	5	6	24	5	5	0	4	10	10	34	58				
Jiangxi Hongda Medical Equipment Group Ltd. China	1025	Disposable Syringe Ordinary (Blister packing) sterile	60ml with nozzle	AT-INGE	3	5	0	5	5	6	24	5	5	0	4	10	10	34	58				
Jiangxi Hongda Medical Equipment Group Ltd. China	1112	I/V fluid administration set sterile and pyrogen free, blister pack	I/V fluid administration set	AT-SET	3	5	0	5	5	6	24	5	5	0	4	10	10	34	58				
Jiangxi Hongda Medical Equipment Group Ltd. China	1113	I/V fluid administration set with additional "Y" injection port sterile and pyrogen free, blister pack	I/V fluid administration set with additional "Y" injection port	AT-SET	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56				
Jiangxi Hongda Medical Equipment Group Ltd. China	1116	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G	AT-CAN	3	5	0	5	5	6	24	5	5	0	2	DTL Substandard	10	22	46				
Jiangxi Hongda Medical Equipment Group Ltd. China	1118	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G	AT-CAN	3	5	0	5	5	6	24	5	5	0	2	DTL Substandard	10	22	46				
Jiangxi Hongda Medical Equipment Group Ltd. China	1120	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G	AT-CAN	3	5	0	5	5	6	24	5	5	0	2	DTL Substandard	10	22	46				
Jiangxi Hongda Medical Equipment Group Ltd. China	1122	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio opaque, as well as latex, pyrogen, and PVC free)	24G	AT-CAN	3	5	0	5	5	6	24	5	0	0	2	DTL Substandard	Non formulary	7	31				
Jiangxi Hongda Medical Equipment Group Ltd. China	1123	I/V Cannula (Sterile having wings with heparin stopper inside sterilized blister packing. The cannula should be radio opaque, as well as latex, pyrogen, and PVC free)	24G	AT-CAN	3	5	0	5	5	6	24	5	0	0	2	10	10	27	51				

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																	
Name of the firm					AQIB TRADING COMPANY																		
					Technical Evaluation Matrix																		
						Principal's and Importer's Evaluation Parameters						Product Technical Evaluation										Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation														
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19			
S. No.	Ref. No. of Item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical				
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70				
1	Jiangxi Hongda Medical Equipment Group Ltd. China	945	Blood Collection Tubes EDTA	EDTA Tube Purple Top	AT-TUBE	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
2	Jiangxi Hongda Medical Equipment Group Ltd. China	948	Blood Collection Tubes Lithium Heparin	Lithium Heparin Green Top	AT-TUBE	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
3	Jiangxi Hongda Medical Equipment Group Ltd. China	949	Blood Collection Tubes Gel	Gel Tube Yellow Top	AT-TUBE	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
4	Jiangxi Hongda Medical Equipment Group Ltd. China	950	Blood Collection Tubes Sodium Citrate	Sodium Citrate Blue Top	AT-TUBE	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
5	Jiangxi Hongda Medical Equipment Group Ltd. China	1009	Disposable Endotracheal Tube with Cuff	6.5mm	AT-TT	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
6	Jiangxi Hongda Medical Equipment Group Ltd. China	1010	Disposable Endotracheal Tube with Cuff	7.0mm	AT-TT	3	5	0	5	6	6	25	0	0	0	0	2	16	18	43			
7	Jiangxi Hongda Medical Equipment Group Ltd. China	1011	Disposable Endotracheal Tube with Cuff	7.5mm	AT-TT	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
8	Jiangxi Hongda Medical Equipment Group Ltd. China	1033	Disposable Sterile Nasogastric Tube	14Fr	AT-NG	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
9	Jiangxi Hongda Medical Equipment Group Ltd. China	1034	Disposable Sterile Nasogastric Tube	16Fr	AT-NG	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
10	Jiangxi Hongda Medical Equipment Group Ltd. China	1035	Disposable Sterile Nasogastric Tube	18Fr	AT-NG	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
11	Jiangxi Hongda Medical Equipment Group Ltd. China	1047	Disposable Sterile Latex Surgical Gloves (Powder Free)	6.5, 7.0, 7.5, 8.0	AT-TEX	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
12	Jiangxi Hongda Medical Equipment Group Ltd. China	1048	Disposable Sterile Latex Surgical Gloves (Powdered)	6.5, 7.0, 7.5, 8.0	AT-TEX	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
13	Jiangxi Hongda Medical Equipment Group Ltd. China	1124	IV Flow Regulator	Dial Flow Standard Size	AT-FLOW	3	3	0	5	6	6	23	0	0	0	0	2	16	18	41			
14	Jiangxi Hongda Medical Equipment Group Ltd. China	1126	Infusion Chamber (Burette Type) Sterile, Disposable	100ml	AT-SET	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
15	Jiangxi Hongda Medical Equipment Group Ltd. China	1255	Two-Way Foley Catheter (Silicon Coated)	14Fr	AT-LEY	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
16	Jiangxi Hongda Medical Equipment Group Ltd. China	1256	Two-Way Foley Catheter (Silicon Coated)	16Fr	AT-LEY	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
17	Jiangxi Hongda Medical Equipment Group Ltd. China	1257	Two-Way Foley Catheter (Silicon Coated)	18Fr	AT-LEY	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			
18	Jiangxi Hongda Medical Equipment Group Ltd. China	1279	Urine Bag with let	2000ML	AT-BAG	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53			

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																														
Name of Firm					ARIES PHARMA PESHAWAR																									
S. No.	Product General Information				Factory Technical Evaluation Parameters															Total Factory Evaluated Score	Product Evaluation Parameters									
					Documents Based Factory Score																Product Technical Parameters									
	Documents Based Factory Score					Factory Evaluation Visit Score										Product Technical Parameters										Total Product Evaluated Score	Total Technical Score			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26					
					Valid ISO 18001:2001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMSRQVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMSRQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificate attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) as in lab - Functional Stability Chamber (Both Accelerated and Real Time) in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP, as per schedule-B shall lead to disqualification of the firm).	Raw material In-process and Finished goods storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts)	Adherence to cGMP guidelines, for in-Schedule-B of DRAP), as evaluated at the time of inspection by the MCC experts	Non-compliance to cGMP guidelines shall lead to disqualification of the firm.	Non-availability or non-functioning of the HVAC system and/or testing, and/or logs, shall lead to Disqualification of the relevant section/ firm.		13	5	5	5	5	3	4	5	5	37	30			
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
2	Metronidazole	Tab, 400mg	Flagynase DS	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
41	Diclofenac Sodium	inj, 25 mg/ml 3 ml	Vollenac	2	2	3	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	9	35				
43	Fentanyl Citrate	inj, 0.05mg/ml 5 ml	Fenject	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
57	Nalbuphine	inj, 10 mg	Hinal	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
67	Paracetamol+Tr amadol	Tab,325mg/37.5 mg	Ultram	2	2	3	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	4	30				
70	Tramadol HCl	inj, 50 mg/ml,2ml	Nael	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	0	0	0	4	5	0	14	40				
148	Fluconazole	Tab. / Cap, 150 mg 1s	Trican	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
176	Amikacin Sulphate	inj, 50mg	Amikac	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
177	Amikacin Sulphate	inj, 100mg	Amikac	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
179	Amikacin Sulphate	inj, 500mg	Amikac	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
202	Azithromycin	Tab. / Cap, 250 mg 12s or less	Macrocap	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
215	Cefepime	inj, 500 mg/Vial	Kion	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	2	5	0	17	43				
216	Cefepime	inj, 1gm/Vial	Kion	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	2	5	0	17	43				
217	Cefixime	Cap, 400 mg 5s	Spectracef	2	2	3	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	9	35				
218	Cefixime	Dry Susp, 100 mg/5ml 30ml	Spectracef	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
219	Cefixime	Dry Susp, 200 mg/5ml 30ml	Spectracef	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
226	Cefoperazone + Sulbactam	inj, 1gm/Vial	Aricef Plus	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	2	5	0	17	43				
227	Cefoperazone + Sulbactam	inj, 2 gm/Vial	Aricef Plus	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	2	5	0	17	43				
230	Ceftriaxone	inj, 500 mg/Vial	Arizon	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	2	5	0	17	43				
231	Ceftriaxone	inj, 1gm/Vial	Arizon	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	2	5	0	17	43				
232	Ceftriaxone	inj, 2 gm Vial	Arizon	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	2	5	0	17	43				
283	Linezolid	Inf, 2 mg/ml 100 ml	Oxalid	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
406	Transcarbic Acid	inj, 250 mg 5 ml	Tranis	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
491	Transcarbic Acid	inj, 500 mg 5 ml	Tranis	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
493	Combined Oral Contraceptives	0.03 mg of ethinyl estradiol and 0.15 mg of Levonorgestrel.	Prevra 28F	2	2	3	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	9	35				
526	Omeprazole	inj, 40 mg / Vial	Omeac	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
530	Ondansetron	inj, 2 mg/ml 4 ml	Averon	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
698	Alprazolam	Tab, 0.5 mg	Pranax	2	2	3	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	9	35				
716	Diazepam	inj, 10 mg/ml 2 ml	Diazip	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				
737	Midazolam	inj, 1mg/ml 5ml	Midaron	2	2	3	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45				

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																																																																											
ARSONS PHARMACEUTICALS, LAHORE																																																																																											
S. No.	Name of Firm				Factory Technical Evaluation Parameters											Product Evaluation Parameters										Total Product Technical Score	Total Technical Score																																																																
	Product General Information				Documents Based Factory Score				Factory Technical Evaluation Parameters			Factory Evaluation Visit Score				Total Factory Evaluated Score		Product Evaluation Parameters																																																																									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26																																																																		
Valid ISO 14001/ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (date attested by senior executive of the firm)				Valid ISO 14001/ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (date attested by senior executive of the firm)				Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firm having (12-Month) Ranking between 21-60th positions shall be awarded 4 marks. 3. Firm having (12-Month) Ranking between 61st to 100th positions shall be awarded 3 marks.				Valid calibration certificates for equipment used in the factory for Measuring, Weighing, Assay/ Analysis of raw material, in-process material and finished products for the quoted products.				Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest.				Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Bolt Accelerated and Real Time) in Schedule B of DRAP (As evaluated at the time of inspection by the MCC experts, as non-availability or non-compliance to cGMP guidelines shall lead to disqualification of the sections or firm).				Raw material, In-process and Finished goods storage as in Schedule-B of DRAP (As evaluated at the time of inspection by the MCC experts).				Non-compliance to cGMP guidelines shall lead to disqualification of the sections or firm).				Adequacy of functional and validated HVAC, with all relevant equipment, testing, logs.				Adequacy of functional and validated HVAC, with all relevant equipment, testing, logs.				Bio-similarity: Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for a panel of marks in this parameter.				Goods Declaration certificate of imported APIs of the quoted items from Pakistan Customs, coupled with valid assay bill or Bill of Lading for the quoted items, not older than 24 months from the cut-off date for submission of bids.				Certificate of Analysis of APIs from the Principal Manufacturer as incorporated in the goods declaration (GD) provided in schedule 19, duly attested by the senior executive of the firm.				Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO, USFDA, EMA /MIRA /TGA/ PMDA/ Swiss Medico or Health Canada or by regulatory authority/body of DRAC country (ies) coupled with Form 6 (Items of undertaking to accompany an application for License to import Drugs).				Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies).				Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies).				Valid Certificate of Analysis of the Type / class of material used for the manufacture of the quoted items, as issued by the manufacturer of the material coupled with assay report of purchase.				Stability studies of quoted items duly attested by the Q.C. (in-house of the firm).				For award of marks, the certificate of analysis must clearly mention: 1. Material e.g., Aluminium foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with U.S., European, British, Japanese Pharmacopoeia standards must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP Class I. (Non-compliance shall lead to disqualification of the quoted products). 3. Type of Glass material for Oral Syringes/ Syringes must be USP Type 2 or better (Non-compliance or non-provision of C.A. of glass material shall lead to disqualification of the quoted products).				For award of marks, the certificate of analysis must clearly mention: 1. Material e.g., Aluminium foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with U.S., European, British, Japanese Pharmacopoeia standards must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP Class I. (Non-compliance shall lead to disqualification of the quoted products). 3. Type of Glass material for Oral Syringes/ Syringes must be USP Type 2 or better (Non-compliance or non-provision of C.A. of glass material shall lead to disqualification of the quoted products).				For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender approach not older than twelve (12 months) from Tendering year. Govt. Hospitals, Health related Govt. projects and as per accepted private hospitals of Pakistan.				10 Tender approach: 01 mark 11 Tender approach: 02 marks 16 Tender approach: 03 marks 18 Tender approach: 04 marks 19 or more Tender approach: 05 marks				Note:			
Ref. No. of Item	Generic Name of Item	Storage Form with strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	23	5	5	5	5	3	4	5	5	37	70																																																																		
2	Metronidazole	Tab. 400mg	Arconazole	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
42	Diclofenac Sodium enteric coated	Tab. 50 mg	Volux	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
50	Metformin, Acid	Tab. 500 mg	Arconox	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
52	Meloxicam	Tab. 15 mg	Arconam	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
53	Meloxicam	Tab. 7.5 mg	Arconam	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
60	Paracetamol	Tab. 500 mg	Parasi	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
66	Paracetamol + Dicyclanolate	Tab.450 mg/25 mg	Arconamide	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
67	Paracetamol+ Tramadol	Tab.325mg/37.5 mg	Tramadol P	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
143	Clonazepam	Vaginal tablet with applicator 500mg	Arizole	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
148	Fluconazole	Tab. / Cap. 150 mg	Arconazole	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
164	Cefixime	Tab. 10 mg	Cefrader	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
171	Mometasone	Tab. 10 mg	Mobasone	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
243	Ciprofloxacin	Tab. 250 mg	Ciprovac	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
244	Ciprofloxacin	Tab. 500 mg	Ciprovac	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
264	Doxycycline	Cap. 100 mg	Arconox	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
277	Levofloxacin	Tab. 250 mg	Arconoxone	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
278	Levofloxacin	Tab. 500 mg	Arconoxone	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
288	Moxifloxacin	Tab. 400 mg	Moxifen	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
313	Amoxicillin + Clavulanic acid	Tab. 40 mg/240mg	Amoxoclavin 4.40/240	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
418	Atenolol	Tab. 50 mg	Arconol	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
419	Atenolol	Tab. 100 mg	Arconol	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
460	Lisinopril	Tab. 10 mg	Lisin	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	5	31																																																																		
513	Drospirenone	Tab. 10 mg	Arconmet	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
528	Esomeprazole	Cap. 40mg	Belger	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
532	Pantoprazole	Tab. 40mg	Torazole	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	5	31																																																																		
862	Clonazepam	Cream 1% 50gm	Arconox	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
868	Fusidic acid	Cream 2% 15gm	Arconox	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
877	Lignocaine HCl (Sterile)	Gel 2%	Dosilign	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		
889	Silver Sulfadiazine	Cream 1% 50 gm	Banilin	2	2	3	0	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41																																																																		

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																					
Name of the firm					ARSONS PHARMACEUTICALS, LAHORE																
S.No	Product General Information				Technical Evaluation Matrix																
					Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters						Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score												
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificate Duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 2 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	Ref. No. of item in	Generic Name of Item	Size & Guage of Medical Device	Trade Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
	917	Adhesive Tapes (Paper)	1" x 5yards	Arsopore	3	5	5	4	3	3	2	2	27	5	5	0	0	10	0	20	47
	918	Adhesive Tapes (Paper)	2" x 5yards	Arsopore	3	5	5	4	3	3	2	2	27	5	5	0	0	10	0	20	47
	919	Adhesive Tapes (Paper)	3" x 5yards	Arsopore	3	5	5	4	3	3	2	2	27	5	5	0	0	10	0	20	47
	920	Adhesive Tapes (Paper)	4" x 5yards	Arsopore	3	5	5	4	3	3	2	2	27	5	5	0	0	10	0	20	47
	921	Adhesive Tapes (Plastic)	1" x 10yards	Multipore	3	5	5	4	3	3	2	2	27	5	5	0	0	10	0	20	47
	922	Adhesive Tapes (Plastic)	2" x 10yards	Multipore	3	5	5	4	3	3	2	2	27	5	5	0	0	10	0	20	47
	923	Adhesive Tapes (Plastic)	3" x 10yards	Multipore	3	5	5	4	3	3	2	2	27	5	5	0	0	10	0	20	47
	924	Adhesive Tapes (Plastic)	4" x 10yards	Multipore	3	5	5	4	3	3	2	2	27	5	5	0	0	10	0	20	47

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2025-26																					
Name of Firm				ARSONS PHARMACEUTICALS, LAHORE																	
S. No.	General Product Information				Technical Evaluation Matrix																
					Factory Technical Evaluation Parameters										Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score	
					Documents Based Factory Score						Evaluation visit Score										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	15	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals-05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength/ dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)				
	Ref. No. of item in MCC Formulary	Generic Name of Item	Sizes and specifications	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70	
	979	Crepe Bandage BPC	7.5cmx4.5m	Crepe Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65	
	980	Crepe Bandage BPC	10cmx4.5m	Crepe Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	DTL Substandard	10	55	
	981	Crepe Bandage BPC	15cmx4.5m	Crepe Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	DTL Substandard	10	55	
	1092	Gauze Cloth Roll Packing	100cmx20m	Crepe Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65	
	1093	Gauze Cloth Roll Packing	100cmx40m	Care Guaze	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65	
	1209	Sterile Gauze Dressing Pad (USP/BP/BPC)	Blister pack 10x10 cm, 8 ply	Care Guaze	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65	

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																						
Name of the firm					ARSONS Pharma, Lahore																	
S.No	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	Technical Evaluation Matrix							Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score													
					5	6	7	8	9	10	11	12		13	14	15	16	17	18	19		
	1	2	3	4	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	13	Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	19	20		
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70		
	1296	Zinc oxide adhesive Plaster (Cloth Tape)	2.5 cm x 5m	Zinco	3	5	5	4	5	5	5	5	37	0	0	0	0	Not recommended	0	37		
	1297	Zinc oxide adhesive Plaster (Cloth Tape)	5 cm x 5m	Zinco	3	5	5	4	5	5	5	5	37	0	0	0	0	Not recommended	0	37		
	1298	Zinc oxide adhesive Plaster (Cloth Tape)	7.5 cm x 5m	Zinco	3	5	5	4	5	5	5	5	37	0	0	0	0	Not recommended	0	37		
	1299	Zinc oxide adhesive Plaster (Cloth Tape)	10 cm x 5 m	Zinco	3	5	5	4	5	5	5	5	37	0	0	0	0	Not recommended	0	37		

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																															
S. No.	Name of Firm				ASPIN PHARMACEUTICALS, KARACHI																										
	Product General Information				Factory Technical Evaluation Parameters												Total Factory Evaluated Score	Technical Evaluation Matrix										Product Evaluation Parameters		Total Product Evaluated Score	Total Technical Score
	Documents Based Factory Score												Factory Evaluation Visit Score					Product Technical Parameters													
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26						
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm)	Latest IMS/RQVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/RQVIA, in the following manner: 1. Firms having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th positions shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (both Accelerated and Real Time) as in Schedule B of DRAP	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) as evaluated at the time of inspection by the MCC experts)	Adherence to cGMP guidelines (as in Schedule B of DRAP) as evaluated by the MCC experts	Adequate availability of qualified & relevant Human Resource as per the requirements in schedule-B of DRAP (As evaluated by the MCC experts at the time of inspection).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs (As evaluated by the MCC experts at the time of inspection).	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and /or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and /or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and /or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (a) not older than 24 months shall be considered. In case of purchases through third party importers a valid valid/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration with Form-1 (form of undertaking to accompany (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-DA / EMA / MHRA / TGA / PMDA / Swiss Medec or Health Canada or by regulatory authority/body of SRA country (en) coupled with Form-1 (form of undertaking to accompany (GD) provided in column 18, duly attested by the senior executive of the firm. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it is issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 10 marks. Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Polypropylene, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral-Syringe Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Document duly attested by the Senior executive of the firm).	Stability studies of quoted items duly attested by the Q.C. in-charge of the firm). 1-10% market share = 1 mark 11-20% market share = 2 marks 21-30% market share = 3 marks 31-40% market share = 4 marks 41-50% market share = 5 marks For items specifically used in institutions where IMS/RQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challans, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted items in Pakistan market as per recent most data of IMS/RQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-20% market share = 2 marks 21-30% market share = 3 marks 31-40% market share = 4 marks 41-50% market share = 5 marks For items specifically used in institutions where IMS/RQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challans, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.									
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70						
75	Mebendazole	Tab. 100mg	Vermox	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	2	17	45						
76	Mebendazole	Tab. 500mg	Vermox	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	2	17	45						
77	Mebendazole	Susp. 100mg/5ml, 30 ml	Vermox	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	2	17	45						
152	Itraconazole	Cap. 100 mg	Sporanox	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	1	16	44						
153	Miconazole	Skin Cream 2% 10 gm	Daktarin	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	3	18	46						
154	Miconazole	Vaginal Cream with Applicator 2%	Gyno-Daktarin	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	3	18	46						
155	Miconazole	Oral Gel 2%	Daktarin	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	3	18	46						
513	Domperidone	Tab. 10 mg	Motilium	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	2	17	45						
514	Domperidone	Susp. 5 mg/5ml 120 ml	Motilium	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	2	17	45						
517	Famotidine	Tab. 40 mg	Pepidine	0	2	3	4	5	4	2	2	2	2	2	28	0	0	0	0	0	0	5	0	5	33						
523	Loperamide	Cap. 2mg	Imodium	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	5	20	48						
529	Ondansetron	Tab. 8 mg	Ondaset	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	5	15	43						
545	Chlorpheniramine	Tab. 50 mg	Ovaline	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43						
576	Misoprostol	Tab. 200 mcg	Misart	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43						
586	Tibolone	Tab. 2.5mg	Tibol	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	3	18	46						
897	Chlorthalidone	Gel. 7.1 % w/w 10gm	Sopidyl	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47						
897	Chlorthalidone	Gel. 7.1 % w/w 15 gm	Sopidyl	0	2	3	4	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47						

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																																
Name of Firm					Aster Life Sciences Lahore																											
S. No.	Product General Information				Technical Evaluation Matrix																			Product Evaluated Score	Total Technical Score							
					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation																		
					Principal Manufacturer Evaluation				Importer's Evaluation					Product Technical Parameters												Product Availability						
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23									
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) (duly attested by senior executive of the firm) Online verification link shall be provided	Valid accreditation of manufacturing unit or its relevant sections by the USFDA or WHO or official accreditation body/ies recognized with International Accreditation Forum (IAF) (duly attested by senior executive of the firm)	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm)	Availability of minimum 20% inventory of the total input of the quoted items during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert(s)) Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item(s) / firm)	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (temperature labile drugs) The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non-compliance to GSP, as evaluated by the MCC expert(s) at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacist is compulsory, & relevant Human Resource (If certified by the senior executive of the firm & evaluated / confirmed by MCC expert(s) at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).	13	Bioavailability / Bioequivalence study conducted by WHO Audited Lab must be attached along with the bill and study must be available on WHO Website and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume potential i.e., greater than 100ml up to 5L, product validation report (as per WHO/USFDA/USP guidelines) shall be submitted and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	14	Goods Declaration certificate of imported finished quoted items from Pakistan Customs, compiled with the bill and study must be available on valid away bill or Bill of Lading for the quoted items, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/bulk/DRAP clearance NDC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	15	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in volume 15, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for C&A will not be awarded.	16	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in volume 15, duly attested by the senior executive of the firm. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, C&A, API source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission.	17	Active Pharmaceutical Ingredient (API) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA/ Swiss Medics or Health Canada or by regulatory authority body of SRA country (ies) Trial of principal manufacturer shall be established from the respective GD, C&A and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, C&A, API source accreditation shall be awarded only if it was issued within the last five (05) years from the date of NIT bid submission.	18	Valid WHO prequalification certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA/ Swiss Medics or Health Canada or by regulatory authority body of SRA country (ies) Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. 2 mark for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm)	19	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase For award of marks, the certificate of analysis must clearly mention: 1. Materials (e.g., Aluminum Foil, PVC, Capsule Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class I (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/Suspensions must be USP Type 3 or better (Non-compliance or non-provision of C&A of glass material shall lead to disqualification of the quoted product)	20	Stability studies of quoted items (the firm) Daily attested by the Q/C incharge of the firm) 1.10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/RVIA data is not applicable (the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tender issue Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals-01 mark 04 Tender approvals-02 marks 06 Tender approvals-03 marks 08 Tender approvals-04 marks 10 or more Tender approvals-05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity (procurement agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	21	Availability of quoted items in Pakistan market as per recent most data of IMS/RVIA Health not older than twelve (12) months. 1.10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/RVIA data is not applicable (the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tender issue Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals-01 mark 04 Tender approvals-02 marks 06 Tender approvals-03 marks 08 Tender approvals-04 marks 10 or more Tender approvals-05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity (procurement agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	22	23
	Ref. No. of item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70									
Chun Kun Dung Pharma, Korea	105	Tacrolimus 1mg	Cap 1mg	TacroBell 1mg Capsules	2	2	2	0	5	4	5	5	25	0	5	5	0	0	0	5	0	15	40									
Chun Kun Dung Pharma, Korea	106	Tacrolimus 0.5mg	Cap 0.5mg	TacroBell 0.5mg Capsules	2	2	2	0	5	4	5	5	25	0	5	5	0	0	0	5	0	15	40									
Chun Kun Dung Pharma, Korea	101	Mycophenolate Mofetil	500mg Cap	My-Rept Capsule 500mg	2	2	2	0	5	4	5	5	25	0	5	5	0	0	0	5	0	15	40									
Chun Kun Dung Pharma, Korea	100	Mycophenolate Mofetil	250mg Cap	My-Rept Capsule 250mg	2	2	2	0	5	4	5	5	25	0	5	5	0	0	0	5	0	15	40									
Beijing SL Pharmaceutical Co Ltd China	525	Ocreotide Acetate	Inj. 0.1mg/ml	Asteriotide acetate Injection 0.1mg	2	0	2	0	5	1. Valid Original cGMP of the Principal Manufacturers and Valid Original Free Sale certificates duly attested by the embassy concerned/Apostille for the quoted item/s were present at the time of inspection except BEIJING SL PHARMACEUTICAL CO LTD, CHINA the cGMP for which is expired, on 27.11.2023). Hence, the firm is NOT_RECOMMENDED for the offered product(s) of BEIJING SL PHARMACEUTICAL CO LTD, CHINA			9	0	5	5	0	0	0	5	0	15	24									
LG Chem Ltd, Korea	367	Epoetin-α	Inj. 4000IU	Epoity Prefilled injection 4000IU/0.4ml	0	0	2	0	5	4	5	5	21	0	5	5	0	0	0	5	0	15	36									
LG Chem Ltd, Korea	368	Epoetin-α	Inj. 10000IU	Epoity Prefilled injection 10000IU/0.4ml	0	0	2	0	5	4	5	5	21	0	5	5	0	0	0	5	0	15	36									

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
Name of Firm					ATCO LABORATORIES PVT LTD KARACHI																							
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score					Factory Evaluation Visit Score							Product Evaluation Parameters											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26		
Ref. No. of Item	Generic Name of Item	Dosage form with strength	Trade Name	Valid ISO 18001/45001	Valid ISO 14001	Valid ISO 9001 certificate	about IHS/SPV/IA marking of the loading	Valid calibration certificate for	Valid documents of the Federal Bond	Availability of calibrated	Raw material, In-process and	Adherence to GMP	Adequate availability of	Availability of Functional and	Bioassayable/Bioequivalence study conducted	Crossed Declaration certificate of imported API of	Certificate of Analysis of API	Active Pharmaceutical Ingredients (APIs) source	Valid WHO recognition	Valid Certificate of Analysis of the Type / class of material used for the immediate	Stability studies of quoted item's date	BD Tender approach- 01 mark						
1	87	Paracetamol + Tramadol	Tab 325mg+37.5mg	Chirogenix	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	37	76		
2	109	Thalidomide	Cap. 100mg	Thalibio	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	5	24	52		
3	138	Phaldonime Chloride	Hq. 20mg/ml (10ml)	P-Phaldime	2	2	2	5	0	0	2	2	2	2	2	20	0	0	0	0	4	5	5	14	42			
4	148	Fluconazole	Cap. 150mg	Flucon	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
5	162	Itraconazole	Cap.100mg	Itracon	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
6	158	Terbinafine	Tab. 250mg	Terbisolem Forte	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5		19	47		
7	160	Voriconazole	Tab. 200mg	Voristar	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	0	0	14	42		
8	170	Loratadine	Tab. 10mg	Lidyl	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
9	398	Rivarnaban	Tab. 10mg	Rivarnaban	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5		19	47		
10	406	Acetylsalicylic Acid	Tab. 75 mg	Aspirin	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	2	21	49		
11	414	Amiodipine+Valsartan	Tab.5/ 80mg	Chopix	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
12	415	Amiodipine+Valsartan	Tab. 5/ 160mg	Chopix	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
13	416	Amiodipine+Valsartan	Tab. 10/ 160mg	Chopix	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
14	421	Bisoprostol Fumarate	Tab. 5mg	Bisoprostol	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
15	422	Bisoprostol Fumarate	Tab. 10mg	Bisoprostol	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
16	444	Glyceryl Trinitrate	Tab. 2.8mg	Cardist	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	2	21	49		
17	445	Glyceryl Trinitrate	Tab. 6.4mg	Cardist	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	2	21	49		
18	450	Lisinopril	Tab. 5 mg	Lamis	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
19	460	Lisinopril	Tab. 10 mg	Lamis	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
20	466	Metoprostol	Tab. 25 mg	Metast	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
21	467	Metoprostol	Tab. 50 mg	Metast	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
22	468	Metoprostol	Tab. 100 mg	Metast	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
23	471	Minoxone	Hq. 1mg/ml	Minoxon	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	5	24	52		
24	478	Nitroglycerinine Bitartrate	Hq 1mg/ml (4ml)	Nitro-Adlin	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	2	21	49		
25	477	Phenylephrine	Hq. 10mg	Symplectine	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	2	21	49		
26	482	Pseudovalatin	Tab. 10mg	Pseudoher	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
27	529	Oxandrolon	Tab. 8mg	Oxibio	2	2	2	5	0	0	2	2	2	2	2	20	0	0	0	0	0	4	0	0	4	32		
28	543	Zinc sulphate	Syr. 20mg/ml (60ml)	Zincal OD	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	2	21	49		
29	550	Eripagliflozin	Tab. 10mg	Adiance	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
30	551	Eripagliflozin	Tab. 25mg	Adiance	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
31	583	Sitagliptin + Metformin	Tab. 50mg/500mg	Neoglip	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
32	584	Sitagliptin + Metformin	Tab. 50mg/1000mg	Neoglip	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
33	588	Vildagliptin	Tab. 50mg	Vildip	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
34	751	Phagablin	Cap. 50mg	Synagab	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
35	752	Phagablin	Cap. 75mg	Synagab	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
36	804	Ipratropium Bromide	Isol 250mg/ ml	Isratrop	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
37	830	Dorzolamide + Timolol	Eye Drops 2% + 0.05%	Dorzolam	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
38	837	Moxifloxacin	Eye drops	Oxeln	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
39	848	Tobiramylin	Eye drops 0.3%	Brechi	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
40	850	Tobiramylin+Decasemethasone	Eye drops	Brechi-D	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
41	858	Betamethasone+Gentamycin	Cream	Betapacnic	2	2	2	5	0	0	2	2	2	2	2	20	0	0	0	0	0	4	5	1	10	38		
42	859	Betamethasone+Gentamycin	Ointment	Betapacnic	2	2	2	5	0	0	2	2	2	2	2	20	0	0	0	0	0	4	5	1	10	38		
43	881	Chlrolbasol propionate	Cream 20 gm	Chlrolbasol	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48		
44	888	Fluotetic acid 2%	Cream 2%	Flutib	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47		
45	883	Pharmethrin	Cream 0%	Phalibion	2	2	2	5	0	0	2	2	2	2	2	20	0	5	5	0	0	4	5	2	21	49		

46	884	Pierresbain	Lotion 5%	Sublime	2	2	2	5	0	5	2	2	2	2	2	20	0	5	5	0	0	4	5	2	21	49
47	885	Biotraim +Polymaxim+ B ad. Noo. L&L	Oil	Brush	2	2	2	5	0	5	2	2	2	2	2	20	0	0	0	0	4	0	0	4	50	
48	886	Tarbitraline Hd	Cream 1%	Tubularem	2	2	2	5	0	5	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48
49	888	Tarbitraline Hd	Lotion 1%	Tubularem	2	2	2	5	0	5	2	2	2	2	2	20	0	5	5	0	0	4	5	1	20	48
50	912	Cholecalciferol	Oil	SOAP	2	2	2	5	0	5	2	2	2	2	2	20	0	5	5	0	0	4	5	0	19	47

GRC Decision

The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

43	528	Esomeprazole	Cap. 40mg	Acing		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	4	5	0	9	42
44	517	Paracetamol	Tab. 40 mg	Acton		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
45	555	Glinapiride	Tab. 1mg	Dabold		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
46	556	Glinapiride	Tab. 2mg	Dabold		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
47	557	Glinapiride	Tab. 3mg	Dabold		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
48	558	Glinapiride	Tab. 4mg	Dabold		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
49	559	Glinapiride + Metformin	Tab. 1 mg/500mg	Dabold		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
50	560	Glinapiride + Metformin	Tab. 2 mg/500mg	Dabold		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
51	383	Iron Hydroxide poly maltoose complex	Tab. 100mg	Polyfer		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	5	38
52	387	Iron Sucrose	inj. 30mg/ml 5 ml	Infedra V		2	2	3	5	5	6	2	2	2	2	2	33	0	5	0	0	0	0	5	1	15	48
53	733	Laxetractam	Tab. 250 mg	Barliv		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	5	38
54	734	Laxetractam	Tab. 500mg	Barliv		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	5	38
55	169	Laxoclozine	Tab. 5 mg 30s	laxo		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	5	38
56	276	Laxofloacin	inf. 5 mg/ml 300 ml	Dynaquin		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	5	38
57	277	Laxofloacin	Tab. 250 mg 30s	Dynaquin		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	5	38
58	278	Laxofloacin	Tab. 500 mg 30s	Dynaquin		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	5	38
59	281	Linoxid	Tab. 600mg	Barixid		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
60	282	Linoxid	Isoservan 100mg/ml 300ml	Barixid		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	20	53
61	283	Linoxid	inf. 2 mg/ml 300 ml	Barixid		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
62	463	Luxetan Polaxum	Tab. 50 mg	Barlan		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
63	388	Mecobalamin	inj. 500 mg 1ml	Hyliaven		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	1	10	43
64	285	Mergoveren	inj. 500 mg/5ml	Barjancem	The quoted product is not recommended due to non full filiment of technical evaluation criteria No 22 (40)				5	5	6	2	2	2	2	2	26	0	0	0	0	0	0	5	1	6	32
65	286	Mergoveren	inj. 1gm /5ml	Barjancem					5	5	6	2	2	2	2	2	26	0	0	0	0	0	0	5	1	6	32
66	171	Mestobekant	Tab. 10 mg	Aerobant		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	1	6	39
67	172	Mestobekant	Tab. 5 mg	Aerobant		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	1	6	39
68	173	Mestobekant	inj. 1ml 4 mg	Aerobant		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	1	6	39
69	288	Mexofloacin	Tab. 400 mg	Barivox		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	0	15	48
70	827	Mexofloacin	Eye Drops 0.5% w/v, 5ml	Atosigan		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49
71	57	Mibugloline	inj. 10 mg	Buphoral		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	0	19	52
72	532	Paracetazole	Tab. 40mg	Parapent		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	5	38
73	67	Paracetamol/Tramadol	Tab. 325mg/27,5 mg	Paradol 7 ml		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	5	38
74	533	Phibonglactol + Trimethyl Phibonglactol	Tab. 80 mg + 80 mg	Isosiril		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	2	17	50
75	534	Phibonglactol + Trimethyl Phibonglactol	inj. 40 mg + 100mg 4 ml	Isosiril		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	2	21	54
76	751	Prepagidulin	Cap. 10 mg	Neogalen		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	9	42
77	752	Prepagidulin	Cap. 25mg	Neogalen		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	0	9	42
78	304	Rifaximin	Tab. 200 mg	Rifaxar		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	0	15	48
79	305	Rifaximin	Tab. 550 mg	Rifaxar		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	0	15	48
80	759	Risperidone	Tab. 2mg	Perach		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	1	6	39
81	760	Risperidone	Tab. 4 mg	Perach		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	1	6	39
82	482	Rosuvastatin	Tab. 10 mg	Rosubar		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	1	6	39
83	762	Sertibaine	Tab. 100 mg	Sertol		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	2	17	50
84	583	Sitagliptin + Metformin	Tab. 50 mg/500 mg	z-Glucosin Plus		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	0	15	48
85	584	Sitagliptin + Metformin	Tab. 50mg /500 mg	z-Glucosin Plus		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	0	15	48
86	814	Tarbutalaine Sulphate	Tab. 2.5 mg	Bikanyl		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	5	10	43
87	815	Tarbutalaine Sulphate	inj. 0.3 mg/ml 80ml	Bikanyl		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	5	16	47
88	69	Tizanidine	Tab. 4mg	Tetax		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	1	6	39
89	849	Tobramycin	Eye Drops 0.3% w/v, 5ml	Oxybak		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	1	6	39
90	850	Tobramycin + Dexamethasone	Eye Drops 0.3% +0.2% w/v 5 ml	Zydrastate		2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	0	5	2	7	40
91	70	Tramadol HCl	inj. 50 mg/ml 2ml	Barifal		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	0	19	52
92	542	Zinc Sulphate	inj. 20 mg/5ml 80ml	OrtoZinc		2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	20	53

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																											
B.Braun, Karachi																											
S. No.	Name of Firm				Technical Evaluation Matrix																						
					Principal's and Importer's Evaluation Parameters												Product Technical Evaluation									Product Evaluated Score	Total Technical Score
																	Product Technical Parameters										
	Product General Information				Principal Manufacturer Evaluation				Importer's Evaluation				Suppliers Technical Score				Product Availability										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23				
				Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.			
				Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.			
				Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.	Valid WHO pre-qualified certificate of the facility where the general product is manufactured issued by the competent authority of the country of origin. The facility shall be accredited with International Pharmaceutical Association (IPA) standards by a member government of the facility.			

Ref. No. of Item in MCC Schedule	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	2	5	5	4	5	5	5	20	5	5	5	6	4	5	5	40	70	
29	Propofol 1MTC/LCT for anesthesia	90, 150mg/ml, 200ml	Propofol 1gm/100	2	2	2	0	5	0	4	5	0	4	5	5	20	0	5	5	5	0	21	44
630	Antonie Acids Solution	500, 100, 500 ml	Antropiponal 10% L	2	2	2	0	5	0	4	5	0	4	5	5	20	0	5	5	5	0	21	44
630	Antonie Acids Solution	500, 100, 500 ml	Antropiponal 10% L	2	2	2	0	5	0	4	5	0	4	5	5	20	0	5	5	5	0	19	42
631	Subcutaneous electrolyte solution	100 ml, 500 ml	Isotonic 100	2	2	2	0	5	0	4	5	0	4	5	5	20	0	5	5	5	0	21	44
646	Subcutaneous Polypropylene	100 ml, 400, 500 ml	Subcutaneous	2	2	2	0	5	0	4	5	0	4	5	5	20	0	5	5	5	0	19	42
652	Liquid Emulsion	100 ml, 200, 250 ml	Emulsion	2	2	2	0	5	0	4	5	0	4	5	5	20	0	5	5	5	0	21	44

				Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26							
Name of the firm B-BRAUN, KARACHI											
S. No.	Technical Evaluation Matrix										
	Product General Parameter			Product Technical Evaluation						Product Evaluated Score	Total Technical Score
	1	2	3	12	13	14	15	16	17	18	20
				Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attasted by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only.(verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	Ref. No. of	Generic Name of Item	Size, Gauge, etc. of	5	5	5	6	10	10	41	70
1	1116.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G	5	5	0	2	10	10	32	56
2	1118.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G	5	5	0	2	10	10	32	56
3	1120.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G	5	5	0	2	DTL Substandard	10	22	46
4	1123.	I.V Cannula (Sterile having wings with heparin stopper inside sterilized blister packing. The cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G	5	5	0	2	10	10	32	56

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																	
Name of the firm					B-BRAUN, KARACHI																	
					Technical Evaluation Matrix																	
					Principal's and Importer's Evaluation Parameters						Product Technical Evaluation									Product Evaluated Score	Total Technical Score	
					Principal Manufacturer Evaluation			Importer's Evaluation														Suppliers Technical Score
1	2		3	4	5	6	7	8	9	10	11	12	13	14		15	16		17	18	19	
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item		Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of	Goods Declaration certificate of imported		Certificate of Analysis	Tender Approvals (not older than twelve 12 months)		Valid WHO prequalification	CE mark/Quality assurance certificate/Quality		Physical examination	Evaluated	Technical
						3	5	5	5	6	6	30	5	5	5		3	6		16	40	70
1	1037.	Disposable Sterile Spinal Needle		18 G	Spinocan	3	5	0	5	6	6	25	5	5	0		0	2		16	28	53
2	1039.	Disposable Sterile Spinal Needle		20 G	Spinocan	3	5	0	5	6	6	25	5	5	0		0	2		16	28	53
3	1040.	Disposable Sterile Spinal Needle		22 G	Spinocan	3	5	0	5	6	6	25	5	5	0		0	2		16	28	53
4	1041.	Disposable Sterile Spinal Needle		23 G	Spinocan	3	5	0	5	6	6	25	5	5	0		0	2		16	28	53
5	1042.	Disposable Sterile Spinal Needle		25 G	Spinocan	3	5	0	5	6	6	25	5	5	0		0	2		16	28	53
6	1043.	Disposable Sterile Spinal Needle		27 G	Spinocan	3	5	0	5	6	6	25	5	5	0		0	2		16	28	53

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																											
S. No.				Name of Firm				BF BIOSCIENCES PVT LTD																				Total Product Evaluated Score		Total Technical Score																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																													
								Technical Evaluation Matrix																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
								Product Evaluation Parameters																Total Factory Evaluated Score																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
																									Factory Technical Evaluation Parameters																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		
Product General Information				Documents Based Factory Score																Factory Evaluation Visit Score																Total Factory Evaluated Score	Product Technical Parameters																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		
				Valid ISO 18001:2015 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 18001:2015 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001:2015 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Latest DMS/DQA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by DMS/DQA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 2 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificate for equipment / instruments used in the factory for Measuring, weighing, Assay Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all lab + Functional Stability Chamber (Both Accelerated and Real Time) in Schedule-B of DRAP) (Evaluated at the time of inspection by the MCC experts, no non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, its process and finished goods storage in its Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts). Non-compliance adherence to GMP shall lead to disqualification of the section/s or firm.	Adherence to cGMP guidelines, for in-Schedule-B Resource as per DRAP) (as evaluated at the time of inspection by the MCC experts). (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection). Non-compliance adherence to cGMP guidelines shall lead to disqualification of the section/s or firm.	Adequate availability of qualified / relevant Human Resource as per DRAP) (as evaluated at the time of inspection by the MCC experts). (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection). Non-compliance adherence to cGMP guidelines shall lead to disqualification of the section/s or firm.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. As evaluated by the MCC experts at the time of inspection).	Bio-availability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter, and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. Moreover, in case of product/agent from having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In case of purchases through third party importers a valid health/DRA/F clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product for Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. Moreover, in case of product/agent from having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In case of purchases through third party importers a valid health/DRA/F clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product for Govt. MCC	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / TGA / PMDA/ Swiss Medico or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (Form of undertaking to accompany GD) provided in column 18, duly attested by the senior executive of the firm. Moreover, in case of product/agent from having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In case of purchases through third party importers a valid health/DRA/F clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product for Govt. MCC	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type -1 class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral/Syringe/Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Class 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (0). (Document duly attested by the Senior executive of the firm).	Stability studies of quoted items duly attested by the Q.C. in-charge of the firm) For items specifically used in institutions where DMS/DQA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 03 marks 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challans, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted items in Pakistan market as per recent most date of DMS/DQA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where DMS/DQA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 03 marks 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challans, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Ref. No. of Item				Generic Name of Item				Dosage Form with Strength				Trade Name																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															
								2				2				3				5								6				2				2				2				2				2				33				3				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5				5			

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																
S. No.	Name of Firm				Bio Labs Islamabad																											
	Product General Information				Technical Evaluation Matrix																Product Evaluation Parameters				Total Product Evaluated Score	Total Technical Score						
					Factory Technical Evaluation Parameters										Total Factory Evaluated Score		Product Technical Parameters															
					Documents Based Factory Score					Factory Evaluation Visit Score																						
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26						
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan - (12 months to date ranking will be considered). Online verification link shall be provided	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks. (The document shall be attested by a Senior	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP) (If evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts) Non-adherence to GSP shall lead to disqualification of the firm.	Adherence to cGMP guidelines, (as in Schedule-B of DRAP) in a area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section's or firm).	Adequate availability of qualified & relevant Human Resource as per requirements mentioned in schedule-B of DRAP (As evaluated by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section's or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system shall lead to Disqualification of the relevant section / firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO (Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume potential i.e. greater than 100lit up to 1L, product validation report (as per WHO/US	Goods Declaration certificate of imported API of the quoted item(s) as mentioned in the goods declaration (GDD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GDD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / USFDA / EMA / MIRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, API source accreditation shall be awarded only where these documents are submitted for the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter head shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certification for the same brand shall	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Use of Glass material	Stability studies of quoted items duly attested by the Q.C. (exchange of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the holder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or RCI accredited private hospitals of Pakistan.	Availability of quoted items in Pakistani market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the holder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or RCI accredited private hospitals of Pakistan.										
Ref. No. of Item	Generic Name of Item			Dosage Form with Strength	Trade Name																											
					2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70						
1	4	Mefenamic Acid	Inf. 500mg, 100 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	0	0	0	0	4	5	0	9	40						
2	48	Ketorolac	Inf. 30 mg/ml 1ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
3	57	Naloxophene	Inf. 10 mg		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	1	16	47						
4	64	Paracetamol	Inf. 1000 mg 100ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	2	5	0	17	48						
5	70	Tramadol HCl	Inf. 50 mg/ml,2ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
6	77	Mefenamic Acid	Susp. 100mg/5ml, 30 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
7	159	Venizomane	Inf. 200 mg		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	19	50						
8	160	Venizomane	Tab. 200 mg		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50						
9	171	Morphine	Tab. 10 mg		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50						
10	172	Morphine	Tab. 5 mg		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50						
11	217	Cefixime	Cap. 400 mg 5s		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50						
12	218	Cefixime	Dry Susp. 100 mg/5ml 30ml		2	2	3	3	5	6	2	2	2	2	2	31	0	0	0	0	0	0	5	0	5	36						
13	219	Cefixime	Dry Susp. 200 mg/5ml 30ml		2	2	3	3	5	6	2	2	2	2	2	31	0	0	0	0	0	0	5	0	5	36						
14	220	Cefepime + Sulbactam	Inf. 1gm/Vial		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
15	221	Cefepime + Sulbactam	Inf. 2 gm/Vial		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
16	230	Cefixime	Inf. 500 mg/Vial		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
17	231	Cefixime	Inf. 1gm/Vial		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
18	232	Cefixime	Inf. 2 gm/Vial		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
19	256	Cefazolin Sodium	Inf. 2 MR/Vial		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
20	307	Erythromycin	Inf. 50 mg /Vial		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	2	5	0	17	48						
21	308	Vancomycin	Inf. 1gm/Vial		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	2	5	0	17	48						
22	309	Vancomycin	Inf. 500 mg/Vial		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	2	5	0	17	48						
23	387	Insulin	Inf. 20 mg/ml 5 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	2	5	0	17	48						
24	400	Tramexic Acid	Inf. 250 mg 5 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
25	401	Tramexic Acid	Inf. 500 mg 5 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	0	0	0	0	0	5	0	5	36						
26	524	Mesolopramide HCl	Inf. 5mg/ml 2ml		2	2	3	3	5	6	2	2	2	2	2	31	0	0	0	0	0	0	5	0	5	36						
27	526	Omeprazole	Inf. 40 mg / Vial		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
28	527	Omeprazole	Cap. 40 mg		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
29	528	Esomeprazole	Cap. 40mg		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46						
30	529	Ondansetron	Tab. 8 mg		2	2	3	3	5	6	2	2	2	2	2	31	0	0	0	0	0	0	5	0	5	36						
31	530	Ondansetron	Inf. 2 mg/ml 4 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	0	0	0	0	0	5	0	5	36						

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																								
Name of the firm				BLUE BIRDS, ISLAMABAD																				
S.No	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	Technical Evaluation Matrix							Product Evaluated Score	Total Technical Score		
					Documents Based Factory Score				Evaluation Visit Score															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20				
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s shall lead to disqualification of the said item/s.							
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70				
1	965	Cord Clamp		Mediplus	0	0	0	0	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. Anhui Kangning Industrial (Group) Co., Ltd. China: The description of quoted items is not mentioned in the Agency agreement. Valid Original free sale certificate of the quoted items duly attested by the Embassy concerned was present at the time of inspection. The EC Full quality assurance issued by UDEM Turkey duly attested by the embassy concerned was present which stand expired on 23-04-2024, however, Confirmation letter issued by UDEM CROATIA was presented in accordance with section 08(vi) of the Bid Form 1 in the approved BSDs FY 2025-26. 2. Jiangsu Website Medical Product Co., Ltd., China: Valid Original free sale certificates, EC certificate and Agency agreement of the quoted items duly attested by the Embassy concerned were not present at the time of inspection. 3. Tanchang City Anrui Medical Equipmens CO., Ltd China: Valid Original free sale certificates, EC certificate and Agency agreement of the quoted items duly attested by the Embassy concerned were not present at the time of inspection. 4. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were not satisfactory/present.				0	0	0	0	0	0	0	0	0	0		
2	1045	Disposable Dignity Sheet having super absorbency		Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
3	1046	Disposable Gown as per WHO or equivalent standard		Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
4	1048	Disposable Sterile Latex Surgical Gloves (Powdered)	6.5, 7.0, 7.5, 8.0, 8.5	Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
5	1052	Disposable Non-Sterile Latex Examination Gloves (Powdered)		Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
6	1055	Disposable Non-sterile Polyethylene Gloves		Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
7	1063	Disposable OT Cap		Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
8	1064	Disposable OT Drapes		Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
9	1140	Medical Shoe Cover (Disposable)		Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
10	1141	Disposable Face Mask		Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
11	1148	Nebulizer mask with chamber and tubing	Peadiatric	Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
12	1149	Nebulzer mask with chamber and tubing	Adult	Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
13	1164	Oxygen Mask	Adult	Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
14	1165	Oxygen Mask	Peadiatric	Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10
15	1279	Urine bag with let	2000 ml	Mediplus	0	0	0	0					0	0	0	0	0	0	0	0	0	10	10	10

GRC Decision

The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

					Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																		
Name of the firm					BN Trading Company,Peshawar																		
S. No.	Product General Parameter				Technical Evaluation Matrix																		
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							Product Evaluated Score	Total Technical Score			
	Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score																
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20					
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US- FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with the relevant standards shall lead to Disqualification of the quoted products) Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.								
	Ref. No.	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70				
industrial group co ltd China	1309	17mm, 1/2 circle round bodied taper point needle, strand length 75cm	4/0	Best Life Silk Braided	0	0	0	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. Anhui Kangning Industrial (Group) Co., Ltd. China: The description of quoted items is not mentioned in the Agency agreement. Valid Original free sale certificate of the quoted items duly attested by the Embassy concerned was present at the time of inspection. The EC Full quality assurance issued by UDEM Turkey duly attested by the embassy concerned was present which stand expired on 23-04-2024, however, Confirmation letter issued by UDEM CROATIA was presented in accordance with section 08(vi) of the Bid Form 1 in the approved BSDs FY 2025-26. 2. Jiangsu Website Medical Product Co., Ltd., China: Valid Original free				0	0	0	0	0	0	0	0	10	0	10	10
industrial group co ltd China	1310	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	3/0	Best Life Silk Braided	0	0	0					0	0	0	0	10	0	10	10				
industrial group co ltd China	1311	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	3/0	Best Life Silk Braided	0	0	0					0	0	0	0	10	0	10	10				
industrial group co ltd China	1312	26mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm	3/0	Best Life Silk Braided	0	0	0					0	0	0	0	10	0	10	10				
industrial group co ltd China	1313	17mm, 1/2 circle round bodied taper point needle, Strand length 75cm	3/0	Best Life Silk Braided	0	0	0					0	0	0	0	10	0	10	10				
industrial group co ltd China	1314	31mm, 1/2 circle round bodied, taper point needle, Strand length 75cm	2/0	Best Life Silk Braided	0	0	0					0	0	0	0	10	0	10	10				
industrial group co ltd China	1315	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	2/0	Best Life Silk Braided	0	0	0					0	0	0	0	10	0	10	10				
industrial group co ltd China	1317	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1	Best Life Silk Braided	0	0	0					0	0	0	0	10	0	10	10				
industrial group co ltd China	1318	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1	Best Life Silk Braided	0	0	0					0	0	0	0	10	0	10	10				
industrial group co ltd China	1319	40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	1	Best Life Silk Braided	0	0	0					0	0	0	0	10	0	10	10				
industrial group co ltd China	1320	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	2	Best Life Silk Braided	0	0	0					0	0	0	0	10	0	10	10				
industrial group co ltd China	1346	17mm, 1/2 circle round bodied taper point needle, Strand length 70cm	5/0	Best Life PGA	0	0	0					0	5	5	0	0	0	10	10				
industrial group co ltd China	1347	17mm, 1/2 circle round bodied needle, Strand length 75cm	4/0	Best Life PGA	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1348	22mm, 1/2 circle round bodied taper point needle, Strand length 75cm	4/0	Best Life PGA	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1349	22mm, 1/2 circle round bodied taper point, strand length 75 cm	3/0	Best Life PGA	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1350	25mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0	Best Life PGA	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1351	30mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0	Best Life PGA	0	0	0					0	5	5	0	0	0	10	10				
industrial group co ltd China	1352	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	0	Best Life PGA	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1353	30mm, 1/2 circle round bodied taper point needle, strand length 75 cm	1	Best Life PGA	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1354	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	1	Best Life PGA	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1355	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	2	Best Life PGA	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1356	48mm, 1/2 circle round bodied taper point needle, strand length 75 cm	2	Best Life PGA	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1362	12mm, 3/8 circle reverse cutting needle, strand length 60cm	6/0	Best Life Polypropylene	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1363	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	6/0	Best Life Polypropylene	0	0	0					0	5	5	0	10	0	20	20				
industrial group co ltd China	1364	13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	6/0	Best Life Polypropylene	0	0	0					0	5	5	0	10	0	20	20				

industrial group co ltd China	1365	16mm, 3/8 circle curved cutting needle, strand length 90cm	6/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1366	13mm, 1/2 circle round bodied taper point double armed needle, strand length 45cm	5/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1367	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	5/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1368	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	4/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1369	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	4/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1370	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	3/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1371	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	3/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1372	30 mm, 1/2 circle round bodied taper point double armed needle, strand length 40cm	3/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1373	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1374	26mm, 3/8 circle reverse cutting needle, strand length 45cm	2/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1375	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	2/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1376	26mm, 1/2 circle round bodied taper cut double armed needle, strand length 75cm	2/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1377	50mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1378	55mm, straight cutting needle, strand length 75cm	2/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1379	60mm, straight cutting needle, strand length 75cm	2/0	Best Life Polypropylene	0	0	0
industrial group co ltd China	1381	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1	Best Life Polypropylene	0	0	0
Medical Product, China	917	Adhesive Tapes (Paper)	1" x 5yards	Best Life Non-Woven Paper Tapes	0	0	0
Medical Product, China	918	Adhesive Tapes (Paper)	2" x 5yards	Best Life Non-Woven Paper Tapes	0	0	0
Medical Product, China	919	Adhesive Tapes (Paper)	3" x 5yards	Best Life Non-Woven Paper Tapes	0	0	0
Medical Product, China	920	Adhesive Tapes (Paper)	4" x 5yards	Best Life Non-Woven Paper Tapes	0	0	0
Medical Product, China	921	Adhesive Tapes (Plastic)	1" x 10yards	Best Life Non-Woven PE Tapes	0	0	0
Medical Product, China	922	Adhesive Tapes (Plastic)	2" x 10yards	Best Life Non-Woven PE Tapes	0	0	0
Medical Product, China	923	Adhesive Tapes (Plastic)	3" x 10yards	Best Life Non-Woven PE Tapes	0	0	0
Medical Product, China	924	Adhesive Tapes (Plastic)	4" x 10yards	Best Life Non-Woven PE Tapes	0	0	0
industrial group co ltd China	1112	I/V fluid administration set		Best Life	0	0	0
industrial group co ltd China	1113	I/V fluid administration set with additional "Y" injection port		Best Life	0	0	0

sale certificates, EC certificate and Agency agreement of the quoted items duly attested by the Embassy concerned were not present at the time of inspection.

3. Tanchang City Anrui Medical Equipmens CO., Ltd China: Valid Original free sale certificates, EC certificate and Agency agreement of the quoted items duly attested by the Embassy concerned were not present at the time of inspection.

4. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were not satisfactory/present.

In view of the above the firm is NOT RECOMMENDED.

0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	5	5	0	0	10	0	20	20
0	0	0	0	0	10	0	10	10
0	0	0	0	0	10	0	10	10
0	0	0	0	0	10	0	10	10
0	0	0	0	0	10	0	10	10
0	0	0	0	0	10	0	10	10
0	0	0	0	0	10	0	10	10
0	0	0	0	0	10	0	10	10
0	5	5	0	0	0	0	10	10
0	0	0	0	0	10	0	10	10

GRC Decision

The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																	
Name of the firm					BN Trading Company,Peshawar																	
					Technical Evaluation Matrix																	
					Principal's and Importer's Evaluation Parameters						Product Technical Evaluation										Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19			
					Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of qualified & relevant Human		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical			
S. No.	Ref. No. of Item In MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	6	6	30	5	5	5	3	6	16	40	70			
Tianchang City Anrui Medical Equipments China	1048	Disposable Sterile Latex Surgical Gloves (Powdered)	6.5, 7.0, 7.5, 8.0	Best Life Latex Powdered Gloves	0	5	0	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. Anhui Kangning Industrial (Group) Co., Ltd. China: The description of quoted items is not mentioned in the Agency agreement. Valid Original free sale certificate of the quoted items duly attested by the Embassy concerned was present at the time of inspection. The EC Full quality assurance issued by UDEM Turkey duly attested by the embassy concerned was present which stand expired on 23-04-2024, however, Confirmation letter issued by UDEM CROATIA was presented in accordance with section 08(vi) of the Bid Form 1 in the approved BSDs FY 2025-26. 2. Jiangsu Website Medical Product Co., Ltd., China: Valid Original free sale certificates, EC certificate and Agency agreement of the quoted items duly attested by the Embassy concerned were not present at the time of inspection. 3. Tianchang City Anrui Medical Equipments CO., Ltd China: Valid Original free sale certificates, EC certificate and Agency agreement of the quoted items duly attested by the Embassy concerned were not present at the time of inspection. 4. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were not satisfactory/present. In view of the above the firm is NOT RECOMMENDED.			5	0	0	0	0	0	0	0	0	5		

GRC Decision

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																													
Name of Firm					BOSCH PHARMACEUTICALS PVT LTD KARACHI																								
S. No.	Product General Information				Technical Evaluation Matrix																							Total Product Evaluated Score	Total Technical Score
					Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Evaluation Parameters													
																Product Technical Parameters													
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26			
					Valid ISO 18001:45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMSRQVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMSRQVIA in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted item and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) in Schedule B of DRAP (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts)	Adherence to cGMP guidelines, (as in Schedule-B of DRAP) in area / section of the quoted product (s) Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs (As evaluated by the MCC experts at the time of inspection).	Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firms.	Bio-availability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-warranty certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)	Goods Declaration certificate of imported API of the quoted item from Pakistan Customs, completed with valid entry bill or Bill of Lading for the quoted item, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/bill,DRAP clearance NOC between the principal manufacturer and the importer from shall be	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US FDA / EMA / MHRA / TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) (maximum of 03 marks). Certificates on company's own letter heads shall not be acceptable. 10 copies of relevant certificates duly attested by the senior executive of the firm	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item, as issued by the manufacturer of the material coupled with Invoice/proof of purchase For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminum Foil, PVC, Capsule Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. Note: Valid Certificates for the same brand shall be	Stability studies of quoted item's duly attested by the Q.C. incharge of the firm).	Availability of quoted items in Pakistan market as per recent most data of IMSRQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMSRQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan.					
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70			
1	57	Nalbuphine	Inj. 10 mg	Bunall	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			
2	64	Paracetamol	Inf. 1000 mg/100 ml	Bofalgan	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			
3	178	Amikacin Sulphate	Inj. 250 mg	Amkay	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	2	26	59			
4	179	Amikacin Sulphate	Inj. 500 mg	Amkay	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	2	26	59			
5	188	Amoxycillin+Clavulanic Acid	Tab. 625 mg	Calamox	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54			
6	189	Amoxycillin+Clavulanic Acid	Tab. 1 gm	Calamox	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54			
7	190	Amoxycillin+Clavulanic Acid	Susp. 125mg +31.5mg/5ml (90ml)	Calamox	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54			
8	192	Amoxycillin+Clavulanic Acid	Susp. 250mg + 62.5mg/5ml (90ml)	Calamox DS	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54			
9	193	Amoxycillin+Clavulanic Acid	Inj. 500+100mg/Vial	Calamox	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54			
10	194	Amoxycillin+Clavulanic Acid	Inj. 1000+200mg/Vial	Calamox	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54			
11	202	Azithromycin	Cap. 250mg	Zezot	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			
12	203	Azithromycin	Tab. 500mg	Zezot	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			
13	204	Azithromycin	Inj. 500mg/Vial	Zezot	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			
14	215	Cefepime	Inj. 500mg/Vial	Nuxipim	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52			
15	216	Cefepime	Inj. 1gm/Vial	Nuxipim	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52			
16	220	Cefoperazone + Sulbactam	Inj. 1gm/Vial	Cebac	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52			
17	221	Cefoperazone + Sulbactam	Inj. 2gm/Vial	Cebac	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52			
18	231	Ceftriaxone	Inj. 1gm/Vial	Cefxone	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			
19	232	Ceftriaxone	Inj. 2gm/Vial	Cefxone	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			
20	245	Ciprofloxacin	Inf. 200mg/100ml	Quinolox	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			
21	273	Imipenem+Clasztatin	Inj. 500+500 mg/Vial	Cilapen	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			
22	284	Linezolid	Inf. 2 mg/ml (300ml)	Zolrest	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			
23	285	Meropenem	Inj. 500mg/Vial	Penro	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	2	26	59			
24	286	Meropenem	Inj. 1 gm/Vial	Penro	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	2	26	59			
25	289	Moxifloxacin	Inf. 400mg/250ml	Itzilion	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52			
26	292	Piperacillin+Tazobactam	Inj. 2gm+0.25gm (2.25 gm) Vial	Tanzo	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	1	25	58			
27	293	Piperacillin+Tazobactam	Inj. 4gm+0.5gm (4.5gm)/Vial	Tanzo	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	2	5	1	23	56			
28	307	Tigecycline	Inj. 50 mg/Vial	B Tig	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53			

29	308	Vancomycin	inj.500 mg/Vial	Vinjec	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
30	309	Vancomycin	inj.1 gm/Vial	Vinjec	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
31	526	Omeprazole	inj.40mg/Vial	Omezol	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																						
Name of the firm					BQ PHARMA PESHAWAR																	
S.No	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	Technical Evaluation Matrix							Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score													
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s. In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates)					
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70		
1	945	Blood Collection Tubes (Purple Top)	5 ml	Vacutube	3	5	5	0	The firm was inspected as per technical evaluation criteria. The firm complied with the physical inspection criteria/checklist; however, the mandatory cGMP of the firm was expired 17-08-2024 and cGMP inspection report was not present at the time of inspection. The firm is NOT RECOMMENDED.				13	5	0	0	0	10	15	28		
2	945	Blood Collection Tubes (Purple Top)	3 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
3	946	Blood Collection Tubes (Red Top)	5 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
4	946	Blood Collection Tubes (Red Top)	3 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
5	946	Blood Collection Tubes (Red Top)	5 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
6	946	Blood Collection Tubes (Red Top)	3 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
7	948	Blood Collection Tubes (Green Top)	5 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
8	948	Blood Collection Tubes (Green Top)	3 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
9	949	Blood Collection Tubes (Yellow Top)	5 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
10	949	Blood Collection Tubes (Yellow Top)	3 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
11	950	Blood Collection Tubes (Blue Top)	5 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
12	950	Blood Collection Tubes (Blue Top)	3 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
13	950	Blood Collection Tubes (Blue Top)	2 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
14	950	Blood Collection Tubes (Blue Top)	1.8 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		
15	951	Blood Collection Tubes (Grey Top)	3 ml	Vacutube	3	5	5	0					13	5	0	0	0	10	15	28		

GRC Decision

The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
Name of Firm				Brookes Pharma Karachi																								
S. No.	Product General Information				Technical Evaluation Matrix																Total Product Evaluated Score	Total Technical Score						
					Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Evaluation Parameters												
					Documents Based Factory Score					Factory Evaluation Visit Score						Product Technical Parameters												
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26		
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 4 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks. (The document shall be attested by a Senior	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts) Non-adherence to cGMP guidelines shall lead to disqualification of the section/s or firm.	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e. greater than 100ml up to 5L, product validation report (as per WHO/US		Goods Declaration certificate of imported API of the quoted item(s) from Pakistan Customs, coupled with valid invoice bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MIRA/ TGA/ PMDA/ Swiss Medc or Health Canada or by regulatory authority/body of SRAs country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs(components of the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type/ class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. Note: Valid Certificates for the same brand shall be of Type of Glass material	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted items in Pakistan market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.				
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70		
	10	Atracurium	Inj. 10mg/ml	Acuron	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50		
	11	Atracurium	Inj. 10mg/ml, 5ml	Acuron	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50		
	12	Bupivacaine	Inj. 5mg/ml, 10ml	Sensocain	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
	13	Bupivacaine Spinal	Inj. 7.5mg/ml, 2ml	Sensocain	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
	14	Cis-Atracurium	Inj. 2mg/ml, 5ml	Cis-curon	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
	15	Dexmedetomidine	Inj. 0.1mg/ml, 2ml	Precitex	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50		
	16	Glycopyrolate + Neostigmine	Inj. 0.5mg+2.5mg, 1ml	neo-pyrilate	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50		
	17	Glycopyrolate	Inj. 0.2 mg/ml, 1ml	Pyrolate	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	5	0	4	5	1	25	55		
	30	Rocuronium	Inj. 10 mg/ml, 5 ml	Rocuron	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
	57	Nalbuphine	Inj. 10 mg	Sonotic	2	2	3	2	5	6	2	2	2	2	2	30	0	0	0	0	0	4	5	0	9	39		
	64	Paracetamol	Inf.1000 mg 100ml	Bramol	2	2	3	2	5	6	2	2	2	2	2	30		5	5		0	2	5	0	17	47		
	70	Tramadol HCl	Inj. 50 mg/ml,2ml	Lamadol	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
	231	Ceftriaxone	Inj. 1gm/Vial	Ryxon	2	2	3	2	5	6	2	2	2	2	2	30	0	The quoted item is not recommended due to non full filment of technical evaluation criterion No: 22(4)(C)				0	5	0	5	35		
	547	Dexamethasone	Inj. 4 mg/ml 1ml	Decort	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5		0	0	4	5	0	19	49	
	894	Tetrachlorodecaoxide	Soln. 0.052 mg/ 5ml 50ml	Oxoferin	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	0	0	0	5	0	15	45		
	903	Povidone Iodine	Soln. 10% 450 ml	Pyodine	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	5	1	0	5	5	26	56		
	904	Povidone Iodine	Scrub 7.5% w/w 450 ml	Pyodine	2	2	3	2	5	6	2	2	2	2	2	30	0	5	5	5	1	0	5	5	26	56		

Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																								
Name of the firm					Care & Cure International, Rahim Yar Khan																			
S. No.	Product General Parameter				Principal's and Importer's Evaluation Parameters							Technical Evaluation Matrix										Product Evaluated Score	Total Technical Score	
					Principal Manufacturer Evaluation			Importer's Evaluation				Suppliers Technical Score	Product Technical Evaluation											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20					
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section's by the U.S-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP.	Adequate availability of qualified, (Presence of Category-A Pharmacists is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).	In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certified duly attested by senior executive of the firm)	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certified duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K)/ US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Physical examination of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.							
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70					
Shandong Chengwu Medical Products Factory China	1112	I/V fluid administration set		Cure	The firm is not recommended due to non full filment of ITB 25.4(h), SCC 5 (8.1)(i)(b)(c)(d) Section -V(1)(D) of the advetised criteria of the approved BSDs, of the Govt. MCC FY 2025-26.							0	0	0	0	0	10	10	20	20				
Shandong Chengwu Medical Products Factory China	1113	I/V fluid administration set with additional "Y" injection port		Cure								0	0	0	0	0	10	10	20	20				

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																	
Name of the firm					Care & Cure International, Rahim Yar Khan																	
					Technical Evaluation Matrix																	
					Principal's and Importer's Evaluation Parameters									Product Technical Evaluation							Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19			
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of qualified &		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical			
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70			
Yangzhou Goldenwell Medical Devices Factory China	965	Cord Clamp		Cure	0	0	0	The firm is not recommended due to non full filment of ITB 25.4(h), SCC 5 (8.1)(b)(c)(d) Section -V(1)(D) of the advetised criteria of the approved BSDs, of the Govt. MCC FY 2025-26.				0	0	0	0	0	16	16	16			
Yangzhou Goldenwell Medical Devices Factory China	1279	Urine bag with let	2000 ml	Cure	0	5	0					5	0	0	0	0	16	16	21			
Anhui Anyu Latex Products., Ltd,China	1047	Disposable Sterile Latex Surgical Gloves (Powder Free)	6.5, 7.0, 7.5, 8.0,	Cure	0	5	0					5	5	0	0	0	16	21	26			
Anhui Anyu Latex Products., Ltd,China	1048	Disposable Sterile Latex Surgical Gloves (Powdered)	6.5, 7.0, 7.5, 8.0,	Cure	0	5	0					5	5	0	0	0	16	21	26			
Shandong Chengwu Medical Products Factory China	1126	Infusion Chamber (Burette Type) Sterile, Disposable	100 ml	Cure	0	5	0					5	0	0	0	0	16	16	21			

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																				
Name of Firm				CCL PHARMACEUTICALS PVT LTD LAHORE																																
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score								
					Documents Based Factory Score						Factory Evaluation Visit Score						Product Evaluation Parameters																			
																	Product Technical Parameters																			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26										
					Valid ISO 18001:45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/IOVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered)	Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IOVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm.)	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs - Functional Stability Chamber (Both Accelerated and Real Time) (as in Schedule II of DRAP) (Evaluated at the time of inspection by the MCC experts, a non-availability or non-functioning of facility chambers and/or non-adherence to GLP as per schedule-II shall lead to disqualification of the firm).	Raw material, in-process and GMP Finished good storage in the warehouse as in Schedule II of DRAP (as evaluated at the time of inspection by the MCC experts).	Adherence to GMP Schedule-II of DRAP (as evaluated at the time of inspection by the MCC experts).	Adequate availability of qualified & relevant Human Resource as per requirements mentioned in schedule-II of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-compliance to cGMP guidelines and/or non-adherence to GMP shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC, inventory log with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).	Availability of Functional and validated HVAC, inventory log with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).	17	Bioavailability/Bioequivalence study conducted by WHO Androed Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or (Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)) In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	18	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, and / or Residence not more than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (if not older than 24 months shall be considered).	19	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GDI) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GDI the marks for C&A will not be awarded.	20	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / TGA / PMDA / Swiss Made or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form 1 (Item of undertaking to accompany in application for License to import Drugs) Moreover, in case of products/quoted items having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only when these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission.	21	Valid WHO prequalification and / or Valid product registration in SRA country(ies) Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	22	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/poof of purchase. For award of marks, the certificate of analysis must clearly mention: a. Materials e.g., Aluminium Foil, PVC, Capable Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, must clearly mention that the material is of a Pharmaceutical grade. b. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). c. Type of Glass material for Oral-Syringe Suspension must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables: a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Class 2 marks will be awarded. c. For products where USP Type 2 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). Document duly attested by the Senior executive of the firm).	23	Stability studies of quoted items duly attested by the Q.C. (In-charges of the firm)	24	Availability of quoted items in Pakistan market as per recent most data of IMS/IOVIA Health not older than twelve (12) months. 1-10% market share = 2 marks 11-30% market share = 3 marks 30% and above market share = 5 marks For items specifically used in institutions where IMS/IOVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months from Teritary care Govt. Hospitals, Health related Govt. projects and or JCI accredited private hospitals of Pakistan). Marks shall be awarded in the following manner: 67 Tender approvals- 01 mark 68 Tender approvals- 02 marks 69 Tender approvals- 03 marks 68 Tender approvals- 02 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challans, invoice/varranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	25	37	70
1	101	Mycophenolate Mofetil	Tab. / Cap. 500 mg	Mycolate	2	2	3	5	0	6	2	2	2	2	2	28	0	5	5	0	0	4	5	1	20	48										
2	105	Tacrolimus	Tab./Cap. 1mg	Tagraf	2	2	3	5	0	6	2	2	2	2	2	28	0	5	5	0	0	4	5	1	20	48										
3	106	Tacrolimus	Tab./ Cap. 0.5 mg	Tagraf	2	2	3	5	0	6	2	2	2	2	2	28	0	5	5	0	0	4	5	1	20	48										
4	121	Deferasirox	Tab. 250mg	Dasiox	2	2	3	5	0	6	2	2	2	2	2	28	0	5	5	0	0	4	5	5	34	52										
5	123	Deferasirox	Tab. 400mg	Dasiox	2	2	3	5	0	6	2	2	2	2	2	28	0	5	5	0	0	4	5	5	34	52										
6	124	Deferasirox	Tab. 500mg	Dasiox	2	2	3	5	0	6	2	2	2	2	2	28	0	5	5	0	0	4	5	5	34	52										
7	203	Azithromycin	Tab. / Cap. 500 mg 6s	Kasla	2	2	3	5	0	6	2	2	2	2	2	28	0	5	5	0	0	4	5	1	20	48										
8	356	Velpasvir + Sofosbuvir	Tab. 100 + 400 mg	Albrio Plus	2	2	3	5	0	6	2	2	2	2	2	28	0	0	0	0	0	4	5	1	10	38										
10	432	Chlopigrel	Tab. 75 mg	Heclot	2	2	3	5	0	6	2	2	2	2	2	28	5	5	0	0	0	4	0	1	15	43										
11	583	Singlitpin + Metformin	Tab. 50 mg/500 mg	Sila-Met	2	2	3	5	0	6	2	2	2	2	2	28	0	5	5	0	0	4	5	2	21	49										
12	584	Singlitpin + Metformin	Tab. 50mg /1000 mg	Sila-Met	2	2	3	5	0	6	2	2	2	2	2	28	0	5	5	0	0	4	5	2	21	49										

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																							
Name of Firm					Chiesi Pharma Lahore & Karachi																		
S. No.	Product General Information				Technical Evaluation Matrix																		
					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation									
					Principal Manufacturer Evaluation				Importer's Evaluation					Product Technical Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
				Valid ISO 14001/ISO9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm	Valid ISO 14001/ISO9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm	Valid accreditation of manufacturing unit or its relevant sections by the USFDA or WHO or official accreditation body or regulatory body in the case of SBA countries duly attested by senior executive of the firm	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Availability of minimum 20% inventory of the total import of the quoted items during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC experts)	Adherence to Good storage practices (GSP) for storage of finished goods, Functional and effective Air-conditioning & Ventilation system and effective cold chain (thermo-stable drugs)	Adequate availability of qualified, Presence of Category A Pharmacist (as per mandatory), & relevant Human Resource	Traceability /Integrity/traceability study conducted by WHO Audited. Labels must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for several of marks in this parameter and / or Bio-similarity certificate from an accredited lab of SBA countries (stringent Regulatory Authorities) In case of purchases through third party importers a valid trade/bill/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Goods Declaration certificate of imported finished quoted items from Pakistan Customs, coupled with valid invoice bill or Bill of Lading for the quoted items, not older than 24 months on the cutoff date for submission of bids.	Certificate of Analysis of finished quoted items) from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in volume 15, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (API) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA/ Swiss Medc or Health Canada or by regulatory authority/body of SBA country (not).	Valid WHO prequalification and / or Valid product registration in SBA country(ies) / Valid free sale certificate issued by regulatory body of any SBA country(ies) and / or Valid certificate of the availability of the quoted item in the US market.	Valid certificate of the availability of the quoted item in the US market. 2 mark for each certification, up to a maximum of 06 marks	Valid WHO prequalification and / or Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase.	Traceability studies of quoted items (as duly attested by the Q/C manager of the firm)	Availability of quoted items in Pakistan market as per recent most data of (MSKVIA/Health not older than twelve (12) months.	1-10% market share = 1 mark 11-10% market share = 2 marks 11-10% market share = 3 marks 9% and above market share = 5 marks		
				Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided		(Valid Calibration Certificate attested by Quality head of the firm)	Non-availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted items/ firm	The physical inspection committee (MCC experts) shall verify the compliance to the GSP in accordance to the last draws criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP.	Nonadherence to GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.		In case of purchases through third party importers a valid trade/bill/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	In case of Non-provision of matching GD the marks for CoA will not be awarded.	Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, API source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products.	In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	2 mark for each certification, up to a maximum of 06 marks	1. Material (e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade 2. Type of Glass material for Liquid ampoules must be USP class I (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral (Syringe, Suppositories must be USP Type 3) or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables,	For award of marks, the certificate of analysis must clearly mention: 1. Material (e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade 2. Type of Glass material for Liquid ampoules must be USP class I (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral (Syringe, Suppositories must be USP Type 3) or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables,	Four items specifically used in institutions where MSKVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months from Tender date Govt. Hospitals, Health related Govt. projects and/or ICT accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 92 Tender approvals- 01 mark 89 Tender approvals- 02 marks 86 Tender approvals- 03 marks 83 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) to the quoted product(s) with the same brand name and specifications/ strength / dosage form. Moreover, the approvals shall			
	Ref. No. of item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
Chiesi Pharmaceutica Italy	689	Pravastatin afa	Intj. 120 mg/ 1.5 ml		2	2	0	5	5	4	5	5	28	0	5	5	5	0	0	5	5	25	53
Chiesi Pharmaceutica Italy	788	Beclomethasone	Soln. 800 mcg/2ml		2	2	0	0	5	4	5	5	23	0	0	5	5	2	4	5	5	26	49
COC Pharmaceutical SRL Italy	803	Ipratropium Bromide	Soln. 250 mcg/ml, 2ml		2	2	0	0	5	4	5	5	23	0	5	5	5	0	4	5	3	27	50

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																
S. No.	Name of Firm				CITI PHARMA KASUR / LAHORE																											
					Factory Technical Evaluation Parameters											Technical Evaluation Matrix																
	Product General Information				Documents Based Factory Score											Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters									Total Product Evaluated Score	Total Technical Score
					Product Technical Parameters																											
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16		17	18	19	20	21	22	23	24	25		
				Valid ISO 14001:2015 certificate of the facility where the general product is manufactured, issued by PNAC, accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001:2015 certificate of the facility where the general product is manufactured, issued by PNAC, accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the general product is manufactured, issued by PNAC, accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/QVYA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered)	Valid calibration certificates for equipment/instruments used in the factory for measuring, weighing, dosing, etc. in process material and finished products for the manufacturing of the general products. Valid Calibration Certificates submitted by Quality head of the firm.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibration equipment for analysis of general items along with validated methods of testing of the general items and adherence to good laboratory practices (GLP) in all aspects of the quality inspection. Stable Chamber (Both MCC accredited and FBR/TDRAP) If evaluated at the time of inspection by the MCC experts, as non-compliance or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material: In-process and Finished good: Scholar-B: DRAP (as per section of the quality inspection) Non-compliance to GMP shall lead to disqualification of the firm. Non-adherence to GMP shall lead to disqualification of the firm. Non-compliance to GMP shall lead to disqualification of the firm.	Adherence to GMP: In-process and Finished good: Scholar-B: DRAP (as per section of the quality inspection) Non-compliance to GMP shall lead to disqualification of the firm. Non-adherence to GMP shall lead to disqualification of the firm. Non-compliance to GMP shall lead to disqualification of the firm.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the Hvac system and/or testing and/or storage of the product in the Hvac system shall lead to disqualification of the relevant section/ firm.	Availability of Functional and validated IQ/OA, SOPs, and / or relevant equipment, testing, logs. As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the Hvac system and/or testing and/or storage of the product in the Hvac system shall lead to disqualification of the relevant section/ firm.	Bioreproducibility/ Biocompatibility study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologics, bio-similarity studies shall be provided for each of the products in the parameter and / or Bio-similarity certificate from an accredited lab of SRA countries (Drug Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/WHO guidelines) shall be submitted and / or Proof of revenue / innovative products from relevant body shall be provided where the firm claims that the biocompatibility/ bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Good Declaration certificate of the general items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the general items, not older than 24 months from the date of submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid invoice/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.	Certificate of Analysis of API from the Principal Manufacturer as per the requirements mentioned in the Form-3 (Form of undertaking to accompany application for License to import Drugs). In case of purchases through third party importers a valid invoice/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / TGA / PMDA / Swiss Medals or Health Canada or by regulatory authorities body of SRA country (s) coupled with Form-3 (Form of undertaking to accompany application for License to import Drugs). In case of purchases through third party importers a valid invoice/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies). Certificates on company's own letter heads shall be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm).	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the general items, as issued by the manufacturer of the material coupled with bio-similarity of product. For award of marks, the certificate of analysis must clearly mention: 1. Material e.g., Aluminium Foil, PVC, Capable Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the general items complying with US, European, British, Japanese pharmaceutical standards, as must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Oral Injections must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the general products). A. For Dry Powder Injections, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 glass 2 marks will be awarded. c. For products where USP Type 2 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the firm (s). Discretionary duty attested by the Senior executive of the firm).	Stability studies of general items duly attested by the Q/C exchange of the firm). For award of marks, the certificate of analysis must clearly mention: 1. Material e.g., Aluminium Foil, PVC, Capable Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the general items complying with US, European, British, Japanese pharmaceutical standards, as must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Oral Injections must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the general products). A. For Dry Powder Injections, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 glass 2 marks will be awarded. c. For products where USP Type 2 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the firm (s). Discretionary duty attested by the Senior executive of the firm).	Availability of general items in Pakistan market as per recent most data of IMS/QVYA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 4 marks For items specifically used in institutions where IMS/QVYA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or ICJ accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 80 Tender approvals- 4 marks 60 Tender approvals- 02 marks 40 Tender approvals- 04 marks 10 or more Tender approvals- 00 marks Note: Tender approval means award of contract(s) for the general product(s) with the same brand name and specifications / strength. Change form, Manufacturer, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challans, invoice/receipt and change from the concerned procuring entity (purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.										
Ref. No. of Item	Generic Name of Item	Design Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70						
47	Inj. 100mg/5ml, 120ml	Kalox		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43						
60	Paracetamol Tab. 500mg	Asipol		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43						
61	Paracetamol Syrup 120mg/5ml, 120ml	Asipol		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43						
202	Amoxicillin Caps. 250mg	Zynik		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47						
205	Amoxicillin Syrup 200mg/5ml	Zynik		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47						
217	Cefixime Caps. 400mg	Ceflok		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47						
218	Cefixime Syrup 100mg/5ml, 120ml	Ceflok		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47						
230	Ceftriaxone Inj. 500mg/5ml	Trinamox		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45						
231	Ceftriaxone Inj. 1g/5ml	Trinamox		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45						
232	Ceftriaxone Inj. 2g/5ml	Trinamox		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45						
244	Ciprofloxacin Tab. 500mg	Flincip		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43						
463	Levetiracetam Potassium Tab. 500mg	Levetin		2	2	3	0	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43						

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2025-26																					
		Name of Firm			COTTON CRAFT Pvt. Ltd. Lahore																
S. No.	General Product Information				Technical Evaluation Matrix																
					Factory Technical Evaluation Parameters										Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score	
	Documents Based Factory Score										Evaluation visit Score										
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non compliance to GLP , cGMP shall lead to disqualification of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	15	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or KCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals-01 mark 04 Tender approvals-02 marks 06 Tender approvals-03 marks 08 Tender approvals-04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)				
	Ref. No. of Item in MCC Formulary	Generic Name of Item		Sizes and specifications	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70
1	967	Cotton (Surgical) Corded Wool BP	Absorbent Cotton	200gm	Absorbent Cotton Wool	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
2	968	Cotton (Surgical) Corded Wool BP	Absorbent Cotton	100gm	Absorbent Cotton Wool	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
3	969	Cotton Bandage (Surgical) Bandage BP type-2	Cotton	6.5cm x 4Mtr.	Open Wove Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
4	970	Cotton Bandage (Surgical) Bandage BP type-2	Cotton	7.5cm x 4Mtr.	Open Wove Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
5	971	Cotton Bandage (Surgical) Cotton Bandage BP type-2		10cm x 4Mtr.	Open Wove Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
6	972	Cotton Bandage (Surgical) Cotton Bandage BP type-2		15cm x 4Mtr.	Open Wove Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
7	979	Crepe Bandages BPC Bandage BP	Cotton Crepe	7.5cm x 4.5Mtr.	Elastrocrafft	3	3	3	4	5	3	6	6	6	6	45	0	10	DTL Substandard	10	55
8	980	Crepe Bandages BPC Bandage BP	Cotton Crepe	10cm x 4.5Mtr.	Elastrocrafft	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
9	981	Crepe Bandages BPC Bandage BP	Cotton Crepe	15cm x 4.5Mtr.	Elastrocrafft	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
10	1076	Eye Pad Sterile (Sterile)	Optic Eye Pad	6cm x 8cm	Optic Eye Pad	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
11	1092	Absorbent Gauze BP Roll		100cm x 20Mtr	Absorbent Gauze	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
12	1093	Absorbent Gauze BP Roll		100cm x 40Mtr	Absorbent Gauze	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
13	1173	Paraffin Tulle Dressing with Chlorhexidine Para-Tulle Dressing		10cm x 10cm	Para-Tulle	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
14	1174	Paraffin Tulle Dressing with Chlorhexidine Para-Tulle Dressing		15cm x 20cm	Para-Tulle	3	3	3	4	5	3	6	6	6	6	45	0	10	DTL Substandard	10	55
15	1175	Sulphachlor Tulle Dressing		10cm x 10cm	Sulphachlor-Tulle	0	0	0	0	0	0	0	0	0	0	0	0	Non formulary	Non Formulary	0	0
16	1181	POP Bandages sizes of Paris Bandage	Plaster	15cm x 2.70m	Orthoplast	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																				
Name of the firm					COTTON CRAFT Pvt. Ltd. Lahore															
	Product General Information				Technical Evaluation Matrix												Product Evaluated Score	Total Technical Score		
					Factory Technical Evaluation Parameter								Factory Evaluated Score							
					Documents Based Factory Score				Evaluation Visit Score											
S.No	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non-adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70
13	1128	Isopropyl Alcohol 70% Disposable Nonwoven Swab	3cm x 3cm 2Ply	Pro-Max Alcohol Swab	3	5	5	6	5	5	5	5	39	0	0	0	0	10	10	49

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																											
Name of Firm				CUREXA HEALTH PVT. LTD																							
S. No.	Product General Information				Technical Evaluation Matrix															Product Evaluation Parameters					Total Product Evaluated Score	Total Technical Score	
					Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Technical Parameters											
					Documents Based Factory Score					Factory Evaluation Visit Score																	
	1	2	3		5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest BIS/QVIA ranking of the leading manufacturer (as duly validated in Pakistan manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)) (12 months to date ranking will be considered) Marks shall be awarded to top 100 firms of Pakistan as ranked by values by BIS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions shall be awarded 4 marks. 3. Firms having (12-Month) Ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) Ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) Ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Weighing, Assay. Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificate attested by Quality head of the firm). Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and up to 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year (i.e., FY 2023-24 or latest). Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and up to 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) in Schedule B of DRAP (Re/evaluated at the time of inspection by the MCC experts, in case of unavailability or non-compliance of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, in-process and Finished good storage (as in Schedule B of DRAP), as assessed at the time of inspection by the MCC experts Non-adherence to GMP shall lead to disqualification of the firm.	Adherence to cGMP guidelines, (as in Schedule B of DRAP), as assessed at the time of inspection of the quoted product (s) Non-compliance to cGMP guidelines shall lead to disqualification of the section or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Bioregulatory / Bioequivalence study conducted by WHO / Audited Labs must be attached along with the bid and study must be available in WHO Website) and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-waiver certificate from an accredited lab (SRA countries (Stringent Regulatory Authorities) In case of large volume potential (i.e., greater than 100mg up to 5L, product validation report to get WHO/USFDA/USP guidelines) shall be submitted, and / or Proof of investment / innovative products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, compiled with valid survey bill or Bill of Lading for the quoted items, not older than 24 months from the quoted date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice shall be considered. In case of purchases through third party suppliers a valid importer's valid (valid link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GDO) provided in column 18, duly attested by the senior executive of the firm In case of Non-provision of matching GDO the marks for CoA will not be awarded. Moreover, in case of product/quoted item having multiple APIs, the marks for GDO, CoA, API source accreditation shall be awarded only where these documents are submitted for all API components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of TIT bid submission.	Active Pharmaceutical Ingredients (API) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA / SwissMedic or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-1 (form of undertaking to accompany an application for License to import Drugs) Moreover, in case of product/quoted item having multiple APIs, the marks for GDO, CoA, API source accreditation shall be awarded only where these documents are submitted for all API components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of TIT bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase to SRA country(ies) For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g. Aluminium Foil, PVC, Capsule Shells, Plastic HDPE, LDPE or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP-Plus 1 (Chem-compliance shall lead to disqualification of the quoted product). Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Stability studies of quoted items duly attested by the QC (usage of the firm) Availability of quoted items in Pakistan market as per recent most data of IMS/QVIA Health not older than twelve(12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Civil Hospitals, Health related Govt. projects and or ACI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals-01 mark 04 Tender approvals-02 marks						
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	23	5	5	5	5	3	4	5	5	5	37	70
1	221	Cefoperazone + Sulbactam	Injectable, 2gm	Xorbaact Injectables	The quoted products are not recommended due to non fulfillment of technical evaluation criteria No. 22 (4)(C)				5	4	2	2	2	2	2	19	0	5	5	0	0	0	0	0	0	10	29
2	230	Ceftriaxone	Injectable, 500mg	Ceftriaxone					5	4	2	2	2	2	2	19	0	5	5	0	0	0	0	0	0	10	29
3	231	Ceftriaxone	Injectable, 1gm	Ceftriaxone					5	4	2	2	2	2	2	19	0	5	5	0	0	0	0	0	0	10	29
4	232	Ceftriaxone	Injectable, 2gm	Ceftriaxone					5	4	2	2	2	2	2	19	0	5	5	0	0	0	0	0	0	10	29

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																															
S. No.	Name of Firm				Factory Technical Evaluation Parameters																Total Factory Evaluated Score	Technical Evaluation Matrix				Product Evaluation Parameters				Total Product Evaluated Score	Total Technical Score
	Product General Information				Factory Technical Evaluation Parameters																	Product Evaluation Parameters									
Documents Based Factory Score				Factory Evaluation Visit Score																Product Technical Parameters											
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26						
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21st to 40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measurement (weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Bios) Accelerated and Real Time (as in Schedule B of DRAP)	Raw material, In-process and Finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, (as in Schedule-B of DRAP) (as mentioned in schedule-B of DRAP	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs.	(As evaluated by the MCC experts at the time of inspection).	Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm.	(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC system and/or testing and/or Disqualification of the relevant section / firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) For biologics, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) and / or In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. In case of Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/bill/DRAP clearance NOK between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GID) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GID the marks for CoA will not be awarded. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, API, source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NTI bid submission.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / TGA/ PMDA/ Swiss Medc or Health Canada or by regulatory authority/body of SRAs country (ies) coupled with Form 3 (form of undertaking to accompany an application for License to import Drugs). Valid free sale certificate issued by regulatory body of any SRA country(ies) I mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificate for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) I mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificate for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item(s), as issued by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminum Foil, PVC, Capsole Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese Pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/ Suspensions must be USP Type 2 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 2 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).	Stability studies of quoted item(s) duly attested by the Q.C incharge of the firm). For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted item(s) in Pakistan market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.					
S. No.	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	3	4	5	5	37	70						
1	42	Ethnic coated	50 mg	CYCLOREN	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
2	50	Metefenamic Acid	500 mg	Gripson Forte	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
3	52	Mefenacem	15 mg	Codebit	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
4	60	Paracetamol	500 mg	DANADOL	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
5	66	Oxyphenadrine	35 mg	NORSPAN	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
6	148	Fluconazole	150 mg	DANFLO CAP.	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
7	158	Tetracycline	250 mg	DANABID	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
8	164	Ceftriaxone	10 mg	D-ZINE	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
9	170	Loratadine	10 mg	LORINIS	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
10	171	Mometasone	10 mg	NONAKAST	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
11	202	Albendazole	250 mg	ZEL TAB.	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
12	203	Albendazole	400 mg	ZEL TAB.	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
13	243	Cefuroxime	250 mg	CANPRO	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
14	244	Cefuroxime	500 mg	DANPRO	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
15	248	Cefuroxime	500 mg	NAMOSOLAR	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
16	277	Levonorgestrel	250 mg	LEVODEN	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
17	278	Levonorgestrel	500 mg	LEVODEN	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
18	280	Lincomycin	500 mg/ml	LINECOMANOLIN	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
19	281	Linezolid	600mg	SENZORDAN	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
20	288	Mefenacem	400 mg	MONITEX	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
21	387	Iron Sucrose	20 mg/ml	DANER	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
22	388	Mecobalamin	500 mcg	METROWIT	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
23	462	Urticaria Potassium	25 mg	DANABIT	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
24	463	Urticaria Potassium	50 mg	DANABIT	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
25	513	Dampersone	10 mg	VOMESTOP	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
26	517	Paracetamol	40 mg	GASTOPK	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	19	45						
27	528	Esomeprazole	40mg	ESODEN	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						
28	530	Ondansetron	2 mg/ml	DANSETRON BMS	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	14	40						
29	547	Dexamethasone	4 mg/ml	DANACOR	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	14	40						
30	587	Tramadol Acetate	40 mg	DANACORT	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						
31	723	Escitalopram	10 mg	DANOPRAM	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	14	40						
32	731	Pragabalin	50 mg	GABFAST	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						
33	732	Pragabalin	75mg	GABFAST	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						
34	733	Pragabalin	150 mg	GABFAST	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						
35	739	Risperidone	2mg	AUTITY	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						
36	760	Risperidone	4 mg	AUTITY	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						
37	762	Terbutaline	100 mg	TERTRAL	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						
38	862	Chlorzoxazone	1%	DANESTEN	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	14	40						
39	868	Folic acid	2%	SEOK	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						
40	884	Paracetamol		PARACET LDT	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						
41	892	Tetracycline	1%	DANABID	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	24	50						

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																															
S. No.	Name of Firm				DAVIS PHARMACEUTICALS, ISLAMABAD																										
					Product General Information										Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Technical Evaluation Matrix				Product Evaluation Parameters	
	Documents Based Factory Score														Factory Evaluation Visit Score											Product Technical Parameters					
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24		25	26				
					Valid ISO 18001:2015 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001:2015 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001:2015 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMSIQVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMSIQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the last financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of the quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) in Schedule B of DRAP).	Raw material, In-process and Finished good storage (as in Schedule II of DRAP) (As evaluated at the time of inspection by the MCC experts).	Adherence to GMP guidelines, for all relevant equipment, testing, logs. Non-compliance to cGMP guidelines shall lead to disqualification of the firm.	Adequate availability of qualified & relevant Human Resource as per requirements mentioned in schedule-II of DRAP. (As certified by the MCC experts at the time of inspection).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).	Non-availability or non-functioning of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Biavailability / Bioequivalence study conducted by WHO Assessed Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral i.e., greater than 100ml up to 3L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. Proof of inventor / innovative products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted items from the Principal Manufacturer as mentioned in the goods declaration of the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchase through third party importers a valid trail/link-DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration of the quoted items, duly attested by the senior executive of the firm. Moreover, in case of production/interim having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only when these documents are submitted for all APIs/components of the quoted products. In case of Non-provision of matching GD for the marks for CoA, will not be awarded. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission. Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / (US-FDA / EMA / MHRA / TGA / PMDA / Swiss Made or Health Canada or by regulatory authority/body of SRA country (es) coupled with Form 3 (form of undertaking to accompany an application for License to import Drugs) Moreover, in case of production/interim having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only when these documents are submitted for all APIs/components of the quoted products. In case of Non-provision of matching GD for the marks for CoA, will not be awarded. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission. Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP Class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral/Syringe/Suspensions must be USP Type 1 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Class 2 marks will be awarded. c. For products where USP Type 2 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Document duly attested by the Senior executive of the firm)	Stability studies of quoted items duly attested by the Q.C. in-charge of the firm) For award of marks, the certificate of analysis must clearly mention: 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For item specifically used in institutions where IMSIQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or ICT accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 42 Tender approvals-01 mark 65 Tender approvals-02 marks 86 Tender approvals-03 marks 88 Tender approvals-04 marks 10 or more Tender approvals-05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challans, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.								
Ref. No. of Item	Generic Name of Rem	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	5	37	70					
168	Levocetirizine	Syr. 2.5 mg/5 ml	Daviet	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
169	Levocetirizine	Tab. 5 mg 10s	Daviet	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
170	Lorazepam	Tab. 10 mg 10s	Lordin	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
171	Mometasone	Tab. 10 mg	Momet-Day	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
202	Azithromycin	Tab. / Cap. 250 mg 12s or less	Zithro	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
203	Azithromycin	Tab. / Cap. 500 mg 6s	Zithro	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
218	Cefixime	Dry Susp. 100 mg/5ml 30ml	Indicef	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		10	38					
219	Cefixime	Dry Susp. 200 mg/5ml 30ml	Indicef	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		10	38					
243	Ciprofloxacin	Tab. 250 mg 10s	Ciproday	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
244	Ciprofloxacin	Tab. 500 mg 10s	Ciproday	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
277	Levofloxacin	Tab. 250 mg 10s	Levoday	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
278	Levofloxacin	Tab. 500 mg 10s	Levoday	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
288	Moxifloxacin	Tab. 400 mg	Moxey-Day	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
383	Iron Hydroxide poly maltose complex	Tab. 100 mg	Makovis	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
384	Iron Hydroxide poly maltose complex	Susp. 50 mg/5ml	Makovis	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
463	Loratadine	Tab. 10 mg	Prozar	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
482	Rosuvastatin	Tab. 10 mg	Rosotin	2	2	3	2	5	4	2	2	2	2	2	28	0	0	0	0	0	0	5	0		5	33					
513	Dompemidone	Tab. 10 mg	Vomil	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
514	Dompemidone	Susp. 5 mg/5ml 120 ml	Vomil	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
527	Omeprazole	Cap. 40 mg	Opro	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
806	Ketotifen	Tab. 1 mg	Asperfin	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
807	Ketotifen	Syr. 0.2 mg/ml 60ml	Asperfin	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		15	43					
868	Fusidic acid	Cream 2% 15gm	Pathodom	2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	0	5	0		10	38					

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																										
Name of Firm				DON VALLEY, LAHORE																						
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix									
					Documents Based Factory Score					Factory Evaluation Visit Score							Product Evaluation Parameters									
																	Product Technical Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan - (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Analyzing / process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023/24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks. (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs - Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as mentioned in schedule-B of the quoted product (s)). Non-compliance to GMP guidelines shall lead to disqualification on of the section/s or firm. Non-adherence to GSP shall lead to disqualification on of the section/s or firm.	Adherence to GMP guidelines, as in Schedule-B of DRAP) (as mentioned in schedule-B of the quoted product (s)). Non-compliance to GMP guidelines shall lead to disqualification on of the section/s or firm.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-availability shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section firm.	In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted, and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Disavailability / Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-warrior certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid away bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice(s) not older than 24 months shall be considered.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in volume 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / TGA / PMDA / Swiss Medic or Health Canada or by regulatory authority/body of SRA country (not) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, API source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it is issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 3 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminum Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups / Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injetables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Class 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).	Stability studies of quoted items duly attested by the Q.C. Incharge of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 03 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 09 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength/ dosage form. Moreover, the approvals(s) shall be duly attested by the concerned procuring entities and accompanied with purchase	Availability of quoted items in Pakistan market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks		
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
180	Amoxycillin	Cap. 250mg		2	2	3	1	5	6	2	2	2	2	2	2	29	0	5	5	0	0	0	5	0	15	44
181	Amoxycillin	Cap. 500mg		2	2	3	1	5	6	2	2	2	2	2	2	29	0	5	5	0	0	0	5	0	15	44
218	Cefixime	Dry Susp. 100 mg/5ml 30ml		2	2	3	1	5	6	2	2	2	2	2	2	29	0	0	0	0	0	0	5	0	5	34
219	Cefixime	Dry Susp. 200 mg/5ml 30ml		2	2	3	1	5	6	2	2	2	2	2	2	29	0	0	0	0	0	0	5	0	5	34
230	Ceftriaxone	Inj. 500 mg/Vial		2	2	3	1	5	6	2	2	2	2	2	2	29	0	5	5	0	0	0	5	0	15	44
231	Ceftriaxone	Inj. 1gm/Vial		2	2	3	1	5	6	2	2	2	2	2	2	29	0	5	5	0	0	0	5	0	15	44
237	Cephadrine	Cap. 250 mg		2	2	3	1	5	6	2	2	2	2	2	2	29	0	0	0	0	0	0	5	0	5	34
238	Cephadrine	Cap. 500 mg		2	2	3	1	5	6	2	2	2	2	2	2	29	0	0	0	0	0	0	5	0	5	34
242	Cephadrine	Dry Susp. 250 mg / 5ml		2	2	3	1	5	6	2	2	2	2	2	2	29	0	0	0	0	0	0	5	0	5	34
288	Moxifloxacin	Tab. 400 mg		2	2	3	1	5	6	2	2	2	2	2	2	29	0	5	5	0	0	0	5	0	15	44
572	Metformin HCl	Tab. 500mg.		2	2	3	1	5	6	2	2	2	2	2	2	29	0	5	5	0	0	0	5	0	15	44
798	Diphenhydramine+ Aminophylline+ Ascorbium Chloride	Sys. 8mg+32mg+30 mg /5ml 120ml		2	2	3	1	5	6	2	2	2	2	2	2	29	0	0	0	0	0	0	5	0	5	34

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologics and IV Fluids for Government MCC 2023-24																																																																																			
S. No.	Name of Firm				EPHORE CHEMICALS INDUSTRIES LTD																																																																														
					Factory Technical Evaluation Parameters															Technical Evaluation Matrix																																																															
	Product General Information				Documents Based Factory Score															Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters									Total Product Evaluated Score	Total Technical Score																																															
					Factory Evaluation Visit Score															Product Technical Parameters																																																															
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26																																																					
Valid ISO 14001:2015 certificate of the facility where the quoted product is manufactured, issued by PMAC, accredited body (duly attested by senior executive of the firm)				Valid ISO 45001:2018 certificate of the facility where the quoted product is manufactured, issued by PMAC, accredited body (duly attested by senior executive of the firm)				Valid ISO 9001:2015 certificate of the facility where the quoted product is manufactured, issued by PMAC, accredited body (duly attested by senior executive of the firm)				Latest IMS/QWA ranking of the leading manufacturer firm (by value in Pakistan - (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QWA, in the following manner: 1. Firm having (12-Month) Ranking in top-25 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 26-41st positions shall be awarded 4 marks. 3. Firms having (12-Month) ranking between 42st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.				Valid Calibration certificates for equipment / instruments used in the factory for Measuring, Weighing, Assay/ Analysis of raw material and finished product for the manufacturing of the quoted products. Valid Calibration Certificates attested by Quality head of the firm).				Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023/24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)				Availability of calibrated equipment for analysis of quoted items along with validated method of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (both Accelerated and Real Time) in Schedule B of DRAP				Non-process and Finished goods storage (as in Schedule B of DRAP) in area / section evaluated at the time of inspection by the MCC experts). Non-compliance to GMP guidelines shall lead to disqualification of the firm & evaluated by the MCC experts at the time of inspection. Non-availability or non-functionality of the sections or firm).				Adherence to GMP guidelines, as per the requirements of DRAP (as in area / section evaluated at the time of inspection by the MCC experts). Non-compliance to GMP guidelines shall lead to disqualification of the firm & evaluated by the MCC experts at the time of inspection. Non-availability or non-functionality of the sections or firm).				Adequate availability of qualified & relevant Human Resource for the testing, logs. (As evaluated by the MCC experts at the time of inspection).				Availability of Functional and validated PMAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).				Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to disqualification of the relevant section / firm.				Bio-reactivity / Biocompatibility study conducted by WHO Accredited Labs must be attached along with the bid and study must be available on WHO Website. For biologic, biocompatibility studies shall be provided for award of marks in this parameter. and / or Bio-safety certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 1L, product validation report (as per WHO/US FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the biocompatibility / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.				Good Declaration certificate of imported APIs of the quoted items from the Principal Manufacturer as mentioned in the goods declaration (DD) provided in column 18, duly attested by the senior executive of the firm. In cases where raw materials are provided (i) not older than 24 months shall be considered. In case of purchases through third party importers a valid Certificate of Origin (COO) clearance from the principal manufacturer and the importer firm shall be submitted with the firm offering the product to Govt. MCC.				Certificate of Analysis of APIs from the Principal Manufacturer as mentioned in the goods declaration (DD) provided in column 18, duly attested by the senior executive of the firm. Moreover, in case of product/quoted item having multiple APIs, the marks for GDC, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of its/their submission.				Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies). 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.				Valid Certificate of Analysis of the Type I glass of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with USP, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP Class 1 (Non-compliance shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables: a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).				Stability studies of quoted items duly attested by the MCC incharge of the firm).				IMS/QWA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QWA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: (2) Tender approvals: 03 marks 04 Tender approvals: 02 marks 08 Tender approvals: 03 marks 10 or more Tender approvals: 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challans, Invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque											
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70																																																									
1	66	Paracetamol + Orphenadrine	450 mg/35 mg, Tab	ALGARMAN TABLETS	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
2	527	Orphenadrine	20mg, Cap	EPHORE CAPSULE 20MG	Non formulary	0	0	0	0	0	2	2	2	2	2	10	0	0	0	0	0	0	0	0	0	10																																																									
3	528	Isomegestrol	40mg, Cap	EPHODOLE CAPSULE 40MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
4	553	Glibenclamide	5mg, Tab	GLUCON TABLETS 5MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
5	51	Metformin Acid	500mg/5ml, Syrup	MEFRAC SUSPENSION 600ML	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
6	49	Metformin Acid	250mg, Tab	MEFRAC TABLETS 250MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
7	50	Metformin Acid	500mg, Tab	MEFRAC-D5 TABLETS 500MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
8	571	Metformin HCl	500mg, Tab	METPHAGE TABLETS 500MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
9	559	Glibenclamide + Metformin	1 mg/500mg, Tab	METCON PLUS TABLET	Non formulary	0	0	0	0	0	2	2	2	2	2	10	0	0	0	0	0	0	0	0	0	10																																																									
10	171	Montelukast	10mg, Tab	MONTET TABLETS 10MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
11	61	Paracetamol	1205/5ml, 60ml or 1L	PANARMAN SUSPENSION 600ML	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
12	61	Paracetamol	1205/5ml, 120ml	PANARMAN SUSPENSION 1200ML	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
13	60	Paracetamol	500mg, Tab	PANARMAN TABLET 500MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
14	36	Acetofenazone	100mg, Tab	PIYFIRE TABLETS	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
15	482	Novocainethal	10mg, Tab	SAVUROS 10MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
16	507	Ammonium Hydroxide + Magnesium Hydroxide + Simethicone	Syrup, 120ml	TRISOL PLUS SUSPENSION	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
17	414	Amelodipine + Valerian	5mg/80mg, Tab	VALCARD TABLETS 5/80MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
18	415	Amelodipine + Valerian	5mg+160 mg, Tab	VALCARD TABLETS 5/160MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									
19	416	Amelodipine + Valerian	10mg+160 mg, Tab	VALCARD TABLETS 10/160MG	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																									

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																								
English Pharma Lahore																																								
S. No.	Name of Firm				Factory Technical Evaluation Parameters															Technical Evaluation Matrix				Product Evaluation Parameters					Total Product Evaluated Score	Total Technical Score										
																								Product General Information							Product Technical Parameters									
	Documents Based Factory Score				Factory Evaluation Visit Score					Total Factory Evaluated Score																														
	1	2	3	4	5	6	7	8	9		10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26													
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered) Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21st to 40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Assay, Weighing, Assay material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) at all lab's - Functional Stability Chamber (Both Accelerated and Real Time) in Schedule II of DRAP) (Evaluated at the time of inspection by the MCC experts, as non-compliance / non-functioning of stability chambers and/or non-adherence to GLP as per schedule-II shall lead to disqualification of the firm).	Raw material: In-process and finished goods storage (as in Schedule II of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, relevant Human Resource as per the requirements mentioned in schedule-II of DRAP (c/certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-compliance on the section/s or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-II of DRAP (c/certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-compliance on the section/s or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs (As evaluated by the MCC experts at the time of inspection) Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral (i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, complied with valid airway bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trade/link/DRAP clearance NOK between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer or Health Canada or by regulatory authority/body of SRA country (s) coupled with Form 1 (Form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NTI bid submission.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US- FDA / EMA / MIRA / TGA / PMDA / Swiss Medec or Health Canada or by regulatory authority/body of SRA country (s) coupled with Form 1 (Form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NTI bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 10 marks. Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese Pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe /Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted products). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). Documents duly attested by the Senior executive of the firm).	Stability studies of quoted items duly attested by the Q.C (incharge of the firm). For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 62 Tender approvals- 01 mark 94 Tender approvals- 02 marks 96 Tender approvals- 03 marks 98 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength (dosage form. Moreover, the approvals) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challans, invoice/warranty and cheque from the concerned procuring entity(purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted items in Pakistan market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 62 Tender approvals- 01 mark 94 Tender approvals- 02 marks 96 Tender approvals- 03 marks 98 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength (dosage form. Moreover, the approvals) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challans, invoice/warranty and cheque from the concerned procuring entity(purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.																	
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6		2	2	2	2	2	30	5		5		3	4	5	5	37	70													
1.	152	Itaconazole	Cap. 100 mg		2	2	3	0	5	4		The inspection team at the time of inspection observed that, NON-FUNCTIONAL HVAC SYSTEM AND ENVIRONMENTAL CONTROL 1. The HVAC was non-functional across all production sections. Additionally, no temperature or humidity monitoring records were maintained, compromising environmental control critical to product quality and regulatory compliance. 2. In the capsule filling area, the HVAC system was non-operational, and no measures were in place to control temperature and relative humidity—posing risks to product quality, especially for moisture-sensitive dosage forms. POOR ADHERANCE TO cGMP 3. Standard Operating Procedures (SOPs) and logbooks were not available or maintained in several critical processing and storage areas, reflecting serious deficiencies in procedural adherence and documentation control. 4. In the in-process quarantine area, mixing machines and blister packaging units were stored without proper arrangement or labeling. No racks were available, and all master cartons were placed directly on the floor, violating basic GMP, GSP and equipment segregation requirements. POOR ADHERANCE TO GOOD LABORATORY PRACTICES (GLP) 5. Real-time stability data for the quoted products was not available at the time of inspection. 6. The calibration sticker on the weighing balance indicated an expiration date of 12/07/2025, and no updated calibration documentation was available, suggesting the equipment may be in use beyond its validated calibration period. 7. Primary reference standards for the quoted products were not available in the Quality Control (QC) department, thereby compromising the reliability and validity of analytical testing. POOR GOOD STORAGE PRACTICES (GSP) 8. Materials stored in the in-process quarantine area were not labeled, and no air conditioning or HVAC systems were installed. 9. Temperature control was not maintained in the Finished Goods Store. 10. Pedestal Fans were operating in Packing Hall In view of the above the firm is NOT RECOMMENDED.	16	0	5	5	0		16	0	5	5	0		16	0	5	5	0		16	0	5	5	0		16	0	19	35
2.	215	Cefixime	Inj. 500 mg /vial 60 ml		2	2	3	0	5	4								16	0	5	5	0	0	2	5	0	17	33												
3.	216	Cefepime	Inj. 1 gm/Vial		2	2	3	0	5	4								16	0	5	5	0	0	2	5	0	17	33												
4.	230	Ceftriaxone	Inj. 500 mg/Vial		2	2	3	0	5	4								16	0	5	5	0	0	2	5	0	17	33												
5.	231	Ceftriaxone	Inj. 1gm/Vial		2	2	3	0	5	4								16	0	5	5	0	0	2	5	0	17	33												
6.	232	Ceftriaxone	Inj. 2 gm Vial		2	2	3	0	5	4								16	0	5	5	0	0	2	5	0	17	33												
7.	257	Colistimethate Sodium	Inj. 1 MU/Vial		2	2	3	0	5	4								16	0	5	5	0	2	5	0	17	33													
8.	293	Piperacillin +Tazobactam	Inj. 4 g/0.5 g (4.5gm)/Vial		2	2	3	0	5	4								16	0	5	5	0	2	5	0	17	33													
9.	394	Phytonadione (Vitamin K1)	Inj. 2mg/ml 1ml		2	2	3	0	5	4								16	0	5	5	0	2	5	0	17	33													
10.	395	Vitamin K	Inj. 10mg/ml 1ml		2	2	3	0	5	4								16	0	5	5	0	2	5	0	17	33													
11.	526	Omeprazole	Inj. 40 mg / Vial		2	2	3	0	5	4								16	0	5	5	0	2	5	0	17	33													
12.	912	Cholecalciferol (Vitamin D3)	IM/ Oral Inj. 200000 IU 1ml		2	2	3	0	5	4								16	0	5	5	0	4	5	0	19	35													

GRC Decision
The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

					Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																							
Name of the firm					ESSITY Karachi (IMPORTER)																							
S. No.	Product General Parameter				Technical Evaluation Matrix															Product Evaluated Score	Total Technical Score							
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation																
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score																	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20									
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item's during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item's. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.													
	Item in MCC	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70									
	1173	Paraffin Gauze dressing (Tulle) with Chlorhexidine 10x10 cm	10cm x 10cm	Bactigras	0	5	0	5	5	6	21	5	5	0	0	10	10	30	51									
	1174	Paraffin Gauze dressing (Tulle) with Chlorhexidine 15x20cm	15cm x 20cm	Bactigras	0	5	0	5	5	6	21	5	5	0	0	10	10	30	51									

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																
Name of the firm					Essity Karachi (IMPORTER)																
					Technical Evaluation Matrix																
					Principal's and Importer's Evaluation Parameters										Product Technical Evaluation					Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19		
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good Storage	Adequate availability of		Goods Declaration certificate of	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical		
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70		
	930	Bacterial Binding Dressing Different Sizes	7.5cm x 8.5cm	Cutimed Sorbact Hydroactive	0	5	0	5	6	6	22	5	5	0	1	2	16	29	51		
	930	Bacterial Binding Dressing Different Sizes	14cm x 14cm	Cutimed Sorbact Hydroactive	0	5	0	5	6	6	22	5	5	1	1	2	16	30	52		
	958	Casting Tape 6"	12.5cm x 3.6m	Flashcast	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50		
	959	Casting Tape 4"	10cm x 3.6m	Flashcast	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50		
	1103	Hydrogel dressing	15cm x 20cm	Cutimed Sorbact Gel	0	5	0	5	6	6	22	5	5	0	1	2	16	29	51		
	1103	Hydrogel dressing	7.5cm x 15cm	Cutimed Sorbact Gel	0	5	0	5	6	6	22	5	5	0	1	2	16	29	51		

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2025-26																					
Name of Firm		ESSITY Karachi, (Manufacturer)																			
S. No.	General Product Information				Technical Evaluation Matrix																
					Factory Technical Evaluation Parameters										Factory Evaluated Score	Product Evaluation Parameters				Product Evaluated Score	Total Technical Score
					Documents Based Factory Score					Evaluation visit Score											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14							
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	15	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)			
	Ref. No. of item in MCC Formulary	Generic Name of Item	Sizes and specifications	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70	
	979	Crepe Bandages BPC	7.5cm x 4.5m	Elasto crepe	3	0	0	4	5	3	6	6	6	6	39	0	10	10	20	59	
	980	Crepe Bandages BPC	10cm x 4.5m	Elasto crepe	3	0	0	4	5	3	6	6	6	6	39	0	10	10	20	59	
	981	Crepe Bandages BPC	15cm x 4.5m	Elasto crepe	3	0	0	4	5	3	6	6	6	6	39	0	10	10	20	59	
	1181	POP Bandages	15cm x 2.7m	Gypsona	3	0	0	4	5	3	6	6	6	6	39	1	10	10	21	60	
	1182	POP Bandages	10cm x 2.7m	Gypsona	3	0	0	4	5	3	6	6	6	6	39	1	10	10	21	60	

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																								
Name of the firm					ESSITY Karachi, (Manufacturer)																			
S.No	Product General Information				Factory Technical Evaluation Parameter												Factory Evaluated Score	Technical Evaluation Matrix					Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score															
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20					
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC experts, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection).	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.						
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70				
	1296	Zinc oxide adhesive Plaster (Cloth Tape)	2.5 cm x 5m	Paragon	3	5	5	6	5	5	5	5	39	0	0	0	0	10	10	49				
	1297	Zinc oxide adhesive Plaster (Cloth Tape)	5 cm x 5m	Paragon	3	5	5	6	5	5	5	5	39	0	0	0	0	10	10	49				
	1298	Zinc oxide adhesive Plaster (Cloth Tape)	7.5 cm x 5m	Paragon	3	5	5	6	5	5	5	5	39	0	0	0	0	10	10	49				
	1299	Zinc oxide adhesive Plaster (Cloth Tape)	10 cm x 5m	Paragon	3	5	5	6	5	5	5	5	39	0	0	0	0	10	10	49				

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																	
S. No.	Name of Firm				EVOLUTION PHARMA, ISLAMABAD																				Total Product Evaluated Score	Total Technical Score							
					Product General Information										Factory Technical Evaluation Parameters												Total Factory Evaluated Score	Technical Evaluation Matrix					
	Documents Based Factory Score														Factory Evaluation Visit Score													Product Evaluation Parameters					
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24			25	26					
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/RQVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered)	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Assay/ weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products (Valid Calibration Certificates attested by Quality head of the firm)	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or later. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule II of DRAP (Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-II shall lead to disqualification of the firm).	Raw material, in-process and finished good storage (as in Schedule-II of DRAP) as evaluated at the time of inspection by the MCC expert/s. Non-adherence to GSP shall lead to disqualification of the firm.	Adherence to cGMP guidelines, (as in relevant Human Resource as per the requirements mentioned in schedule-II of DRAP (Certified by the senior executive of the firm & guidelines issued by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Adequate availability of qualified & relevant equipment, testing logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or logs, shall lead to Disqualification of the relevant section/ firm.	Availability of Functional and validated IVAC, with all relevant equipment, testing logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the IV AC system and/or logs, shall lead to Disqualification of the relevant section/ firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importer a valid trail/bill/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GID) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GID the marks for CoA will not be awarded.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO /US- FDA / EMA / MIRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA's country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NTI/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringes/ Suspensions must be USP Type 2 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injections, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded.	Stability studies of quoted items duly attested by the Q.C. (incharge of the firm) For items specifically used in institutions where IMS/RQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and	Availability of quoted items in Pakistan market as per recent most data of IMS/RQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 30% and above market share = 3 marks For items specifically used in institutions where IMS/RQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and										
Ref. No. of item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70								
60	Paracetamol 500mg	Tab. 500mg	Acetadol	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
66	Paracetamol + Oxiprenadine Citrate	Tab. 450/35mg	Corilax	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
67	Tramadol Hydrochloride + Paracetamol	Tab. 37.5/325mg	Tralgix Plus	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
149	Fluconazole	Dry. Susp. 50mg	Aviflu	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	1	20	45								
173	Montelukast Sodium	Granules 4mg	Evokast	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44								
180	Amoxicillin Trihydrate	Cap. 250mg	Moxevo	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44								
181	Amoxicillin Trihydrate	Cap. 500mg	Moxevo	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44								
182	Amoxicillin Trihydrate	Dry Susp. 125mg	Moxevo	2	2	3	1	5	2	2	2	2	2	2	25	0	0	0	0	0	5	5	0	5	30								
185	Amoxicillin Trihydrate	Dry Susp. 250mg	Moxevo	2	2	3	1	5	2	2	2	2	2	2	25	0	0	0	0	0	5	5	0	5	30								
202	Azithromycin	Cap. 250mg	Azitec	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44								
203	Azithromycin 500mg	Tab. 500mg	Azitec	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
205	Azithromycin	Dry Susp. 200mg	Azitec	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44								
215	Cefepime HCl 500mg	Inj. 500mg	Adipime	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
216	Cefepime HCl 1g	Inj. 1g	Adipime	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
217	Cefixime	Cap. 400mg	Sefixim	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44								
218	Cefixime	Dry Susp. 100mg	Sefixim	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44								
219	Cefixime	Dry Susp. 200mg	Sefixim	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44								
220	Cefoperazone Sodium + Subactam Sodium	Inj. 1g	Bactonis	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
221	Cefoperazone Sodium + Subactam Sodium	Inj. 2g	Bactonis	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
222	Cefotaxime Sodium	Inj. 250mg	Taxcef	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
223	Cefotaxime Sodium	Inj. 500mg	Taxcef	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
224	Cefotaxime Sodium	Inj. 1g	Taxcef	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
230	Ceftriaxone Sodium	Inj. 500mg	Controx	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
231	Ceftriaxone Sodium	Inj. 1g	Controx	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
232	Ceftriaxone Sodium	Inj. 2g	Controx	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
237	Cephradine	Cap. 250mg	Xepran	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44								
238	Cephradine	Cap. 500mg	Xepran	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44								
242	Cephradine	Dry Susp. 250mg	Xepran	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
243	Ciprofloxacin HCl	Tab. 250mg	Spivox	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
244	Ciprofloxacin HCl	Tab. 500mg	Spivox	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
277	Levofloxacin	Tab. 250mg	Evolat	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								
278	Levofloxacin	Tab. 500mg	Evolat	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40								

	292	Piperacilin Sodium + Tazobactam Sodium	Inj. 2.25g	Piptaz	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40
	293	Piperacilin Sodium + Tazobactam Sodium	Inj. 4.5g	Piptaz	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	2	5	0	17	42
	527	Omeprazole	Cap. 40mg	Zolum	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	868	Fusidic Acid	Cream 2%ww	Evocort	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40
	903	Povidone-Iodine	Solution 10%	Porvid	2	2	3	1	5	2	2	2	2	2	2	25	0	5	5	0	0	0	5	0	15	40

Name of Firm		Faisal Pharmaceutical Industries Faisalabad																									
S. No.	General Product Information				Technical Evaluation Matrix																Factory Evaluated Score	Product Evaluation Parameters				Product Evaluated Score	Total Technical Score
					Factory Technical Evaluation Parameters						Evaluation visit Score																
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20							
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / Instruments in QC labs performing relevant official tests as well as compliance to Good Laboratory Practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to cGMP / cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).													
	No. of Item in MCC	Generic Name of Item	Sizes and specifications	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70							
	969	Cotton Bandage (Surgical) BP Type II 6.5cm x 4m	6.5cm*4m	Surgical Bandage	0	0	0	0	5	0	The inspection team at the time of inspection observed that, cGMP was expired at the time of inspection (Issue Date: 20-03-2020 valid for 03 years) NOT RECOMMENDED				5	0	10	10	20	25							
	970	Cotton Bandage (Surgical) BP Type II 7.5cm x 4m	7.5cm*4m	Surgical Bandage	0	0	0	0	5	0					5	0	10	10	20	25							
	971	Cotton Bandage (Surgical) BP Type II 10cm x 4m	10cm*4m	Surgical Bandage	0	0	0	0	5	0					5	0	10	10	20	25							
	972	Cotton Bandage (Surgical) BP Type II 15cm x 4m	15cm*4m	Surgical Bandage	0	0	0	0	5	0					5	0	10	10	20	25							
	978	Crepe Bandage BPC 5cm x 4m	5cm x 4m	Crepe Bandage	0	0	0	0	5	0					5	0	10	0	10	15							
	979	Crepe Bandage BPC 7.5cm x 4.5m	7.5cm x4.5m	Crepe Bandage	0	0	0	0	5	0					5	0	10	10	20	25							
	980	Crepe Bandage BPC 10cm x 4.5m	10cm x4.5m	Crepe Bandage	0	0	0	0	5	0					5	0	10	0	10	15							
	981	Crepe Bandage BPC 15cm x 4.5m	15cm x4.5m	Crepe Bandage	0	0	0	0	5	0					5	0	10	0	10	15							
	1076	Eye Pads Sterile 6cm x 8cm	6cm*8cm	Steripax	0	0	0	0	0	0					0	0	0	0	0	0							
	1092	Gauze Cloth Roll Packing 100cm x 20m	100cm*20m	Steriband Gauze Roll BPC	0	0	0	0	5	0					5	0	10	10	20	25							
	1093	Gauze Cloth Roll Packing 100cm x 40m	100cm*40m	Steriband Gauze Roll BPC	0	0	0	0	5	0					5	0	10	10	20	25							
	1173	Paraffin Gauze Dressing (Tulle) with chlorhexidine 10cm x 10cm	10cm*10cm	Septa-Chlor	0	0	0	0	5	0					5	0	10	10	20	25							
	1174	Paraffin Gauze Dressing (Tulle) with chlorhexidine 15cm x 20cm	15cm*20cm	Septa-Chlor	0	0	0	0	5	0					5	0	10	0	10	15							
	1175	Paraffin Gauze Dressing (Tulle) with Framycetin 10cm x 10cm	10cm*10cm	Steri-Tin	0	0	0	0	0	0					0	0	10	10	20	20							
	1206	Sterile Gauze Dressing Pad (X-Ray Detectable) BPC 10cm x 10cm 8ply	10cm x10 cm 8ply	Steriband	0	0	0	0	5	0					5	0	10	10	20	25							
	1206	Sterile Gauze Dressing Pad (X-Ray Detectable) USP 10cm x 10cm 8ply	10cm x10 cm 8ply	Gazin	0	0	0	0	0	0					0	0	10	10	20	20							
	1207	Sterile Gauze Dressing Pad (X-Ray Detectable) BPC 15cm x 15cm 8ply	15cm x15 cm 8ply	Steriband	0	0	0	0	5	0					5	0	10	10	20	25							

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																														
S. No.	Name of Firm				FRONTIER DEXTROSE LIMITED, HARPUR																									
	Product General Information				Factory Technical Evaluation Parameters											Technical Evaluation Matrix													Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters													
																	Product Technical Parameters													
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26				
Ref.	Generic Name of Item	Dosage Form with Strength	Trade Name	Valid ISO 14001:45001	Valid ISO 14001	Valid ISO 9001 certificate of	most MSCI/DVIA ranking of the	Valid calibration certificate for	Valid documents of the Federal Board	Availability of calibrated equipment for	Raw material, in-process and Finished	Adherence to cGMP guidelines (as in	Adequate availability of qualified &	Availability of Functional and validated	Bioavailability/Bioequivalence study	Good Declaration certificate of	Certificate of Analysis of API from the	Active Pharmaceutical Ingredients	Valid WHO registration/certificate	Valid Certificate of Analysis of the Type	Stability studies of quoted items, date	Availability of quoted items in Pakistan								
675	Sterile Water For Injection - Ampoule	5ml	Mini WF1	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70					
675	Sodium Bicarbonate 8.4% B.P. Ampoule	200ml	Mini BC	2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	4	5	0	9	37					
675	Sodium Bicarbonate 8.4% B.P. Ampoule	500ml	Mini BC	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47					
664	Potassium Chloride 7.46% Ampoule	250ml	Mini KCL	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52					
640	Dextrose 5%	100ml	Sterifluid 5%	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52					
656	0.9% Sodium Chloride	100ml	Sterifluid NS	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52					
276	Levofloxacin 500mg/100ml	100ml	Sterilevo	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47					
4	Metronidazole 500mg/ 100ml	100ml	Sterimet	2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	4	5	0	9	37					
245	Ciprofloxacin 200mg/100ml	100ml	Stericipro	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47					
64	Paracetamol 1g	100ml	Stericetamol	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47					
289	Moxifloxacin 400mg/250ml	250ml	Sterimox	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52					
655	Marenbol 20%	500ml	Sterifluid	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52					
641	Dextrose 5%	500ml	Sterifluid 5%	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
638	Dextrose 10%	500ml	Sterifluid 10%	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
644	Dextrose 5% +0.9% Sodium Chloride	500ml	Sterifluid DS	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
657	0.9% Sodium Chloride	500ml	Sterifluid NS	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
645	Dextrose 5% + 0.45% Sodium Chloride	500ml	Sterifluid DS 1/2	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
668	Compound Sodium Lactate	500ml	Sterifluid RL	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
666	Dextrose 5% + Lactated Ringer's	500ml	Sterifluid RLD	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
674	Dextrose 4.3% + 0.18% Sodium Chloride	500ml	Sterifluid Pands	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
642	Dextrose 5%	1000ml	Sterifluid 5%	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
639	Dextrose 10%	1000ml	Sterifluid 10%	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
645	Dextrose 5% +0.9% Sodium Chloride	1000ml	Sterifluid DS	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
659	0.9% Sodium Chloride	1000ml	Sterifluid NS	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
669	Compound Sodium Lactate	1000ml	Sterifluid RL	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57					
667	Dextrose 5% + Lactated Ringer's	1000ml	Sterifluid RLD	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52					

[illegible]

Evaluation Criteria for Manufacturers of General Medicine, Drug, Powder Injectable Drug, Biologics and IV Fluids for Government MOC 2025-26																													
Name of Firm				FICLS AND RULES (26 JAN 2025)																									
S. No.	Product General Information				Factory Technical Evaluation Parameters															Technical Evaluation Matrix								Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score										Factory Evaluation V&V Score					Product Evaluation Parameters									
																				Product Technical Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26			
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate of the	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate	Valid G.D. (2025-2026) Certificate			
1	47	Aspirin Sup. 100mg/Tab, 100ml	Aspirin 100mg Oral Suspension	Aspirin	2	2	3	0	5	4	2	2	2	2	2	23	5	5	5	0	4	5	0	5	37	70			
2	48	Paracetamol Sup. 100mg/Tab, 100ml	Paracetamol 100mg Oral Suspension	Paracetamol	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	39	62			
3	49	Paracetamol + Hydrocodone Tab. 40mg/10mg	Paracetamol Tablets	Hydrocodone	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	35	43			
4	143	Clotrimazole 500mg, Vaginal Tablet with applicator	Clotrimazole Vaginal Tablet 500mg	Clotrimazole V	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	0	0	30	36			
5	144	Clotrimazole 1% Vaginal Cream with Applicator	Clotrimazole 1% Vaginal Cream	Clotrimazole V	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
6	145	Bethacholine Tab. 5mg	Bethacholine Tablets 5mg	Bethacholine	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	33			
7	146	Bethacholine Tab. 10mg	Bethacholine Tablets 10mg	Bethacholine	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	33			
8	170	Loratadine Tab. 10mg	Loratadine 10mg Tablets	Loratadine	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
9	171	Mometasone Tab. 10mg	Mometasone 10mg Tablets	Mometasone	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
10	172	Mometasone Tab. 5mg	Mometasone 5mg Tablets	Mometasone	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
11	203	Aspirin + Tab.Cap. 100 mg	Aspirin Capsules 100mg	Aspirin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
12	205	Aspirin + Tab.Cap. 100mg/Tab, 100ml	Aspirin 100mg Oral Suspension 100mg/Tab	Aspirin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
13	217	Clotrimazole Cap. 400mg	Clotrimazole 400mg Capsules	Clotrimazole	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
14	218	Clotrimazole Sup. 100mg/Tab, 100ml	Clotrimazole 100mg Oral Suspension 100mg/Tab	Clotrimazole	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
15	219	Clotrimazole Sup. 100mg/Tab, 100ml	Clotrimazole 100mg Oral Suspension 100mg/Tab	Clotrimazole	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
16	243	Opivonazole Tab. 250mg	Opivonazole 250mg Tablets	Opivonazole	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
17	244	Opivonazole Tab. 500mg	Opivonazole 500mg Tablets	Opivonazole	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
18	277	Urofollitropin Tab. 250mg	Urofollitropin 250mg Tablets	Urofollitropin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
19	278	Urofollitropin Tab. 500mg	Urofollitropin 500mg Tablets	Urofollitropin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
20	280	Mometasone Tab. 400mg	Mometasone 400mg Tablets	Mometasone	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	33			
21	313	Aspirin + Lorazepam Tab. 40mg + 10mg	Aspirin 40mg Tablets	Aspirin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
22	314	Aspirin + Lorazepam Tab. 40 + 10mg	Aspirin 40mg Tablets	Aspirin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
23	315	Aspirin + Lorazepam Sup. 10mg + 10mg / 10ml	Aspirin 10mg Suspension	Aspirin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
24	383	Iron (II) Hydroxide Polymethacrylate Complex Tab. 100mg	Iron (II) Hydroxide Polymethacrylate Complex Tablets	Iron (II) Hydroxide Polymethacrylate Complex	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
25	517	Fenofibrate Tab. 40mg	Fenofibrate 40mg Tablets	Fenofibrate	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
26	528	Domperidone Cap. 40mg	Domperidone 40mg Capsules	Domperidone	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
27	723	Clotrimazole Tab. 100mg	Clotrimazole 100mg Tablets	Clotrimazole	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	33			
28	734	Urofollitropin Tab. 100mg	Urofollitropin 100mg Tablets	Urofollitropin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
29	751	Phagstatin Cap. 50 mg	Phagstatin 50mg Capsules	Phagstatin	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	33			
30	752	Phagstatin Cap. 75mg	Phagstatin 75mg Capsules	Phagstatin	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	33			
31	806	Metformin Tab. 10mg	Metformin Tablets	Metformin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
32	807	Metformin Sup. 100mg/Tab, 100ml	Metformin 100mg Oral Suspension	Metformin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			
33	848	Clotrimazole Acid Cream 2% 50gm	Clotrimazole 2% Cream	Clotrimazole	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	35	43			

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																	
Name of the firm					FRESENIUS MEDICAL CARE LAHORE																	
					Technical Evaluation Matrix																	
					Principal's and Importer's Evaluation Parameters						Product Technical Evaluation										Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation														
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19				
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical			
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70			
1	1101	Haemodialyzer with tubing Adults Fresenius Helixone membrane FX-Class Low Flux dialyzer FX8 Surface Area 1.4m2 with Fresenius Blood Tubing Line 6.5 mm for adult with One Fluid barrier & Pre-Pump Arterial Pressure Monitoring line.	FX8 Dialyzer Bloodline 6.5mm	Fresenius		5		5	6	6	22	5	5	0	0	2	16	28	50			
2	1101	Fresenius Helixone membrane FX-Class Low Flux dialyzer FX10 Surface Area 1.8m2 with Fresenius Blood Tubing Line 6.5 mm for adult with One Fluid barrier & Pre-Pump Arterial Pressure Monitoring line	FX10 Dialyzer Bloodline 6.5mm	Fresenius		5		5	6	6	22	5	5	0	0	2	16	28	50			
3	1101	Fresenius Polysulfone Membrane Low Flux dialyzer F6HPS Surface Area 1.3m2 with Fresenius Blood Tubing Line 6.5 mm for adult with One Fluid barrier & Pre-Pump Arterial Pressure Monitoring line	F6HPS Dialyzer Bloodline 6.5mm	Fresenius		5		5	6	6	22	5	5	0	0	2	16	28	50			
4	1101	Fresenius Helixone membrane high flux dialyzer for adult FX100 Classic Surface Area 2.2m2 with Fresenius Blood Tubing Line 6.5 mm for adult with One Fluid barrier & Pre-Pump Arterial Pressure Monitoring line	FX100 Classic Dialyzer Bloodline 6.5mm	Fresenius		5		5	6	6	22	5	5	0	0	2	16	28	50			
5	1102	Haemodialyzer with tubing Peads Fresenius Helixone membrane FX-Class Low Flux dialyzer FX5 Surface Area 1.0m2 with Fresenius Blood Tubing Line 6.5 mm for adult with One Fluid barrier & Pre-Pump Arterial Pressure Monitoring line.	FX5 Dialyzer Bloodline 6.5mm	Fresenius		5		5	6	6	22	5	5	0	0	2	16	28	50			
6	1102	Fresenius polysulfone mambrane dialyzer low Flux F4HPS Surface Area 0.8m2 with Fresenius Blood Tubing Line 6.5mm for adult with One Fluid barrier & Pre-Pump Arterial Pressure Monitoring line.	F4HPS Dialyzer Bloodline 6.5mm	Fresenius		5		5	6	6	22	5	5	0	0	2	16	28	50			

Name of Firm					Friends Pharma, Lahore																								
S. No.	Product General Information				Technical Evaluation Matrix																				Total Product Evaluated Score	Total Technical Score			
					Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Evaluation Parameters													
					Documents Based Factory Score						Factory Evaluation Visit Score					Product Technical Parameters													
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26			
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	Valid ISO 18001/45001	Valid ISO 14001	Valid ISO 9001	Latest IMS/IQVIA	Valid calibration	Valid documents of the	Availability of	Raw material, In-	Adherence to cGMP	Adequate availability of	Availability of		Bioavailability/	Goods Declaration	Certificate of Analysis	Active Pharmaceutical	Valid WHO	Valid Certificate of	Stability studies of	Availability of quoted						
				2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70				
	752	Pregabalin	Cap. 75mg	Free-Gaba	0	0	3	0	5	2	The inspection team at the time of inspection observed that, NON-FUNCTIONAL HVAC SYSTEM AND ENVIRONMENTAL CONTROL 1. The Cephalosporin production section was undergoing renovation, and the HVAC system was non-functional and under maintenance at the time of inspection, rendering the area non-compliant for pharmaceutical manufacturing activities. POOR ADHERANCE TO cGMP 2. Materials stored in the in-process quarantine area were not labeled, making it impossible to verify product identity and status. Additionally, humidity was not adequately controlled, with recorded levels reaching 69%, which exceeds acceptable limits for many pharmaceutical materials. 3. Required Standard Operating Procedures (SOPs) and logbooks were not maintained in critical operational areas, representing a major lapse in documentation and procedural control as per GMP requirements. POOR ADHERANCE TO GOOD LABORATORY PRACTICES (GLP) 4. Real-time stability data for the quoted products was not available at the time of inspection. 5. The quoted items were not placed in the real-time stability chambers, reflecting a deficiency in the execution of the approved stability study protocol. POOR GOOD STORAGE PRACTICES (GSP) 6. Temperature control was not maintained in the Finished Goods Store, putting product quality and stability at risk due to potential exposure to unfavorable storage conditions.				10	0	5	5	0	0	4	5	0	19	29				
	334	Acyclovir	Inj. 250 mg/Vial	Friclov	0	0	3	0	5	2					10	0	5	5	0	0	0	0	0	5	0	15	25		
	335	Acyclovir	Inj. 500 mg/Vial	Friclov	0	0	3	0	5	2					10	0	5	5	0	0	0	0	0	5	0	15	25		
	526	Omeprazole	Inj. 40mg/vial	Preazit-L with water	0	0	3	0	5	2					10	0	5	5	0	0	0	0	0	5	0	15	25		
	42	Diclofenac Sodium	Tab. 50mg	Frendic-S	0	0	3	0	5	2					10	0	5	5	0	0	4	5	0	0	4	5	0	19	29
	418	Atenolol	Tab. 50mg	Ateno-Heart	0	0	3	0	5	2					10	0	5	5	0	0	4	5	0	0	4	5	0	19	29
	419	Atenolol	Tab. 100mg	Ateno-Heart	0	0	3	0	5	2					10	0	5	5	0	0	4	5	0	0	4	5	0	19	29
	517	Famotadine	Tab. 40mg	Famcet	0	0	3	0	5	2					10	0	5	5	0	0	4	5	0	0	4	5	0	19	29
	170	Loratadine	Tab. 10mg	Famcet	0	0	3	0	5	2					10	0	5	5	0	0	4	5	0	0	4	5	0	19	29
	723	Escitalopram	Tab. 10mg	Prism	0	0	3	0	5	2	In view of the above the firm is NOT RECOMMENDED.				10	0	5	5	0	0	4	5	0	19	29				

GRC Decision
The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																
Name of the firm					Fujifilm, Karachi																
					Technical Evaluation Matrix																
Principal's and Importer's Evaluation Parameters									Product Technical Evaluation							Product Evaluated Score	Total Technical Score				
Principal Manufacturer Evaluation					Importer's Evaluation			Suppliers Technical Score													
	1	2		3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item		Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance	Physical examination	Evaluated	Technical	
						3	5	5	5	6	6	30	5	5	5	3	6	16	40	70	
	1287	X-Ray Film RXN 8x10 (100 Sheets)		8x10	Fujifilm Japan	3	5	0	5	6	6	25	5	5	0	3	2	16	31	56	
	1288	X-Ray Film RXN 12x15 (100 Sheets)		12x15	Fujifilm Japan	3	5	0	5	6	6	25	5	5	0	3	2	16	31	56	
	1289	X-Ray Film RXN 10x12 (100 Sheets)		10x12	Fujifilm Japan	3	5	0	5	6	6	25	5	5	0	3	2	16	31	56	
	1291	X-Ray film CR DIHL (150-sheets) Valid where FUJI CR installed		8x10	Fujifilm Japan	3	5	0	5	6	6	25	5	5	0	3	2	16	31	56	
	1291	X-Ray CR Film 10x14 DIHL (150-Sheets) Valid where FUJI CR installed		10x14	Fujifilm Japan	3	5	0	5	6	6	25	5	5	0	3	2	16	31	56	
	1292	X-Ray Films CT scan 14x17 DIHL (100-sheets)		14x17	Fujifilm Japan	3	5	0	5	6	6	25	5	5	0	3	2	16	31	56	

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																										
Name of Firm					FYNK PHARMA, LAHORE																					
S. No.	Product General Information				Technical Evaluation Matrix																					
					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
																	Documents Based Factory Score						Factory Evaluation Visit Score			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
					Valid ISO 18001/45001	Valid ISO 14001	Valid ISO 9001	Latest IMS/IOVIA	Valid calibration	Valid documents of the	Availability of	Raw material, In-	Adherence to cGMP	Adequate availability of	Availability of		Bioavailability/	Goods Declaration	Certificate of Analysis	Active Pharmaceutical	Valid WHO	Valid Certificate of	Stability studies of	Availability of quoted		
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
	48	Ketorolac	Inj. 30 mg/ml 1ml		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52
	70	Tramadol HCl	Inj. 50 mg/ml,2ml		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52
	148	Fluconazole	Tab. / Cap. 150 mg 1s		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	168	Levocetirizine	Syp. 2.5 mg/5 ml		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	202	Azithromycin	Tab. / Cap. 250 mg 12s or less		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	203	Azithromycin	Tab. / Cap. 500 mg 6s		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	205	Azithromycin	Dry Susp. 200 mg/5ml 25ml or less		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	217	Cefixime	Cap. 400 mg 5s		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	218	Cefixime	Dry Susp. 100 mg/5ml 30ml		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	223	Cefotaxime Sodium	Inj. 500 mg/Vial		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	224	Cefotaxime Sodium	Inj. 1gm/Vial		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	230	Ceftriaxone	Inj. 500 mg/Vial		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	231	Ceftriaxone	Inj. 1gm/Vial		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	232	Ceftriaxone	Inj. 2 gm Vial		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	308	Vancomycin	Inj. 500 mg/Vial		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52
	309	Vancomycin	Inj. 1gm/Vial		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52
	384	Iron Hydroxide poly maltose complex	Syp. 50 mg/5ml		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	463	Losartan Potassium	Tab. 50 mg		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	515	Drotaverine	Tab. 40 mg		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	1	20	48
	516	Drotaverine	Inj. 20 mg/ml 2ml		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	1	20	48
	526	Omeprazole	Inj. 40 mg / Vial		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	530	Ondansetron	Inj. 2 mg/ml 4 ml		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	868	Fusidic acid	Cream 2% 15gm		2	2	3	2	5	4	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2025-26																				
Name of Firm				GENERAL PHARMA KAMOKE PUNJAB																
S. No.	General Product Information				Technical Evaluation Matrix															
					Factory Technical Evaluation Parameters										Factory Evaluated Score	Product Evaluation Parameters				Product Evaluated Score
	Documents Based Factory Score					Evaluation visit Score					16									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		care Govt. hospitals, treatment centers Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength/ dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the transaction against the cheque	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)			
	Ref. No. of item in MCC Formulary	Generic Name of Item	Sizes and specifications	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70
	967	Cotton (Surgical) Corded BPC	200gm	Hospitex	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	968	Cotton (Surgical) Corded BPC	100gm	Hospitex	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	971	Cotton Bandage (Surgical) B.P Type II	10cmx4m	Hospitex	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	972	Cotton Bandage (Surgical) B.P Type II	15cmx4m	Hospitex	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	1092	Gauze Cloth Roll Packing	100cmx20M	Hospitex	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	1093	Gauze Cloth Roll Packing	100cmx40M	Hospitex	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	1208	Sterile Gauze Dressing Pad (x-ray detectable radiopaque) BP	30cmx30cm, 4ply	Hospitex	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
Name of Firm				Genetics Pharma Lahore																								
S. No.	Product General Information				Factory Technical Evaluation Parameters												Total Factory Evaluated Score	Technical Evaluation Matrix								Total Product Evaluated Score	Total Technical Score	
					Documents Based Factory Score				Factory Evaluation Visit Score									Product Technical Parameters										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16		17	18	19	20	21	22	23	24			25
					Valid ISO 18001:45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMSI/QVIA ranking of the leading manufacturer firm (by value) in Pakistan - (12 months to date ranking will be considered) Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMSI/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firm having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. [Valid Calibration Certificates attested by Quality head of the firm].	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all inspection by the manufacturing of the quoted products. (Evaluate at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, in-process and finished good storage (as in Schedule-B of DRAP) (as a section of the quoted product (c). Non-compliance of the firm & MCC guidelines shall lead to disqualification of the section/s or firm.	Adherence to cGMP / Good Manufacturing Practices (GMP) as mentioned in the schedule-B of DRAP. Non-compliance of the firm & MCC experts shall lead to disqualification of the section/s or firm.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in the schedule-B of DRAP. [Certified by the senior executive of the firm & MCC experts at the time of inspection.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).	Non-availability of or non-functionality of the HVAC system and/or testing and/or disqualification of the relevant section / firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. (As evaluated by the MCC experts at the time of inspection).	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid way bill or bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the schedule-B of DRAP (as a section of the quoted product (c). Column 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA, Swiss Medico or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs).	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies).	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g. Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).	Stability studies of quoted items, duly attested by the Q.C. manager of the firm).	Availability of quoted items in Pakistan market as per recent most data of IMSI/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks	For items specifically used in institutions, where IMSI/QVIA data is not applicable, the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 62 Tender approvals- 01 mark 64 Tender approvals- 02 marks 66 Tender approvals- 03 marks 68 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks	Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transactions against the cheque received shall also be submitted with each purchase order.		
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	3	4	5	5	5	37	70		
1	36	Acetofenac	Tab. 100 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	24	54		
2	67	Paracetamol + Tramadol	Tab. 325mg/37.5 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
3	69	Tizanidine	Tab. 4mg		0	2	3	4	5	6	2	2	2	2	2	30	0	0	0	0	0	4	5	0	9	39		
4	147	Fluconazole	Tab. / Cap. 50 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	0	0	0	0	4	5	0	9	39		
5	161	Betahistine	Tab. 8 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50		
6	162	Betahistine	Tab. 16 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50		
7	171	Montelukast	Tab. 10 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
8	202	Azithromycin	Tab. / Cap. 250 mg 12s or less		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
9	203	Azithromycin	Tab. / Cap. 500 mg 6s		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
10	277	Levofloxacin	Tab. 250 mg 10s		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	24	54		
11	278	Levofloxacin	Tab. 500 mg 10s		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	24	54		
12	288	Moxifloxacin	Tab. 400 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
13	414	Amlodipine + Valsartan	Tab. 5mg+80 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
14	415	Amlodipine + Valsartan	Tab. 5mg+160 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
15	416	Amlodipine + Valsartan	Tab. 10 mg+160 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
16	482	Rosuvastatin	Tab. 10 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
17	528	Esomeprazole	Cap. 40mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
18	531	Pantoprazole	Tab. 20mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
19	532	Pantoprazole	Tab. 40mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
20	550	Empagliflozin	Tab. 10 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
21	551	Empagliflozin	Tab. 25 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
22	583	Sitagliptin + Metformin	Tab. 50 mg/500 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
23	584	Sitagliptin + Metformin	Tab. 50mg /1000 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
24	683	Fexofenadine	Tab. 40 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
25	695	Tamsulosin HCl	Cap. 0.4mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
26	700	Aripiprazole	Tab. 15 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
27	714	Desvenlafaxine	Tab. 50 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
28	715	Desvenlafaxine	Tab. 100 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
29	717	Duloxetine	Cap. 30 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
30	718	Duloxetine	Cap. 60 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
31	719	Divalproex Sodium	Tab. 250 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	0	0	0	0	4	5	0	9	39		
32	723	Escitalopram	Tab. 10 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50		
33	731	Lamotrigine	Tab. 50 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
34	732	Levodopa + Carbidopa	Tab. 250 mg+25mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	5	0	4	5	0	24	54		
35	733	Levetiracetam	Tab. 250 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	5	0	4	5	0	24	54		
36	734	Levetiracetam	Tab. 500mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	5	0	4	5	0	24	54		
37	740	Olanzapine	Tab. 5mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
38	741	Olanzapine	Tab. 10 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49		
39	751	Pregabalin	Cap. 50 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50		

a0	752	Pregabalin	Cap. 75mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50
a1	753	Pregabalin	Cap. 150 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50
a2	758	Quetiapine	Tab. 100 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49
a3	759	Risperidone	Tab. 2mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	5	0	4	5	1	25	55
a4	760	Risperidone	Tab. 4 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	5	0	4	5	1	25	55
a5	762	Sertraline	Tab. 100 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49
a6	764	Topiramate	Tab. 50 mg		0	2	3	4	5	6	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																			
Name of Firm				GENIX PHARMA PVT LTD KARACHI																															
				Product General Information															Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Evaluation Parameters				Total Product Evaluated Score	Total Technical Score
																			Documents Based Factory Score											Factory Evaluation Visit Score					
S. No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26									
					Valid ISO 18001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 18001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/ISO/VA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Mark shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/ISO/VA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firm having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firm having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firm having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firm having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificate for equipment used in the factory for instruments used in the factory for Manufacturing, Assay/ Analysis of raw material, in process material and finished products for the manufacturing of the quoted products. 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 4 marks. 2. Firm having (12-Month) ranking between 21-40th positions shall be awarded 3 marks. 3. Firm having (12-Month) ranking between 41st to 60th position shall be awarded 2 marks. 4. Firm having (12-Month) ranking between 61st to 80th position shall be awarded 1 mark.	Valid documents of the Federal Board of Revenue (FBR) showing the local financial turnover of the firm for the last year (i.e., FY 2023-24 or latest). Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR: 100 to 500 million : 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be submitted by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practice (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule II of DRAP. If validated at the time of inspection by the MCC experts, it is non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-II shall lead to disqualification of the firm(s).	Raw material, in-process and finished goods, as in Schedule-II of DRAP, as per the equipment mentioned in schedule II of DRAP. (As evaluated by the MCC experts at the time of inspection).	Adequate availability of qualified & relevant Human Resource as per the equipment mentioned in schedule II of DRAP. (As evaluated by the MCC experts at the time of inspection).	Availability of Functional and qualified HVAC, with all relevant equipment, testing, logs + (As evaluated by the MCC experts at the time of inspection).	Non-availability or non-functionality of the HVAC system and/or testing, and/or logs, shall lead to disqualification of the relevant section firm.	Disavailability/ Inexistence study conducted by WHO, Audited Lab must be attached along with the bid and study must be available on WHO Website) For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or Dis-availability certificate from an accredited lab of SRA countries (European Regulatory Authorities). In case of Large volume parenteral (i.e., greater than 100ml up to 5L, product validation report as per WHO/US FDA/ATF guidelines) shall be submitted and / or Proof of sector / innovative products from relevant body shall be provided where the firm claims that the bioprocess/ bio-similarity is not applicable. Proof on company's own letter head shall be acceptable	Disavailability/ Inexistence study conducted by WHO, Audited Lab must be attached along with the bid and study must be available on WHO Website) For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or Dis-availability certificate from an accredited lab of SRA countries (European Regulatory Authorities). In case of Large volume parenteral (i.e., greater than 100ml up to 5L, product validation report as per WHO/US FDA/ATF guidelines) shall be submitted and / or Proof of sector / innovative products from relevant body shall be provided where the firm claims that the bioprocess/ bio-similarity is not applicable. Proof on company's own letter head shall be acceptable	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where raw materials are acquired from Local sources valid invoices (i) not older than 24 months shall be considered. In case of purchases through third party, importers a valid Invoices/IRAP clearance NOC between the principal manufacturer and the importer shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer or Active Pharmaceutical Ingredient (API) source accreditation certificate issued by WHO / US, FDA, EMA, MHRA, TGA, PMDA, Swiss Meds or Health Canada or by regulatory authority/body of SRA countries (not coupled with Form-I (Form of undertaking to accompany GMP) provided in volume I-X, duly attested by the senior executive of the firm. Moreover, in case of products/quoted item having multiple APIs, the marks for G.D., C.A., API, source accreditation shall be awarded only where these documents are submitted for all APIs components of the quoted products. In case of Non-provision of matching G.D. the marks for C.A. will not be awarded. In cases where the validity period is not explicitly mentioned in the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission.	Valid WHO prequalification and / or Valid product registration in SRA countries) and / or Valid free sale certificate issued by regulatory body of any SRA country(s) Mark for each certification, up to a maximum of 3 marks Certificates on company's own letter heads shall not be acceptable Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase For award of marks, the certificate of analysis must clearly mention: 1. Materials (e.g., Aluminium foil, PVC, Capable Shells, Plastics (HDPE, LDPE) or any other material used for the immediate container of the quoted items complying with US, European, British, Japanese Pharmacopoeial standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid containers must be USP class I (Non-compliance shall lead to disqualification of the quoted products). 3. Type of Glass material for Oral Syringes must be USP Type I or better (Non-compliance or non-provision of C.A. of glass material shall lead to disqualification of the quoted products). 4. For Dry Powder Injectables, a. For USP Type I glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 2 Glass is used or where the C.A. of Glass material is not provided shall lead to disqualification of the item(s). Documents duly attested by the Senior executive of the firm)	Stability studies of quoted items duly attended by the Q.C. (As per the scope of the form) 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 4 marks For items specifically used in institutions where IMS/ISO/VA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tattarys Care Govt. Hospitals, Health related Govt. projects and/or RCT accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 10 Tender approvals: 01 mark 20 Tender approvals: 02 marks 30 Tender approvals: 03 marks 40 Tender approvals: 04 marks 50 or more Tender approvals: 05 marks Note: Tender approval means (award of contracts) for the quoted product(s) with the same brand name and specifications / strength/ dosage form. Moreover, the approvals shall be duly attested by the concerned processing entities and accompanied with purchase orders, delivery challans, invoice/warranty and cheque from the concerned processing entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque receipt shall also be submitted with each purchase order.	Availability of quoted items in Pakistan market as per recent most data of IMS/ISO/VA Health or other data within 12 months 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 4 marks For items specifically used in institutions where IMS/ISO/VA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tattarys Care Govt. Hospitals, Health related Govt. projects and/or RCT accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 10 Tender approvals: 01 mark 20 Tender approvals: 02 marks 30 Tender approvals: 03 marks 40 Tender approvals: 04 marks 50 or more Tender approvals: 05 marks Note: Tender approval means (award of contracts) for the quoted product(s) with the same brand name and specifications / strength/ dosage form. Moreover, the approvals shall be duly attested by the concerned processing entities and accompanied with purchase orders, delivery challans, invoice/warranty and cheque from the concerned processing entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque receipt shall also be submitted with each purchase order.													
Ref. No. of Item	Generic Name of Item			Design Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	3	4	5	5	5	27	70								
1	334	Acyclovir	250mg Inj	Acicvir 250mg Inj	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
2	335	Acyclovir	500 mg Inj	Acicvir 500mg Inj	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
3	273	Imipenem+Glasatafin	500mg Inj	Clenem Injection 500mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
4	912	Cholecalciferol	8 mg	DAU 5mg Injection	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
5	337	Dactatavir As Dihydrochloride	60 mg Tab	Dactil 60mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
6	550	Empagliflozin	10 mg Tab	Emgflf 10mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	10	42									
7	551	Empagliflozin	25 mg Tab	Emgflf 25mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	10	42									
8	416	Amlodipine + Valsartan	10/160 mg tab	Exval-A 10mg/160mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
9	415	Amlodipine + Valsartan	5/160 mg tab	Exval-A 5mg/160mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
10	414	Amlodipine + Valsartan	5mg/80 mg Tab	Exval-A 5mg/80mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
11	317	Artesunate	120 mg Inj	Gen-M Injection 120mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	2	17	49									
12	316	Artesunate	60 mg Inj	Gen-M Injection 60mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	2	17	49									
13	202	Azithromycin (As Dihydrate)	250 mg Tab	Genthro 250mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
14	203	Azithromycin (As Dihydrate)	500 mg Tab	Genthro 500mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
15	355	Tenofovir Disoproxil Fumarate	300 mg Tab	Gentrovir 300mgr Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
16	399	Tranexamic Acid	500 mg Cap	Haemic 500mg Capsules	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
17	686	Ibandronate Sodium Monohydrate	3mg/3 ml Inj	Ibtrate Injection 3mg/3ML	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	1	16	48									
18	687	Ibandronate Sodium Monohydrate	150 mg Tab	Ibtrate Tablets 150mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	1	16	48									
19	250	Clarithromycin	125 mg/5ml Susp	Larilf Dry Suspension 125mg/5ml	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
20	247	Clarithromycin	250 mg Tab	Larilf Tablets 250mg. Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
21	248	Clarithromycin	500 mg Tab	Larilf Tablets 500mg. Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
22	526	Omeprazole (E.C. Pellets)	40 mg IV Inf	Mep 40mg IV Infusion	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
23	95	Lefunomide	20 mg Tab	Novelof 20mg Tablet	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
24	7	Nitazoxanide	500 mg Tab	NT-Tox Tablets 500mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	1	16	48									
25	286	Menoprenem	1 gm Inj	Oliver Injection 1g	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
26	285	Menoprenem	500 mg Inj	Oliver Injection 500mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
27	910	Oselein Mineral Complex + Vitamin D	Tab	Omc- D Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
28	911	Oselein Mineral Complex + Vitamin D	120 ml Susp	Omc-D Suspension 120ml	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
29	734	Levetiracetam	500 MG IAB	Receatam 500mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
30	735	Levetiracetam	5ML/500 MG Inj	Receatam 5ml/500mg Injection	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
31	354	Sofosbuvir	400 mg Tab	Sofos 400mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
32	694	Sofifenacin As Succinate	10 mg Tab	Soffl Tabs. 10mg.	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	1	16	48									
33	695	Tamoxifen	0.4 mg Tab	Tampro 0.4mg Cap	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
34	309	Vancomycin (As Hcl) 1G/Vial	1gm Inj	Vancom 1g Injection	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
35	308	Vancomycin (As Hcl) 500mg/Vial	500 mg Inj	Vancom 500mg Injection	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
36	356	Sofosbuvir 400Mg + Velpatasvir 100Mg	100mg/400 mg Tab	Velso 100mg/400mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	1	16	48									
37	288	Moxifloxacin As Hcl	400 mg Tab	X-Gen Tablets 400mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									
38	281	Linezolid	600 mg Tab	Zyspan 600mg Tablets	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47									

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26														
Name of the firm					Genome Pharma (Importer), Islamabad														
					Technical Evaluation Matrix														
Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							Product Evaluated Score	Total Technical Score				
Principal Manufacturer Evaluation					Importer's Evaluation											Suppliers Technical Score			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
S. No.	Ref. No. of item in MCC Formulary	Generic Name of item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good Storage	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70
Demophorious, Cyprus	938	Blood Bags (CPDA-1) Single	Single 450ml	Demotech	0	5	0	5	6	6	22	0	0	0	0	0	16	16	38
Demophorious, Cyprus	940	Blood Bags (CPDA-1) Double	Double 450ml	Demotech	0	5	0	5	6	6	22	0	0	0	0	0	16	16	38
Demophorious, Cyprus	942	Blood Bags (CPDA-1) Double	Triple 450ml	Demotech	0	5	0	5	6	6	22	0	0	0	0	0	16	16	38

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																					
Name of Firm Genome Pharma Hattar RPK																																					
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix																				
					Documents Based Factory Score												Factory Evaluation Visit Score											Product Evaluation Parameters									
					Documents Based Factory Score												Factory Evaluation Visit Score											Product Evaluation Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26											
					Valid ISO 18001:45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMSIQVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered)	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all phases - Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP)	Raw material, in-process and Finished good stored (as in schedule-II of DRAP) as evaluated at the time of inspection by the MCC expert(s).	Adherence to cGMP guidelines, as in schedule-II of DRAP, as mentioned in section of the quoted product (s).	Adequate availability of qualified & relevant Human Resource as per requirements mentioned in schedule-II of DRAP	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).		Bio-availability: Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or	Goods Declaration certificate of imported API of the quoted item(s) from Pakistan Customs, coupled with valid survey bill or Bill of Lading for the quoted item(s), not older than 24 months from the consignment date for submission of bids.	Certificate of Analysis of API from the Principal Manufacturer or authority/body of SRA country (ies) coupled with Form-I (item of undertaking to accompany GDI) provided in column 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / USFDA / EMA / MHRA/ TGA/ PMDA/ Swiss Med or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-I (item of undertaking to accompany GDI) provided in column 18, duly attested by the senior executive of the firm.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item(s), as issued by the manufacturer of the material coupled with Invoice/proof of purchase.	Stability studies of quoted item(s) duly attested by the Q.C. (exchange of the firm).	Availability of quoted item(s) in Pakistani market as per recent most data of IMSIQVIA Health not older than twelve (12) months. 1:10% market share = 1 mark 11:30% market share = 2 marks 11:50% market share = 3 marks 50% and above market share = 5 marks Five items specifically used in institutions where IMSIQVIA data is not applicable: the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specification / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.													
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	31	5	5	5	3	4	5		5	37	70												
1	120	Difenhydramine	Tab. 50mg	0	0	3	0	0	4	2	2	2	2	2	2	22	0	0	0	0	0	0	5	0	5	27											
2	121	Difenhydramine	Tab. 250mg	0	0	3	0	0	4	2	2	2	2	2	2	22	0	0	0	0	0	0	5	0	5	27											
3	122	Difenhydramine	Tab. 500mg	0	0	3	0	0	4	2	2	2	2	2	2	22	0	0	0	0	0	0	5	0	5	27											
4	124	Difenhydramine	Tab. 250mg	0	0	3	0	0	4	2	2	2	2	2	2	22	0	0	0	0	0	0	5	0	5	27											

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																					
S. No.	Name of Firm				Geofman Pharma Karachi																																
	Product General Information				Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Technical Evaluation Matrix										Product Evaluation Parameters		Total Product Evaluated Score	Total Technical Score								
					Documents Based Factory Score											Factory Evaluation Visit Score														Product Technical Parameters							
					1	2	3	4	5	6	7	8	9	10		11	12	13	14	15	16	17	18	19	20	21	22			23	24	25	26				
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/IVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of IMS/IVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accredited and Real Time)(as in Schedule II of DRAP) (Evaluated at the time of inspection by the MCC experts, in case of non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule II of DRAP) (as evaluated at the time of inspection by the MCC experts)	Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm.	Non-adherence to GSP shall lead to disqualification of the section/s or firm.	(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Adequate availability of qualified & relevant Human Resource as per of (DRAP) of area /section of the quoted product (s). (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to disqualification of the relevant section / firm.	Availability of functional and validated HVAC, with all relevant equipment, testing logs. (As evaluated by the MCC experts at the time of inspection).	Bio-water certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities).	In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid airway bill or bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/Link/DRAP-reference NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MIRA/ TGA/ PMDA/ Swiss Medico or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium foil, PVC, Capsule Shells, Plastics (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class I (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type I glass 4 marks.	Stability studies of quoted items duly attested by the Q.C incharge of the firm) 1-10% market share = 1 mark 11-50% market share = 2 marks 50% and above market share = 3 marks For items specifically used in institutions where IMS/IVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or ICJ accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted items in Pakistan market as per recent most data of IMS/IVIA. Health not older than twelve (12) months. 1-10% market share = 1 mark 11-50% market share = 2 marks 50% and above market share = 3 marks For items specifically used in institutions where IMS/IVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or ICJ accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.											
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	2	33	5	5	5	5	5	4	5	5	5	37	70										
1	143	Clostrimazole	Vaginal tablet	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	43									
2	202	Azithromycin	Tab. / Caps.	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	47									
3	217	Cefixime	Cap. 400 mg	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	47									
4	220	Cefepime	inj. 4gm/Vial	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	43									
5	221	Cefazolin	inj. 2 gm/Vial	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	43									
6	228	Ceftriaxone	inj. 500 mg	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	43									
7	229	Ceftriaxone	inj. 1gm/Vial	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	43									
8	230	Ceftriaxone	inj. 500 mg	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	43									
9	231	Ceftriaxone	inj. 1gm/Vial	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	43									
10	243	Ciprofloxacin	Tab. 250 mg	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	20	48									
11	244	Ciprofloxacin	Tab. 500 mg	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	20	48									
12	272	Clostrimazole	inj. 40 mg/ml	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	47									
13	388	Micoclaxam	inj. 500 mg	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	47									
14	532	Pantoprazole	Tab. 40mg	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	47									
15	547	Dexamethasone	inj. 4 mg/ml	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	47									
16	578	Cefixime	inj. 400 mg	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	47									
17	580	Prochlorperazine	Tab. 5 mg	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	47									
18	862	Clostrimazole	Cream 0.01	2	2	3	5	5	6	2	2	2	2	2	2	28	0	5	5	0	0	0	0	0	0	0	15	47									

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																											
Name of Firm				GETZ PHARMA KARACHI																							
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix									Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score					Factory Evaluation Visit Score							Product Evaluation Parameters										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Onsite verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs = Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule II of DRAP (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, in-process and finished goods stored in bins in Schedule II of DRAP (as evaluated at the time of inspection by the MCC experts). Non-compliance to cGMP guidelines shall lead to disqualification of the firm.	Adherence to GMP guidelines, just in case of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the firm.	Adequate availability of qualified & relevant Human Resource per the requirements mentioned in schedule-II of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the sections or firm).	Availability of Functional and validated HVAC, Humidity control, equipment, testing, logs (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section /firm.		Bioavailability/Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported APIs of the quoted items from Pakistan Customs, coupled with valid inward bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. The cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchase through third party importers a valid In/Out/DRAP clearance NCC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GDP) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GDP the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / TGA/ PMDA/ Swiss Medics or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form 3 (Form of undertaking to accompany an application for License to import Drugs) Moreover, in case of product/section item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Document duly attested by the Senior executive of the firm).	Stability studies of quoted items duly attested by the Q.C. (exchange of the firm) For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 03 mark 06 Tender approvals- 02 marks 08 Tender approvals- 03 marks 10 or more Tender approvals- 05 marks	Availability of quoted items in Pakistan market as per recent most date of IMS/QVIA Health or other than twice (12) months: 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 03 mark 06 Tender approvals- 02 marks 08 Tender approvals- 03 marks 10 or more Tender approvals- 05 marks			
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70		
48	Ketorolac	Inj. 30 mg/ml 1ml	Ketorogel	2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	4	5	1	10	43		
220	Cefoperazone + Sulbactam	Inj. 1gm/Vial	Cefoperz	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	0	0	14	47		
221	Cefoperazone + Sulbactam	Inj. 2 gm/Vial	Cefoperz	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	0	0	14	47		
222	Cefotaxime Sodium	Inj. 250 mg/Vial	Ximutof	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	0	0	14	47		
223	Cefotaxime Sodium	Inj. 500 mg/Vial	Ximutof	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	0	0	14	47		
224	Cefotaxime Sodium	Inj. 1gm/Vial	Ximutof	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	0	0	14	47		
230	Ceftriaxone	Inj. 500 mg/Vial	Getofin	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	0	1	15	48		
231	Ceftriaxone	Inj. 1gm/Vial	Getofin	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	0	1	15	48		
232	Ceftriaxone	Inj. 2 gm Vial	Getofin	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	0	1	15	48		
285	Mefenem	Inj. 500 mg/Vial	Mefogel	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53		
286	Mefenem	Inj. 1gm /Vial	Mefogel	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53		
388	Mecobalamin	Inj. 500 mcg 1ml	Nervon	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52		
566	Human Insulin 70/30 (Pre-mixed)	Inj. 100 IU / ml 10ml	Inouget 70/30	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54		
567	Insulin Regular (Human)	Inj. 100 IU/ml 10ml	Inouget -R	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54		
568	Insulin Glargine	Inj. 100 IU/ml 10ml	Basagline	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53		
735	Levetiracetam	Inj. 100 mg/ml 5 ml	Xetcam	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53		

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																
S. No.	Name of Firm				GLOBAL PHARMACEUTICALS ISLAMABAD																											
	Product General Information				Factory Technical Evaluation Parameters												Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score			
					Documents Based Factory Score										Factory Evaluation Visit Score					Product Evaluation Parameters												
																				Product Technical Parameters												
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26						
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered).	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material and finished products for the manufacturing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs - Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP)	Raw material, in-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, relevant Human Resource as per Schedule-B of DRAP, (as mentioned in the section of the quoted product (i).	Adequate availability of qualified & validated HVAC, with all relevant equipment, testing, logs.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).	Non-availability of the firm & non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Dis-availability of Bio-equivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO (Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Dis- waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)	Goods Declaration certificate of imported API (of the quoted items) from Pakistan Customs, complied with valid survey bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the authority body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs).	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / USFDA / EMA / MIRA / TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs).	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 10 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g. Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/ Suspension must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm)	Stability studies of quoted items duly attested by the Q.C. incharge of the firm).	Availability of quoted items in Pakistan market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide: Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks.								
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	2	33	5	5	5	3	4	5			37	70						
Toll	4	Metronidazole	Inf. 500mg, 100 ml	Toll manufacturing	The quoted products are not recommended due to non fulfillment of bid form-3 (TJ2)			4	0	6	2	2	2	2	2	20	0	0	0	0	0	5	1	6	26							
Toll	48	Ketorolac	Inf. 30 mg/ml 1ml	Toralac	Toll manufacturing				4	0	6	2	2	2	2	20	0	0	0	0	0	5	0	5	25							
	57	Nalbughine	Inf. 10 mg	Nalbin	2	2	3	4	0	6	2	2	2	2	2	27	0	5	5	0	0	4	5	1	20	47						
	148	Fluconazole	Tab. / Cap. 150 mg 1s	Fungicure	2	2	3	4	0	6	2	2	2	2	2	27	0	5	5	0	0	5	1	16	43							
	220	Cefoperazone + Sulbactam	Inf. 1gm/Vial	Gloper	2			4	0	6	2	2	2	2	2	22	0	5	5	0	0	5	0	15	37							
	221	Cefoperazone + Sulbactam	Inf. 2 gm/Vial	Gloper	2			4	0	6	2	2	2	2	2	22	0	5	5	0	0	5	0	15	37							
	231	Ceftriaxone	Inf. 1gm/Vial	Norbiac	2			4	0	6	2	2	2	2	2	22	0	5	5	0	0	5	1	16	38							
Toll	245	Ciprofloxacin	Inf. 200 mg/100ml 100 ml	Nafkin	Toll manufacturing			4	0	6	2	2	2	2	2	20	0	0	0	0	0	5	0	5	25							
	285	Meropenem	Inf. 500 mg/Vial	Merem	2			4	0	6	2	2	2	2	2	22	0	5	5	0	0	5	0	15	37							
	286	Meropenem	Inf. 1gm /Vial	Merem	2	2	3	4	0	6	2	2	2	2	2	27	0	5	5	0	0	5	0	15	42							
	292	Piperacillin +Tazobactam	Inf. 2 gm+0.25gm (2.25gm/Vial	Zoycin	2	2	3	4	0	6	2	2	2	2	2	27	0	5	5	0	0	5	0	15	42							
	293	Piperacillin +Tazobactam	Inf. 4 gm+2.5 gm (4.5gm/Vial	Zoycin	2	2	3	4	0	6	2	2	2	2	2	27	0	5	5	0	0	5	0	15	42							
Toll	513	Domperidone	Tab. 10 mg	Petkon	Toll manufacturing	0	0	4	0	6	2	2	2	2	2	20	0	5	5	0	0	5	1	16	36							
	695	Tamulosin HCl	Cap. 0.4mg	Tamsol	2	2	3	4	0	6	2	2	2	2	2	27	0	0	0	0	0	5	1	6	33							
	696	Tamulosin HCl + Dinitrosteride	Cap. 0.4 mg+ 0.5mg	Tamsol-D	2	2	3	4	0	6	2	2	2	2	2	27	0	0	0	0	0	5	1	6	33							

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																										
S. No.	Name of Firm				GRATON PHARMA PVT LTD																					
	Product General Information				Principal's and Importer's Evaluation Parameters									Suppliers Technical Score	Product Technical Evaluation Matrix										Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation				Importer's Evaluation						Product Technical Parameters											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23			
					Valid ISO 11001/15001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm)	Valid calibration certificate for equipment / instrument used in the facility for measuring, weighing, Assay/ Analysis of raw material, process material and finished products for the manufacturing of the quoted product)	Availability of minimum 20% inventory of the total import of the quoted items during last one year, certificate to the effect duly signed by the senior executive of the firm, evaluated by the MCC expert(s).	Adherence to Good Storage practices (GSP) for storage of finished goods, Functional and effective Alarm, Monitoring & Ventilation System and effective cold chain thermostable drugs)	Adequate availability of qualified, Presence of Category A, Pharmacia (as mandatory) & relevant Items Resource	13	Irrevocability/ Irreversibility study conducted by WHO Audited, also must be attached along with the bill and study must be available on WHO Website	Intends Declaration certificate of reported finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in section 15, duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in section 15, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (API) source accreditation certificate issued by WHO /USFDA /EMA /MHRA /TGA /PMDA, Bn in India or Health Canada or by equivalent authority body of SRA or country (ies)	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA country(ies) and / or	Valid Certificate of Analysis of the immediate container of the quoted items, as issued by the manufacturer of the material supplied with Invoice/proof of purchase.	Stability studies of quoted items duly attested by the Q.C. in charge of the firm.	Availability of quoted items on Pharmacy website in pre recent most date of MIS/QVIA Health not older than twelve (12) months.	22	23				
					Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	(Valid Calibration Certificates attested by Quality head of the firm)	No availability of the 20% stock at the warehouse of the time of inspection of the importer shall lead to disqualification of the quoted items / firm)	The physical inspection certificate/ IAC, reports shall verify the compliance in the GSP as according to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations issued by the DRAP	In case of purchases through third party Importer a valid Health/DRAP Assurance NDC and the importer firm shall be established with the firm offering the product to Govt. MCC		In case of Non-provision of matching GD the marks for C&A will not be awarded.	Moreover, in case of products/quoted item having multiple APIs, the marks for C&A, API source accreditation shall be awarded only where these documents are submitted for all API components of the quoted products.	It must comply with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade.	2 mark for each certification, up to a maximum of 06 marks.	Valid certificate of the availability of the quoted items in the US market.	For award of marks, the certificate of analysis must clearly mention:- 1. Material: e.g., Aluminium foil, PVC, Capsule, Tablet, HDPE, LDPE or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid suspensions must be USP Class I (Non-compliance shall lead to disqualification of the quoted products). 3. Type of Glass material for Oral Syringe/ Suspensions must be USP Type I or better (Non-compliance or non-provision of C&A of glass material shall lead to disqualification of the quoted products).	4. For Dry Powder Injectables,	1-10% market share = 1 mark 1-10% market share = 2 marks 11-10% market share = 3 marks 10% and above market share = 4 marks	For items specifically used in institutions where MIS/QVIA data is not applicable, the bidder shall provide Tender Approvals not older than twelve (12) months from Tertiary care Govt. Hospitals, Health related Govt projects and/or A's accredited private hospitals of Pakistan.					
																</										

				Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																	
Name of the firm				GreenStar, Karachi																	
					Technical Evaluation Matrix																
					Principal's and Importer's Evaluation Parameters						Product Technical Evaluation									Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation													
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19		
					Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical		
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	6	6	30	5	5	5	3	6	16	40	70		
	495	Male Latex Condom		Saathi	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made: 1. Karex Industries SDN BHD Malaysia: Valid original agency agreement of the principal manufacturer was not presented to the inspection team at the time of inspection. In view of the above the firm is NOT-RECOMMENDED and marks in importer's evaluation parameters for the quoted items may be awarded.						0	5	5	0	0	0	NR	10	10		

[illegible]

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2025-26																				
S. No.	Name of Firm				63 HAFIZ PHARMA INDUSTRY KAMOKE															
	General Product Information				Technical Evaluation Matrix															
					Factory Technical Evaluation Parameters										Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score
	Documents Based Factory Score					Evaluation visit Score														
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC Labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)			
	Ref. No. of item in MCC Formulary	Generic Name of Item	Sizes and specifications	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70
1	967	Cotton (Surgical) Corded BPC	200 GM	Surgeon	3	3	3	4	5	3	The inspection team at the time of inspection observed that, POOR ADHERANCE TO cGMP 1. Only one registered pharmacist was present on-site at the time of inspection, which is insufficient for ensuring adequate supervision across all manufacturing, quality control, and storage areas as per GMP and regulatory staffing requirements. 2. Materials stored in the RMS and packaging storage area were not labeled, violating essential GSP principles related to material identification, status indication, and traceability. 3. No qualified microbiologist was available at the time of inspection, indicating a deficiency in the facility's quality control capability, particularly for microbiological testing and environmental monitoring POOR GOOD STORAGE PRACTICES (GSP) 4. No hygrometers or humidity monitoring devices were installed in the Raw Material Store (RMS), in-process areas, or Finished Goods Store (FGS), preventing real-time monitoring of environmental conditions critical for material stability. 5. No temperature or relative humidity records were maintained in any of the storage or production areas, indicating a serious lapse in environmental monitoring and documentation control. 6. Finished goods were stored directly on the floor without the use of pallets or storage racks, increasing the risk of contamination and				21	0	10	10	20	41
2	968	Cotton (Surgical) Corded BPC	100 GM	Surgeon	3	3	3	4	5	3					21	0	10	10	20	41
3	969	Cotton Bandages (Surgical) B.P Type II	6.5cm x 4 m	Surgeon	3	3	3	4	5	3					21	0	10	10	20	41
4	970	Cotton Bandages (Surgical) B.P Type II	7.5cm x 4m	Surgeon	3	3	3	4	5	3					21	0	10	10	20	41
5	971	Cotton Bandages (Surgical) B.P Type II	10cm x 4m	Surgeon	3	3	3	4	5	3					21	0	10	10	20	41
6	972	Cotton Bandages (Surgical) B.P Type II	15cm x 4m	Surgeon	3	3	3	4	5	3					21	0	10	10	20	41
7	979	Cotton Crepe Bandage BPC	7.5cm x 4.5m	Surgeon	3	3	3	4	5	3					21	0	10	10	20	41
8	980	Cotton Crepe Bandage BPC	10cm x 4.5m	Surgeon	3	3	3	4	5	3					21	0	10	10	20	41

Evaluation Criteria for Importers of General Medicines, Drugs, Parental Injectable Products, Biologics and IV Fluids for Government MCC 2025-26																								
Name of Firm																								
S. No.	Product General Information				Technical Evaluation Matrix																			
					Principal's and Importer's Evaluation Parameters									Product Technical Evaluation										
					Principal/Manufacturer Evaluation			Importer's Evaluation						Supplier Technical Score	Product Technical Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	
				Valid ISO 18001:43001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm) Online verification link shall be provided	Valid accreditation of manufacturing unit or its relevant sections by the US- FDA or WHO or official accreditation bodies/regulatory body in the case of SRA countries (duly attested by the senior executive of the firm) quoted products.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm)	Availability of minimum 20% inventory of the total import of the quoted items during last one year (certificate to be effected duly signed by the senior executive of the firm & evaluated by the MCC experts)	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-stable drugs)	Adequate availability of qualified (Presence of Category A Pharmacist's issue mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance in this parameter shall lead to disqualification of the firm).	Bioavailability / Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO (Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. Bio-waiver certificate from an accredited lab of SRA country (Shanghai Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, provided	Goods Declaration certificate of imported finished quoted item/ Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. In case of purchases through third party importers a valid (true/bill)/DIAP clearance /NOC from importer shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA country (ies). Trail of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned in the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. 2 mark for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be	For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminum foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a	Stability studies of quoted item's duly attested by the Q.C incharge of the firm).	Availability of quoted item's in Pakistan market as per recent most date of DHS/RQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where DHS/RQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks.					
	Ref. No. of item in MCC formulary	Generic Name of item	Dosage Form with Strength	Trade Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70	
Baharat Serum and Vaccine Ltd. INDIA	590.	Anti-Rabies Serum	200 IU/ml, 5ml	EQAR Rab 5ml	2	2	2	0	5	4	5	5	25	0	5	5	0	0	4	5	0	19	44	
CSL BEHRING GMBH, Germany	599.	Hepatitis B Immunglobulin (Adult)	inj.	Hepatitis B Ki	0	0	0	5	5	4	5	5	24	0	5	5	5	2	4	5	0	26	50	
CSL BEHRING GMBH, Germany	600.	Hepatitis B Immunglobulin (Neonatal)	inj.	Hepatitis B Ki	0	0	0	5	5	4	5	5	24	0	5	5	5	2	4	5	0	26	50	
Zydus Life science Ltd. INDIA	612.	Purified Chick Embryo Cell Rabies Vaccine (PCECV)	inj.	Vaxi Rab 5ml	2	2	2	0	5	4	5	5	25	0	5	5	0	0	4	5	0	19	44	
CSL BEHRING GMBH, Germany	617.	Rho (D) Immune globulin	300 mg. Iij	Rhoglyfac	0	0	0	5	5	4	5	5	24	0	5	5	5	2	4	5	0	26	50	
Baharat Serum and Vaccine Ltd. INDIA	624.	Snake Venom Antiserum (Lyophilized) with diluent	inj.	Anti Snake Venom Serum	2	2	2	0	5	4	5	5	25	0	5	5	0	0	4	5	0	19	44	
CSL BEHRING GMBH, Germany	670.	Salt free Albumin	20% Soln. IV/Inf. 50ml	Human Albumin 20%	0	0	0	5	5	4	5	5	24	0	5	5	5	2	4	5	0	26	50	
CSL BEHRING GMBH, Germany	671.	Salt free Albumin	20% Soln. IV/Inf. 100ml	Human Albumin 20%	0	0	0	5	5	4	5	5	24	0	5	5	5	2	4	5	0	26	50	

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																											
Name of Firm				Hansel Pharmaceuticals, Lahore																							
S. No.	Product General Information				Factory Technical Evaluation Parameters												Total Factory Evaluated Score	Technical Evaluation Matrix									
					Documents Based Factory Score										Factory Evaluation Visit Score			Product Evaluation Parameters									
																		Product Technical Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Latest DMS/SQVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by DMS/SQVIA, in the following manner: [Valid Calibration Certificates attested by Quality head of the firm]. 1. Firms having (12-Month) Ranking in top-20 position shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. [Valid Calibration Certificates attested by Quality head of the firm]. Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks. [The document shall be attested by a Senior executive of the firm]	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) in Schedule B of DRAP. [Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm].	Raw material: In-process and Finished good storage (as in Schedule-B of DRAP) as per requirements of DRAP, as per / section of the time of product (i). Non-compliance to GMP guidelines shall lead to disqualification of the firm. Non-adherence to CSP shall lead to disqualification of the firm.	Adherence to GDP Guideline. Prescribed good storage (as in Schedule-B of DRAP) as per requirements of DRAP, as per / section of the time of product (i). Non-compliance to GMP guidelines shall lead to disqualification of the section's or firm).	Adequate availability of qualified & relevant Human Resource as per requirements of DRAP, as per / section of the time of product (i). [As evaluated by the MCC experts at the time of inspection].	Non-availability or non-functionality of the IV AC system and/or testing and/or logs, shall lead to disqualification of the relevant section / firm.	Bio-equivalency / Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO website (USFDA/USP guidelines) shall be submitted. and / or Proof of investor / innovator product from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO (USFDA/USP guidelines)) shall be submitted. and / or Proof of investor / innovator product from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid away bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-similar certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities and / or In case of purchases through third party Importers a valid TradeLink DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GDT) provided in column 11, duly attested by the senior executive of the firm. In case of Non-provision of matching GDT the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA / Swiss Medix or Health Canada or by regulatory authority/body of SRA's country (ies) coupled with Form-3 (Form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GDT, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of (3) marks. Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase and / or For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium foil, PVC, Capable Sheet, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables: a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). Documents duly attested by the Senior executive of the firm).	Stability studies of quoted items duly attested by the Q.C. (incharge of the firm). For items specifically used in institutions where DMS/SQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 62 Tender approvals- 01 mark 64 Tender approvals- 02 marks 66 Tender approvals- 03 marks 68 Tender approvals- 04 marks 70 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specification / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted items in Pakistan market as per recent most data of DMS/SQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where DMS/SQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 62 Tender approvals- 01 mark 64 Tender approvals- 02 marks 66 Tender approvals- 03 marks 68 Tender approvals- 04 marks 70 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specification / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.				
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70		
217	Cefixime	Cap. 400mg	Cefix	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	0	5	0	15	39		
220	Cefoperazone + Sulbactam	inj. 2gm/Vial	Infalix	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	0	5	0	17	41		
230	Ceftriaxone	inj. 1gm/Vial	Infalix	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	2	5	0	17	41		
378	Ferrus Fumarate +Folic Acid	Tab. 150mg + 0.5mg	Infalix	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	0	5	0	15	39		
388	Mecobalamin	inj. 500mcg	Infalix	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	0	5	0	15	39		
493	Combined Oral Contraceptives	Tab. Contraceptive tablets: 21 Each tablet shall contain 0.03 mg of ethinyl estradiol and 0.15 mg of Levonorgestrel. Spacing tablets: 7 Each tablet shall contain 75 mg Ferrus fumarate.	Queen F	2	2	3	0	5	2	2	2	2	2	2	24	0	0	0	0	0	0	5	0	5	29		
494	Drosp. Multivitamin/Mineral Acetate	inj. 4 mg/ml 1ml	Drosp Queen	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43		
548	Disopropione	Vaginal Tab. 3 mg	V. Prostone Vaginal	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	0	5	0	15	39		
695	Tamoxifen HCl	Cap. 0.4mg	Quiflo	2	2	3	0	5	2	2	2	2	2	2	24	0	0	0	0	0	0	5	0	5	29		
837	Moxifloxacin	Eye Drops. 0.5% w/v	Quiflo	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	0	5	0	15	39		
912	Cholecalciferol	inj. 20000 IU	Infalix O	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	0	5	0	15	39		

				Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																		
Name of the firm					HASHIR SURGICAL SERVICES, PESHAWAR																	
S. No.	Product General Parameter				Technical Evaluation Matrix																	
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation									Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20			
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted items. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacist/s /are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.						
Principal	of item in MCC Formula	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70			
Jiangxi Fenglin Medical Appliances Co. Ltd, China	1016	Disposable Auto Disable Syringe (Blister Packing) Sterile	3ML	BIO SOFT	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Jiangxi Fenglin Medical Appliances Co. Ltd, China	1017	Disposable Auto Disable Syringe (Blister Packing) Sterile	5ML	BIO SOFT	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Jiangxi Fenglin Medical Appliances Co. Ltd, China	1112	IV Fluid Administration Set (Sterile & Pyrogen Free, minimum 150 cm Tube Length, Blister Pack)	150cm, Blister Pack	BIO SOFT	3	5	0	5	5	6	24	5	5	3	2	10	10	35	59			
Jiangxi Fenglin Medical Appliances Co. Ltd, China	1113	IV Fluid Administration Set with additional →Y→ Injection Port (Sterile & Pyrogen Free, minimum 150 cm Tube Length, Blister Pack)	150cm, Y-Port, Blister Pack	BIO SOFT	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Jiangxi Fenglin Medical Appliances Co. Ltd, China	1116	IV Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, except and BVC free)	With Wings+ Inj: Port+ G-18,	FLOWCATH	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Jiangxi Fenglin Medical Appliances Co. Ltd, China	1117	(Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, except and BVC free)	With Wings+ Inj: Port+ Heparin Stopper G-18,	FLOWCATH	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Jiangxi Fenglin Medical Appliances Co. Ltd, China	1118	(Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, except and BVC free)	With Wings+ Inj: Port+ G-20,	FLOWCATH	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Jiangxi Fenglin Medical Appliances Co. Ltd, China	1119	(Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, except and BVC free)	With Wings+ Inj: Port+ Heparin Stoppper G-20,	FLOWCATH	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Jiangxi Fenglin Medical Appliances Co. Ltd, China	1120	(Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, except and BVC free)	With Wings+ Inj: Port, G-22,	FLOWCATH	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			

Jiangxi Fenglin Medical Appliances Co, Ltd, China	1121	(Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex,	With Wings+ Inj: Port+ Heparin Stopper G-22,	FLOWCATH	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Jiangxi Fenglin Medical Appliances Co, Ltd, China	1122	IV Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ Inj: Port + Heparin Stopper G-24,	FLOWCATH	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Jiangxi Fenglin Medical Appliances Co, Ltd, China	1123	IV Cannula (Sterile having wings with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Small Wings+ Heparin Stopper G-24,	FLOWCATH	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
RIASA S.R.L. Argentina	917	Adhesive Tapes (Paper)	1" (2.5cm) x 4.5m	HIPOALERGIC PORE	0	5	0	5	5	6	21	5	5	0	0	10	10	30	51
Shandong Yixing Medical Co., Ltd., China	1112	IV Fluid Administration Set (Sterile & Pyrogen Free, minimum 150 cm Tube Length, Blister Pack)	150cm, Blister Pack	BIO FLOW	0	5	0	5	5	6	21	5	5	0	2	10	10	32	53
Shandong Yixing Medical Co., Ltd., China	1113	IV Fluid Administration Set with additional →Y→ Injection Port (Sterile & Pyrogen Free, minimum 150 cm Tube Length, Blister Pack)	150cm, Y-Port, Blister Pack	BIO FLOW	0	5	0	5	5	6	21	5	5	0	2	10	10	32	53
USM Healthcare Medical Device Factory Vietnam	1114	IV Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ Inj: Port+ G-14,	FAVOCATH	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
USM Healthcare Medical Device Factory Vietnam	1115	IV Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ Inj: Port+ G-16,	FAVOCATH	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
USM Healthcare Medical Device Factory Vietnam	1116	IV Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ Inj: Port+ G-18,	FAVOCATH	3	5	0	5	5	6	24	5	5	1	2	10	10	33	57
USM Healthcare Medical Device Factory Vietnam	1117	IV Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ Inj: Port+ Heparin Stopper G-18,	FAVOCATHU	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
USM Healthcare Medical Device Factory Vietnam	1118	IV Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ Inj: Port+ G-20,	FAVOCATH	3	5	0	5	5	6	24	5	5	5	2	10	10	37	61
USM Healthcare Medical Device Factory Vietnam	1119	IV Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ Inj: Port+ Heparin Stoppper G-20,	FAVOCATHU	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56

USM Healthcare Medical Device Factory Vietnam	1120	IV Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ Inj: Port, G-22,	FAVOCATH	3	5	0	5	5	6	24	5	5	5	2	10	10	37	61
USM Healthcare Medical Device Factory Vietnam	1121	IV Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ Inj: Port+ Heparin Stopper G-22,	FAVOCATHU	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
USM Healthcare Medical Device Factory Vietnam	1122	IV Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ Inj: Port + Heparin Stopper G-24,	FAVOCATHU	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26															
Name of the firm					HASHIR SURGICAL SERVICES, PESHAWAR															
					Technical Evaluation Matrix															
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	
Principal	Ref. No. of item	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good Storage	Adequate availability of		Goods Declaration certificate of	Certificate of	Tender Approvals (not older than twelve 12	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality control	Physical examination of the	Product Evaluated Score	Total Technical Score	
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70	
N. A. Z Medical Supplies Sdn, Bhd, Malaysia	1051	Disposable Non-sterile Latex Examination Gloves (Powder Free)	Small, Medium, Large	NAZCAR E	0	5	0	5	6	6	22	5	5	0	0	0	16	26	48	
N. A. Z Medical Supplies Sdn, Bhd, Malaysia	1052	Disposable Non-sterile Latex Examination Gloves (Powdered)	Small, Medium, Large	NAZCAR E	0	5	0	5	6	6	22	5	5	0	0	0	16	26	48	
Jiangsu Kanglin Medical Instrument Co, Ltd, China	1279	Urine bag with let	2000ml,	Bio Bag	0	5	0	5	6	6	22	5	5	5	0	2	16	33	55	
Jiangxi Fenglin Medical Appliances Co, Ltd, China	1126	Infusion Chamber (Burette Type) Sterile, Disposable	100ml	BIO SOFT	3	5	0	5	6	6	25	0	0	0	0	2	16	18	43	
Jiangxi Fenglin Medical Technology Co, Ltd, China	1247	Two-Way Foley Catheter 100% Silicon	Size.16FR	Uro Cath Foley Catheter	3	5	0	5	6	6	25	0	0	0	0	2	16	18	43	
Jiangxi Fenglin Medical Technology Co, Ltd, China	1251	Two-Way Foley Catheter (Silicon Coated)	Size.6FR	Uro Cath Foley Catheter	3	5	0	5	6	6	25	0	0	0	0	2	16	18	43	
Jiangxi Fenglin Medical Technology Co, Ltd, China	1252	Two-Way Foley Catheter (Silicon Coated)	Size.8FR	Uro Cath Foley Catheter	3	5	0	5	6	6	25	0	0	0	0	2	16	18	43	
Jiangxi Fenglin Medical Technology Co, Ltd, China	1253	Two-Way Foley Catheter (Silicon Coated)	Size.10FR	Uro Cath Foley Catheter	3	5	0	5	6	6	25	0	0	0	0	2	16	18	43	
Jiangxi Fenglin Medical Technology Co, Ltd, China	1254	Two-Way Foley Catheter (Silicon Coated)	Size.12FR	Uro Cath Foley Catheter	3	5	0	5	6	6	25	0	0	0	0	2	16	18	43	
Jiangxi Fenglin Medical Technology Co, Ltd, China	1255	Two-Way Foley Catheter (Silicon Coated)	Size.14FR	Uro Cath Foley Catheter	3	5	0	5	6	6	25	0	0	0	0	2	16	18	43	
Jiangxi Fenglin Medical Technology Co, Ltd, China	1256	Two-Way Foley Catheter (Silicon Coated)	Size.16FR	Uro Cath Foley Catheter	3	5	0	5	6	6	25	0	0	0	0	2	16	18	43	
Jiangxi Fenglin Medical Technology Co, Ltd, China	1257	Two-Way Foley Catheter (Silicon Coated)	Size.18FR	Uro Cath Foley Catheter	3	5	0	5	6	6	25	0	0	0	0	2	16	18	43	
Tianda Medical Instruments C., Ltd, China	1222	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.10	BIO BLADE	0	5	0				5	0	0	0	0	2	16	18	23	
Tianda Medical Instruments C., Ltd, China	1224	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.15	BIO BLADE	0	5	0				5	0	0	0	0	2	16	18	23	

Tianda Medical Instruments C., Ltd. China	1225	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.20	BIO BLADE	0	5	0	20% Inventory of the quoted items, Disposable surgical blade of HauiAn TianDa Medical Instruments Co., Ltd., China, were not available, In view of the above the firm is Not RECOMMENDED for the award of marks in importer's evaluation parameters for quoted disposable surgical blade.	5	0	0	0	0	2	16	18	23
Tianda Medical Instruments C., Ltd. China	1226	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.21	BIO BLADE	0	5	0		5	0	0	0	0	2	16	18	23
Tianda Medical Instruments C., Ltd. China	1227	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.22	BIO BLADE	0	5	0		5	0	0	0	0	2	16	18	23
Tianda Medical Instruments C., Ltd. China	1228	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.23	BIO BLADE	0	5	0		5	0	0	0	0	2	16	18	23
Tianda Medical Instruments C., Ltd. China	1229	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.24	BIO BLADE	0	5	0		5	0	0	0	0	2	16	18	23

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																		
S. No.	Name of Firm				Heal Pharma Peshawar																													
	Product General Information				Factory Technical Evaluation Parameters											Technical Evaluation Matrix											Total Product Evaluated Score	Total Technical Score						
					Documents Based Factory Score											Factory Evaluation Visit Score													Total Factory Evaluated Score	Product Evaluation Parameters				
																														Product Technical Parameters				
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26									
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP (Evaluated at the time of inspection by the MCC experts, a non-availability of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and finished good storage as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, (as in Schedule-B of DRAP) in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO /US-FDA / EMA / MHRA / TGA/ PMDA / Swiss Medic or Health Canada or by regulatory authority/body of SRA country (es) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Tons of Glass material	Stability studies of quoted items duly attested by the Q.C incharge of the firm).	Availability of quoted items in Pakistan market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan.										
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70								
1	1	Metronidazole	Tab, 200mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
2	2	Metronidazole	Tab, 400mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
3	3	Metronidazole	Susp, 200mg/5ml, 120ml or less		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
4	36	Acetoclofenac	Tab, 100 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
5	47	Ibuprofen	Susp, 100 mg/ 5ml		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
6	52	Meloxicam	Tab, 15 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
7	53	Meloxicam	Tab, 7.5 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
8	60	Paracetamol	Tab, 500 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
9	61	Paracetamol	Susp,120 mg/ 5 ml		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
10	62	Paracetamol	Susp,250 mg/ 5ml		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
11	148	Fluconazole	Tab, / Cap, 150 mg 1s		2	2	3	0	5	2	Not Recommended in Mandatory Physical Inspection					14	0	5	5	0	0	4	5	0	19	33								
12	149	Fluconazole	Susp, 50 mg/5 ml		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
13	164	Cetirizine	Tab, 10 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
14	165	Cetirizine	Syp, 5 mg/5 ml 60 ml		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
15	170	Loratadine	Tab, 10 mg 10s		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
16	171	Montelukast	Tab, 10 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
17	173	Montelukast	Sachet 4 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
18	202	Azithromycin	Tab, / Cap, 250 mg 12s or less		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
19	203	Azithromycin	Tab, / Cap, 500 mg 6s		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
20	205	Azithromycin	Dry Susp, 200 mg/5ml 25ml or less		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
21	217	Cefixime	Cap, 400 mg 5s		2	2	3	0	5	2	Not Recommended in Mandatory Physical Inspection	14	0	5	5	0	0	4	5	0	0	4	5	0	19	33								
22	218	Cefixime	Dry Susp, 100 mg/5ml 30ml		2	2	3	0	5	2																								
23	219	Cefixime	Dry Susp, 200 mg/5ml 30ml		2	2	3	0	5	2																								
24	238	Cephadrine	Cap, 500 mg		2	2	3	0	5	2																								
25	241	Cephadrine	Dry Susp, 125mg / 5ml		2	2	3	0	5	2																								
26	242	Cephadrine	Dry Susp, 250 mg / 5ml		2	2	3	0	5	2	Not Recommended in Mandatory Physical Inspection	14	0	5	5	0	0	4	5	0	0	4	5	0	19	33								
27	243	Ciprofloxacin	Tab, 250 mg 10s		2	2	3	0	5	2																								
28	244	Ciprofloxacin	Tab, 500 mg 10s		2	2	3	0	5	2																								
29	277	Levofloxacin	Tab, 250 mg 10s		2	2	3	0	5	2																								
30	278	Levofloxacin	Tab, 500 mg 10s		2	2	3	0	5	2																								
31	383	Iron Hydroxide poly maltose complex	Tab, 100 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
32	384	Iron Hydroxide poly maltose complex	Syp, 50 mg/5ml		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
33	412	Amlodipine Besylate	Tab, 5 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	9	33								
34	413	Amlodipine Besylate	Tab, 10 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	9	33								
35	462	Losartan Potassium	Tab, 25 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
36	463	Losartan Potassium	Tab, 50 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
37	513	Domperidone	Tab, 10 mg		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43								
38	514	Domperidone	Susp, 5 mg/5ml 120 ml		2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	15	39								
39	527	Omeprazole	Cap, 40 mg		2	2	3	0	5	2	Not Recommended in Mandatory Physical Inspection					14	0	5	5	0	0	4	5	0	19	33								
40	528	Esomeprazole	Cap, 40mg		2	2	3	0	5	2	Not Recommended in Mandatory Physical Inspection	14	0	5	5	0	0	4	5	0	0	4	5	0	19	33								
41	532	Pantoprazole	Tab, 40mg		2	2	3	0	5	2																								
42	647	Flavored Oral Rehydration Salt (Low Osmolality)	Sachet Sodium Chloride Sachet (2.6 g/L)Glucose Anhydrous(13.5 g/L) PotassiumChloride (1.5 g/L)Trisodium citrate(2.9 g/L)		2	2	3	0	5	2	2	2	2	2	2	24	0	0	0	0	0	4	5	0	9	33								

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																		
Name of Firm				HIGHNOON LABORATORIES																														
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix								Product Evaluation Parameters				Total Product Evaluated Score	Total Technical Score				
					Documents Based Factory Score												Factory Evaluation Visit Score								Product Technical Parameters									
					1	2	3	4	5	6	7	8	9	10	11		12	13	14	15	16	17	18	19	20	21	22	23			24	25	26	
	Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, as in the following manner: 1. Firm having (12-Month) Ranking in top-10 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods in the factory for testing of the quoted items and adherence to practices (GMP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) as mentioned in schedule-B of product (G). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm. (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP Non-adherence to GSP shall lead to disqualification of the section/s or firm.	Availability of Functional and validated HVAC, with all relevant equipment, testing logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter. and / or His-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources, valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/inh,DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MIRA / TGA / PMDA / Swiss Medec or Health Canada or by regulatory authority/body of SRA's country (ies) coupled with Form 3 (Form of undertaking to accompany (GD) provided in column 18, duly attested by the senior executive of the firm). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/Syringes must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Class 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Document duly attested by the Senior executive of the firm).	Stability studies of quoted item/s duly attested by the Q.C. incharge of the firm) For terms specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Territory case Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 62 Tender approvals-01 mark 64 Tender approvals-02 marks 66 Tender approvals-03 marks 68 Tender approvals-04 marks 70 or more Tender approvals-05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same Brand name and specifications / strength/ dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies/etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted item/s in Pakistani market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For terms specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Territory case Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 62 Tender approvals-01 mark 64 Tender approvals-02 marks 66 Tender approvals-03 marks 68 Tender approvals-04 marks 70 or more Tender approvals-05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same Brand name and specifications / strength/ dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies/etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.																
Bid. No. of Item	Generic Name	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70								
1	337	Tah. Dacthavariv 60mg	Tah 60mg	Dacthavis 60mg	0	3	3	5	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	3	22	54								
2	354	Tah. Sofosbuvir 400mg	Tah 400mg	Fusha 400mg	0	3	3	5	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	2	21	53								
3	356	Tah. Sofosbuvir + Valopatesvir 400	Tah 400/1000mg	Fusha V 400/1000mg	0	3	3	5	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	2	21	53								
4	406	Tah. Aspirin 75mg	Tah 75mg	Luprin 75mg	0	3	3	5	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	2	21	53								
5	414	Tah. Amiodipine 5mg + Valartan 160mg	Tah 5/160mg	Biforge 5/160mg	0	3	3	5	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	1	20	52								
6	415	Tah. Amiodipine 5mg + Valartan 160mg	Tah 5/160mg	Biforge 5/160mg	0	3	3	5	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	1	20	52								
7	416	Tah. Amiodipine 10mg + Valartan 160mg	Tah 10/160mg	Biforge 10/160mg	0	3	3	5	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	1	20	52								

[illegible]

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																									
Name of Firm					HIMMEL LAHORE																				
S. No.	Product General Information				Technical Evaluation Matrix																				
					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation										Product Evaluated Score	Total Technical Score
														Principal Manufacturer Evaluation						Importer's Evaluation		Product Technical Parameters			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23		
					Valid ISO 14001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm) Online verification link shall be provided	Valid accreditation of manufacturing unit or its relevant sections by the USFDA or WHO or official accreditation body (ie: regulatory body in the case of SRA countries duly attested by senior executive of the firm)	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates released by Quality head of the firm)	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC experts)	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-stable drugs) (The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/Regulations framed by the DRAP. Nonadherence to GSP, as evaluated by the MCC experts at the time of inspection shall lead to disqualification of the firm.	Adequate availability of qualified. (Presence of Category-A Pharmacist/ senior mandatory). & relevant Human Resource (Certified by the senior executive of the firm & evaluated/ confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Bio-equivalency / Bio-equivalence study conducted by WHO / WHO Authorized Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral (i.e., greater than 100ml up to 5L, product validation report (as per WHO/USFDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided when the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Good Declaration certificate of imported finished quoted items from Pakistan Customs, coupled with valid assay bill or Bill of Lading (in the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid In-Link/DKIP clearance NCC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GDP) provided in column 15, duly attested by the senior executive of the firm. In case of Non-provision of matching GDP the marks for CoA will not be awarded. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, API source accreditation shall be awarded only where these documents are submitted for all API components of the quoted products. In case where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NCT bid submission.	Active Pharmaceutical Ingredient's (API) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA / Swiss Medics or Health Canada or by regulatory authority/body of SRA country (ies) Trial of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, API source accreditation shall be awarded only where these documents are submitted for all API components of the quoted products.	Valid WHO prequalification certificate issued by regulatory body of any SRA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. 2 mark for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificate duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/ proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials (e.g., Aluminium Foil, PVC, Capsule Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1. (Non-compliance shall lead to disqualification of the quoted product) 3. Type of Glass material for Oral Syringe / Syringes must be USP Type 1 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables,	Stability studies of quoted items duly attested by the Q.C. (in charge of the firm) 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/RVIA data is not applicable, the bidder shall provide Tender Approvals (not older than twelve (12) months from Tertiary care Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 60 Tender approvals-01 mark 64 Tender approvals-02 marks 66 Tender approvals-03 marks 68 Tender approvals-04 marks 69 or more Tender approvals-05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase order, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.					
	Ref. No. of item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70		
Atabay Kerney	363	Enoxaparin	Inj. 40 mg	Enox	0	0	2	0	0	4	5	5	16	0	5	5	0	0	0	5	0	15	31		
Atabay Kerney	364	Enoxaparin	Inj. 60 mg	Enox	0	0	2	0	0	4	5	5	16	0	5	5	0	0	0	5	0	15	31		
Atabay Kerney	365	Enoxaparin	Inj. 80 mg	Enox	0	0	2	0	0	4	5	5	16	0	5	5	0	0	0	5	0	15	31		
Duapharm	382	Heparin Sodium	Inj. 5000 IU/ml	Unihopa	0	0	0	0	0	4	5	5	14	0	5	5	0	0	0	5	0	15	29		
Veldepharm	407	Adenosine	Inj.	Caden	0	0	0	5	0	4	5	5	19	0	5	5	0	2	0	5	0	17	36		

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																										
Name of Firm				Hiran Pharma Karachi.																						
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix									
					Documents Based Factory Score					Factory Evaluation Visit Score							Product Evaluation Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th position-4 marks. 3. Firms having (12-Month) ranking between 41st to 80th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 101st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment used in the factory for Measuring, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs - Functional Stability Chamber (Both Accelerated and Real Time) in Schedule-B of DRAP (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, in-process and finished goods storage (as in Schedule-B of DRAP), in evaluated at the time of inspection by the MCC experts. Non-compliance to GMP shall lead to disqualification of the firm.	Adherence to GMP guidelines, (as in Schedule-B of DRAP), in evaluated at the time of inspection by the MCC experts at the time of inspection. Non-compliance to GMP shall lead to disqualification of the section's or firm).	Adequate availability of qualified relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-compliance to GMP shall lead to disqualification of the section's or firm).	Availability of functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.		Bio-availability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) and / or Bio-waiver certificate from a accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of the quoted items from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of purchases through third party importers a valid valid DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / PMDA/ Swiss Medc or Health Canada or by regulatory authority/body of SRA's country (es) coupled with Form 3 (Form of undertaking to accompany an application for License to import Drugs) Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese, pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Injecs/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm)	Stability studies of quoted items duly attested by the Q.C. incharge of the firm). 1+10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specification / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency(ies), etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.			
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	23	5	5	5	3	4	5	5	37	70	
1	101	Mycophenolate Mofetil	Tab / Cap. 500 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
2	105	Tacrolimus	Tab / Cap. 1mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
3	106	Tacrolimus	Tab/ Cap. 0.5 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
4	148	Plicetazole	Tab / Cap. 150 mg 1s		2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	5	0	5	33	
5	152	Itraconazole	Cap. 100 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
6	158	Terbinafine	Tab. 250 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	5	0	5	33	
7	171	Montelukast	Tab. 10 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	5	0	5	33	
8	202	Azithromycin	Tab / Cap. 250 mg 12s or 500 mg 6s		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
9	203	Azithromycin	Tab / Cap. 500 mg 6s		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
10	243	Ciprofloxacin	Tab. 250 mg 10s		2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	5	0	5	33	
11	244	Ciprofloxacin	Tab. 250 mg 10s		2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	5	0	5	33	
12	277	Levofloxacin	Tab. 250 mg 10s		2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	5	0	5	33	
13	278	Levofloxacin	Tab. 500 mg 10s		2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	5	0	5	33	
14	279	Lincomycin	Cap. 500 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
15	288	Moxifloxacin	Tab. 400 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
16	414	Amlodipine + Valsartan	Tab. 5mg+80 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
17	415	Amlodipine + Valsartan	Tab. 5mg+160 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
18	416	Amlodipine + Valsartan	Tab. 10 mg+160 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
19	482	Rosuvastatin	Tab. 10 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
20	520	Ibuproide	Tab. 150mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	10	38	
	528	Esomeprazole	Cap 40 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	5	0	5	33	
	532	Pantopranole	Tab/Cap 40 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
21	580	Prednisolone	Tab. 5 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	5	33	
22	583	Stagglitin + Metformin	Tab. 50 mg/500 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
23	683	Febuxostat	Tab. 40 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	0	0	0	5	0	10	38	
24	684	Febuxostat	Tab. 80 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	0	0	0	5	0	10	38	
25	687	Bundronic Acid	Tab. 150mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	0	0	0	5	0	5	33	
26	701	Carbamazepine	Tab. 200 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
27	702	Carbamazepine	Syr. 100 mg / 5 ml 120 ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
28	717	Duloxetine	Cap. 30 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	0	0	0	5	0	10	38	
29	719	Divalproex Sodium	Tab. 250 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43	
30	720	Divalproex Sodium	Tab. 500 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	0	5	0	0	5	0	10	38	
31	723	Eucalyptum	Tab. 10 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	0	0	0	5	0	10	38	
32	733	Levetiracetam	Tab. 250 mg		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	10	38	

[illegible]

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																							
Name of Firm					HOECHST, KARACHI (IMPOTER)																		
S. No.	Product General Information				Technical Evaluation Matrix																		
					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation									
					Principal Manufacturer Evaluation				Importer's Evaluation					Product Technical Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
					Valid ISO 14001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm)	Valid accreditation of manufacturing equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, process material and finished products for the manufacturing of the quoted products	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, process material and finished products for the manufacturing of the quoted products	Availability of minimum 20% inventory of the total import of the quoted items during last one year certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert's	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs)	Adequate availability of qualified, experienced & relevant Human Resource		Bioassayability / Bioequivalence study conducted by WHO / USFDA / EMA / MHRA / TGA / PMDA / Swiss Medix or Health Canada or by regulatory authority/body of SRA country (ies)	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GDD) provided in the quoted items, not older than 24 months on the cutoff date for submission of bids	In case of Non-provision of matching CD the marks for C&A will not be awarded.	Moreover, in case of product quoted item having multiple APIs, the marks for C&A, API source accreditation shall be awarded only when these documents are submitted for all APIs/components of the quoted products	Valid certificate of the availability of the quoted item in the US market	For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium foil, PVC, Capable Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP Class 1 (Non-compliance shall lead to disqualification of the quoted product)	2 mark for each certification, up to a maximum of 06 marks	For items specifically used in institutions where IMS/QVIA data is not applicable the holder shall provide / Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or Accredited private hospitals of Pakistan	For items specifically used in institutions where IMS/QVIA data is not applicable the holder shall provide / Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or Accredited private hospitals of Pakistan		
					Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	(Valid Calibration Certificates attested by Quality head of the firm)	Non-availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted items / (Item)	The physical inspection committee / MCC experts shall verify the compliance to the GSP in accordance to the last down criteria and terms and conditions of the Drug Regulatory Authority	(Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm)		In case of purchases through third party importers, a valid trail/trail/CDAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	In case of Non-provision of matching CD the marks for C&A will not be awarded.	Moreover, in case of product quoted item having multiple APIs, the marks for C&A, API source accreditation shall be awarded only when these documents are submitted for all APIs/components of the quoted products	Valid certificate of the availability of the quoted item in the US market	For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium foil, PVC, Capable Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP Class 1 (Non-compliance shall lead to disqualification of the quoted product)	2 mark for each certification, up to a maximum of 06 marks	For items specifically used in institutions where IMS/QVIA data is not applicable the holder shall provide / Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or Accredited private hospitals of Pakistan	For items specifically used in institutions where IMS/QVIA data is not applicable the holder shall provide / Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or Accredited private hospitals of Pakistan			
																						</	

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																										
Name of Firm				HOECHST, KARACHI (MANUFACTURER)																						
S. No.	Product General Information				Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Technical Evaluation Matrix										
					Documents Based Factory Score					Factory Evaluation Visit Score						Product Evaluation Parameters										
																Product Technical Parameters										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/RQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered)	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted item and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, in area / section of the quoted product(s).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Evaluated at the time of inspection, Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).	Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Bioavailability / Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Springer Regulatory Authorities). In case of Large volume parenteral (i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of that quoted item from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cut-off date for submission of bids. In cases where Raw material is acquired from Local sources valid invoice (to not older than 24 months) shall be considered.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MIRA / TGA / PMDA / Swiss Medics or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, API source accreditation shall be awarded only where these documents are submitted for all API components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter head shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe / Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). Documents duly attested by the Senior executive of the firm)	Stability studies of quoted items duly attested by the Q.C. incharge of the firm).	Availability of quoted item/s in Pakistan market as per recent most date of IMS/RQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/RQVIA data is not applicable, the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and /or NCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned governing entities and accompanied with purchase order.		
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70	
2	Metronidazole	Tab. 400mg	Flagyl	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	5	24	57	
3	Metronidazole	Susp. 200 mg/5ml	Flagyl	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	5	24	57	
4	Metronidazole	Inf. 500 mg 100ml	Flagyl	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	5	24	57	
648	Gelatin Polypeptide	Inf. 3.5%, 500ml	Haemacel	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	5	24	57	
481	Ramipril	Tab. 5mg	Tritace	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54	
572	Metformin	Tab. 500mg	Medipar	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53	
515	Drotaverine	Tab. 40mg	Nospa	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	5	24	57	
553	Glibenclamide	Tab. 5mg	Daonil	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	5	24	57	
441	Furosemide	Tab. 40mg	Lasix	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	5	24	57	

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																										
Name of Firm				3H Hoffman, Lahore																						
S. No.	Product General Information			Technical Evaluation Matrix																			Product Evaluated Score	Total Technical Score		
				Principal's and Importer's Evaluation Parameters										Suppliers Technical Score	Product Technical Evaluation											
	Principal Manufacturer Evaluation					Importer's Evaluation					Product Technical Parameters														Product Availability	
	1	2	3	4	5	6	7	8	9	10	11	12	13		14	15	16	17	18	19	20	21				22
					Valid ISO 14001:14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) duly attested by senior executive of the firm	Valid ISO 14001:14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) duly attested by senior executive of the firm	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) duly attested by senior executive of the firm	Valid accreditation of manufacturing unit as in relevant section by the USFDA or WHO or official accreditation body in regulatory body in the case of SRA countries duly attested by senior executive of the firm	Valid addition certificate for equipment installed general items for Facility for Manufacturing, weighing, Analyze, Analysis of raw material in process material and finished products for the manufacturing of the quoted products.	Availability of minimum 20% inventory of finished product from the quoted source for the period exceeding the shelf life of the product as declared by the firm and attested by the senior executive of the firm	Adherence to Good storage practices (GSP) for storage of finished product and effective Air-conditioning & Ventilation System to ensure effective cold chain (thermo-stable drugs)	Adequate availability of qualified, Phosphate of Calcium & Phosphate sodium mandatory, & relevant Human Resource	House-utility: Bioware/ventilation study conducted by WHO Auditing Labs must be attached along with the bid and study must be available in the case of SRA countries (WHO White)	Goods Declaration certificate of imported finished general items from the Principal Manufacturer countries, coupled with valid entry bill or Bill of Lading for the quoted items, not older than 24 months as on the start date for the purchase of the firm	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (CO) provided in column 15, duly attested by the senior executive of the firm	Active Pharmaceutical Ingredient (API) source accreditation certificate issued by WHO/USFDA/EMA/MBRA/TCG/PMDA/ Swiss Medical & Health Canada or by regulatory authority body of SRA country (ies)	Total of principal manufacturer shall be established from the respective GID card and other supporting documents.	Valid WHO prequalification certificate issued by WHO/USFDA/EMA/MBRA/TCG/PMDA/ Swiss Medical & Health Canada or by regulatory authority body of SRA country(ies)	Valid Certificate of Analysis of the Type/ Class of finished and for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase	Stability studies of quoted items duly attested by the QCT, including of the firm	Availability of quoted items in Pakistan market as per recent most data of (MSKVIA) Health and welfare twice (12 months)					
					Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	(Valid Calibration Certificates attested by Quality head of the firm)	Non availability of the 20% stock at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	The physical inspection committee/ MCC's experts at the time of inspection of the importer shall verify the compliance to the GSP as accordance to the bid documents and terms and conditions of the Drug Sales Rules/ Medical Device Regulations issued by the DRAP.	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)	As per MCC's experts at the time of inspection of the importer shall lead to disqualification of the quoted items (firm)				
					Ref. No. of Item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	2	5	5	4	5	30	5	5	5	5	5	40	70			
85		Cyclosporine	Cap. 25mg	Cipol-n	2	2	0	0	0	4	5	18	0	5	5	0	0	0	0	0	10	28				
87		Cyclosporine	Cap. 100mg	Cipol-n	2	2	0	0	0	4	5	18	0	5	5	0	0	0	0	0	5	15	33			

Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																						
Name of the firm					HOORA PHARMA PVT LTD																	
S. No.	Product General Parameter				Technical Evaluation Matrix																	
					Principal's and Importer's Evaluation Parameters						Product Technical Evaluation										Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20			
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacists/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s)	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s shall lead to disqualification of the said item/s.					
	Ref. No. of item in MCC Formulary	Generic Name of Item		Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70		
1	1270	Ligaclip LT300		Ligaclip LT300	LT300	0	0	0	The Inspection team inspected the firm as per the advertised criteria and observed the following: The items quoted are registered with DRAP in the name of Johnson & Johnson and not in the name of importer. Thereby not fulfilling the mandatory criteria of DRAP registration as mentioned in the bid form-1. In view of the above, the firm is NOT-RECOMMENDED.			0	0	0	0	0	10	10	20	20		
2	1271	Ligaclip LT400		Ligaclip LT400	LT400	0	0	0				0	0	0	0	0	10	10	20	20		
3	1307	Black Braided Silk, size 3-0, 26mm, 1/2 circle, Taperpoint Plus, single needle, length 75cm.	Mersilk , SIZE 3-0 , 26MM , 1/2 CIRCLE , Taperpoint Plus , SINGLE NEEDLE , 75CM	Mersilk	0	0	0	0				0	0	0	0	10	10	20	20			
4	1310	Black Braided Silk, size 2-0 , 30mm , 1/2 CIRCLE , Taperpoint , single needle, length 75cm.	Mersilk , SIZE 2-0 , 30MM , 1/2 CIRCLE , Taperpoint , SINGLE NEEDLE , 75CM	Mersilk	0	0	0	0				0	0	0	0	10	10	20	20			
5	1313	Black Braided Silk, size 1 , 31mm , 1/2 circle, Taperpoint , single needle , length 75cm.	Mersilk , SIZE 1 , 31MM , 1/2 CIRCLE , Taperpoint , SINGLE NEEDLE , 75CM	Mersilk	0	0	0	0				0	0	0	0	10	10	20	20			
6	1316	Black Braided Silk, size 2 , 40mm , 1/2 circle, Taperpoint , single needle , length 75cm.	Mersilk , SIZE 2 , 40MM , 1/2 CIRCLE , Taperpoint , SINGLE NEEDLE , 75CM	Mersilk	0	0	0	0				0	0	0	0	10	10	20	20			
7	1318	Polyglactin 910, size 6-0 , 8mm , 1/4 circle, Spatula Reverse Cutting , double needle, length 45cm.	Vicryl , SIZE 6-0 , 8MM , 1/4 CIRCLE , Spatula Reverse Cutting , DOUBLE NEEDED , 45CM	Coated Vicryl	0	0	0	0				0	0	0	0	10	10	20	20			
8	1320	Polyglactin 910, size 6-0, 13mm, 1/2 circle, Taperpoint, single needle, length 45cm.	Vicryl , SIZE 6-0 , 13MM , 1/2 CIRCLE , Taperpoint , SINGLE NEEDLE , 45CM	Coated Vicryl	0	0	0	0				0	0	0	0	10	10	20	20			
9	1327	Triclosan Coated Plus Antibacterial (Polyglactin 910) Violet 4/0, 22mm, SH-1, 1/2 Taper Point, 70cm Length.	Vicryl Plus , SIZE 4-0 , 22MM , 1/2 CIRCLE , Taperpoint , SINGLE NEEDLE , 70CM	Vicryl plus	0	0	0	0				0	0	0	0	10	10	20	20			
10	1330	Triclosan Coated Plus Antibacterial (Polyglactin 910) Violet 3/0, 22mm, SH-1, 1/2 Taper Point, 70cm Length.	Vicryl Plus , SIZE 3-0 , 22MM , 1/2 CIRCLE , Taperpoint Plus , SINGLE NEEDLE , 70CM	Vicryl plus	0	0	0	0				0	0	0	0	10	10	20	20			
11	1331	Triclosan Coated Plus Antibacterial (Polyglactin 910) Violet 3/0, 26mm, SH, 1/2 Taper Point, 70cm Length.	Vicryl Plus , SIZE 3-0 , 26MM , 1/2 CIRCLE , Taperpoint Plus , SINGLE NEEDLE , 70CM	Vicryl plus	0	0	0	0				0	0	0	0	10	10	20	20			
12	1332	Triclosan Coated Plus Antibacterial (Polyglactin 910) Violet 2/0, 26mm, SH, 1/2 Taper Point, 70cm Length.	Vicryl Plus , SIZE 2-0 , 26MM , 1/2 CIRCLE , Taperpoint Plus , SINGLE NEEDLE , 70CM	Vicryl plus	0	0	0	0				0	0	0	0	10	10	20	20			
13	1333	Triclosan Coated Plus Antibacterial (Polyglactin 910) Violet 2/0, 31mm, MH-1, 1/2 Taper Point, 70cm Length.	Vicryl Plus , SIZE 2-0 , 31MM , 1/2 CIRCLE , Taperpoint Plus , SINGLE NEEDLE , 70CM	Vicryl plus	0	0	0	0				0	0	0	0	10	10	20	20			

Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																					
Name of the firm																					
75 Hospital Sales and Services Karachi																					
S. No.	Product General Parameter				Principal's and Importer's Evaluation Parameters							Technical Evaluation Matrix								Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation		Suppliers Technical Score		Product Technical Evaluation									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20		
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant sections by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted items during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC experts). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted items. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacists is mandatory) & relevant Human Resource (Certified by the senior executive of the firm & evaluated/ confirmed by MCC experts at the time of inspection as non-compliance in this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/trail/DRAP clearance NDC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency i.e., etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance/ Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (MHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products. The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC experts. Rejection of the quoted item/s by the MCC experts shall lead to disqualification of the said item/s.				
	Ref. No. of Item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70		
1	1016	Disposable Auto Disable Syringe (Blister packing) sterile	3ml	Yushou	3	5	5	5	5	4	27	5	5	0	6	10	10	36	63		
1	1017	Disposable Auto Disable Syringe (Blister packing) sterile	5ml	Yushou	3	5	5	5	5	4	27	5	5	0	6	10	10	36	63		

Name of Firm				Hudson Pharma				Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2023-26																										
S. No.	Product General Information				Factory Technical Evaluation Parameters																		Total Factory Evaluated Score		Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Factory Evaluation Visit Score														Product Technical Parameters											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26								
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	Valid ISO 18001/45001	Valid ISO 14001 certificate	Valid ISO 9001 certificate of	Latest BMS/QVIA ranking of	Valid calibration certificates	Valid documents of the	Availability of calibrated	Raw material, In-process	Adherence to cGMP	Adequate availability of	Availability of Functional and		Bioavailability	Goods Declaration	Certificate of Analysis of API	Active Pharmaceutical	Valid WHO prequalification	Valid Certificate of Analysis	Stability studies of quoted	Availability of quoted Item/s										
					2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70								
1	48	Ketorolac Tromethamine 30mg / 1ml Inj	30mg/ml	Torason 30mg/1ml Inj	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	9	35								
2	177	Amikacin Sulfate 100mg / 2ml Inj	100mg/2ml	Amak 100mg / 2ml Inj	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								
3	178	Amikacin Sulfate 250mg / 2ml Inj	250mg/2ml	Amak 250mg / 2ml Inj	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								
4	179	Amikacin Sulfate 500mg / 2ml Inj	500mg/2ml	Amak 500mg / 2ml Inj	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								
5	387	Iron Sucrose 100mg / 5ml	100mg/5ml	Ferris 100mg / 5ml	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								
6	788	Bedomethasone Dipropionate 0.8mg / 2ml	0.8mg/2ml	Beeko 0.8mg / 2ml Nebulization Suspension	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								
7	803	Ipratropium Bromide 0.025% / 2ml	0.025%/2ml	Esechale 0.025% / 2ml Respules	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								
8	805	Ipratropium Bromide + Salbutamol 0.5mg + 2.5mg / 2.5ml		Combihale 0.5mg+2.5mg/2.5ml Respules	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								
9	822	Brinzolamide + Brimonidine Tartrate 10mg + 2mg / 5ml	BrimonidineTartrate10mg+ 2mg/mg	Colbrino 10mg+2mg/5ml Eye Drop	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								
10	837	Moxifloxacin HCL 0.5% / 5ml	0.5%/5ml	Moxiept 0.5% / 5ml Eye Drop	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	9	35								
11	850	Tobramycin + Dexamethasone 0.3% + 0.1% / 5ml	0.3% + 0.1%/5ml	Tobroid 0.3%+0.1% / 5ml Eye Drop	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								
12	851	Travoprost 0.004% / 2.5ml	0.004%/2.1	Travson 0.004% / 2.5ml Eye Drop	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								
13	912	Cholecalciferol 5mg / 1ml Oral / M	/1mlOral/Oral	Vydee 5mg / 1ml Oral / M	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45								

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																
	Name of the firm				IBL Healthcare, Karachi																
					Technical Evaluation Matrix																
Principal's and Importer's Evaluation Parameters											Product Technical Evaluation					Product Evaluated Score	Total Technical Score				
Principal Manufacturer Evaluation					Importer's Evaluation			Suppliers Technical Score													
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19		
					Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good Storage	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical		
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	6	6	30	5	5	5	3	6	16	40	70		
	938	Single Blood Bag 500ml, CPDA-1	500ml	WEGO Single Blood Bag	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
	939	Single Blood Bag 250ml, CPDA-1	250ml	WEGO Single Blood Bag	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
	940	Double Blood Bag 500ml, CPDA-1	500ml	WEGO Double Blood Bag	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
	942	Triple Blood Bag 500ml, CPDA-1	500ml	WEGO Triple Blood Bag	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
	944	Blood Transfusion Set	sterile and pyrogen free, minimum 125cm tube length, blister pack	WEGO Blood Transfusion Set	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
	1126	I/V Chamber Burette 100ml	100ml	WEGO	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53		
Kawasumi Japan	938	Single Blood Bag 500ml, CPDA-1	500ml	Single Blood bags	3	5	0	The original EC certificate is not presented to the inspection team at the time of inspection. Moreover, the principal manufacturer has applied for the conformation letter for CE certificate i.e. Conformation letter was not present at the time of inspection. Hence, not recommended in the mandatory inspection			8	5	5	0	0	0	16	26	34		
Kawasumi Japan	940	Double Blood Bag 500ml, CPDA-1	500ml	Double Blood bags	3	5	0				8	5	5	0	0	0	16	26	34		

					Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																
Name of the firm					IBL Healthcare, Karachi																
S. No.	Product General Parameter				Technical Evaluation Matrix															Product Evaluated Score	Total Technical Score
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation									
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20		
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm). In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert's). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for Category-A Pharmacist/s is / are mandatory), & relevant Human Resource The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attasted by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 04 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Physical examination of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.						
	Ref. No. of Item in MCC	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70		
	1112	I/V fluid administration sets	(sterile, minimum 150cm)	WEGO	3	5	0	Valid CGMP and free sale certificates/COPPs of the quoted items duly attested from the embassy concerned were present at the time of inspection except IV Set and IV set with Y-port were not covered in the scope of conformation letter of CE certificate of Shandong Weigo China. Moreover, IV set with Y-port is not enlisted with DRAP.			8	5	5	0	2	10	10	32	40		
	1113	I/V fluid administration sets (sterile, minimum 150cm with Y Port)	Y-Port	WEGO	3	5	0				8	0	0	0	2	10	10	22	30		

Name of the firm					INJECTION SYSTEM PVT LTD																		
S.No	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	4						Product technical Evaluation Parameters		Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score														
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21			
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC (accredited body duly attested by senior executive of the firm) <u>Online verification link shall be provided.</u>	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by PNAC (accredited body duly attested by senior executive of the firm) <u>Online verification link shall be provided.</u>	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. <u>[Valid Calibration Certificates attested by Quality head of the firm]</u>	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks <u>(The document shall be attested by a Senior executive of the firm)</u>	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. <u>(to be evaluated at the time of inspection by the MCC experts. Non adherence to GSP shall lead to disqualification of the firm.</u>	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAAP regulations. <u>(to be evaluated by the MCC experts at the time of inspection. Non-compliance to cGMP shall lead to disqualification of the relevant section or firm)</u>	Availability of Functional and validated HVAC, with all relevant equipment, testing, and logs. <u>(As evaluated by the MCC experts at the time of inspection)</u>	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAAP regulations. <u>(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the section/s or firm).</u>		Goods Declaration certificate of imported raw material of the quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. <u>In case of purchases through third party Importers a valid trail/bill/DRAAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC</u> <u>(Certificate Duly attested by Senior Executive of the firm)</u>	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods Declaration (GD) provided in column 14, duly attested by the senior executive of the firm. <u>In case of Non-provision of matching GD the marks for CoA will not be awarded.</u> Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks <u>2 marks for each certification, up to a maximum of 06 marks.</u> <u>Certificates on company's own letter heads shall not be acceptable.</u> <u>(copies of relevant certificates duly attested by the senior executive of the firm)</u>	Valid WHO prequalification and / or valid product registration in SRA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products by the MCC experts)	Physical examination of the quoted items by the MCC experts. Rejection of the quoted items by the MCC experts shall lead to disqualification of the said item/s.				
	Ref. No. of Item in MCC Formulary	Generic Name of Item	Size & Gauge of Medical Device	Trade Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70		
1	1015	Disposable Auto Disable Syringe (Blister packing) sterile	2ml	Biosafe	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57		
2	1016	Disposable Auto Disable Syringe (Blister packing) sterile	3ml	Biosafe	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57		
3	1017	Disposable Auto Disable Syringe (Blister packing) sterile	5ml	Biosafe	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57		
4	1020	Disposable Syringe Ordinary (Blister packing) sterile	1ml	Biosafe	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57		
5	1021	Disposable Syringe Ordinary (Blister packing) sterile	10ml	Biosafe	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57		
6	1022	Disposable Syringe Ordinary (Blister packing) sterile	20ml	Biosafe	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57		
7	1023	Disposable Syringe Ordinary (Blister packing) sterile	50ml	Biosafe	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57		
8	1024	Disposable Syringe Ordinary (Blister packing) sterile	60ml	Biosafe	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57		
9	1025	Disposable Syringe Ordinary with nozzle/catheter tip (Blister packing) sterile	60ml	Biosafe	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57		

10	1112	I/V fluid administration set	sterile and pyrogen free, minimum 150cm tube length, blister pack	Biosafe	3	5	5	4	The firm was inspected by the inspection team as per technical evaluation criteria, and the following observations were made: Non-functional HVAC System and Poor environmental controls: 1. HVAC was not functioning properly at the time of inspection, in the Infusion set section. 2. No environmental control recording devices were available in the release area of Infusion set section at the time of inspection. 3. The environmental control devices in the infusion set manufacturing area were not functioning properly. 4. The Emergency Exit door was open during assembling process of the Infusion set thereby compromising environmental controls. 5. The production of Infusion set was carried on in contaminated environment due to the open emergency exit.	17	5	5	0	0	10	10	30	47
11	1113	I/V fluid administration set with additional "Y" injection port	Sterile, minimum 150cm length tubing, latex, and pyrogen free, blister pack	Biosafe	3	5	5	4	6. Humidity in the Packing area of the infusion set was 70%, in contravention to the upper limit of 65%. Poor Good Laboratory Practices (GLP): 7. GLP were not observed in the infusion set section at the time of inspection 8. Media control of sterility were not available in the microbiology section of the QC at the time of inspection. Poor adherence to cGMP: 9. Compromised area control was observed in the Infusion set manufacturing section. In view of the above findings, the firm is RECOMMENDED for the quoted items except infusion set/Intravenous administration set Section.	17	5	5	0	0	10	10	30	47

					Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																				
Name of the firm					Innovate Medical Technologies Karachi																				
S. No.	Product General Parameter				Technical Evaluation Matrix															Product Evaluated Score	Total Technical Score				
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation													
					Principal Manufacturer Evaluation			Importer's Evaluation														Suppliers Technical Score			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20						
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only.(verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products,	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.									
	Ref. No. of	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70						
Yasemin Turkey	1173	Paraffin Gauze dressing (Tulle) with Chlorhexidine	10x10 cm Hexatulle Dressing	DRAP Reg. NA	0	5	0	GRC Decision: The firm failed to submit the mandatory DRAP registration under bid-form 1 (8)(ii). Hence not recommended.							0	0	0	0	0	0					
Yasemin Turkey	1174	Paraffin Gauze dressing (Tulle) with Chlorhexidine	15x20cm Hexatulle Dressing	DRAP Reg. NA	0	5	0								0	0	0	0	0	0	0				

Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																					
Name of the firm						Innovate Medical Technologies Karachi															
						Technical Evaluation Matrix														Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters						Product Technical Evaluation									
						Principal Manufacturer Evaluation			Importer's Evaluation												
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19			
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or UNFPA or official accreditation body/es/regulatory body/ies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC Duly attested by the	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. (In case of non-provision of matching GD the marks for GD will not be awarded).	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s)	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union (Verification link shall be provided), and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US FDA (510 K) / US free sale certificate of the quoted products	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Product Evaluated Score	Total Technical Score			
	S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	6	6	30	5	5	5	3	6	16	40	70	
	954	Calcium Alginate Dressing	7.5cm x12cm	IMT Kalgistat	Zhejiang Kanglidi China	GRC Decision; The firm failed to submit the mandatory DRAP registration under bid-form 1 (8)(ii), Hence not recommended.				5	6	6	17	5	0	0	0	16	21	38	
	955	Calcium Alginate Dressing	10 cm x 20cm	IMT Kalgistat	Zhejiang Kanglidi China					5	6	6	17	5	0	0	0	16	21	38	
	956	Calcium Alginate Dressing	15cm x 25cm	IMT Kalgistat	Zhejiang Kanglidi China					5	6	6	17	5	0	0	0	16	21	38	
	957	Calcium Alginate Dressing	Rope 2gm	IMT Kalgistat Rope	Zhejiang Kanglidi China					5	6	6	17	5	0	0	0	16	21	38	

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injctable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																				
Name of Firm				Ipsram Pharma Rawalpindi																																
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix												Total Product Evaluated Score	Total Technical Score						
					Documents Based Factory Score						Factory Evaluation Visit Score						Product Evaluation Parameters																			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15		16	17	18	19	20	21	22	23	24	25	26									
					Valid ISO 18001:2015 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firm having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 at least. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all phases - Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP (Evaluated at the time of inspection by the Inspection team during inspection made following observations: 1. Diclofenac Sodium (API) in raw material store was placed in released area but no QC number was allotted to it for the identification purposes as required under good storage practices. 2. Released labels on Diclofenac sodium were not affixed/placed on all containers. 3. Stability chambers were on ground floor while quality control was on first floor, thereby compromising good laboratory practices. 4. The temperature and humidity recorded by inspection team for accelerated stability chamber was 37 C & 46 H, which is out of the range specified under ICH guidelines. 5. Similarly, the temperature and humidity recorded by inspection team for real time stability chamber was 33.4 C & 56 H, which too is out of range specified under ICH guidelines. 6. In filling area of liquid injectable entry of personnel and material was same which is in clear disregard of good manufacturing practices for sterile products. 7. Optical checking worker when asked about protocols was ignorant of differentiation between bubbles and dust particles which amounts to non-compliance of SOPs/Guidelines under cGMP of sterile products. 8. Samples placed in cold incubators after sterility testing were not properly labeled while those in hot incubators were not labeled at all thereby compromising good laboratory practices. 9. The raw data in the form of calculations and ancillary evidence was not shown for Sodium Meta Bisulphite (raw material) and nor was any reference made towards such raw data in the final test and analysis report in violation of Good Laboratory & Good documentation practices. 10. In carbapenim section optical checking was carried out in in-process quarantine which is a dedicated area for the storage of in-process/intermediate materials and is thus against good manufacturing practices. 11. In Cephalosporin area quarantine had no supply of HVAC or any other alternate arrangement for maintaining temperature and humidity thereby compromising good storage practices. Since the above observations are not in accordance with criteria laid down for the evaluation of physical inspection of the firm and good manufacturing practices, good storage practices and good laboratory practices, therefore, the firm is NOT RECOMMENDED for the award of marks as specified for physical inspection in the relevant pro-forma	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts)	Adherence to GMP guidelines (as per of the quoted product (s)). Non-compliance to GMP guidelines shall lead to disqualification	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs (As evaluated by the MCC experts at the time of inspection).	Non-availability or non-functionality of	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO (Vebite) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)	In case of Large volume parenteral i.e., greater than 100ml upto 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted.	In case of purchases through third party importers a valid																	
1	11	Atracurium	Inj. 10mg/mL 5ml		2	2	3	5	5	6	23	5	5	5	5	3	4	5	5	5	3	4	5	5	37	60										
2	41	Diclofenac Sodium (IM/IV formulation)	Inj. 25 mg/ml 3 ml		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	1	20	36											
3	48	Retorolac	Inj. 30 mg/ml 1ml		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	19	35												
4	177	Amikacin Sulphate	Inj. 100mg		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	15	31													
5	178	Amikacin Sulphate	Inj. 250mg		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	3	18	34												
6	179	Amikacin Sulphate	Inj. 500mg		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	3	18	34												
7	202	Azithromycin	Tab. / Cap. 250 mg, 125 or 500 mg/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	3	18	34												
8	215	Cefepime	Inj. 500 mg/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	0	19	35												
9	216	Cefepime	Inj. 1 gm/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	0	17	33												
10	217	Cefixime	Cap. 400 mg 5s		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	0	19	35											
11	218	Cefixime	Dry Susp. 100 mg/5ml 30ml		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	0	19	35											
12	219	Cefixime	Dry Susp. 200 mg/5ml 30ml		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	0	19	35											
13	220	Cefoperazone + Sulbactam	Inj. 1gm/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	2	5	0	17	33												
14	221	Cefoperazone + Sulbactam	Inj. 2 gm/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	2	5	0	17	33												
15	222	Cefotaxime Sodium	Inj. 250 mg/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	0	17	33												
16	223	Cefotaxime Sodium	Inj. 500 mg/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	0	17	33												
17	224	Cefotaxime Sodium	Inj. 1gm/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	0	17	33												
18	230	Ceftriaxone	Inj. 500 mg/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	0	17	33												
19	231	Ceftriaxone	Inj. 1gm/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	5	0	17	33												
20	238	Cephradine	Cap. 500 mg		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	1	20	36											
21	241	Cephradine	Dry Susp. 125mg / 5ml		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	1	20	36											
22	242	Cephradine	Dry Susp. 250 mg / 5ml		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	1	20	36											
23	273	Imipenem + Cilastatin	Inj. 500 mg+500mg / 5ml		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	2	5	1	18	34											
24	285	Meropenem	Inj. 500 mg/Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	2	5	1	17	33											
25	286	Meropenem	Inj. 1gm /Vial		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	2	5	1	18	34											
26	388	Mecobalamin	Inj. 500 mcg 1ml		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	1	20	36											
27	527	Omeprazole	Cap. 40 mg		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	2	21	37											
28	912	Cholecalciferol (Vitamin D3)	IM/ Oral Inj. 200000 IU 1ml		2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	0	4	5	2	21	37											

Observations:
The 48% sources attached in the bid at page 299-489 are not according to the advertised criteria (older than 05 years)
COA/Proof of purchase are not attached for amikacin 300, 250, 500 mg.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
Name of Firm					JHK PHARMA PVT LTD																							
S. No.	Product General Information				Factory Technical Evaluation Parameters														Total Factory Evaluated Score	Technical Evaluation Matrix							Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score										Factory Evaluation Visit Score					Product Evaluation Parameters								
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18		19	20	21	22	23	24	25		
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysts of raw material, in-process material and finished products for the manufacturing of the quoted product. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted item along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as per Schedule-B of DRAP)	Raw material, In-process and finished goods storage (as in Schedule-B of DRAP), (as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, (as in Schedule-B of DRAP, (as evaluated at the time of inspection by the MCC experts).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).	Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm. Non-adherence to GSP shall lead to disqualification of the firm. (Evaluated at the time of inspection by the MCC experts, as non-functionality of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Bio-availability/ Bioequivalence study conducted by WHO Andral Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter; and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/USFDA/USP guidelines) shall be submitted. and / or Proof of invoice / innovator products from relevant body shall be provided where the firm claims that the bioequivalence/ bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid away bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local source valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid serial/bid/DRAP clearance 'NOC' between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded. In cases where the accreditation certificate, the certificate shall be considered valid only if it is issued within the last five (05) years from the date of NIT/bid submission.	Active Pharmaceutical Ingredient's (API) source accreditation certificate issued by WHO / USFDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA's country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it is issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 3 marks. Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item(s), as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g. Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).	Stability studies of quoted item's duly attested by the manufacturer of the material coupled with the Q.C Incharge of the firm). For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g. Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).	Availability of quoted item's in Pakistan market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or ICTI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specification/ strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase order, delivery challan.				
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70		
1	4	Metronidazole	Inf. 500mg/100 ml	J-Metro	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	9	35		
2	64	Paracetamol	Inf. 1000mg/100 ml	J-Para	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45		
3	276	Levofloxacin	Inf. 5mg/ml 100 ml	J-Levo	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	0	0	4	30		
4	638	Dextrose 10% infusion	Inf. 10 % 500 ml	JHK-SOL	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
5	639	Dextrose 10% infusion	Inf. 10 % 1000 ml	JHK-SOL	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
6	640	Dextrose 5% infusion	Inf. 5 % 100 ml	JHK-SOL	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45		
7	641	Dextrose 5% infusion	Inf. 5 % 500 ml	JHK-SOL	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
8	642	Dextrose 5% infusion	Inf.5 % 1000 ml	JHK-SOL	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
9	643	Dextrose + Sodium chloride 5%+0.45 % infusion	Inf.1/2 500 ml	JHK-SOL DS	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45		
10	644	Dextrose + Sodium chloride 5%+0.9% infusion	Inf.500 ml	JHK-SOL DS	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
11	645	Dextrose + Sodium chloride 5%+0.9% infusion	Inf. 1000 ml	JHK-SOL DS	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
12	656	Normal Saline 0.90% infusion	Inf.100 ml	JHK-SOL NS	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45		
13	657	Normal Saline 0.90% infusion	Inf.500 ml	JHK-SOL NS	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
14	659	Normal Saline 0.90% infusion	Inf.1000 ml	JHK-SOL NS	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
15	666	Ringer's Lactate+5% Dextrose infusion	Inf.500 ml	JHK SOL RLD	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
16	667	Ringer's Lactate + 5 % Dextrose infusion	Inf.1000 ml	JHK SOL RLD	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
17	668	Ringer's Lactate solution infusion	Inf.L 500 ml	JHK SOL RL	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
18	669	Ringer's Lactate solution infusion	Inf.1000 ml	JHK SOL RL	2	2	3	0	5	4	2	2	2	2	2	26	5	5	5	0	0	4	5	0	24	50		
19	674	Sodium chloride + dextrose 0.18 % + 4.3% infusion	Inf. 500 ml	JHK SOL Pea	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45		
20	675	Sterile water for injection 5 ml Injection	Inf. 5 ml	JHK SOL WFI	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	0	0	4	30		

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																											
Name of Firm				Kaizen Pharmaceuticals, Karachi																							
S. No.	Product General Information				Technical Evaluation Matrix																						
					Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Evaluation Parameters										Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score					Factory Evaluation Visit Score						Product Technical Parameters											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	
Ref. No. of item	Generic Name of Item	Dosage Form with Strength	Trade Name	Valid ISO	Valid ISO	Valid ISO	Latest IMS/IQVIA	Valid calibration	Valid documents of the	Availability of	Raw material, In-	Adherence to cGMP	Adequate availability of	Availability of		Bioavailability/	Goods Declaration	Certificate of Analysis	Active Pharmaceutical	Valid WHO	Valid Certificate of	Stability studies of	Availability of quoted				
				2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70		
	9	Tinidazole	Tab. 500mg	Tinibact	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	46	Ibuprofen	Susp. 200 mg/ 5 ml	Torfen	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	47	Ibuprofen	Susp. 100 mg/ 5 ml	Torfen	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	101	Mycophenolate Mofetil	Tab. 500 mg	Revograf	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	102	Mycophenolate Sodium	Tab. 180 mg	Actorgan	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	103	Mycophenolate Sodium	Tab. 360 mg	Actorgan	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	105	Tacrolimus	Tab. 1mg	Unigraf	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	
	106	Tacrolimus	Tab. 0.5mg	Unigraf	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	
	121	Deferasirox	Tab. 250mg	Revosirox	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	124	Deferasirox	Tab. 500mg	Revosirox	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	168	Levocetirizine	Syp. 2.5 mg/5 ml	Welcet	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	169	Levocetirizine	Tab. 5mg	Welcet	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	202	Azithromycin	Tab. 250 mg	Servaz	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	203	Azithromycin	Tab. 500 mg	Servaz	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	205	Azithromycin	Susp. 200 mg/5ml	Servaz	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	243	Ciprofloxacin	Tab. 250mg	Cipotent	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	244	Ciprofloxacin	Tab. 500mg	Cipotent	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	279	Lincomycin	Cap. 500mg	Mylinco	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	305	Rifaximin	Tab. 550mg	Orifax	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	529	Ondansetron	Tab. 8mg	Unisetron	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	
	535	Prucalopride	Tab. 2mg	Prucalax	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	543	Zinc Sulphate	Syp. 20 mg/5ml	Unizinc	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	
	694	Solifenadin Succinate	Tab. 10mg	Vesivel	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	717	Duloxetine	Cap. 30mg	Produlox	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	718	Duloxetine	Cap. 60mg	Produlox	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41	
	719	Divalproex Sodium	Tab. 250mg	Divalpro	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	
	720	Divalproex Sodium	Tab. 500mg	Divalpro	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	
	799	Doxofylline	Tab. 400mg	Profylline	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	
	800	Doxofylline	Syp. 100mg/5ml 60m	Profylline	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	
	910	Ossein Mineral Comple	Tab. 830mg + 400iu	Ossvit-D	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	
	911	Ossein Mineral Comple	Syp. 250mg+400iu/5l	Ossvit-D	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	
	912	Cholecalciferol	Inj. 200000 IU	Invital-D	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31	

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologics and IV Fluids for Government MCC 2025-26																																				
Name of Firm				Kensal Pharma																																
S. No.	Product General Information				Factory Technical Evaluation Parameters										Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score										
					Documents Based Factory Score										Factory Evaluation Visit Score												Product Evaluation Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24			25	26								
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (only attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (only attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (only attested by senior executive of the firm)	Latest IMSQ/IVA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered).	Valid calibration certificates for the equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted product.	Valid documents of the Federal Board of Revenue (FBR) showing the total Financial turnover of the firm for the last year i.e. FY 2023-24 or latest.	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs - Functional Stability, Chamber (Dish), Accelerated and Real Time as in Schedule B of DRAP.	Raw material, In-process and Finished goods storage (as in Schedule B of DRAP), (as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines (as in Schedule B of DRAP), Resource as per the requirements mentioned in schedule B of DRAP.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule B of DRAP.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs.	Valid WHO prequalification and / or	Bioreliability/ Bioprocess/ Biologics (API) source accreditation certificate issued by WHO/ UNCTAD/ EMA/ MHRA/ TGA/ PMDA/ Swiss Medic/ or Health Canada or by regulatory authority/body of SRA country (as coupled with Form-3 form of / undertaking to accompany an application for Licence to import Drugs).	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, completed with valid air-way bill of Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (CD) provided in column 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (API) source accreditation certificate issued by WHO/ UNCTAD/ EMA/ MHRA/ TGA/ PMDA/ Swiss Medic/ or Health Canada or by regulatory authority/body of SRA country (as coupled with Form-3 form of / undertaking to accompany an application for Licence to import Drugs).	Valid WHO prequalification and / or	Valid Certificate of Analysis of the Type: class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with invoice/proof of purchase.	Stability studies of quoted items duly attested by the Q.C (incharge of the firm).	Availability of quoted items in Pakistan market as per recent most data of IMSQ/IVA. Health not older than twelve (12) months.												
					Online verification link shall be provided.	Online verification link shall be provided.	Online verification link shall be provided.	1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 3 marks. 2. Firm having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firm having (12-Month) Ranking between 41st to 60th position shall be awarded 3 marks. 4. Firm having (12-Month) Ranking between 61st to 80th position shall be awarded 2 marks. 5. Firm having (12-Month) Ranking between 81st to 100th position shall be awarded 1 mark.	Valid Calibration Certificates attested by Quality head of the firm).	Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Non-adherence to cGMP guidelines shall lead to disqualification of the sections or firm).	Non-adherence to CSP shall lead to disqualification of the firm.	Non-compliance to cGMP guidelines shall lead to disqualification of the sections or firm).	(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the sections or firm).	(As evaluated by the MCC experts at the time of inspection).	Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Bioreliability/ Bioprocess/ Biologics (API) source accreditation certificate issued by WHO/ UNCTAD/ EMA/ MHRA/ TGA/ PMDA/ Swiss Medic/ or Health Canada or by regulatory authority/body of SRA country (as coupled with Form-3 form of / undertaking to accompany an application for Licence to import Drugs).	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, completed with valid air-way bill of Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (CD) provided in column 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (API) source accreditation certificate issued by WHO/ UNCTAD/ EMA/ MHRA/ TGA/ PMDA/ Swiss Medic/ or Health Canada or by regulatory authority/body of SRA country (as coupled with Form-3 form of / undertaking to accompany an application for Licence to import Drugs).	Valid WHO prequalification and / or	Valid Certificate of Analysis of the Type: class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with invoice/proof of purchase.	Stability studies of quoted items duly attested by the Q.C (incharge of the firm).	Availability of quoted items in Pakistan market as per recent most data of IMSQ/IVA. Health not older than twelve (12) months.												
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70										
1	712	Clozapine 100mg		Cepine 100mg	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
2	711	Clozapine 25mg		Clozapine	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
3	884	Permethrin 50mg (2% w/w)		Kermith lotion	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
4	415	Amlodipine		Valken-A	2	2	3	0	5	2	2	2	2	2	2	24	0	0	0	0	0	4	5	0	9	33										
5	414	Amlodipine 5/80mg		Valken-A	2	2	3	0	5	2	2	2	2	2	2	24	0	0	0	0	0	4	5	0	9	33										
6	695	Tamsulosin HCl		Tamcin	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
7	723	Escitalopram 10mg		Hitalo 10mg	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
8	532	Pantoprazole Sodium		Kanprazole	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
9	739	Mirtazapine 15mg		Mirtaget 15mg	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
10	762	Sertraline 100mg		Kasertine	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
11	758	Quetiapine 100mg		Karidef 100mg	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
12	683	Febuxostate 40mg		Burict 40mg	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
13	684	Febuxostate 80mg		Burict 80mg	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
14	868	Fusidic acid 20mg (2% w/w)		Exiderm Cream	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
15	211	Cefadroxil 125mg		Kanadrox	2	2	3	0	5	2	2	2	2	2	2	24	0	0	0	0	0	4	5	0	9	33										
16	212	Cefadroxil 250mg		Kanadrox	2	2	3	0	5	2	2	2	2	2	2	24	0	0	0	0	0	4	5	0	9	33										
17	487	Valsartan 80mg		Valken-80MG	2	2	3	0	5	2	2	2	2	2	2	24	0	0	0	0	0	4	5	0	9	33										
18	694	Solifenacin succinate 10mg		Solikane 10mg	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
19	764	Topiramate 50mg		Kapkan 50mg	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										
20	734	Levetiracetam 500mg		Kavitrax	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43										

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2025-26																				
	Name of Firm				Karim Industries pvt. Ltd															
S. No.	General Product Information				Technical Evaluation Matrix															
					Factory Technical Evaluation Parameters										Factory Evaluated Score 15	Product Evaluation Parameters			Product Evaluated Score 19	Total Technical Score 20
					Documents Based Factory Score					Evaluation visit Score						16	17	18		
	1	2	3	4	5	6	7	8	9	10	11	12	13	14		16	17	18		
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)		
	Ref. No. of item in MCC Formulary	Generic Name of Item	Sizes and specifications	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70
1	967	Cotton (Surgical) Corded 200gm BPC		Medi Cot	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
2	968	Cotton (Surgical) Corded 100gm BPC		Medi Cot	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
3	969	Cotton Bandage (Surgical) B.P Type II 6.5cm x 4m		Medi Band	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
4	970	Cotton Bandage (Surgical) B.P Type II 7.5cm x 4m		Medi Band	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
5	971	Cotton Bandage (Surgical) B.P Type II 10cm x 4m		Medi Band	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
6	972	Cotton Bandage (Surgical) B.P Type II 15cm x 4m		Medi Band	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
7	979	Crepe Bandage 7.5cm x 4.5m		Medi Crepe	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
8	980	Crepe Bandage 10cm x 4.5m		Medi Crepe	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
9	981	Crepe Bandage 15cm x 4.5m		Medi Crepe	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
10	1092	Gauze Cloth Roll Packing 1m x 20m		Soft Gauze	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
11	1093	Gauze Cloth Roll Packing 1m x 40m		Soft Gauze	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
12	1173	Paraffin Gauze Dressing (Tulle) with Chlorohexidine 10cm x 10cm (Antiseptic)		Septi Grass Tulle	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
13	1174	Paraffin Gauze Dressing (Tulle) with Chlorohexidine 15cm x 20cm (Antiseptic)		Septi Grass Tulle	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
14	1175	Paraffine Gauze Dressing (Tulle) with Framycetin 10cm x 10cm (Antibiotic)		Medi Sofa Tulle	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65

15	1181	Plaster of Paris (POP) Bandage 15cm x 2.7m		Medi Plast	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
16	1182	Plaster of Paris (POP) Bandage 10cm x 2.7m		Medi Plast	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
17	1206	Sterile Gauze Dressing Pad (X- Ray Detectable Radiopaque) 10cm x 10cm (BPC) (8ply)		Soft Gauze Swab	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																			
Name of Firm				Kohinoor Industries																															
S.No.	Product General Information				Factory Technical Evaluation Parameters																Technical Evaluation Matrix						Total Product Evaluated Score		Total Technical Score						
					Documents Based Factory Score				Factory Evaluation Visit Score				Total Factory Evaluated Score	Product Evaluation Parameters																					
	1	2	3	4	5	6	7	8	9	10	11	12		13	14	15	16	17	18	19	20	21	22	23	24	25	26								
					Valid ISO 18001:45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered).	Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Weighing, Assay/ Analysis of raw material, in-process material and finished	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto	Availability of calibrated equipment for analysis of quoted item along with validated methods of testing of the quoted item and adherence to good laboratory practices (GLP) in all labs - Functional Stability Chamber (Both Accelerated and Real	Raw material, In-process and Finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC.	Adherence to cGMP guidelines, (as in Schedule-B of DRAP) as mentioned in schedule-B of DRAP (Certified by the senior executive of the firm)	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (As evaluated by the MCC experts at the time of inspection)	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs	16	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-waiver certificate from an accredited lab	17	Goods Declaration certificate of imported API of the quoted item's from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item's, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid	18	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GDP) provided in column 18, duly attested by the senior executive of the firm	19	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA / Swiss Medic or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product quoted item having multiple APIs, the marks for GDP, CoA, API's	20	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies)	21	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item's, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European,	22	Stability studies of quoted item's duly attested by the Q.C. incharge of the firm)	23	Availability of quoted item's in Pakistani market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where	24	25	26
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70									
1	646	Flavoured Oral Re-hydration Salt WHO Approved formula		ORSK Sachet	0	2	3	0	0	4	2	2	2	2	2	19	0	0	0	0	4	5	0	9	28										
2	884	Permethrine BP Specs		E Scab Lotion 60ml	0	2	3	0	0	4	2	2	2	2	2	19	0	0	0	0	0	5	0	5	24										
3	889	Silver Sulphadiazine USP Specs		Safe Burn 50gm	0	2	3	0	0	4	2	2	2	2	2	19	0	0	0	0	0	5	0	5	24										
4	903	Povidone Iodine 10% w/v USP Specs Equivalent to 1% available		Prodine Solution 450ml	0	2	3	0	0	4	The inspection team at the time of inspection observed that: POOR ADHERANCE TO cGMP 1. Mixing Tank for Povidone Iodine Solution/Scrub had unmixed residues of the previous batch which shows poor cGMP adherence. POOR ADHERANCE TO GOOD LABORATORY PRACTICES (GLP) 2. Quoted Items (Povidone Iodine Solution 10% and Povidone Iodine Scrub 7.5%) were not available in Stability chambers / As per ICH guidelines One batch in a year should be kept for Stability Testing). 3. Potentiometer/ Auto Titrator required for Povidone Iodine Solution and Scrub testing was out of order. Hence, the firm NOT-RECPMMENDED for Povidone Iodine (solution and scrub)	9	0	5	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
5	904	Povidone Iodine 7.5% w/w USP Specs		Prodine Scrub 450ml	0	2	3	0	0	4		9	0	0	0	0	0	0	0	0	0	5	0	5	14										

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2025-26																				
	Name of Firm				Kohinoor Industries Sahiwal															
S. No.	General Product Information				Technical Evaluation Matrix															
					Factory Technical Evaluation Parameters										Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score
	Documents Based Factory Score					Evaluation visit Score														
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP, cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	15	16	17	18	19	20	
	Ref. No. of item in MCC	Generic Name of Item	Sizes and specificat	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70
1	967	Cotton (Surgical) Corded	200g	Leader Absorbent Cotton Woll 200 gm	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
2	968	Cotton (Surgical) Corded	100g	Leader Absorbent Cotton Woll 100	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
3	969	Cotton Bandage (Surgical) B.P Type II	6.5*4	Leader Bandage B.P Type II 6.5cmX4m	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
4	970	Cotton Bandage (Surgical) B.P Type II	7.5*4	Leader Bandage B.P Type II 7.5cmX4m	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
5	971	Cotton Bandage (Surgical) B.P Type II	10*4	Leader Bandage B.P Type II 10cmX4m	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
6	972	Cotton Bandage (Surgical) B.P Type II	15*4	Leader Bandage BPC 15cmX4m	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
7	979	Crepe Bandage BPC	7.5*4.5	Elatomer (Cotton Crepe Bandage) 7.5cmx4.5m	3	3	3	4	5	3	6	6	6	6	45	0	10	DTL	10	55
8	980	Crepe Bandage BPC	10*4.5	Elatomer (Cotton Crepe Bandage) 10cmx4.5m	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
9	981	Crepe Bandage BPC	15*4.5	Elatomer (Cotton Crepe Bandage) 15cmx4.5m	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
10	1092	Gauze Cloth Roll Packing	100*20	Absorbent Gauze BPC 100cmx20m	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
11	1093	Gauze Cloth Roll Packing	100*40	Absorbent Gauze BPC 100cmx40m	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
12	1173	Praffin Gauze dressing (Tulle) with Chlorhexidine	10*10	Medi Tulle 10X10cm	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
13	1206	Strile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP/BP/BPC) Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	10*10 8p	Ray Gauze Blister Pack 10cmx10cm 8ply	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
14	1208	Strile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP/BP/BPC) Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	30*30 4p	Ray Gauze Blister Pack 30cmx30cm 4ply	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
15	1209	Sterile Gauze Dressing Pad (USP/BP/BPC)	10*10 8p	Medi Gauze BP-13 Blister Pack 10cmx10cm 8ply	Non formulary			4	5	3	6	6	6	6	36	0	10	10	20	56
16	1210	Sterile Gauze Dressing Pad (USP/BP/BPC)	15*15 8p	Medi Gauze BP-13 Blister Pack 15cmx15cm 8ply	Non formulary			4	5	3	6	6	6	6	36	0	10	10	20	56

Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2023-26																			
Name of the firmKS AGENCIES KARACHI																			
S. No.	Product General Parameter				Technical Evaluation Matrix														
					Principal's and Importer's Evaluation Parameters						Product Technical Evaluation								
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacists/ s / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GDS) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only.(Verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLEW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks.	Samples evaluation by DTI, (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70
1	1309.	17mm, 1/2 circle round bodied taper point needle, strand length 75cm	4/0	Glysilk	0	5	0	5	5	6	21	5	5	0	4	10	0	24	45
2	1314.	31mm, 1/2 circle round bodied, taper point needle, Strand length 75cm	2/0	Glysilk	0	5	0	5	5	6	21	5	5	0	4	10	0	14	35
3	1317.	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1	Glysilk	0	5	0	5	5	6	21	5	5	0	4	10	0	24	45
4	1318.	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1	Glysilk	0	5	0	5	5	6	21	5	5	0	4	10	0	24	45
5	1319.	40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	1	Glysilk	0	5	0	5	5	6	21	5	5	0	4	10	0	24	45
6	1346.	17mm, 1/2 circle round bodied taper point needle, Strand length 70cm	5/0	Glytin	0	5	5	5	5	6	26	5	5	0	2	10	0	22	48
7	1347.	17mm, 1/2 circle round bodied needle, Strand length 75cm	4/0	Glytin	0	5	5	5	5	6	26	0	0	0	2	10	0	12	38
8	1349.	22mm, 1/2 circle round bodied taper point, strand length 75 cm	3/0	Glytin	0	5	5	5	5	6	26	0	0	0	2	10	0	12	38
9	1351.	30mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0	Glytin	0	5	5	5	5	6	26	5	5	0	2	10	0	22	48
10	1352.	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	0	Glytin	0	5	5	5	5	6	26	5	5	0	2	10	0	22	48
11	1354.	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	1	Glytin	0	5	5	5	5	6	26	5	5	0	2	10	0	22	48
12	1355.	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	2	Glytin	0	5	5	5	5	6	26	5	5	0	2	10	0	22	48
13	1368.	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	4/0	Glylene	0	5	0	5	5	6	21	5	5	0	4	10	0	24	45
14	1370.	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	3/0	Glylene	0	5	0	5	5	6	21	0	0	0	4	10	0	14	35
15	1371.	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	3/0	Glylene	0	5	0	5	5	6	21	5	5	0	4	10	0	24	45
16	1375.	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	2/0	Glylene	0	5	0	5	5	6	21	0	0	0	4	10	0	14	35

17	1377.	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0	Glylene	0	5	0	5	5	6	21	5	5	0	4	10	0	24	45
18	1379.	60mm, straight cutting needle, strand length 75cm	2/0	Glylene	0	5	0	5	5	6	21	5	5	0	4	10	0	24	45
19	1381.	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1	Glylene	0	5	0	5	5	6	21	5	5	0	4	10	0	24	45

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologics, and IV Fluids for Government MCC 202-26																									
		B9 LAB DIAGNOSTIC SYSTEM																							
		Name of firm				Technical Evaluation Matrix																			
		Product General Information				Principal's and Importer's Evaluation Parameters										Supplier's Technical Score	Product Technical Evaluation						Product Evaluation Score	Total Technical Score	
						Principal's Manufacture Evaluation					Importer's Evaluation						Product Technical Parameters								Product Availability
						1	2	3	4	5	6	7	8	9	10		11	12	13	14	15	16			17
						Valid ISO 10001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided	Valid accreditation of manufacturing unit or its relevant sections by the US-FDA or WHO or official accreditation body/ies regulatory body in the case of SRA countries (duly attested by senior executive of the firm)	Valid calibration certificates for the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificate attested by Quality head of the firm)	Availability of minimum 20% inventory of the total import of the quoted items during last one year certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC experts. Non-availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s (firm)	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-stable drugs).	Adequate availability of qualified, (Presence of Category-A Pharmacists) is not mandatory), & relevant Human Resource		For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-waiver certificate from an accredited lab of SRA countries (stringent Regulatory Authorities) In case of Large volume (greater than 100mg up to 5g), product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted, and / or Proof of novelty / innovative	Goods Declaration certificate of imported finished quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months on the cutoff date for submission of bids.	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for each will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA, Swiss Meds or Health Canada or by regulatory authority/body of SRA's country (ies). Trail of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. 2 mark for each certification, up to a maximum of 06 marks.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European,	Stability studies of quoted items duly attested by the Q.C incharge of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 3 marks For items specifically used in institutions where IMS/RQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks	Availability of quoted items in Pakistan market as per recent most data of IMS/RQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 3 marks For items specifically used in institutions where IMS/RQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks			
		or item is MCC formulae	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70	
Naprod Life sciences India	1	159	Voriconazole	200mg INJ	Vencozole			0		5				5	0	5	5	5	0	0	5	20	25		
Nanjing King-Friend biochemical china	2	363	Enoxaparin	40mg INJ	Vinox 40mg				5	5				16	0	5	5	5	6	4	5	0	46		
Nanjing King-Friend biochemical	3	364	Enoxaparin	60mg INJ	Vinox 60mg	2	2	2						10	0	5	5	5	6	4	5	0	40		
Nanjing King-Friend biochemical	4	365	Enoxaparin	80mg INJ	Vinox 80mg	0	0	0	5	5				10	0	5	5	5	6	4	5	0	40		
Nanjing King-Friend biochemical	5	382	Heparin Sodium	5000 IU/ML 5ml	Hepalid 5000 IU/ML 5ML	0	0	0	5	5				10	0	5	5	5	6	0	5	26	36		
Xian Libang Pharmaceutical China	6	652	Emulsion 20% Lipid emulsion	1% x 250ml INJ	Liposol 5000IU/ml injection (5ml Vial)	0	0	0	0	0				0	0	5	5	0	0	0	5	15	15		
Changchun Zauoy Biological China	7	603	Inactivated Rabies	≥2.5 IU/INJ	V BioShoot	2	2	2	0	0	4	4	5	19	0	5	5	0	6	4	5	25	44		
Indipta Vaccine Bangladesh	8	604	Meningococcal Vaccine "Meningococcal Polysaccharide Vaccine"	10 Dose /Vial (Multi dose)	Ingovax	0	0	0	0	5	4	4	5	18	0	5	5	0	6		4	5	25	43	

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
S. No.	Name of Firm				LSKO KARACHI																							
	Product General Information				Factory Technical Evaluation Parameters										Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score		
					Documents Based Factory Score										Product Evaluation Parameters													
															Product Technical Parameters													
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26		
					Valid ISO 14001 certificate of the facility where the general product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the general product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the general product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm)	Latest IMS/VOYA ranking of the leading manufacturer firm (by value) in Pakistan - (12 months to date ranking will be considered).	Valid calibration certificate for equipment / instrument used in the factory for Measuring, weighing, Assay/ Analysis of raw material, processed material and finished products for the analytical testing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 at least. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (This document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) as per WHO / IMS/VOYA, in the following manner: 1. Functional Stability Chamber (Both Accelerated and Real Time) as per schedule II of DHPAP (As evaluated by the MCC experts at the time of inspection)	Raw material, In-process and Finished good storage as per schedule II of DHPAP (As evaluated by the MCC experts at the time of inspection)	Adherence to GMP guidelines, as per schedule II of DHPAP (As evaluated by the MCC experts at the time of inspection)	Adequate availability of qualified & relevant Human Resource as per requirements mentioned in schedule-II of DHPAP (As evaluated by the MCC experts at the time of inspection)	Availability of Functional and validated HVAC, with all relevant equipment, testing and / or (As evaluated by the MCC experts at the time of inspection)	Bioavailability/ Bioequivalence study conducted by WHO / Accredited Labs must be attached along with the bid and study must be available on WHO (Website)	Goods Declaration certificate of imported APIs of the quoted items from Pakistan Customs, coupled with valid invoice bill or Bill of Lading for the quoted items, not older than 24 months from the count date for submission of bids.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GDD) provided in scheme 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA/ Swiss Medic / Health Canada or by regulatory authority/body of SRA country (not coupled with Form-1 (Letter of undertaking to accompany an application for License to Import Drugs) and / or	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies)	Valid Certificate of Analysis of the Type / class of material used for the production container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase.	Stability studies of the quoted items duly attested by the Q.C. (exchange of the firm)	Availability of quoted items in Pakistan market in per recent most data of IMS/VOYA (Health not older than twelve (12) months).	1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 4 marks				
					Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.	2. Firm having (12-Month) Ranking between 21-40th positions 4 marks.	3. Firm having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.	4. Firm having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.	5. Firm having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.																
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	The inspection team inspected the firm and observed the following: Non-Functional HVAC system: 1. HVAC was not functional at the time of inspection in all areas. Non-Adherence to Good Storage Practices (GSP): 2. Most of the area were out of limits in temperature and humidity such as in raw material store the temperature recorded was 30.4 °C and humidity was 61 %. In liquid packing, the temperature was 28.9 °C and humidity was 82%. In tablet section, temperature was 30.5 °C and humidity was 84%. 3. Food items were found in QC refrigerator. 4. The temperature of the refrigerator was uncontrolled and without any thermo-hygrometer, and chemical/ solutions were frozen at the time of inspection (storage conditions mentioned on the label of the frozen chemicals were 25 °C). Moreover, there was no record of temperature and humidity for the said refrigerator. The above storage conditions are gross violation of good storage practices (GSP) particularly for temperature sensitive chemicals/reagents/solutions, on which the whole testing of the raw material and finished products is dependent. Thus, leading to compromised quality/products. 5. Damp sugar was present in the RMS which shows a continuous uncontrolled humidity 6. The paint was peeled off from the edges of the walls at various points of the production areas. 7. Frequent power outage was observed during the inspection and the backup generator was not working properly. In view of the above, the firm is NOT-RECOMMENDED.					23	5	5	5	5	3	4	5	37	60			
	46	Bupropion 200 mg/ 5 ml Syrup	200 mg/ 5 ml Syrup	Buc-Prolin DSX syrup	2	2	3	0	5	4						18	0	5	5	0	0	4	5	0	19	35		
	47	Bupropion 100 mg/ 5 ml Syrup	100 mg/ 5 ml Syrup	Buc-Prolin syrup	2	2	3	0	5	4						18	0	5	5	0	0	4	5	0	19	35		
	51	Mefenamic Acid 50 mg/5ml Syrup	50 mg/5ml Syrup	Paracetamol Syrup	2	2	3	0	5	4						18	0	5	5	0	0	4	5	0	19	35		
	149	Fluconazole 50 mg/5 ml Syrup	50 mg/5 ml Syrup	Flucan Dry Powder Syrup	2	2	3	0	5	4						18	0	5	5	0	0	4	5	0	19	35		
	152	Bicucanazole 100 mg Cap	100 mg Cap	Canisole capsule	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	156	Nystatin drops 100,000 IU/ml	100,000 IU/ml	Mycostatin drops	2	2	3	0	5	4						18	0	5	5	5	0	0	5	0	20	36		
	158	Turbutaline 250 mg tab	250 mg tab	Turbo tablet	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	167	Chlorpheniramine Maleate 2 mg/ 5 ml Syrup	2mg/ 5 ml Syrup	Histacine syrup	2	2	3	0	5	4						18	0	0	0	0	0	4	5	0	9	25		
	181	Amoxycillin 500mg Cap	500mg Cap	Amoxycap capsule	2	2	3	0	5	4						18	0	5	5	5	0	0	5	0	20	36		
	182	Amoxycillin 125 mg/ 5ml Dry Syrup	125 mg/ 5ml Dry Syrup	Amoxycap Dry suspension	2	2	3	0	5	4						18	0	5	5	5	0	4	5	0	24	40		
	183	Amoxycillin 125 mg/ 5ml Dry Syrup	125 mg/ 5ml Dry Syrup	Amoxycap Dry suspension	2	2	3	0	5	4						18	0	5	5	5	0	4	5	0	24	40		
	185	Amoxycillin 250 mg/ 5ml Syrup	250 mg/ 5ml Syrup	Amoxycap forte syrup	2	2	3	0	5	4						18	0	5	5	5	0	4	5	0	24	40		
	186	Amoxycillin 250 mg/ 5ml Syrup	250 mg/ 5ml Syrup	Amoxycap forte syrup	2	2	3	0	5	4						18	0	5	5	5	0	4	5	0	24	40		
	288	Mefenamic Acid 50 mg/ 5ml Syrup	50 mg/ 5ml Syrup	Mevoic tablet	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	412	Amidolipine Dicyclanil 2 mg/ 5ml Syrup	2 mg/ 5ml Syrup	Amidolipine tablet	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	413	Amidolipine Dicyclanil 10 mg/ 5ml Syrup	10 mg/ 5ml Syrup	Amidolipine tablet	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	414	Amidolipine + Valerianum Syrup/10 mg/ 5ml Syrup	Syrup/10 mg/ 5ml Syrup	Valerianum-AM tablet	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	459	Lidocaine Syrup/ 5ml Syrup	5mg/ 5ml Syrup	Lidocaine tablet	2	2	3	0	5	4						18	0	5	5	5	0	0	5	0	20	36		
	460	Lidocaine Syrup/ 5ml Syrup	5mg/ 5ml Syrup	Lidocaine tablet	2	2	3	0	5	4						18	0	5	5	5	0	0	5	0	20	36		
	507	Aluminum Hydroxide 250mg + Magnesium Hydroxide 500mg + Simethicone 25mg Syrup	250mg + 500mg + 25mg Syrup	Alumagene syrup	2	2	3	0	5	4						18	0	5	5	0	0	4	5	0	19	35		
	510	Dicyclanil 12.5 mg/5ml Syrup	12.5mg/5ml Syrup	Hydramate Liquid	2	2	3	0	5	4						18	0	5	5	0	0	4	5	0	19	35		
	512	Dicyclanil 10 mg/ 5ml Syrup	10 mg/ 5ml Syrup	Hydramate tablet	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	513	Dicyclanil 10 mg/ 5ml Syrup	10 mg/ 5ml Syrup	Dicyclanil tablet	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	515	Dicyclanil 40 mg/ 5ml Syrup	40 mg/ 5ml Syrup	Dicyclanil tablet	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	528	Esomeprazole 40mg Cap	40mg Cap	Zetecap capsule	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	543	Zinc Sulphate 20 mg/5ml Syrup	20 mg/5ml Syrup	Zincolipine syrup	2	2	3	0	5	4						18	0	5	5	5	0	4	5	0	24	40		
	576	Misoprostol 200 mg/ 5ml Syrup	200 mg/ 5ml Syrup	Misoprostol tablet	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	752	Progesterone 75mg Cap	75mg Cap	Progesterone capsule	2	2	3	0	5	4						18	0	5	5	0	0	0	5	0	15	31		
	798	Dicyclanil + Amoxicillin Syrup/ 10 mg/ 5ml Syrup	10mg + 500mg Syrup	Lidocaine Syrup	2	2	3	0	5	4						18	0	0	0	0	0	0	4	5	0	9	25	
	800	Dicyclanil 10mg/ 5ml Syrup	10mg/5ml Syrup	Dicyclanil syrup	2	2	3	0	5	4						18	0	0	0	0	0	0	4	5	0	9	25	
	807	Ketocifen 1mg/ 5ml Syrup	1mg/5ml Syrup	Ketocifen syrup	2	2	3	0	5	4						18	0	5	5	0	0	0	4	5	0	19	35	
	808	Salbutamol 2 mg/ 5ml Syrup	2 mg/ 5ml Syrup	Salbutamol tablet	2	2	3	0	5	4						18	0	0	0	0	0	0	5	0	5	21		
	810	Salbutamol 2mg/ 5ml Syrup	2mg/ 5ml Syrup	Salbutamol syrup	2	2	3	0	5	4						18	0	0	0	0	0	4	5	0	9	25		
	815	Terbutaline Sulphate 0.3 mg/ 5ml Syrup	0.3 mg/ 5ml Syrup	Terbutaline syrup	2	2	3	0	5	4						18	0	0	0	0	0	0	4	5	0	9	25	
	906	Allicin 0.3 mg/ 5ml Syrup	0.3 mg/ 5ml Syrup	Allicin tablet	2	2	3	0	5	4						18	0	0	0	0	0	0	5	0	5	21		

GHC Decision
The GMC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																
Name of the firm					LUCKY LAB INDUSTRIES																
					Technical Evaluation Matrix																
					Principal's and Importer's Evaluation Parameters										Product Technical Evaluation					Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19		
S. No.	Ref. No. of Item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good Storage	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	C/E mark/Quality assurance certificate/Quality control certificate issued by	Physical examination	Evaluated	Technical		
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70		
Hebai Kangweishi China	1	945	Blood Collection Tubes (purple top)	BacTsys	0	5	0	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate (CoP/CoPC) for the quoted items were checked			5	5	0	0	0	0	16	21	26		
Hebai Kangweishi China	2	946	Blood Collection Tubes (red top)	BacTsys	0	5	0		5	5	0	0	0	0	0	0	16	21	26		
Hebai Kangweishi China	3	947	Blood Collection Tubes (black top)	BacTsys	0	5	0		5	5	0	0	0	0	0	0	16	21	26		
Hebai Kangweishi China	4	948	Blood Collection Tubes (green top)	BacTsys	0	5	0		5	5	0	0	0	0	0	0	16	21	26		
Hebai Kangweishi China	5	949	Blood Collection Tubes (yellow top)	BacTsys	0	5	0		5	5	0	0	0	0	0	0	16	21	26		
Hebai Kangweishi China	6	950	Blood Collection Tubes (blue top)	BacTsys	0	5	0		5	5	0	0	0	0	0	0	16	21	26		

					Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26															
Name of the firm					M. Islam & Sons															
S. No.	Product General Parameter				Technical Evaluation Matrix															
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20	
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC experts). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted items / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated	Adequate availability of qualified, (Presence of Category-A Pharmacist's is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).	In case of supply/purchase through different facility, a valid trail/link/DRAP clearance-NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance-NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GID) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US Free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification n of the quoted products)	Physical examination of the quoted item/s by the MCC experts. Rejection of the quoted item/s by the MCC experts shall lead to disqualification of the said items.			
	Ref. No. of	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70	
	1309	Black Braided Silk	17mm, 1/2 circle round bodied taper point needle, strand length 75cm 4/0	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1310	Black Braided Silk	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm 3/0	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1311	Black Braided Silk	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm 3/0	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1312	Black Braided Silk	26mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm 3/0	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1313	Black Braided Silk	17mm, 1/2 circle round bodied taper point needle, Strand length 75cm 3/0	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1314	Black Braided Silk	31mm, 1/2 circle round bodied, taper point needle, Strand length 75cm 2/0	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1315	Black Braided Silk	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm 2/0	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1316	Black Braided Silk	31mm, 1/2 circle round bodied taper point needle, Strand length 75cm 0	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1317	Black Braided Silk	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1318	Black Braided Silk	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm 1	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1319	Black Braided Silk	40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm 1	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1320	Black Braided Silk	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	RTMED SILK	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1324	Polyglactin 910/PGLA	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm 6/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1326	Polyglactin 910/PGLA	13mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm 5/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1327	Polyglactin 910/PGLA	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm 5/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1328	Polyglactin 910/PGLA	16mm, 3/8 circle conventional or curved cutting needle, strand length 75cm 4/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	
	1329	Polyglactin 910/PGLA	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 4/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56	

	1331	Polyglactin 910/PGLA	22mm, 1/2 circle round bodied taper point, strand length 75 cm 4/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1332	Polyglactin 910/PGLA	16mm, 3/8 circle conventional or curved cutting needle, strand length 75cm 3/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1334	Polyglactin 910/PGLA	22mm, 1/2 circle round bodied taper point, strand length 70 cm 3/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1336	Polyglactin 910/PGLA	26mm, 1/2 circle round bodied taper point, strand length 70 cm 2/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1337	Polyglactin 910/PGLA	31mm, 1/2 circle round bodied taper point, strand length 75 cm 2/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1338	Polyglactin 910/PGLA	36mm, 1/2 circle round body taper cut needle, strand length 90 cm 2/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1339	Polyglactin 910/PGLA	45mm, 1/2 circle round bodied taper cut needle, strand length 75 cm 2/0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1341	Polyglactin 910/PGLA	40mm, 1/2 circle round bodied taper point, strand length 90 cm 0	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1342	Polyglactin 910/PGLA	40mm, 1/2 circle round bodied taper point, strand length 70 cm 1	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1343	Polyglactin 910/PGLA	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm 1	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1344	Polyglactin 910/PGLA	40mm, 1/2 circle round bodied taper point, strand length 90 cm 2	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1345	Polyglactin 910/PGLA	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm 2	RTMED PGLA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1346	Polyglycolic Acid	17mm, 1/2 circle round bodied taper point needle, strand length 70cm 5/0	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1347	Polyglycolic Acid	17mm, 1/2 circle round bodied needle, strand length 75cm 4/0	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1348	Polyglycolic Acid	22mm, 1/2 circle round bodied taper point needle, strand length 75cm 4/0	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1349	Polyglycolic Acid	22mm, 1/2 circle round bodied taper point, strand length 75 cm 3/0	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1350	Polyglycolic Acid	25mm, 1/2 circle round bodied taper point, strand length 75 cm 2/0	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1351	Polyglycolic Acid	30mm, 1/2 circle round bodied taper point, strand length 75 cm 2/0	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1352	Polyglycolic Acid	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm 0	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1353	Polyglycolic Acid	30mm, 1/2 circle round bodied taper point needle, strand length 75 cm 1	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1354	Polyglycolic Acid	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm 1	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1355	Polyglycolic Acid	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm 2	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1356	Polyglycolic Acid	48mm, 1/2 circle round bodied taper point needle, strand length 75 cm 2	RTMED PGA	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1366	Polypropylene	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm 5/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1367	Polypropylene	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 5/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1368	Polypropylene	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 4/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1369	Polypropylene	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm 4/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1370	Polypropylene	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 3/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1371	Polypropylene	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm 3/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1372	Polypropylene	30 mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm 3/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56

	1373	Polypropylene	26mm, 1/2 circle round bodied taper point needle, strand length 75cm 2/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1374	Polypropylene	26mm, 3/8 circle reverse cutting needle, strand length 45cm 2/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1375	Polypropylene	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 2/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1376	Polypropylene	26mm, 1/2 circle round bodied taper cut double armed needle, strand length 75cm 2/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1377	Polypropylene	30mm, 1/2 circle round bodied taper point needle, strand length 75cm 2/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1378	Polypropylene	35mm, straight cutting needle, strand length 75cm 2/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1379	Polypropylene	60mm, straight cutting needle, strand length 75cm 2/0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1380	Polypropylene	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 0	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
	1381	Polypropylene	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 1	RTMED PROLENE	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56

Name of the firm					M. Islam & Sons																		
					Technical Evaluation Matrix																		
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation										Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score												
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19					
S. No.	Ref. No. of Item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical				
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70				
JS BANA Hernia Patch	1416	Polypropylene Mesh	30cm x 30cm		0	5	0	5	6	6	22	5	5	0	0	0	Not recommended	10	32				
JS BANA Hernia Patch	1417	Polypropylene Mesh	15cm x 15cm		0	5	0	5	6	6	22	5	5	0	0	0	Not recommended	10	32				
JS BANA Hernia Patch	1419	Polypropylene Mesh	6cm x 11cm		0	5	0	5	6	6	22	5	5	0	0	0	Not recommended	10	32				
RT MED	1382	Polyamide	6.5mm, 3/8 circle micro-point spatula double needle, strand length 30cm 10/0	RTMED POLYAMIDE	3	5	0	5	6	6	25	5	5	0	0	0	16	26	51				
RT MED	1361	Polypropylene	9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm 7/0	RTMED PROLENE	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53				
RT MED	1363	Polypropylene	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm 6/0	RTMED PROLENE	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53				

Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																			
Name of the firm					MA TRADERS PESHAWAR														
Technical Evaluation Matrix															Product Evaluated Score	Total Technical Score			
Principal's and Importer's Evaluation Parameters										Product Technical Evaluation									
Principal Manufacturer Evaluation			Importer's Evaluation				Suppliers Technical Score												
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant sections by the US-FDA or WHO or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA countries (duly attested by senior executive of the firm). In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item's during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert's). Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted items and/or firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item's. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist's is/are mandatory) as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert's at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).	Goods Declaration certificate of imported finished quoted item's from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item's, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC. Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item's from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. (In case of non-provision of matching GD the marks for GD will not be awarded).	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union (Verification link shall be provided). and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US FDA (510 K) / US free sale certificate of the quoted products certificates with same brand name shall be considered. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by	Physical examination of the quoted item's by the MCC expert's. Rejection of the quoted item's by the MCC expert's shall lead to disqualification of the said item's.			
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	6	6	30	5	5	5	3	6	16	40	70
Baihe, China	982	CVP Line Single Lumen 14G	14G	MED SURG	0	5	0	5	6	6	22	0	0	0	0	2	16	18	40
Baihe, China	982	CVP Line Single Lumen 16G	16G	MED SURG	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50
Baihe, China	982	CVP Line Single Lumen 18G	18G	MED SURG	0	5	0	5	6	6	22	0	0	0	0	2	16	18	40
Baihe, China	983	CVP Line Double 4Fr x 6cm	4Fr x 6cm	MED SURG	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50
Baihe, China	983	CVP Line Double 5Fr x 8cm	5Fr x 8cm	MED SURG	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50
Baihe, China	983	CVP Line Double 7Fr x 16cm	7Fr x 16cm	MED SURG	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
Name of Firm					95 Macter International																							
S. No.	Product General Information				Technical Evaluation Matrix																						Total Product Evaluated Score	Total Technical Score
					Factory Technical Evaluation Parameters												Total Factory Evaluated Score				Product Evaluation Parameters							
	Documents Based Factory Score				Factory Evaluation Visit Score				Product Technical Parameters				Product Technical Parameters				Product Technical Parameters											
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26			
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, In-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm). Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). Non-adherence to GSP shall lead to disqualification of the firm.	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral (i.e., greater than 100ml) up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medec or Health Canada or by regulatory authority/body of SRAs country (ies) coupled with Form-3 (Form of undertaking to accompany an application for license to import Drugs). Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm)	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringes/ Suppositories must be USP Type 3 or better (Non-compliance shall lead to disqualification of the quoted product).	Stability studies of quoted item/s duly attested by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringes/ Suppositories must be USP Type 3 or better (Non-compliance shall lead to disqualification of the quoted product).	Availability of quoted item/s in Pakistan market as per recent most data of IMS/IQVIA Health, not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks						
	Ref. No. of item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70			
1	362	Enoxaparin Sodium 40 mg	40 mg	Hepanox 40mg	2	2	3	4	5	6	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47			
2	363	Enoxaparin Sodium 60 mg	60 mg	Hepanox 60mg	2	2	3	4	5	6	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47			
3	423	Erythropoietin 4000IU	4000 IU	Mac-Epo 4000 IU	2	2	3	4	5	6	2	2	2	2	32	0	5	5	0	0	0	5	3	18	50			
4	425	Erythropoietin 10000IU	10000 IU	Mac-Epo 10000 IU	2	2	3	4	5	6	2	2	2	2	32	0	5	5	0	0	0	5	3	18	50			
5	315	Heparin Sodium Solution	5000IU	INHIXA	2	2	3	4	5	6	2	2	2	2	32	0	5	5	0	0	0	5	1	16	48			

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																										
Name of Firm				Martin Dow Marker																						
S.No.	Product General Information				Technical Evaluation Matrix																Product Evaluation Parameters				Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score								Factory Technical Evaluation Parameters					Factory Evaluation Visit Score								
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest BMS QVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by BMS QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 conditions shall be awarded 5 marks	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, Weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 for latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing in all labs + Functional Safety Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP. (Evaluated at the time of inspection by the MCC experts)	Raw material, In-process and Finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC expert/s) Non-adherence to GSP shall lead to disqualification of the firm.	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s) Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Availability of functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	16	Bioequivalence study conducted by WHO (Qualified Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of FDA shall be considered.	Goods Declaration certificate of imported API of the quoted item's from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item's, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (i) not older than 24 months shall be considered.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / USAFDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medec or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs).	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification in this section.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item's, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic	Stability studies of quoted item's duly attested by the Q/C incharge of the firm).	Availability of quoted item's in Pakistani market as per recent most data of BMS QVIA Health not older than twelve (12) months 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 4 marks	25	26	
Ref. No. of Item	Generic Name of Item	Dosage Form with strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
1	243	Ciprofloxacin	Tab. 250mg	Merclip 250mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52
2	344	Ciprofloxacin	Tab. 500mg	Merclip 500mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52
3	277	Levofloxacin	Tab. 250mg	Levomerc 250mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
4	278	Levofloxacin	Tab. 250mg	Levomerc 500mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
5	412	Amlodipine Besylate	Tab. 5mg	Lodopin 5mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54
6	413	Amlodipine Besylate	Tab. 10mg	Lodopin 10mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54
7	414	Amlodipine + Valsartan	Tab. 5mg/80mg	Lodopin V 5/80mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
8	415	Amlodipine + Valsartan	Tab. 5mg/160mg	Lodopin V 5/160mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
9	416	Amlodipine + Valsartan	Tab. 10mg/160mg	Lodopin V 10/160mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
10	482	Rosuvastatin	Tab. 10mg	Crescor 10mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
11	519	Hydrocortisone Acetate	Tab. 10mg + 500mg	Buscopan Plus Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	5	24	57
12	539	Sodium Picosulphate	7.5mg/ml Liquid	Laxoberon Liquid	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	5	24	57
13	550	Empagliflozin	Tab. 10mg	Empagliflozin 10mg Tab	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
14	551	Empagliflozin	Tab. 25mg	Empagliflozin 25mg Tab	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
15	555	Glinapiptide	Tab. 1mg	Glipotin 1mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
16	556	Glinapiptide	Tab. 2mg	Glipotin 2mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
17	557	Glinapiptide	Tab. 3mg	Glipotin 3mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
18	558	Glinapiptide	Tab. 4mg	Glipotin 4mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
19	572	Metformin HCL	Tab. 500mg	Glucophage 500mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	5	24	57
20	583	Sitagliptin + Metformin	Tab. 50mg/500mg	Sitagliptin 50/500mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
21	584	Sitagliptin + Metformin	Tab. 50mg/1000mg	Sitagliptin 50/1000mg Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
22	697	Alprazolam	Tab. 0.25mg	Azolam Tablet 0.25mg	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
23	698	Alprazolam	Tab. 0.5mg	Azolam Tablet 0.5mg	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53
24	701	Carbamazepine	Tab. 800mg	Tenil Tablet	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54
25	716	Diazepam	Inj. 10mg/5ml	Vallium Ampoule 10mg	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	24	57
26	724	Fluoxetine HCL 20mg	Cap. 20mg	Depex Capsule	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54
27	737	Midazolam	Inj. 5mg/5ml	Proversol Ampoule 5mg/5ml	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																
Name of Firm				Martin Dsw Limited Karachi																												
Sl. No.	Product General Information			Factory Technical Evaluation Parameters													Total Factory Evaluated Score	Technical Evaluation Score													Total Points Available from Score	Total Points Scored
				Document Based Factory Score						Factory Evaluation Visit Score								Product Technical Parameters														
				5	2	4	8	9	10	11	12	13	14	15	16	17		18	19	20	21	22	23	24	25	26						
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26						
1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
4	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
5	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
6	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
7	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
8	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
9	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
10	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
11	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
12	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
13	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
14	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
15	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
16	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
17	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
18	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
19	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
20	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
21	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
22	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
23	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
24	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
25	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
26	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
27	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
28	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
29	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
30	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
31	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
32	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
33	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
34	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
35	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
36	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
37	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1					
38	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1</						

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																										
Name of the firm					MediPak Pharma Lahore																					
	S.No	Product General Information				Factory Technical Evaluation Parameter												Factory Evaluated Score	Technical Evaluation Matrix						Product Evaluated Score	Total Technical Score
						Documents Based Factory Score				Evaluation Visit Score																
						1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s. Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.								
		Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70					
KotLakpath	1	651	Haemodialysis Concentrate	Part A- Solution, Part B- Powder			The inspection team at the time of inspection observed that PLANT-2: (Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore) The inspection team has NOT RECOMMENDED awarding the specified marks for the products manufactured at this facility as the cGMP certificate was expired, which was issued on 19/11/2020 and remained valid for 2 years.							0			0	0	0	0	10	10	10			

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																					
Name of the firm					MediPak Pharma Lahore																
S.No	Product General Information				Technical Evaluation Matrix																
					Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters					Product Evaluated Score	Total Technical Score	
					Documents Based Factory Score				Evaluation Visit Score												
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of more than PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC expert/s at the time of inspection. Non-compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of: Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	13	Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC. (Certificate Duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 2 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	No. of item in MCC Form	Generic Name of Item	Size & Gauge of Medical Device	Trade Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
	1112	I/V fluid administration set	sterile and pyrogen free, minimum 150cm tube length, blister pack		0	5	5	6	The inspection team at the time of inspection observed that PLANT-2: (Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore) The inspection team has NOT RECOMMENDED awarding the specified marks for the products manufactured at this facility as the cGMP certificate was expired, which was issued on 19/11/2020 and remained valid for 2 years.				16	0	0	0	0	10	10	10	26
	1113	I/V fluid administration set with additional "Y" injection port	Sterile, minimum 150cm length tubing, latex, and pyrogen free, blister pack		0	5	5	6					16	0	0	0	0	10	10	10	26

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
Name of Firm					MediPak Pharma Lahore																							
S. No.	Product General Information				Technical Evaluation Matrix															Product Evaluation Parameters					Total Product Evaluated Score	Total Technical Score		
					Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Technical Parameters												
					Documents Based Factory Score					Factory Evaluation Visit Score																		
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26		
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) Ranking between 41-60th positions 3 marks.	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Maximum 5 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior Executive of the firm).	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert's) Non-adherence to GSP shall lead to disqualification of the firm.	Adherence to cGMP guidelines, (as in Schedule-B of DRAP in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section's or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC expert's at the time of inspection, Non-availability shall lead to disqualification of the section's or firm).	Availability of functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC expert's at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Availability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of purchases through third party importers a valid trail link-DRAP clearance NOC between the principal manufacturer and the importer firm shall be	Goods Declaration certificate of imported API of the quoted item from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail link-DRAP clearance NOC between the principal manufacturer and the importer firm shall be	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GID) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GID the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GID, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all API's/components of the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of (3) marks. Certificates on company's own letter heads shall not be acceptable. In case of purchases through third party importers a valid trail link-DRAP clearance NOC between the principal manufacturer and the importer firm shall be	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. Note: Valid Certificates for the same brand shall be accepted.	Stability studies of quoted item's duly attested by the Q.C incharge of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Teritary care Govt Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan.	Availability of quoted item's in Pakistan market as per recent most data of IMS/IQVIA (Health not older than twelve (12) months). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Teritary care Govt Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan.				
Sunder Industrial		Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70	
Sunder Industrial	1	4	Metronidazole	Inf. 500mg, 100 ml		0	0	3	0	5	6	2	2	2	2	2	24	0	0	0	0	0	4	5	0	9	33	
Sunder Industrial	2	631	Balanced electrolyte solution	I/V Inf. 1000 ml		0	0	3	0	5	6	2	2	2	2	2	24	5	0	0	0	0	4	5	0	14	38	
Sunder Industrial	3	640	Dextrose	I/V Inf. 5% 100ml		0	0	3	0	5	6	2	2	2	2	2	24	0	0	0	0	0	4	5	0	9	33	
Sunder Industrial	4	656	Normal Saline	I/V Inf. 0.9% 100 ml		0	0	3	0	5	6	2	2	2	2	2	24	0	0	0	0	0	4	5	0	9	33	
Sunder Industrial	5	657	Normal Saline	I/V Inf. 0.9% 500 ml		0	0	3	0	5	6	2	2	2	2	2	24	5	0	0	0	0	4	5	0	14	38	
Sunder Industrial	6	666	Ringer's Lactate + Dextrose 5% Soln.	I/V Inf. 500 ml		0	0	3	0	5	6	2	2	2	2	2	24	5	0	0	0	0	4	5	0	14	38	
Sunder Industrial	7	668	Ringer's Lactate Soln.	I/V Inf. 500 ml		0	0	3	0	5	6	2	2	2	2	2	24	5	0	0	0	0	4	5	0	14	38	
Kotlakpath	8	825	Ciprofloxacin	Eye Drops 0.3% w/v 5ml		0	2	3	The inspection team at the time of inspection observed that PLANT-2: (Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore) The inspection team has NOT RECOMMENDED awarding the specified marks for the products manufactured at this facility as the cGMP certificate was expired, which was issued on 19/11/2020 and remained valid for 2 years.			2	2	2	2	2	2	15	0	0	0	0	0	4	5	0	9	24
Kotlakpath	9	828	Dexamethasone	Eye Drops 0.1% w/v		0	2	3				2	2	2	2	2	2	15	0	0	0	0	0	4	5	0	9	24
Kotlakpath	10	830	Dorzolamide + Timolol	Eye Drops 2 + 0.5% 5ml		0	2	3				2	2	2	2	2	2	15	0	0	0	0	0	4	5	0	9	24
Kotlakpath	11	835	Latanoprost	Eye Drops 0.5%, 2.5ml		0	2	3				2	2	2	2	2	2	15	0	0	0	0	0	4	5	0	9	24
Kotlakpath	12	837	Moxifloxacin	Eye Drops 0.5% w/v, 5ml		0	2	3				2	2	2	2	2	2	15	0	0	0	0	0	4	5	0	9	9
Kotlakpath	13	848	Timolol Maleate	Eye Drops 0.5% w/v, 5ml		0	2	3				2	2	2	2	2	2	15	0	0	0	0	0	4	5	0	9	24
Kotlakpath	14	849	Tobramycin	Eye Drops 0.3% w/v, 5ml		0	2	3				2	2	2	2	2	2	15	0	0	0	0	0	4	5	0	9	24
Kotlakpath	15	850	Tobramycin + Dexamethasone	Eye Drops 0.3% + 0.1% w/v, 5ml		0	2	3				2	2	2	2	2	2	15	0	0	0	0	0	4	5	0	9	24

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
S. No.	Name of Firm				Medisave Pharma Lahore																							
	Product General Information				Factory Technical Evaluation Parameters															Total Factory Evaluated Score	Product Evaluation Parameters						Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score						Factory Evaluation Visit Score										Product Technical Parameters							
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	23	24	25	26					
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year (i.e., FY 2023-24 or latest). Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP (Evaluated at the time of inspection by the	Raw material, In-process and Finished good storage (as in Schedule B of DRAP), in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification Non-adherence to GSP shall lead to	Adherence to cGMP guidelines, storage in Schedule-B of DRAP), in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification Non-adherence to GSP shall lead to	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC expert's at the time of inspection). Non-availability or non-functionality of	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC expert's at the time of inspection). Non-availability or non-functionality of		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO (Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)	Goods Declaration certificate of imported API of the quoted item's from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item's, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA	Stability studies of quoted item's duly attested by the Q.C (incharge of the firm).	Availability of quoted item's in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks							
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	5	37	70					
	1	22	Lignocaine HCl	Inj. 0.02 10 ml	2	2	3	0	0	4	The inspection team at the time of inspection observed that NON-FUNCTIONAL HVAC SYSTEM AND ENVIRONMENTAL CONTROL 1. An air curtain/air shower system was not installed at the personnel entry point of the receiving bay, compromising contamination control measures. 2. The HVAC system in the Cephalosporin manufacturing area was found non-functional, posing a risk to environmental control and product quality. 3. The airlock system between classified areas was non-operational, compromising area segregation and environmental control. 4. Structural damage was observed in the Class A area of the injectable section, with broken ceiling panels and extensive seepage on the walls and ceiling, posing a serious risk of contamination. 5. Air filters across multiple areas were observed in a visibly deteriorated and contaminated condition, with accumulation of dust and particulate matter. 6. The ampoule washing area was found unclean, with stained water pooled on the floor, indicating poor sanitation and housekeeping practices. POOR ADHERANCE TO cGMP 7. Dispensing activities in the Raw Material Store (RMS) were conducted in the absence of a qualified pharmacist or technical personnel, violating GMP requirements. 8. Temperature and relative humidity monitoring records were not maintained or updated in the designated logbook, indicating non-compliance with documentation practices. 9. Packaging materials were observed to be disorganized and scattered within the RMS, lacking systematic storage and segregation. 10. In-process drying operations were ongoing without appropriate labeling, making batch identification and status unclear POOR GOOD STORAGE PRACTICES (GSP) 11. Released finished product batches were stored improperly in the corridor area, breaching storage and GMP compliance requirements 12. No racks or pallets were available in the RMS for proper storage of raw materials, which were observed to be placed directly on the floor, leading to potential contamination risks 13. Packaging materials were placed directly on the floor without the use of pallets or racks, violating material handling and storage protocols. ADHERANCE TO GOOD LABORATORY PRACTICES (GLP) 14. No primary reference standards were available in the Quality Control (QC) department at the time of inspection, affecting the validity of analytical testing					11	0	0	0	0	0	4	15					
	2	36	Acetofenac	Tab. 100 mg	2	2	3	0	0	4						11	0	5	0	5	0	14	25					
	3	41	Diclofenac Sodium (IM/IV for Infusion)	Inj. 25 mg/ml 3 ml	2	2	3	0	0	4						11	0	5	5	5	0	19	30					
	4	48	Ketorolac	Inj. 30 mg/ml 1ml	2	2	3	0	0	4						11	0	5	0	5	0	14	25					
	5	52	Meloxicam	Tab. 15 mg	2	2	3	0	0	4						11	0	0	0	0	0	4	15					
	6	53	Meloxicam	Tab. 7.5 mg	2	2	3	0	0	4						11	0	0	0	0	0	4	15					
	7	64	Paracetamol	Inf. 1000 mg 100ml	2	2	3	0	0	4						11	0	0	0	0	0	4	15					
	8	67	Paracetamol+Tr amadol	Tab.325mg/37.5 mg	2	2	3	0	0	4						11	0	0	0	0	0	4	15					
	9	110	Zoledronic Acid	Inj. 4 mg /Vial	2	2	3	0	0	4						11	0	5	0	5	0	14	25					
	10	147	Fluconazole	Tab. / Cap. 50 mg	2	2	3	0	0	4						11	0	5	5	5	0	19	30					
	11	152	Itraconazole	Cap. 100 mg	2	2	3	0	0	4						11	0	0	0	0	0	4	15					
	12	158	Terbinafine	Tab. 250 mg	2	2	3	0	0	4	11	0	5	5	5	0	19	30										
	13	171	Montelukast	Tab. 10 mg	2	2	3	0	0	4	11	0	5	5	0	0	10	21										
	14	172	Montelukast	Tab. 5 mg	2	2	3	0	0	4	11	0	5	5	5	0	19	30										
	15	177	Amikacin Sulphate	Inj. 100mg	2	2	3	0	0	4	11	0	5	0	0	0	9	20										
	16	178	Amikacin Sulphate	Inj. 250mg	2	2	3	0	0	4	11	0	5	0	5	0	10	21										
	17	179	Amikacin Sulphate	Inj. 500mg	2	2	3	0	0	4	11	0	5	0	5	0	10	21										
	18	202	Azithromycin	Tab. / Cap. 250 mg 12s or less	2	2	3	0	0	4	11	0	0	0	0	0	0	11										
	19	205	Azithromycin	Dry Susp. 200 mg/5ml 25ml or less	2	2	3	0	0	4	11	0	0	0	5	0	5	16										
	20	215	Cefepime	Inj. 500 mg/vial	2	2	3	0	0	4	11	0	5	0	5	0	10	21										
	21	216	Cefepime	Inj. 1 gm/vial	2	2	3	0	0	4	11	0	5	0	5	0	10	21										
	22	217	Cefixime	Cap. 400 mg 5s	2	2	3	0	0	4	11	0	0	0	5	0	5	16										
	23	218	Cefixime	Dry Susp. 100 mg/5ml 30ml	2	2	3	0	0	4	11	0	0	0	5	0	5	16										
	24	219	Cefixime	Dry Susp. 200 mg/5ml 30ml	2	2	3	0	0	4	11	0	0	0	5	0	5	16										

	25	220	Cefoperazone + Sulbactam	Inj. 1gm/Vial		2	2	3	0	0	4
	26	221	Cefoperazone + Sulbactam	Inj. 2 gm/Vial		2	2	3	0	0	4
	27	222	Cefotaxime Sodium	Inj. 250 mg/Vial		2	2	3	0	0	4
	28	223	Cefotaxime Sodium	Inj. 500 mg/Vial		2	2	3	0	0	4
	29	224	Cefotaxime Sodium	Inj. 1gm/Vial		2	2	3	0	0	4
	30	225	Cefpodoxime	Tab. 100 mg		2	2	3	0	0	4
	31	226	Cefpodoxime	Dry Susp. 40 mg/5ml 50 ml		2	2	3	0	0	4
	32	230	Ceftriaxone	Inj. 500 mg/Vial		2	2	3	0	0	4
	33	231	Ceftriaxone	Inj. 1gm/Vial		2	2	3	0	0	4
	34	233	Cefuroxime	Inj. 1.5gm/Vial		2	2	3	0	0	4
	35	234	Cefuroxime	Tab. 250 mg		2	2	3	0	0	4
	36	236	Cefuroxime	Inj 750 mg							
	37	235	Cefuroxime	Dry Susp. 125 mg/5ml		2	2	3	0	0	4
	38	243	Ciprofloxacin	Tab. 250 mg 10s		2	2	3	0	0	4
	39	244	Ciprofloxacin	Tab. 500 mg 10s		2	2	3	0	0	4
	40	250	Clarithromycin	Dry Susp. 125 mg/5ml 60 ml		2	2	3	0	0	4
	41	276	Levofloxacin	Inf. 5 mg/ml 100 ml		2	2	3	0	0	4
	42	277	Levofloxacin	Tab. 250 mg 10s		2	2	3	0	0	4
	43	278	Levofloxacin	Tab. 500 mg 10s		2	2	3	0	0	4
	44	281	Linezolid	Tab. 600mg		2	2	3	0	0	4
	45	282	Linezolid	Suspension 100mg/5ml 60ml		2	2	3	0	0	4
	46	283	Linezolid	Inf. 2 mg/ml 100 ml		2	2	3	0	0	4
	47	284	Linezolid	Inf. 2 mg/ml 300 ml		2	2	3	0	0	4
	48	285	Meropenem	Inj. 500 mg/Vial		2	2	3	0	0	4
	49	286	Meropenem	Inj. 1gm /Vial		2	2	3	0	0	4
	50	287	Minocycline	Tab. 100 mg		2	2	3	0	0	4
	51	288	Moxifloxacin	Tab. 400 mg		2	2	3	0	0	4
	52	289	Moxifloxacin	Inf. 400 mg/250ml 250 ml		2	2	3	0	0	4
	53	292	Piperacillin +Tazobactam	Inj. 2 gm+0.25gm (2.25gm)/Vial		2	2	3	0	0	4
	54	293	Piperacillin +Tazobactam	Inj. 4 g/0.5 g (4.5gm)/Vial		2	2	3	0	0	4
	55	312	Artemether	Inj. 80 mg/ml 1ml		2	2	3	0	0	4
	56	313	Artemether + Lumefantrine	Tab. 40 mg/240mg 8s		2	2	3	0	0	4
	57	314	Artemether + Lumefantrine	Tab. 80 mg/480mg 6s		2	2	3	0	0	4
	58	315	Artemether + Lumefantrine	Susp. 15 mg/ 90 mg/5ml 60ml		2	2	3	0	0	4
	59	383	Iron Hydroxide poly maltose complex	Tab. 100 mg		2	2	3	0	0	4
	60	387	Iron Sucrose	Inj. 20 mg/ml 5 ml		2	2	3	0	0	4

affecting the validity of analytical testing.

Based on the aforementioned findings, the inspection team recommends that the firm be classified as NOT RECOMMENDED

11	0	5	0	5	0	10	21
11	0	5	0	5	0	10	21
11	0	5	0	5	0	10	21
11	0	5	0	5	0	10	21
11	0	5	0	5	0	10	21
11	0	0	0	5	0	5	16
11	0	0	0	5	0	5	16
11	0	5	5	5	0	15	26
11	0	5	5	5	0	15	26
11	0	5	5	5	0	15	26
11	0	5	5	5	0	15	26
		5	5	0	0	10	10
11	0	5	5	5	0	15	26
11	0	0	0	5	0	5	16
11	0	0	0	5	0	5	16
11	0	0	0	5	0	5	16
11	0	5	5	5	0	15	26
11	0	5	5	5	0	15	26
11	0	5	0	5	0	10	21
11	0	5	5	5	0	15	26
11	0	5	5	5	0	15	26
11	0	5	0	5	0	10	21
11	0	5	0	0	0	5	16
11	0	5	0	0	0	5	16
11	0	5	0	0	0	5	16
11	0	5	0	0	0	5	16
11	0	5	5	0	0	10	21
11	0	5	0	0	0	5	16
11	0	0	0	5	0	5	16
11	0	5	5	5	0	15	26
11	0	5	5	5	0	15	26

	61	388	Mecobalamin	Inj. 500 mcg 1ml		2	2	3	0	0	4
	62	399	Tranexamic Acid	Cap. 500 mg		2	2	3	0	0	4
	63	401	Tranexamic Acid	Inj. 500 mg 5 ml		2	2	3	0	0	4
	64	414	Amlodipine + Valsartan	Tab. 5mg+80 mg		2	2	3	0	0	4
	65	416	Amlodipine + Valsartan	Tab. 10 mg+160 mg		2	2	3	0	0	4
	66	417	Amlodipine + Valsartan + Hydrochlorothiazide	Tab. 10mg+160mg+12.5mg		2	2	3	0	0	4
	67	432	Clopidogrel	Tab. 75 mg		2	2	3	0	0	4
	68	482	Rosuvastatin	Tab. 10 mg		2	2	3	0	0	4
	69	513	Domperidone	Tab. 10 mg		2	2	3	0	0	4
	70	514	Domperidone	Susp. 5 mg/5ml 120 ml		2	2	3	0	0	4
	71	526	Omeprazole	Inj. 40 mg / Vial		2	2	3	0	0	4
	72	527	Omeprazole	Cap. 40 mg		2	2	3	0	0	4
	73	528	Esomeprazole	Cap. 40mg		2	2	3	0	0	4
	74	529	Ondansetron	Tab. 8 mg		2	2	3	0	0	4
	75	530	Ondansetron	Inj. 2 mg/ml 4 ml		2	2	3	0	0	4
	76	583	Sitagliptin + Metformin	Tab. 50 mg/500 mg		2	2	3	0	0	4
	77	584	Sitagliptin + Metformin	Tab. 50mg /1000 mg		2	2	3	0	0	4
	78	683	Febuxostat	Tab. 40 mg		2	2	3	0	0	4
	79	751	Pregabalin	Cap. 50 mg		2	2	3	0	0	4
	80	752	Pregabalin	Cap. 75mg		2	2	3	0	0	4
	81	753	Pregabalin	Cap. 150 mg		2	2	3	0	0	4
	82	912	Cholecalciferol (Vitamin D3)	IM/ Oral Inj. 200000 IU 1ml		2	2	3	0	0	4

GRC Decision
The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

11	0	0	0	5	0	5	16
11	0	5	0	5	0	10	21
11	0	5	0	5	0	10	21
11	0	0	0	5	0	5	16
11	0	0	0	5	0	5	16
11	0	0	0	5	0	5	16
11	0	5	5	5	0	15	26
11	0	5	5	5	0	15	26
11	0	5	5	5	0	15	26
11	0	0	0	5	0	5	16
11	0	0	0	5	0	5	16
11	0	0	0	5	0	5	16
11	0	5	0	5	0	10	21
11	0	5	0	5	0	10	21
11	0	0	0	5	0	5	16
11	0	0	0	5	0	5	16
11	0	5	0	5	0	10	21
11	0	5	0	5	0	10	21
11	0	5	0	5	0	10	21

[illegible]

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																																																													
Name of Firm												Muller & Phipps, Karachi																																																	
S. No.	Product General Information				Technical Evaluation Matrix																																																								
					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation										Product Evaluated Score	Total Technical Score																																				
														Principal Manufacturer Evaluation				Importer's Evaluation				Product Technical Parameters																																							
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23																																						
					Valid ISO 14001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm) Online verification link shall be provided	Valid accreditation of manufacturing unit or its relevant section by the USFDA or WHO or official accreditation body/ or regulatory body in the case of SRA countries duly attested by senior executive of the firm)	Valid calibration certificates for equipment/ factors for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products (Valid Calibration Certificates attested by Quality head of the firm)	Availability of minimum 30% inventory of the total report of the quoted items signed by the senior executive of the firm & evaluated by the MCC experts	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning & Ventilation system and effective cold chain thermo-labile drugs	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air conditioning &

[illegible]

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																
Name of Firm				Nabi Qasim, Karachi																												
S. No.	Product General Information				Technical Evaluation Matrix																											
					Factory Technical Evaluation Parameters															Total Factory Evaluated Score	Product Evaluation Parameters						Total Product Evaluated Score	Total Technical Score				
																					Product Technical Parameters											
	Documents Based Factory Score				Factory Evaluation Visit Score																											
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26							
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by the manufacturer of the material coupled with Invoice/proof of purchase: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) Ranking between 41-100th positions 3 marks.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of more than PKR 500 million - 4 marks. Financial turnover of more than PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior Executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s).	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO (Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be provided.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the	Valid WHO prequalification and / or source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistan market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.									
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70						
	786	Acetyline	Syp. 125ml	Acetyl	2	2	3	5	5	6	2	2	2	2	2	33	0				0	4		2	6	39						
	167	Chlorophenamine	Syp. 120ml	Allergex	2	2	3	5	5	6	2	2	2	2	2	33	0	Older than 2 years	0		0	4	Not Attached	0	4	37						
	412	Amlodipine	Tab. 5mg	Amdipine	2	2	3	5	5	6	2	2	2	2	2	33	0	Airway bill not attached	0		0	0	0	0	0	33						
	423	Bosentan	Tab. 62.5mg	Bosphan	2	2	3	5	5	6	2	2	2	2	2	33	0				0	0		2	2	35						
	759	Risperidone	Tab. 2mg	Bozan	2	2	3	5	5	6	2	2	2	2	2	33	0	Airway bill not attached	0		0	0	0	0	0	0	33					
	760	Risperidone	Tab. 4mg	Bozan	2	2	3	5	5	6	2	2	2	2	2	33	0	Airway bill not attached	0		0	0	0	0	0	0	33					
	243	Ciprofloxacin	Tab. 250mg	Bacip	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	0	15	48						
	244	Ciprofloxacin	Tab. 500mg	Bacip	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	0	15	48						
	222	Cefotaxime	Inj. 250mg	Baxim	2	2	3	5	5	6	2	2	2	2	2	33	0	Airway Bill Not Matching	0		0	4	0	0	4	37						
	223	Cefotaxime	Inj. 500mg	Baxim	2	2	3	5	5	6	2	2	2	2	2	33	0	Airway Bill Not Matching	0		0	4	0	0	4	37						
	224	Cefotaxime	Inj. 1g	Baxim	2	2	3	5	5	6	2	2	2	2	2	33	0	Airway Bill Not Matching	0		0	4	0	0	4	37						
	462	Losartan Potassium	Tab. 25mg	Bapsar	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	0	0	10	43						
	463	Losartan Potassium	Tab. 50mg	Bapsar	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	0	0	10	43						
	460	Losartan Potassium+Hydrochlorothiazide	Tab. 50+12.5mg	Bepsar Plus	2	2	3	5	5	6	2	2	2	2	2	33	0	0	0		0	0	0	0	0	33						
	217	Cefixime	Cap. 400mg	Cefbol	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	0	15	48						
	218	Cefixime	Susp100mg/5ml	Cefbol	2	2	3	5	5	6	2	2	2	2	2	33	0	GD and invoice not attached	0		0	4	5	0	9	42						
	545	Clomiphene	Tab. 50mg	Clomilab	2	2	3	5	5	6	2	2	2	2	2	33	0				0	0		1	1	34						
	724	Fluoxetine	Cap. 20mg	Depricap	2	2	3	5	5	6	2	2	2	2	2	33	0				0	0		1	1	34						
	548	Dinoprostone	Tab. 3mg	Glindine E2	2	2	3	5	5	6	2	2	2	2	2	33	0	Airway bill not attached	0		0	0	5	1	6	39						
	723	Escitalopram	Tab. 10mg	Es-Prancit	2	2	3	5	5	6	2	2	2	2	2	33	0				0	0		0	0	33						
	550	Empagliflozin	Tab. 10mg	Glempa	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	0	15	48						
	551	Empagliflozin	Tab. 25mg	Glempa	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	0	15	48						
	381	Folic Acid	Tab. 5mg	Folilab	2	2	3	5	5	6	2	2	2	2	2	33	0				0	0		0	0	33						
	583	Sitagliptin+Metformin	Tab. 50mg+500mg	Glytec-M XR	2	2	3	5	5	6	2	2	2	2	2	33	0	Metformin Airway Bill Not Attached	0		0	0	5	0	5	38						
	584	Sitagliptin+Metformin	Tab. 50mg+1000mg	Glytec-M XR	2	2	3	5	5	6	2	2	2	2	2	33	0	Metformin Airway Bill Not Attached	0		0	0	Not Attached	0	0	33						
	143	Clotrimazole	Vaginal Tab. 500mg	Gynosporin	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	0	15	48						
	144	Clotrimazole	Cream30gm	Gynosporin	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	3	18	51						
	537	Sodium Phosphate + Sodium Bi-Phosphate	7.2 gm + 19.2gm	Kleen Enema	2	2	3	5	5	6	2	2	2	2	2	33	0				0	0		1	1	34						
	335	Acyclovir	Inj. 500mg	Hypovir	2	2	3	5	5	6	2	2	2	2	2	33	0				0	4		0	4	37						
	281	Linezolid	Tab. 600mg	Linox	2	2	3	5	5	6	2	2	2	2	2	33	0	Airway bill not attached	0		0	0	5	0	5	38						
	526	Omeprazole	Inj. 40mg	Loprot	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	4	5	0	19	52						
	288	Moxifloxacin	Tab. 400mg	Medlox	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	0	15	48						
	157	Terbinafine	Tab. 250mg	Myco Derm	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	0	15	48						
	892	Terbinafine	Cream	Myco Derm	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	0	15	48						
	529	Ondansetron	Tab. 8mg	Nivom	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	5	0	15	48						
	530	Ondansetron	Inj. 8mg/4ml	Nivom	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	0	Stability done by Surge Lab	0	10	43						
	256	Colistimethate	Inj. 2Mlillion	Nbogotex	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5		0	4	5	0	19	52						

	257	Colistimethate	Inj. 1Mlillion	Nogotex	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	4	5	0	19	52
	555	Glinapiptide	Tab. 1mg	Norlim	2	2	3	5	5	6	2	2	2	2	33	0				0	0		0	0	33
	556	Glinapiptide	Tab. 2mg	Norlim	2	2	3	5	5	6	2	2	2	2	33	0				0	0		0	0	33
	557	Glinapiptide	Tab. 3mg	Norlim	2	2	3	5	5	6	2	2	2	2	33	0				0	0		0	0	33
	558	Glinapiptide	Tab. 4mg	Norlim	2	2	3	5	5	6	2	2	2	2	33	0				0	0		0	0	33
	418	Atenonol	Tab. 50mg	Normitab	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	0	5	1	16	49
	419	Atenonol	Tab. 100mg	Normitab	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	0	5	1	16	49
	758	Quetiapine	Tab. 100mg	Nabaquel	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	0	Not Attached	0	10	43
	414	Amlodipine+Valsartan	Tab. 5mg/80mg	Redupres-AM	2	2	3	5	5	6	2	2	2	2	33	0	Amlodipine airway bill not attached	0		0	0	5	0	5	38
	415	Amlodipine+Valsartan	Tab. 5mg/160mg	Redupres-AM	2	2	3	5	5	6	2	2	2	2	33	0	Amlodipine airway bill not attached	0		0	0	5	0	5	38
	152	Itraconazol	Cap. 100mg	Raena	2	2	3	5	5	6	2	2	2	2	33	0				0	0		1	1	34
	202	Azithromycin	Tab. 250mg	Romycin	2	2	3	5	5	6	2	2	2	2	33	0				0	0		0	0	33
	203	Azithromycin	Tab. 500mg	Romycin	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	0	5	0	15	48
	204	Azithromycin	Inj. 500mg	Romycin	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	4	5	0	19	52
	205	Azithromycin	Susp. 200 mg/5ml	Romycin	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	0	Not Attached	0	10	43
	482	Rosuvastatin	Tab. 10mg	Roviros	2	2	3	5	5	6	2	2	2	2	33	0	Airway bill not attached	5	0		0	0	1	1	34
	307	Tigecycline	Inj. 50mg	Tigetral	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	4	5	0	19	52
	417	Amlodipine+Valsartan+Hydrochloro thiazide	Tab. 10/160/12.5mg	Tri-Redupres	2	2	3	5	5	6	2	2	2	2	33	0	Amlodipine airway bill not attached	0		0	0		0	0	33
	308	Vancomycin	Inj. 500mg	Vanbact	2	2	3	5	5	6	2	2	2	2	33	0	5	5	Older than 5 years	0	4	5	0	19	52
	309	Vancomycin	Inj. 1gm	Vanbact	2	2	3	5	5	6	2	2	2	2	33	0	5	5	Older than 5 years	0	4	5	0	19	52
	910	Ossein Mineral Complex + Vitamin D	Tab. 830mg+400IU	Ognis-D	2	2	3	5	5	6	2	2	2	2	33	0	Airway bill not attached	0		0	0	5	0	5	38
	911	Ossein Mineral Complex + Vitamin D	Susp. 830mg+400IU	Ognis-D	2	2	3	5	5	6	2	2	2	2	33	0	Airway bill not attached	0		0	4	Not Attached	0	4	37
	704	Citalopram	Tab. 20mg	Pramcit	Non formulary			5	5	6	2	2	2	2	26	0	Non-Formulary Strength			0	0		0	0	26
	751	Pregabalin	Cap. 50mg	Preneu	2	2	3	5	5	6	2	2	2	2	33	0				0	0		1	1	34
	752	Pregabalin	Cap. 75mg	Preneu	2	2	3	5	5	6	2	2	2	2	33	0				0	0		1	1	34
	753	Pregabalin	Cap. 150mg	Preneu	2	2	3	5	5	6	2	2	2	2	33	0				0	0		1	1	34
	159	Voriconazole	Inj. 200mg	Vecot	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	4	5	0	19	52
	277	Levofloxacin	Tab. 250mg	Warlor	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	0	5	0	15	48
	278	Levofloxacin	Tab. 500mg	Warlor	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	0	5	0	15	48
	683	Febuxostat	Tab. 40mg	Xostat	2	2	3	5	5	6	2	2	2	2	33	0	5	5	5	0	0	5	0	20	53
	684	Febuxostat	Tab. 80mg	Xostat	2	2	3	5	5	6	2	2	2	2	33	0	5	5	5	0	0	5	0	20	53
	868	Fusidic Acid	Cream15gm	Zudic	2	2	3	5	5	6	2	2	2	2	33	0	5	5		0	0	5	0	15	48
	110	Zoledronic Acid	Inj. 4mg	Zoldronic	2	2	3	5	5	6	2	2	2	2	33	0	Not Attached	0		0	4	5	0	9	42
	543	Zinc Sulphate	Syp. 60ml	Zynq	2	2	3	5	5	6	2	2	2	2	33	0	Order trans 2 years and airway bill not attached.	0		0	0	5	1	6	39

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																													
Name of Firm				Neutro Pharma Lahore																									
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix											Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score					Factory Evaluation Visit Score							Product Evaluation Parameters												
																	Product Technical Parameters												
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26			
					Valid ISO 18001:2001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firms having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Assay Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 at latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all phases of the product (s).	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adherence to GMP guidelines, (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).	Bio-availability Bio-equivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or	Goods Declaration certificate of imported API or the quoted item's from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item's, not older than 24 months from the cutoff date for submission of bids.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GdD) provided in volume 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Made or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs).	Valid WHO prequalification and / or Valid product registration in SRA country(ies)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item's, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrops/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).	Stability studies of quoted item's duly attested by the Q.C (incharge of the firm).	Availability of quoted item's in Pakistani market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 62 Tender approvals- 01 mark 64 Tender approvals- 02 marks 66 Tender approvals- 03 marks 68 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks						
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70			
1	4	Metformin	Inj. 500mg/100 ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47			
2	41	Diclofenac Sodium (IM/IV for Infants)	Inj. 25 mg/ml 3 ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43			
3	217	Cefixime	Cap. 400 mg 5s		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47			
4	218	Cefixime	Dry Susp. 100 mg/5ml 30ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43			
5	219	Cefixime	Dry Susp. 200 mg/5ml 30ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43			
6	230	Ceftriaxone	Inj. 500 mg/Val		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	0	0	12	40			
7	231	Ceftriaxone	Inj. 1gm/Val		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45			
8	516	Drotaverine	Inj. 20 mg/ml 2ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43			
9	547	Dexamethasone	Inj. 4 mg/ml 1ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	0	15	43			
10	656	Normal Saline	I/V Inf. 0.9% 100 ml		2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	4	5	0	9	37			

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
Name of Firm					NEXT PHARMA LAHORE																							
S. No.	Product General Information				NEXT PHARMA LAHORE																							
					Factory Technical Evaluation Parameters															Total Factory Evaluated Score	Product Evaluation Parameters						Total Product Evaluated Score	Total Technical Score
	Documents Based Factory Score						Factory Evaluation Visit Score									Product Technical Parameters												
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26			
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). Non-adherence to cGMP guidelines shall lead to disqualification of the firm.	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-		Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA / Swiss Medic or Health Canada or by regulatory authority/body of SRAs country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.					
Ref. No. of Item	Generic Name of Item	Dosage Form & Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70			
42	Diclofenac Sodium	Tab 50mg	Painext	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
60	Paracetamol	Tab 500mg	Paranext	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
67	Tramadol HCL + Paracetamol	Tab 37.5mg + 325mg	Paranext-T	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
162	Betahistine Dihydrate	Tab 16mg	Gerohist	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
171	Montelukast Sodium	Tab 10mg	Airmont	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
281	Linezolid	Tab 600mg	Linzanext	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
413	Amlodipine as Besylate	Tab 10mg	Amlonext	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
414	Amlodipine + Valsartan	Tab 5/80mg	Velvet-AM	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
415	Amlodipine + Valsartan	Tab 5/160mg	Velvet-AM	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
416	Amlodipine + Valsartan	Tab 10/160mg	Velvet-AM	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
432	Clopidogrel	Tab 75mg	Clopinex	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
482	Rosuvastatin	Tab 10mg	Rosumext	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
513	Domperidone	Tab 10mg	Domflash	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
514	Domperidone	Syp 10mg/ml	Domflash	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
527	Omeprazole	Cap 40mg	Omecap	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45			
528	Esomeprazole	Cap 40mg	Esonext	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45			
550	Empagliflozin	Tab 10mg	Empanext	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
583	Sitagliptin + Metformin	Tab 50/500mg	Sitanext	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			
584	Sitagliptin + Metformin	Tab 50/1000mg	Sitanext	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41			

	695	Tamsulosin HCL	Cap 0.4mg	Tamlin MR	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
	723	Escitalopram	Tab 10mg	Gleetal	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	752	Pregabalin	Cap 75mg	Reslorton	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45

[illegible]

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																						
Name of the firm					NISA SF Lahore																	
S.No	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	Technical Evaluation Matrix							Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score					Product technical Evaluation Parameters								
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21		
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC expert/s at the time of inspection. Non-compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificate Duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 2 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.			
	Ref. No. of item in	Generic Name of Item	Size & Guage of Medical Device	Trade Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70	
1	944	BLOOD TRANSFUSION SET	BM Blood Transfusion Set		0	5	5	6	3	3	2	2	26	5	5	0	6	10	10	26	52	
2	1016	AUTO DISPOSABLE SYRINGE 3ML	BM Auto Disposable syringe 3ml		0	5	5	6	3	3	2	2	26	5	5	0	6	10	10	26	52	
3	1017	AUTO DISPOSABLE SYRINGE 5ML	BM Auto Disposable syringe 5ml		0	5	5	6	3	3	2	2	26	5	5	0	6	10	10	26	52	
4	1020	DISPOSABLE SYRINGE 1ML	BM Disposable syring 1ml		0	5	5	6	3	3	2	2	26	5	5	0	6	10	10	26	52	
5	1021	DISPOSABLE SYRINGE 10ML	BM Disposable syring 10ml		0	5	5	6	3	3	2	2	26	5	5	0	6	10	10	26	52	
6	1022	DISPOSABLE SYRINGE 20ML	BM Disposable syring 20ml		0	5	5	6	3	3	2	2	26	5	5	0	6	10	10	26	52	
7	1023	DISPOSABLE SYRINGE 50ML	BM Disposable syring 50ml		0	5	5	6	3	3	2	2	26	5	5	0	6	10	10	26	52	
8	1024	DISPOSABLE SYRINGE 60ML	BM Disposable syring 60ml		0	5	5	6	3	3	2	2	26	5	5	0	6	10	10	26	52	
9	1126	IV BURETTE 100ML	BM IV BURETTE 100ML		0	5	5	6	3	3	2	2	26	5	5	0	6	10	10	26	52	
10	1189	INFUSION SET	BM INFUSION SET		0	5	5	6	3	3	2	2	26	5	5	0	6	10	DTL substandard	26	52	

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
Name of Firm				Nasim Pharma Labors																								
S. No.	Product General Information				Factory Technical Evaluation Parameters															Technical Evaluation Matrix						Total Product Evaluated Score	Total Technical Score	
					Documents Based Factory Score															Total Factory Evaluated Score	Product Evaluation Parameters							
																					Product Technical Parameters							
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26		
				Valid ISO 14001 (Labs) certificate of the facility where the product is manufactured, issued by PNAC, accredited body duly attested by senior executive of the firm)	Valid ISO 14001 (Labs) certificate of the facility where the product is manufactured, issued by PNAC, accredited body duly attested by senior executive of the firm)	Valid ISO 9001 (Labs) certificate of the facility where the product is manufactured, issued by PNAC, accredited body duly attested by senior executive of the firm)	Latest IMSR/VIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMSR/VIA, in the following manner: 1. Firms having (12-Month) Ranking in top-10 positions shall be awarded 1 mark. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 2 marks.	Valid calibration certificates attested by the firm)	Valid documents of the Federal Board of Revenue (FBR) showing the valid financial turnover of the firm for the last year i.e. FY 2023-24 at least. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 100 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quality control items along with validated methods of testing of the product in the laboratory to ensure adherence to good laboratory practices, period time and adherence to good laboratory practices in all lab tests + Functional Safety Counter (Blood Accidental and Heat Trazojin in Schedule B of DRAP)	Raw material, In-process and Finished product storage in an approved facility as per schedule-B of DRAP (as may) section of the product (s) as evaluated at the time of inspection by the MCC experts)	Adherence to cGMP guidelines, (as per schedule-B of DRAP) (as may) section of the product (s) as evaluated at the time of inspection by the MCC experts)	Adequate availability of purified & relevant chemical substances as per the requirements mentioned in schedule-B of DRAP (as may) section of the product (s) as evaluated at the time of inspection by the MCC experts)	Availability of technical and validated HVAC, with all relevant equipment, testing, logs, as evaluated by the MCC experts at the time of inspection)	Stability (Bioprocess) study conducted by WHO/ National Labs must be attached along with the bid and study must be available on WHO Website)	Cross Declaration certificate of reported API of the product and from Pakistan Customs, complied with valid entry bill or Bill of Lading for the product, not older than 24 months from the date of submission of bid.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the product declaration (GDP) provided in bid.	Active Pharmaceutical Ingredient (API) cross declaration certificate issued by WHO/ USA, FDA, EMA, MHRA, TGA, PMDA Swiss Medic or Health Canada or the regulatory authority body of SRA country (not complied with Form 1 (Form of declaration to accompany an application for License to import Drugs).	Valid WHO prequalification and/or valid product registration in SRA country(ies) and/or Valid sale certificate issued by regulatory body of any SRA country(ies)	Valid Certificate of Analysis of the type of glass material used in the immediate container of the product, as issued by the manufacturer of the material, complied with below proof of purchase: 1. Material e.g. Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used in the immediate container of the product must comply with US, European, British, Japanese Pharmacopoeial standards, or must clearly mention that the material is of pharmaceutical grade. 2. Type of Glass material for liquid products must be USP class 1 (Non-cylindrical, shall lead to disqualification of the product). 3. Type of Glass material for Oral Sterile Suspension must be USP Type 3 or better (Non-compliance or non-approval of each of glass material shall lead to disqualification of the product).	Stability studies of product done in Pakistan market as per recent test data of IMSR/VIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-20% market share = 2 marks 21-30% market share = 3 marks 31% and above market share = 4 marks For items specifically used in institutions where IMSR/VIA data is not applicable the bidder shall provide Tender Approach (not older than twelve (12) months from Tender issue date). Hospital, Health related test, progress and or PC1 accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 30 Tender approach: 10 marks 31 Tender approach: 10 marks 32 Tender approach: 10 marks	Availability of quality data in Pakistan market as per recent test data of IMSR/VIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-20% market share = 2 marks 21-30% market share = 3 marks 31% and above market share = 4 marks For items specifically used in institutions where IMSR/VIA data is not applicable the bidder shall provide Tender Approach (not older than twelve (12) months from Tender issue date). Hospital, Health related test, progress and or PC1 accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 30 Tender approach: 10 marks 31 Tender approach: 10 marks 32 Tender approach: 10 marks						
All lots of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26				Group 1: 100 mg/ml 3 ml	2	2	2	1	1	4	2	2	2	2	2	20	1	1	1	1	1	4	1	1	27	70		
1	41	Diclofenac Sodium (IMV for infusion)	Tab. 25 mg/ml 3 ml		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
2	42	Diclofenac Sodium enteric coated	Tab. 50 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
3	164	Ceftriaxone	Tab. 10 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	12	43	
4	170	Levodopa	Tab. 10 mg 30s		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	12	43	
5	213	Cefepime	Eq. 500 mg/vial		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
6	216	Cefepime	Eq. 1 g/vial		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
7	222	Ceftriaxone Sodium	Eq. 250 mg/Vial		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
8	223	Ceftriaxone Sodium	Eq. 500 mg/Vial		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
9	224	Ceftriaxone Sodium	Eq. 1gm/Vial		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
10	243	Cefepime	Tab. 250 mg 30s		2	2	2	0	1	4	2	2	2	2	2	20	0	1	0	0	0	0	0	0	1	12	43	
11	244	Cefepime	Tab. 500 mg 30s		2	2	2	0	1	4	2	2	2	2	2	20	0	1	0	0	0	0	0	0	1	12	43	
12	247	Clarithromycin	Tab. 250 mg 30s		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	0	10	28	
13	248	Clarithromycin	Tab. 500 mg 30s		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	0	10	28	
14	264	Doxycycline	Cap. 100 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	12	33	
15	277	Levofloxacin	Tab. 250 mg 30s		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	0	0	18	
16	278	Levofloxacin	Tab. 500 mg 30s		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	21		
17	311	Atracurium + Tansclorine	Eq. 10 mg / 50 mg / 5ml 30ml		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	0	0	28	
18	337	Diclofenac	Tab. 60 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	0	0	28	
19	383	Iron Hydroxide poly malox complex	Tab. 120 mg	Iron hydroxide (poly malox)	2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	0	0	28	
20	384	Iron Hydroxide poly malox complex	Eq. 50 mg/5ml		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	23		
21	412	Ambipolone Bupropion	Tab. 5 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	23		
22	413	Ambipolone Bupropion	Tab. 10 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	23		
23	418	Ambipolone	Tab. 50 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	23		
24	432	Clapadipril	Tab. 75 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
25	517	Fenofibrate	Tab. 40 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	12	33	
26	526	Omeprazole	Eq. 40 mg / Vial		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
27	527	Omeprazole	Cap. 40 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	28	
28	528	Esomeprazole	Cap. 40mg		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
29	555	Omeprazole	Tab. 1mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	12	33	
30	556	Omeprazole	Tab. 2mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	0	0	28	
31	557	Omeprazole	Tab. 3mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	0	0	28	
32	558	Omeprazole	Tab. 6mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	12	33	
33	723	Diclofenac	Tab. 10 mg		2	2	2	0	1	4	2	2	2	2	2	20	0	0	0	0	0	0	0	0	1	12	33	
34	776	Ibuprofen	Eq. 200mg/ml 50ml		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	
35	777	Ibuprofen	Eq. 200mg/ml 100ml		2	2	2	0	1	4	2	2	2	2	2	20	0	1	1	0	0	0	0	0	1	12	43	

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																									
Name of Firm					Novartis Importer Karachi																				
S. No.	Product General Information				Technical Evaluation Matrix																				
					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation										Product Evaluated Score	Total Technical Score
														Principal Manufacturer Evaluation				Importer's Evaluation				Product Technical Parameters			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23		
					Valid WHO 100% (GMP) certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm)	Valid WHO 100% (GMP) certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm)	Valid WHO 100% (GMP) certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm)	Valid accreditation of manufacturing unit or its relevant section by the (USFDA or WHO) or official accreditation body or regulatory body in the case of SRA countries. (duly attested by senior executive of the firm)	Valid calibration certificate for equipment / statements used in the facility for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Availability of customer 20% (recovery of the total import of the quoted items during last one year) certificate to the effect duly signed by the senior executive of the firm (evaluated by the MCC expert).	Adherence to Good storage practices (GSP) for storage of finished goods (Pharmaceuticals) or (non-pharmaceuticals) & Ventilation System and effective cold chain (thermo-labile drugs).	Adequate availability of qualified personnel as mentioned in the valid assay/ test or IRL or I/L testing for the quoted items, not older than 36 months on the cutoff date for submission of bids.	Manufacture Declaration certificate of imported finished quoted items from Pakistan Customs, coupled with valid assay/ test or IRL or I/L testing for the quoted items, not older than 36 months on the cutoff date for submission of bids.	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GDD) provided in section 16, duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted items from the Principal Manufacturer as mentioned in the goods declaration (GDD) provided in section 16, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / USFDA / EMA / MHRA/ TGA/ PMDA / Swiss Meds or Health Canada or by regulatory authority body of SRA country (ies)	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA country(ies)	Valid certificate of Analysis of the Type / class of material used for the immediate container of the quoted items as issued by the manufacturer of the material coupled with invoice/proof of purchase	Reliability (within 6 quoted items) duly attested by the Q/C (recharge of the firm)	A reliability of quoted items in Pakistan market as per recent most date of IMS/RVIA Health not older than twelve (12) months					
					Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	(Valid Calibration Certificates attested by Quality head of the firm)	Non-availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to the disqualification of the quoted item(s) / firm	The physical inspection committee (MC) experts shall verify the compliance to the GSP as accordance to the laid down criteria and terms and conditions of the Drug Sales Restrict Modified Device (Disruptive Regulatory Authorities).	MC experts shall verify the compliance to the GSP as accordance to the laid down criteria and terms and conditions of the Drug Sales Restrict Modified Device (Disruptive Regulatory Authorities).	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm	Disqualification of the quoted item(s) / firm		
	Ref. No. of Item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70		
Novartis Switzerland	90	Everolimus	Tab. 5 mg		0	0	2	5	0	4	5	5	21	0	0	0	0	2	4	5	1	12	33		
Novartis Switzerland	91	Everolimus	Tab. 10 mg		0	0	2	5	0	4	5	5	21	0	0	0	0	2	4	5	1	12	33		
Novartis Singapore/Switzerland	489	Valsartan + Sacubitril	Tab. 100mg		0	0	2	5	0	4	5	5	21	0	0	0	0	2	4	5	0	11	32		
Novartis Switzerland	845	Ramiprilumab	Inj. 10 mg/ ml		0	0	2	5	0	4	5	5	21	0	0	0	0	2	4	5	2	13	34		
Novartis UK/Switzerland	621	Secukinumab	Inj. 150 mg		0	0	2	5	0	4	5	5	21	0	0	0	0	2	4	5	5	16	37		

GRC Decision
The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

GRC Decision
The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																							
Name of the firm					112 OPHTH PHARMA (SUTURES) KARACHI																		
S.No	Product General Information				Technical Evaluation Matrix												Product Evaluated Score	Total Technical Score					
					Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters									
	Documents Based Factory Score				Evaluation Visit Score				14	15	16	17		18	19	20			21				
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21			
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured. Issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificate Duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form.	Valid WHO prequalification and / or valid product registration in SRA country(ies) / valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.							
	Ref. No. of Item in MCC Formulary	Generic Name of Item	Size & Gauge of Medical Device	Trade Name	3	5	5	6	The firm was inspected as per technical evaluation criteria and the following observations were made by the inspection team: Non-adherence to Good Storage Practices (GSP): 1. There was no temperature log in steroid raw material store. 2. The labelling in the raw material quarantine was not in a proper way, moreover, in the release area most of the raw material were not having "quarantine", "sample taken" labels rather a single released label was affixed on most of the raw material containers. 3. Various raw material were found expired at the time of inspection such as Dextran, Polymyxin B sulfate, Ofloxacin, Adrenaline, Nor adrenaline, etc. 4. The warehouse in charge was requested for purchase trail of Ofloxacin and Adrenaline raw material but he failed to produce the required documents, thereby creating ambiguity on the channel through which the firm is acquiring raw material. Poor Good Laboratory Practices (GLP): 5. Ciprofloxacin infusion batch No. OP102 was present in the stability chamber with visible precipitates/particles. The in- charge QC was repeatedly asked to provide the stability data of the afore-mentioned batch No, but he failed to provide the documents till the end of inspection. 6. In in-process quarantine, labelling of containers were not proper that is some containers of the same batch were released while some were quarantined. 7. LAL test kit was stored at freezing temperature (in freezer) while on the label, the recommended storage temperature was 2-10 °C. 8. There was no quarantine in the suture raw material store. 9. There was no temperature & humidity log in the refrigerators of suture RMS and the humidity noted was 80%. Non-Compliance to current Good Manufacturing Practices (cGMP): 10. Huge quantity of expired polyglolic acid raw material was found in the refrigerator of suture RMS. 11. Food/drinking items were found in the refrigerator of quality control lab. 12. Vitamin E powder 50% with manufacturing date 5th July 2010 was present in the refrigerator of QC while the staff was unaware about the same.				19	5	5	5	6	10	10	41	60		
1	1301	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	12 sachet	B.T Chromic Catgut Sutures	3	5	5	4					17	5	0	0	0	0	0	10	0	15	32
2	1302	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	12 sachet	B.T Chromic Catgut Sutures	3	5	5	4					17	5	0	0	0	0	0	10	0	15	32
3	1304	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	12 sachet	B.T Chromic Catgut Sutures	3	5	5	4					17	5	0	0	0	0	0	10	0	15	32
4	1306	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	12 sachet	B.T Chromic Catgut Sutures	3	5	5	4					17	5	0	0	0	0	0	10	0	15	32
5	1308	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	12 sachet	B.T Chromic Catgut Sutures	3	5	5	4					17	5	0	0	0	0	0	10	0	15	32
6	1317	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	12 sachet	B.T Silk Suture	3	5	5	4					17	0	0	0	0	0	0	10	0	10	27
7	1318	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	12 sachet	B.T Silk Suture	3	5	5	4					17	0	0	0	0	0	0	10	0	10	27
8	1319	40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	12 sachet	B.T Silk Suture	3	5	5	4					17	0	0	0	0	0	0	10	0	10	27
9	1320	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	12 sachet	B.T Silk Suture	3	5	5	4					17	0	0	0	0	0	0	10	0	10	27
10	1337	31mm, 1/2 circle round bodied taper point, Strand length 70 cm	12 sachet	B.T PGLA Suture	3	5	5	4					17	5	0	0	0	0	0	10	0	15	32
11	1342	40mm, 1/2 circle round bodied taper point, strand length 70 cm	12 sachet	B.T PGLA Suture	3	5	5	4					17	5	0	0	0	0	0	10	0	15	32
12	1344	40mm, 1/2 circle round bodied taper point, strand length 90 cm	12 sachet	B.T PGLA Suture	3	5	5	4					17	5	0	0	0	0	0	10	0	15	32
13	1354	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	12 sachet	B.T PGA Suture	3	5	5	4					17	5	0	0	0	0	0	10	0	15	32
14	1377	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	12 sachet	B.T Polypropylene Suture	3	5	5	4					17	0	0	0	0	0	0	10	0	10	27
15	1378	55mm, straight cutting needle, strand length 75cm	12 sachet	B.T Polypropylene Suture	3	5	5	4					17	0	0	0	0	0	0	10	0	10	27
16	1379	60mm, straight cutting needle, strand length 75cm	12 sachet	B.T Polypropylene Suture	3	5	5	4					17	0	0	0	0	0	0	10	0	10	27
17	1380	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	12 sachet	B.T Polypropylene Suture	3	5	5	4					17	0	0	0	0	0	0	10	0	10	27
18	1381	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	12 sachet	B.T Polypropylene Suture	3	5	5	4					17	0	0	0	0	0	0	10	0	10	27

GRC Decision

The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																		
S. No.	Name of Firm				Oroska Karachi																													
	Product General Information				Factory Technical Evaluation Parameters															Total Factory Evaluated Score	Technical Evaluation Matrix													
																					Product Evaluation Parameters													
																					Total Product Evaluated Score										Total Technical Score			
	Documents Based Factory Score															Factory Evaluation Visit Score										Product Technical Parameters								
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26									
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm)	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan - (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firms having (12-Month) Ranking in top-20 position shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th position 4 marks. 3. Firms having (12-Month) ranking between	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of more than PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks. (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP	Raw material, In-process and Finished goods storage (as in Schedule II of DRAP) as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, relevant Human Resource as per the requirements mentioned in schedule-II of DRAP.	Adequate availability of qualified & experienced Quality Control/Quality Assurance personnel (as per the requirements mentioned in schedule-II of DRAP).	Availability of functional and validated IQVAC with all relevant equipment, testing, logs, and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or	(As evaluated by the MCC experts at the time of inspection). Non-compliance to cGMP guidelines shall lead to disqualification. (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection). Non-availability or non-functionality of	Bioavailability/ Bioequivalence study conducted by WHO Assayed Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months from the cut-off date for submission of bids.	In cases where Raw materials are acquired from Local sources, valid invoice (s) not older than 24 months shall be considered.	In case of purchases through third party importers a valid	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US- FDA / EMA / MHRA / TGA / PMDA / NCS / Medic or Health Canada or by regulatory authority/body of SRA's country (ies) coupled with Form 3 (form of undertaking to accompany an application for License to import Drugs).	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/copy of purchase.	For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/Suspensions must be USP Type 3 or better (Non-compliance or non-provision of Cox of glass material shall lead to disqualification of the quoted product).	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks	Availability of quoted item/s in Pakistan market as per recent most data of IMS/IQVIA Health not older than twelve (12) months.							
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70								
1	630	Amino acid Solution 2.7% 500ml	Pan Amin G 500ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47								
2	630	Amino acid Solution 5% 500ml	Aminovet 600 500ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47								
3	630	Amino acid Solution 8% 500ml	Aminobolan 500ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47								
4	632	Liquid Emulsion 20%	Fatolip 200ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47								

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																								
Name of Firm				Pacifi Pharma Lahore																																				
S. No.	Product General Information				Factory Technical Evaluation Parameters												Total Factory Evaluated Score	Technical Evaluation Matrix																						
					Documents Based Factory Score													Factory Evaluation Visit Score												Product Evaluation Parameters									Total Product Evaluated Score	Total Technical Score
																														Product Technical Parameters										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26														
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all phases of the quoted product (s). (If evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability	Raw material, In-process and Finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability or non-functionality of the HVAC system and/or testing and/or	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).	Non-availability or non-functionality of the HVAC system and/or testing and/or	Biowareability: Bioprocessability study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted and / or Proof of inventor / innovator products from relevant body shall be provided where the firm	Biowareability: Bioprocessability study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted and / or Proof of inventor / innovator products from relevant body shall be provided where the firm	Goods Declaration certificate of imported API or the quoted item's from Pakistan Customs, coupled with valid away bill or Bill of Lading for the quoted item's, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importer a valid trail/bill/DRAP clearance NDC between the principal manufacturer and the	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GDI) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NTD submission.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medec or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NTD submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies). Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item's, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the	Stability studies of quoted items duly attested by the Q.C (incharge of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 62 Tender approvals- 01 marks 64 Tender approvals- 02 marks 66 Tender approvals- 03 marks 68 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks	Availability of quoted item's in Pakistani market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 62 Tender approvals- 01 marks 64 Tender approvals- 02 marks 66 Tender approvals- 03 marks 68 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks																
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	31	5	5	5	5	3	4	5	5	37	70														
1	4	Metronidazole	Inf. 500mg, 100 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50														
2	638	Dextrose	I/V Inf. 0.1 500ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50														
3	639	Dextrose	I/V Inf. 0.1 1000ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50														
4	640	Dextrose	I/V Inf. 5% 100ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50														
5	641	Dextrose	I/V Inf. 0.05 500ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50														
6	642	Dextrose	I/V Inf. 0.05 1000ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50														
7	644	Dextrose + Sodium Chloride	I/V Inf. 5% + 0.9% 500ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50														
8	645	Dextrose + Sodium Chloride	I/V Inf. 5% + 0.9% 1000ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50														
9	656	Normal Saline	I/V Inf. 0.9% 100 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51														
10	657	Normal Saline	I/V Inf. 0.9% 500 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51														
11	659	Normal Saline	I/V Inf. 0.009 1000 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51														
12	666	Ringer's Lactate + Dextrose 5% Soln.	I/V Inf. 500 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51														
13	667	Ringer's Lactate + Dextrose 5% Soln.	I/V Inf. 1000 ml		2	2	3	3	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	1	20	51														

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																								
Name of the firm					Pak Disposables Syringes Gadoon Sawabi																			
S.No	Product General Information				Technical Evaluation Matrix												Product Evaluated Score	Total Technical Score						
					Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters										
					Documents Based Factory Score				Evaluation Visit Score															
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21				
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC expert/s at the time of inspection). Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm). (Certificate Duly attested by Senior Executive of the firm)	Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificate Duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 2 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted product/s)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.						
	Ref. No. of item in	Generic Name of Item	Size & Guage of Medical Device	Trade Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70			
1016	Disposab le Auto Disable Syringe (Blister packing) sterile	3 ml	PDS AD Syringe		3	0	5	0	The firm was inspected by the inspection team as per technical evaluation criteria, and the following observations were made; Compromised Good Manufacturing Practices (cGMP): 1. Production process incomplete with gaps in implementation, creating potential risks to product consistency. 2. SOPs for production flow and validation are not fully implemented. 3. Overall Hygiene was compromised in quoted sections. 4. The Calibration of multiple equipment in the QC and microbiology section were expired. 5. No record of recent validation/qualification or preventive maintenance record of the equipment were provided during the inspection. Impaired environmental control and HVAC System: 6. The HVAC (16*2 tons) system was found non-functional during inspection. 7. The SOPs for entering the temperature and humidity maintenance logs were missing. 8. Open ventilation and room cooler were observed in the production section during active production of disposable syringes 9. Sterility and pharmaceutical hygiene were compromised due to inadequate air handling and environmental control. 10. Fake entries in the log sheets or no temperature/humidity mapping, was maintained. Compromised Good Storage Practices (GSP) 11. Raw materials WERE stored in one location without segregation for approved, rejected, or quarantined lots. 12. The RMS was an open area with no environmental controls. 13. The Packing material, active material and rejected material were lying in a single section. 14. The overall hygiene in the so-called RMS was very poor and unhygienic. 15. No dusting on receiving as performed for the received raw materials. 16. No GRN (Goods Receipt Note), QC, or QA rejection protocols observed. 17. No Segregated areas with environmental monitoring systems are were observed during inspection essential to prevent cross-contamination and ensure traceability. Quality Control (QC) / Quality Assurance (QA) / GLP 1. No qualified staff was available in the QC or Quality assurance to perform the requisite tests at the time of inspection. 2. Microbiology lab equipped but non-operational due to lack of qualified microbiologist. 3. Validation and in-process testing procedures absent. 4. Documentation incomplete or missing for analytical testing. In view of the above findings, the firm is NOT-RECOMMENDED.				8	0	0	0	0	0	0	8	0	0	0	8
1017	Disposab le Auto Disable Syringe (Blister packing) sterile	5 ml	PDS AD Syringe		3	0	5	0	8	0	0	8	0	0	0	0	0	0	0	0	8			
1921	Disposab le Syringe Ordinary (Blister packing) sterile	10ml	PDS Syringe		3	0	5	0	8	0	0	8	0	0	0	0	0	0	0	0	8			
1112	IV Fluid administ ration set	Sterile and pyrogen free, minimum 150cm tube length, blister pack	PDS I.V Set		3	0	5	0	8	0	0	8	0	0	0	0	0	0	0	0	8			

GRC Decision
The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2025-26																									
Name of Firm				Paktex Pharma Lahore																					
S. No.	General Product Information				Technical Evaluation Matrix															Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score
					Factory Technical Evaluation Parameters										Evaluation visit Score										
					Documents Based Factory Score																				
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20					
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)								
	Ref. No. of Item in MCC Formulary	Generic Name of Item	Sizes and specifications	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70					
	1 969	Cotton Bandage (Surgical) B.P Type II	6.5cmX4m		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	2 970	Cotton Bandage (Surgical) B.P Type II	7.5cmX4m		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	3 971	Cotton Bandage (Surgical) B.P Type II	10cmX4m		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	4 972	Cotton Bandage (Surgical) B.P Type II	15cmX4m		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	5 979	Crepe Bandage BPC	7.5cmx4.5m		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	6 980	Crepe Bandage BPC	10cmx4.5m		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	7 981	Crepe Bandage BPC	15cmx4.5m		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	8 1092	Gauze Cloth Roll Packing	100cmx20m		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	9 1093	Gauze Cloth Roll Packing	100cmx40m		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	10 1151	Non-Medicated sterilized adhesive post-operative wound dressing	6x7cm		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	11 1152	Non-Medicated sterilized adhesive post-operative wound dressing	9x10cm		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	12 1153	Non-Medicated sterilized adhesive post-operative wound dressing	9x15cm		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	13 1154	Non-Medicated sterilized adhesive post-operative wound dressing	9x20cm		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	14 1155	Non-Medicated sterilized adhesive post-operative wound dressing	9x25cm		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	15 1156	Non-Medicated sterilized adhesive post-operative wound dressing	9x30cm		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	16 1173	Praffin Gauze dressing (Tulle) with Chlorhexidine	10X10cm		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65					
	17 1206	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP/BP/BPC) Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	Blister pack 10cmx10cm 8ply	Non formulary (BP Light 13)	3	3	3	4	5	3	6	6	6	6	45	0	Non formulary (BP Light 13)	10	10	55					
	18 1206	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP) Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	Blister pack 10cmx10cm 8ply	Non formulary (BP Light 13)	3	3	3	4	5	3	6	6	6	6	45	0	Non formulary (BP Light 13)	10	10	55					
	19 1207	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP/BP/BPC) Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	Blister pack 15cmx15cm 8ply	Sample not provided	3	3	3	4	5	3	6	6	6	6	45	0	Non formulary (BP Light 13)	10	10	55					
	20 1207	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP) Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	Blister pack 15cmx15cm 8ply	Sample not provided	3	3	3	4	5	3	6	6	6	6	45	0	Sample not provided	10	10	55					

21	1208	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP/BP/BPC) Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	Blister pack 30cmx30cm 4ply		3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
22	1209	Sterile Gauze Dressing Pad (BP Light 13), Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition		Non formulary (BP Light 13)	3	3	3	4	5	3	6	6	6	6	45	0	Non formulary (BP Light 13)	0	0	45
23	1209	Sterile Gauze Dressing Pad (USP), Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	Blister pack 10x10 cm, 8 ply	Sample not provided	3	3	3	4	5	3	6	6	6	6	45	0	Sample not provided	10	10	55
24	1210	Sterile Gauze Dressing Pad (BP Light 13), Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition		Non formulary (BP Light 13)	3	3	3	4	5	3	6	6	6	6	45	0	Non formulary (BP Light 13)	0	0	45
25	1210	Sterile Gauze Dressing Pad (USP), Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	Blister pack 15x15 cm, 8 ply	Non formulary (BP Light 13)	3	3	3	4	5	3	6	6	6	6	45	0	Non formulary (BP Light 13)	10	10	55

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																						
Name of the firm					Paktex Lahore																	
S.No	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	Technical Evaluation Matrix							Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score					14	15	16	17	18				
					5	6	7	8	9	10	11	12										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.				
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70		
	1 965	Cord Clamp			GRC Decision: The quoted product of the firm is not recommended due to non fulfillment of Bid form-1 (7)(ii).						5	5	10	0	0	5	0	10	15	25		
	2 1128	Isopropyl Alcohol 70% Disposable Nonwoven Swabs									5	5	10	0	0	5	0	10	15	25		

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																											
Name of Firm					PHARMASOL, LAHORE																						
S. No.	Product General Information				Technical Evaluation Matrix																				Total Product Evaluated Score	Total Technical Score	
					Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Evaluation Parameters											
					Documents Based Factory Score					Factory Evaluation Visit Score						Product Technical Parameters											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	
	Ref. No. of item	Generic Name of Item	Dosage Form with Strength	Trade Name	Valid ISO 18001/45001	Valid ISO 14001	Valid ISO 9001	Latest IMS/QVIA	Valid calibration	Valid documents of the	Availability of	Raw material, In-	Adherence to cGMP	Adequate availability of	Availability of		Bioavailability/	Goods Declaration	Certificate of Analysis	Active Pharmaceutical	Valid WHO	Valid Certificate of	Stability studies of	Availability of quoted			
					2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70	
	48	Ketorolac 30mg 1ml	Inj. 30mg/ml	Inj Ketrol 30mg/1ml	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	93	Hydroxyurea 500mg Pack Size 10's	Cap. 500mg	Cap Hydroxa 500mg 10's	2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	4	5	0	9	37	
	109	Thalidomide 100mg Pack size 10's	Cap. 100mg	Cap Tholimid 100mg 10's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	218	Cefixime 100mg/5ml Bottle 30ml	Susp. 100mg/5ml	Axoral 400mg 5's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	219	Cefixime 200mg/5ml Bottle 30ml	Susp. 200mg/5ml	Susp Axoral 100mg 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	285	Meropenem 500mg with water	Inj. 500mg	Inj: Merosol 500mg	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	286	Meropenem 1gm with water	Inj. 1gm	Inj. Merosol 500mg 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45	
	308	Vancomycin 500mg With Water	Inj. 500mg	Inj. Vancosol 500mg 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45	
	309	Vancomycin 1gm With Water	Inj. 1gm	Inj. Vancosol 1gm 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45	
	401	Tranexmic Acid 500mg/5ml Pack 0	Inj. 500mg	Inj: Inaxamic 500mg 10's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	530	Ondansetrone	Inj. 2mg/ml 4ml		2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0			
	563	Hydrocortisone 100mg with water	Inj. 100mg	Inj: Hicartif 100mg 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	564	Hydrocortisone 250mg with water	Inj. 250mg	Inj. Hicartif 100mg 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	573	Methyl Prednisolone 500mg with water	Inj. 500mg	Inj. Solomed 500gm 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	574	Inj Methyl Predinisolone 1gram with Water	Inj. 1gm	Inj. Solomed 1gm 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	837	Moxifloxacin 0.5w/V 5ml	Drops. 0.5% w/v 5ml	Moxol E/D 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	850	Tobramucin+Dexamethasone 0.3/1.5ml	Drops. 0.3% + 0.1% w/v 5ml	Tobracort E/D 1,s	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	858	Betamethasone Diproplonate+ Gentamycin Sulphate 0.05% +0.1% Cream 15gm	Cream. 0.05 % + 0.1% 15gm	Betrasol-G Cream 15gm 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	868	Fusidic Acid 2% Cream 15gm	Cream. 2% 15gm	Fucyn Cream 2% 15gm 1,s	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	889	Silver Sulfadiazine 1% Cream 50gm	Cream. 1% 50gm	Silverex Cream 1% 50gm 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	892	Terbinafine 1% Cream 10gm	Cream. 1% 10gm	Tigsol Cream 1% 10gm 1's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	
	912	Cholecaliferal (Vitamin D3) 2000000/U 1ml Pack Size 5's	Inj. 2000000 IU, 1ml	Inj: Oraject-D 2000000U 1ml 5's	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47	

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																											
PHARMAWISE LAHORE																											
Name of Firm					Technical Evaluation Matrix																						
S. No.	Product General Information				Factory Technical Evaluation Parameters																Product Evaluation Parameters					Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score								Factory Evaluation Visit Score								Total Factory Evaluated Score	Product Technical Parameters					
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25		
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/RQVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/RQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 6 marks. 2. Firms having (12-Month) Ranking between 21-40th position 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between	Valid calibration certificates for equipment/instrument used in the factory for Measuring, weighing, Assay / Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (both Accelerated and Real Time) in Schedule B of DRAP (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, in-process and Finished good storage (as in Schedule B of DRAP) in area / section of the quoted product (s) Non-adherence to GSP shall lead to disqualification of the firm.	Adherence to cGMP guidelines, (as in Schedule B of DRAP) in area / section of the quoted product (s) Non-compliance to cGMP guidelines shall lead to disqualification of the MCC section or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firms).	Availability of functional and validated HVAC, with all relevant equipment, testing logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs shall lead to Disqualification of the relevant section / firm.	Bioavailability/Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Web-site) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-waiver certificate from an accredited lab of SRA countries (Singapore Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/USDA/USP guidelines) shall be submitted and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bio-equivalence / bio-similarity is not applicable.	In cases where Raw materials are acquired from Local sources valid invoice (a) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm In case of Non-provision of matching GD the marks for CoA will not be awarded. Moreover, in case of product quoted item having multiple APIs, the marks for GD, CoA, API source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NCTI/initial submission.	Active Pharmaceutical Ingredient's (API)s source accreditation certificate issued by WHO / US-FDA/ EMA / MHRA / TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Copies of relevant certificate duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies)	For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product) 3. Type of Glass material for Oral Syringe/ Suspension must be USP Type 3 or better (Non-	Stability studies of quoted items duly attested by the Q/C incharge of the firm)	Availability of quoted items in Pakistani market as per recent most data of IMS/RQVIA Health not older than twelve (12) months 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/RQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or ICJ accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals-01 mark 04 Tender approvals-02 marks				
	Ref. No. of Item	Generic Name of Item	Dosage Form with strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70	
	1	2	Metronidazole Tablet 400mg	Tab 400mg	Elaryl	0	0	0	0	5	2	The inspection team at the time of inspection observed that, POOR ADHERANCE TO cGMP				7	0	5	5	0	0	0	5	0	15	22	
	2	3	Metronidazole suspension 60ml	Susp 60ml	Elaryl	0	0	0	0	5	2	1. The in-process areas for capsule, tablet, and syrup manufacturing were not inspected, as these sections were closed at the time of the visit. As a result, in-process controls and compliance with GMP requirements in these sections could not be verified				7	0	5	5	0	0	0	5	0	15	22	
	3	47	Ibuprofen 100mg/5ml syrup	Syrup 90ml	Profenwise	0	0	0	0	5	2	2. The facility layout is congested, potentially disrupting unidirectional flow and increasing contamination risk. Inadequate lighting in both critical and non-critical areas may hinder visual inspection and cleaning, affecting overall contamination control.				7	0	5	5	0	0	0	5	0	15	22	
	0	646	Flavored Oral Rehydration salt	Sache 27.9gm	Paedifol	0	0	0	0	5	2	POOR ADHERANCE TO GOOD LABORATORY PRACTICES (GLP)				7	0	0	0	0	0	0	5	0	5	12	
	5	647	Oral Rehydration salt: 20.5gm (Low osmolal)	Sache 20.5gm	Rehydrate ors	0	0	0	0	5	2	3. Stability chambers were found empty with no ongoing studies or quoted products placed inside, reflecting non-compliance with ongoing stability program requirements as per ICH guidelines.				7	0	0	0	0	0	0	5	0	5	12	
	6	810	Salbutamol sulphate syrup 60ml	Syrup 60ml	Faktolin	0	0	0	0	5	2	POOR GOOD STORAGE PRACTICES (GSP)				7	0	0	0	0	0	0	5	0	5	12	
	7	877	Lignocain Gel 15gm	Gel 15gm	Zycain gel 2%	0	0	0	0	5	2	5. In the Raw Material Store (RMS), excipients were stored directly against the wall with excessive vertical stacking, compromising proper airflow, inspection accessibility, and material traceability—violating standard GMP storage practices.				7	0	5	0	0	0	0	5	0	10	17	
	8	889	Silver Sulphadiazine cream 50 gm	Cream 50gm	Silvazin	0	0	0	0	5	2	NON-FUNCTIONAL HVAC SYSTEM AND ENVIRONMENTAL CONTROL				7	0	5	5	0	0	0	5	0	15	22	
	9	890	Silver Sulphadiazine cream 250 gm	Cream 250gm	Silvazin	0	0	0	0	5	2	6. The filling process for Povidone-iodine was carried out manually in an uncontrolled area. No defined or maintained filling, cleaning, or sealing zones were observed, indicating serious lapses in facility control, hygiene, and cross-contamination prevention.				7	0	5	5	0	0	0	5	0	15	22	
	10	895	Chloroxylenol Solution 5%	Solution 5% 1000ml	Xyletal	0	0	0	0	5	2	PRODUCTION CAPACITY TO MEET UP MCC DEMANDS				7	0	0	0	0	0	0	5	0	5	12	
	11	902	Hydrogen Peroxide: 6% w/v	soltion 6% w/v450ml	Hydrogen peroxide 450ml	0	0	0	0	5	2	7. The current production line, including machinery, equipment, and workforce, appears insufficient to meet the substantial demand from the government/MCC				7	0	0	0	0	0	0	5	0	5	12	
	12	903	Povidone iodine solution 10% w/v	Sol 10% 450ml	Povine	0	0	0	0	5	2	Based on the aforementioned findings, the inspection team recommends that the firm be classified as NOT RECOMMENDED				7	0	5	5	0	0	0	5	0	15	22	
	13	904	Povidone Iodine Surgical Scrub	Scrub 7.5% 450ml	Povine	0	0	0	0	5	2					7	0	5	5	0	0	0	5	0	15	22	

The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
Name of Firm					Pharmadic Pharma Lahore																							
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score												Product Evaluation Parameters											
					Factory Evaluation Visit Score												Product Technical Parameters											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26		
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.	Valid calibration certificate for analysis of equipment / instruments used in the factory for Measuring, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm)	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks. (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP)	Raw material, In-process and Finished goods, storage (as in Schedule B of DRAP) in a dedicated area / section of the product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the firm.	Adherence to cGMP guidelines, (as in Schedule B of DRAP) in a dedicated area / section of the product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the firm.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the quoted goods declaration (GID) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredient(s) (API)s source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medics or Health Canada or by regulatory authority/body of SRAAs country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item(s), as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastics (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/ Suspension must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted products). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Class 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s).	Stability studies of quoted items duly attested by the Q.C. (in-charge of the firm) For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the	Availability of quoted items in Pakistan market as per recent most data of IMS/IQVIA. Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the					
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70			
1	36	Acetofenac	Tab. 100 mg		2	2	3	4	5	6	2	2	2	2	2	32	0	0	0	0	0	0	5	0	5	37		
2	52	Meloxicam	Tab. 15 mg		2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47		
3	53	Meloxicam	Tab. 7.5 mg		2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	10	42		
4	60	Paracetamol	Tab. 500 mg		2	2	3	4	5	6	2	2	2	2	2	32	0	5	0	0	0	0	5	0	10	42		
5	67	Panacetamol+Tramadol	Tab.325mg/37.5 mg.		2	2	3	4	5	6	2	2	2	2	2	32	0	5	0	0	0	0	5	0	10	42		
6	70	Tramadol HCl	Inj. 50 mg/ml,2ml		2	2	3	4	5	6	2	2	2	2	2	32	0	5	0	0	0	0	5	0	10	42		
7	202	Azithromycin	Tab. / Cap. 250 mg 12x or		2	2	3	4	5	6	2	2	2	2	2	32	0	0	0	0	0	0	5	0	5	37		
8	205	Azithromycin	Dry Susp. 200 mg/5ml 25ml		2	2	3	4	5	6	2	2	2	2	2	32	0	0	0	0	0	0	5	0	5	37		
9	215	Cefixime	Inj. 500 mg/Vial					4	5	6	2	2	2	2	2	25	0	0	0	0	0	0	0	0	0	25		
10	216	Cefixime	Inj. 1 gm/Vial		2	2	3	4	5	6	2	2	2	2	2	32	0	0	0	0	0	0	5	0	5	37		
11	217	Cefixime	Cap. 400 mg 5x		2	2	3	4	5	6	2	2	2	2	2	32	0	0	0	0	0	0	5	0	10	42		
12	219	Cefixime	Dry Susp. 200 mg/5ml 30ml		2	2	3	4	5	6	2	2	2	2	2	32	0	5	0	0	0	0	5	0	5	37		
13	220	Cefoperazone + Sulbactam	Inj. 1gm/Vial					4	5	6	2	2	2	2	2	25	0	5	5	0	0	0	0	0	10	35		
	221	Cefoperazone + Sulbactam	Inj. 2gm/Vial					4	5	6	2	2	2	2	2	25	0	5	5	0	0	0	0	0	10	35		
14	228	Cefazolin	Inj. 500 mg/Vial					4	5	6	2	2	2	2	2	25	0	0	0	0	0	0	0	0	0	25		
15	229	Cefazolin	Inj. 1gm/Vial					4	5	6	2	2	2	2	2	25	0	0	0	0	0	0	0	0	0	25		
16	230	Ceftriaxone	Inj. 500 mg/Vial					4	5	6	2	2	2	2	2	25	0	5	5	0	0	0	0	0	10	35		
17	231	Ceftriaxone	Inj. 1gm/Vial					4	5	6	2	2	2	2	2	25	0	5	5	0	0	0	0	0	10	35		
18	243	Ciprofloxacin	Tab. 250 mg 10x		2	2	3	4	5	6	2	2	2	2	2	32	0	0	0	0	0	0	5	0	5	37		
19	244	Ciprofloxacin	Tab. 500 mg 10x		2	2	3	4	5	6	2	2	2	2	2	32	0	0	0	0	0	0	5	0	5	37		
20	247	Clarithromycin	Tab. 250 mg 10x		2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47		
21	248	Clarithromycin	Tab. 500 mg 10x		2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47		
22	250	Clarithromycin	Dry Susp. 125 mg/5ml 60 ml		2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	10	42		
23	288	Moxifloxacin	Tab. 400 mg		2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47		
24	329	Sulfadoxine + Pyrimethamine	Tab.500mg+25 mg		2	2	3	4	5	6	2	2	2	2	2	32	0	5	0	0	0	0	5	0	5	37		
25	383	Iron Hydroxide poly maltose complex	Tab. 100 mg		2	2	3	4	5	6	2	2	2	2	2	32	0	5	0	0	0	0	5	0	10	42		
26	384	Iron Hydroxide poly maltose complex	Syp. 50 mg/5ml		2	2	3	4	5	6	2	2	2	2	2	32	0	5	0	0	0	0	5	0	10	42		
27	388	Mecobalamin	Inj. 500 meg 1ml		2	2	3	4	5	6	2	2	2	2	2	32	0	0	0	0	0	0	5	0	5	37		
28	526	Omeprazole	Inj. 40 mg / Vial					4	5	6	2	2	2	2	2	10	0	5	0	0	0	0	5	0	10	20		
29	527	Omeprazole	Cap. 40 mg		2	2	3	4	5	6	2	2	2	2	2	32	0	5	0	0	0	0	5	0	10	42		
30	528	Esomeprazole	Cap. 40mg		2	2	3	4	5	6	2	2	2	2	2	32	0	5	0	0	0	0	5	0	10	42		
31	529	Ondansetron	8 mg		2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	3	18	50		
	530	Ondansetron	Inj. 2 mg/ml 4 ml		2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	3	18	50		
32	756	Proscyclidine HCl	Tab. 5mg		2	2	3	4	5	6	2	2	2	2	2	32	0	0	0	0	0	0	5	0	5	37		
33	545	Clomipraphene	Tab. 50mg		2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47		

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injctable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																			
Name of Firm				PHARMEVO, KARACHI																															
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix										Product Evaluation Parameters		Total Product Evaluated Score	Total Technical Score					
					Documents Based Factory Score												Factory Evaluation Visit Score					Product Technical Parameters													
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26									
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body (duly attested by senior executive of the firm)	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered).	Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th position shall be awarded 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Analyzing, Assaying / material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule H of DRAP	Raw material, in-process and finished good inventories, storage (as in schedule-B of DRAP) or area / section of the quoted product (s), as evaluated at the time of inspection by the MCC experts.	Adherence to GMP guidelines, storage (as in schedule-B of DRAP) or area / section of the quoted product (s), as evaluated at the time of inspection by the MCC experts.	Non-compliance to cGMP guidelines shall lead to disqualification of the firm.	(Certified by the senior executive of the firm as evaluated by MCC experts at the time of inspection, Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to disqualification of the relevant section / firm.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to disqualification of the relevant section / firm.	Availability of Bioavailability / Bioequivalence study conducted by WHO / Audited Labs must be attached along with the bid and study must be available on WHO Website) For biologics, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-warrior certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid invoice (i) not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (i) not older than 24 months shall be considered. In case of purchases through third party importer a valid trade link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer or Health Canada or by regulatory authority/body of SRA country (not coupled with Form-3 (form of undertaking to accompany GID) provided to submitors). Valid first sale certificate issued by regulatory body of any SRA country(ies) Moreover, in case of product/quoted item having multiple APIs, the marks for GID, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all API components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MIRA / TGA / PMDA / Swiss Medico or Health Canada or by regulatory authority/body of SRA country (not coupled with Form-3 (form of undertaking to accompany GID) provided to submitors). Moreover, in case of product/quoted item having multiple APIs, the marks for GID, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all API components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid first sale certificate issued by regulatory body of any SRA country(ies) Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Type Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).	Stability studies of quoted items duly attested by the Q/C incharge of the firm) For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide: Tender Approval/ (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted items in Pakistan market as per recent most data of IMS/QVIA. Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide: Tender Approval/ (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.										
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70										
171	Montelukast Sodium	Tab 10 mg	Alirez	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53										
172	Montelukast Sodium	Tab 5 mg	Alirez	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53										
173	Montelukast Sodium	Sachet 4 mg	Alirez	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	1	16	49										
288	Moxifloxacin	Tab 400 mg	Zilfom	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52										
424	Candesartan cilexetil	Tab 4 mg	Treatan	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	1	25	58										
425	Candesartan cilexetil	Tab 8 mg	Treatan	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	1	25	58										
426	Candesartan cilexetil	Tab 16 mg	Treatan	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	1	25	58										
427	mg + Hydrochlorothiazide 12.5mg	Tab 16mg + 12.5mg	Treatan	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52										
463	Losartan Potassium	Tab 50 mg	Tansin	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	1	25	58										
526	Omeprazole Sodium	Inf 40 mg	Zoltar	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	0	15	48										
527	Omeprazole	Cap 40 mg	Zoltar	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	0	5	0	15	48										
528	Esomeprazole	Tab 40 mg	Fastoso	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52										
556	Glimepiride	Tab 2 mg	Evopride	2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	4	5	1	10	43										
558	Glimepiride	Tab 4 mg	Evopride	2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	0	4	5	1	10	43										
733	Levetiracetam	Tab 250 mg	Klevra	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	0	24	57										
734	Levetiracetam	Tab 500 mg	Klevra	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	0	24	57										

Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																				
Name of the firm					POPULAR INTERNATIONAL KARACHI															
S. No.	S. No.	Product General Parameter				Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters						Product Technical Evaluation								
		Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score												
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted items, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.					
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	1	1305	17mm, 1/2 circle round bodied taper point needle, strand length 75cm	SOFSILK, SIZE 4-0, 17MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	29	5	5	5	6	10	10	41	70
Covidien LLC USA, (origin Usa)	2	1306	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, SIZE 3-0, 30MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	3	1307	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, SIZE 3-0, 25MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	4	1307	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, SIZE 3-0, 26MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	5	1308	26mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm	SOFSILK, SIZE 3-0, 24MM, 3/8 CIRCLE, REVERSE CUTTING, 45CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	6	1309	17mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, SIZE 3-0, 17MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	7	1310	31mm, 1/2 circle round bodied, taper point needle, Strand length 75cm	SOFSILK, 2-0, 30MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	8	1310	31mm, 1/2 circle round bodied, taper point needle, Strand length 75cm	SOFSILK, SIZE 2-0, 30MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	9	1311	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, SIZE 2-0, 25MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	10	1311	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, SIZE 2-0, 26MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	11	1312	31mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, 0, 30MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	12	1312	31mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, SIZE 0, 30MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	13	1313	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, SIZE 1, 35MM, 1/2 CIRCLE, TAPER POINT ROBUST, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	14	1313	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, SIZE 1, 37MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	15	1314	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	SOFSILK, SIZE 1, 26MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOFSILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50

Covidien LLC USA, (origin Usa/ Dominican Republic)	16	1315	40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	SOF SILK, SIZE 1, 39MM, 3/8 CIRCLE, REVERSE CUTTING, 75CM, BLACK	SOF SILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	17	1316	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	SOF SILK, SIZE 2, 37MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLACK	SOF SILK	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	18	1320	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm	POLYSORB, SIZE 6-0, 12MM, 1/2 CIRCLE, TAPER POINT, 45CM, UNDYED	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	19	1321	11mm, 3/8 circle reverse cutting needle, Strand length 45 cm	POLYSORB, SIZE 5-0, 13MM, 3/8 CIRCLE, PREMIUM REVERSE CUTTING, 45CM, UNDYED	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	20	1322	13mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm	POLYSORB, SIZE 5-0, 13MM, 3/8 CIRCLE, PREMIUM REVERSE CUTTING, 45CM, UNDYED	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	21	1323	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm	POLYSORB, SIZE 5-0, 13MM, 1/2 CIRCLE, TAPER POINT, 75CM, UNDYED	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	22	1324	16mm, 3/8 circle conventional or curved cutting needle, strand length 75cm	POLYSORB, SIZE 4-0, 16MM, 3/8 CIRCLE, PREMIUM CONVENTIONAL CUTTING, 45CM, UNDYED	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	23	1325	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	POLYSORB, SIZE 4-0, 19MM, 3/8 CIRCLE, PREMIUM CONVENTIONAL CUTTING, 45CM, UNDYED	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	24	1326	19mm, 3/8 circle reverse cutting needle, strand length 75cm	POLYSORB, SIZE 4-0, 19MM, 3/8 CIRCLE, PREMIUM CONVENTIONAL CUTTING, 45CM, UNDYED	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	25	1327	22mm, 1/2 circle round bodied taper point strand length 70 cm	POLYGLACTIN, SIZE 4-0, 22MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	26	1328	16mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	POLYSORB, SIZE 3-0, 16MM, 3/8 CIRCLE, REVERSE CUTTING, 75CM, VIOLET	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	27	1330	22mm, 1/2 circle round bodied taper point strand length 70 cm	POLYGLACTIN, 3-0, 22MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	28	1331	26mm, 1/2 circle round bodied taper point Strand length 70 cm	POLYGLACTIN, 3-0, 26MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	29	1332	26mm, 1/2 circle round bodied taper point strand length 70 cm	POLYGLACTIN, 2-0, 26MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	30	1333	31mm, 1/2 circle round bodied taper point Strand length 70 cm	POLYGLACTIN, 2-0, 30MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET, 1X36 FOILS	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	31	1334	36mm, 1/2 circle round body taper cut needle, strand length 90 cm	POLYSORB, SIZE 2-0, 40MM, 1/2 CIRCLE, TAPER CUTTING, 75CM, VIOLET	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	32	1335	45mm, 1/2 circle round bodied taper cut needle, strand length 75 cm	POLYSORB, SIZE 2-0, 48MM, 1/2 CIRCLE, TAPER POINT, 90CM, UNDYED	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	33	1337	40mm, 1/2 circle round bodied taper point strand length 90 cm	POLYGLACTIN, 0, 40MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	34	1338	40mm, 1/2 circle round bodied taper point strand length 70 cm	POLYGLACTIN, 1, 40MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	35	1339	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm	POLYGLACTIN, 1, 48MM, 1/2 CIRCLE, TAPER POINT, 90CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	36	1340	40mm, 1/2 circle round bodied taper point strand length 90 cm	POLYSORB, SIZE 2, 40MM, 1/2 CIRCLE, TAPER POINT, 90CM, VIOLET	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	37	1341	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm	POLYSORB, SIZE 2, 48MM, 1/2 CIRCLE, TAPER CUTTING, 75CM, VIOLET	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	38	1342	17mm, 1/2 circle round bodied taper point needle, Strand length 70cm	POLYSORB, SIZE 5-0, 17MM, 1/2 CIRCLE, TAPER POINT, 75CM, VIOLET	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	39	1343	17mm, 1/2 circle round bodied needle, Strand length 75cm	POLYSORB, SIZE 4-0, 17MM, 1/2 CIRCLE, TAPER POINT, 75CM, VIOLET	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	40	1344	22mm, 1/2 circle round bodied taper point needle, Strand length 75cm	POLYGLACTIN, SIZE 4-0, 22MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	41	1345	22mm, 1/2 circle round bodied taper point strand length 75 cm	POLYGLACTIN, 3-0, 22MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50

Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	42	1346	25mm, 1/2 circle round bodied taper point, strand length 75 cm	POLYGLACTIN, 2-0, 26MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	43	1347	30mm, 1/2 circle round bodied taper point, strand length 75 cm	POLYGLACTIN, 2-0, 30MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET, 1X36 FOILS	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	44	1348	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	POLYGLACTIN, 0, 40MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	45	1349	30mm, 1/2 circle round bodied taper point needle, strand length 75 cm	POLYSORB, SIZE 1, 30MM, 1/2 CIRCLE, TAPER POINT, 75CM, VIOLET	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	46	1350	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	POLYGLACTIN, 1, 40MM, 1/2 CIRCLE, TAPER POINT, 70CM, VIOLET	POLYGLACTIN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	47	1351	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	POLYSORB, SIZE 2, 40MM, 1/2 CIRCLE, TAPER POINT, 90CM, VIOLET	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	48	1352	48mm, 1/2 circle round bodied taper point needle, stand length 75 cm	POLYSORB, SIZE 2, 48MM, 1/2 CIRCLE, TAPERCUTTING, 75CM, VIOLET	POLYSORB	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	49	1356	6.5mm, 3/8 circle round bodied taper point double armed needle, strand length 40cm	SURGIPRO II, SIZE 8-0, 6.5MM, 3/8 CIRCLE, TAPER POINT, DOUBLE NEEDED, 45CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	50	1357	9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	SURGIPRO II, SIZE 7-0, 9MM, 3/8 CIRCLE, TAPER POINT, DOUBLE NEEDED, 60CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	51	1358	12mm, 3/8 circle reverse cutting needle, strand length 60cm	SURGIPRO, SIZE 6-0, 13MM, 3/8 CIRCLE, TAPERCUTTING, DOUBLE NEEDED, 60CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	52	1359	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	SURGIPRO, SIZE 6-0, 13MM, 3/8 CIRCLE, TAPER POINT, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	53	1360	13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	SURGIPRO II, SIZE 6-0, 13MM, 3/8 CIRCLE, TAPER POINT, DOUBLE NEEDED, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	54	1361	16mm, 3/8 circle curved cutting needle, strand length 90cm	SURGIPRO, SIZE 6-0, 16MM, 3/8 CIRCLE, PREMIUM CONVENTIONAL CUTTING, 45CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	55	1362	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	SURGIPRO, SIZE 5-0, 13MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	56	1363	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	SURGIPRO, SIZE 5-0, 16MM, 3/8 CIRCLE, PREMIUM CONVENTIONAL CUTTING, 45CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	57	1364	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	SURGIPRO, SIZE 5-0, 16MM, 3/8 CIRCLE, PREMIUM CONVENTIONAL CUTTING, 45CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	58	1365	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	SURGIPRO II, SIZE 4-0, 25MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	59	1366	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	SURGIPRO, SIZE 3-0, 19MM, 3/8 CIRCLE, PREMIUM CONVENTIONAL CUTTING, 45CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	60	1367	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	SURGIPRO II, SIZE 3-0, 26MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	61	1368	30 mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	SURGIPRO II, SIZE 3-0, 26MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	62	1369	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	SURGIPRO II, SIZE 2-0, 25MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	63	1370	26mm, 3/8 circle reverse cutting needle, strand length 45cm	SURGIPRO, SIZE 2-0, 24MM, 3/8 CIRCLE, PREMIUM REVERSE CUTTING, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	64	1371	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	SURGIPRO, SIZE 2-0, 26MM, 1/2 CIRCLE, TAPERCUTTING, DOUBLE NEEDED, 90CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	65	1372	26mm, 1/2 circle round bodied taper cut double armed needle, strand length 75cm	SURGIPRO, SIZE 2-0, 26MM, 1/2 CIRCLE, TAPERCUTTING, DOUBLE NEEDED, 90CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	66	1373	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	SURGIPRO, SIZE 2-0, 27MM, 1/2 CIRCLE, TAPER POINT, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	67	1374	55mm, straight cutting needle, strand length 75cm	SURGIPRO, SIZE 2-0, 60MM, STRAIGHT, CONVENTIONAL CUTTING, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50

Covidien LLC USA, (origin Usa/ Dominican Republic)	68	1375	60mm, straight cutting needle, strand length 75cm	SURGIPRO, SIZE 2-0, 60MM, STRAIGHT, CONVENTIONAL CUTTING, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	69	1376	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	SURGIPRO II, SIZE 0, 40MM, 1/2 CIRCLE, TAPER POINT ROBUST, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	70	1377	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	SURGIPRO II, SIZE 1, 40MM, 1/2 CIRCLE, TAPER POINT ROBUST, 75CM, BLUE	SURGIPRO	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	71	1378	6.5mm, 3/8 circle micro-point spatula double needle, strand length 30cm	MONOSOF, 10-0, 6.2MM, 3/8 CIRCLE, PREMIUM SPATULA, DOUBLE NEEDED, 30CM, UNDYED	MONOSOF	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	72	1379	48mm, 1/2 circle round bodied taper point, strand length 150cm	MONOSOF, SIZE 1, 48MM, 1/2 CIRCLE, TAPER POINT, 150CM, LOOP, BLACK	MONOSOF	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	73	1380	26mm, 1/2 circle round bodied taper point double needle, strand length 100cm	TI-CRON, SIZE 3-0, 25MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 105CM, BLUE	TICORN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	74	1381	17mm, 1/2 circle round bodied taper cut double needle, strand length 75cm	TI-CRON, SIZE 2-0, 17MM, 1/2 CIRCLE, TAPERCUTTING, DOUBLE NEEDED, 90CM, BLUE	TICORN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	75	1382	26mm, 1/2 circle round bodied taper cut double needle, strand length 75cm	TI-CRON, SIZE 2-0, 26MM, 1/2 CIRCLE, TAPERCUTTING, DOUBLE NEEDED, 90CM, BLUE	TICORN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	76	1383	26mm, 1/2 circle round bodied taper point double needle, strand length 90cm	TI-CRON, SIZE 2-0, 26MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 90CM, BLUE	TICORN	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	77	1384	13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm	MAXON, SIZE 7-0, 9MM, 3/8 CIRCLE, TAPER POINT, DOUBLE NEEDED, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	78	1385	13mm, 1/2 circle round bodied taper point needle, strand length 45cm	MAXON, SIZE 6-0, 13MM, 3/8 CIRCLE, TAPER POINT, DOUBLE NEEDED, 45CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	79	1386	13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm	MAXON, SIZE 6-0, 13MM, 3/8 CIRCLE, TAPER POINT, DOUBLE NEEDED, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	80	1388	13mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	MAXON, SIZE 5-0, 13MM, 1/2 CIRCLE, TAPER POINT, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	81	1389	13mm, 1/2 circle round bodied taper point needle, strand length 75cm	MAXON, SIZE 5-0, 13MM, 1/2 CIRCLE, TAPER POINT, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	82	1390	17mm, 1/2 circle round bodied taper point double needle, strand length 75cm	MAXON, SIZE 5-0, 17MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	83	1391	17mm, 3/8 circle round bodied taper point double armed needle, strand length 75cm	MAXON, SIZE 5-0, 17MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	84	1393	17mm, 1/2 circle round bodied taper point needle, strand length 75cm	MAXON, SIZE 4-0, 17MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 90CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	85	1394	17mm, 1/2 circle round bodied taper point double armed, strand length 75cm	MAXON, SIZE 4-0, 17MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDED, 90CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	86	1395	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	MAXON, SIZE 4-0, 20MM, 1/2 CIRCLE, TAPER POINT, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	87	1397	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	MAXON, SIZE 3-0, 20MM, 1/2 CIRCLE, TAPER POINT, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	88	1398	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	MAXON, SIZE 3-0, 26MM, 1/2 CIRCLE, TAPER POINT, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	89	1399	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	MAXON, SIZE 3-0, 26MM, 1/2 CIRCLE, TAPER POINT, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	90	1400	26mm, 1/2 circle round bodied taper point needle, strand length 70cm	MAXON, SIZE 2-0, 26MM, 1/2 CIRCLE, TAPER POINT, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	91	1401	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	MAXON, SIZE 2-0, 30MM, 1/2 CIRCLE, TAPER POINT, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	92	1404	40mm, 1/2 circle round bodied taper point needle, strand length 150cm.	MAXON, SIZE 0, 40MM, 1/2 CIRCLE, TAPER POINT, 150CM, LOOP, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic)	93	1405	40mm, 1/2 circle round bodied taper point needle, Strand length 70cm	MAXON, SIZE 0, 40MM, 1/2 CIRCLE, TAPER POINT, 75CM, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50

Covidien LLC USA, (origin Usa/ Dominican Republic)	94	1407	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	MAXON, SIZE 1.40MM, 1/2 CIRCLE, TAPER POINT, 150CM, LOOP, GREEN	MAXON	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	95	1408	6 mm, 3/8 circle micro point spatula double needle, strand length 30cm	MONOSOF, 10-0, 6.2MM, 3/8 CIRCLE, PREMIUM SPATULA, DOUBLE NEEDED, 30CM, UNDYED	MONOSOF	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50
Covidien LLC USA, (origin Usa/ Dominican Republic/Brazil)	96	1409	6.2mm, 3/8 circle micro point spatula double needle, strand length 30cm	MONOSOF, 10-0, 6.2MM, 3/8 CIRCLE, PREMIUM SPATULA, DOUBLE NEEDED, 30CM, UNDYED	MONOSOF	0	5	5	5	5	6	26	0	0	0	4	10	10	24	50

SOFRADIM FRANCE	28	1414	Polypropylene	PARIETENE MACRO PP 15X10CMX6	PARIETENE MACROPORU S MESH	0	5	5	5	6	6	27	0	0	0	1	4	16	21	48
SOFRADIM FRANCE	29	1415	Polypropylene	PARIETENE MACRO PP 11X8CMX6	PARIETENE MACROPORU S MESH	0	5	5	5	6	6	27	0	0	0	1	4	16	21	48

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																																																																																																																																																			
Name of Firm																																																																																																																																																																			
S. No.	Product General Information				Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score																																																																																																																																								
					Documents Based Factory Score					Factory Evaluation Visit Score						Product Evaluation Parameters																																																																																																																																																			
																Product Technical Parameters																																																																																																																																																			
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26																																																																																																																																									
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body duly attested by senior executive of the firm) Online verification link shall be provided										Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body duly attested by senior executive of the firm) Online verification link shall be provided										Latest IMSQVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMSQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions shall be awarded 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.										Valid calibration certificates for equipment / instruments used in the factory for measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid C calibration Certificates attested by Quality head of the firm).										Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year (i.e., FY 2023-24 or latest). Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)										Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs - Functional Stability Chamber (Both Accelerated and Real Time) in Schedule B of DRAP. (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers under non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).										Raw material inspection and finished goods inspection as in Schedule B of DRAP (as evaluated at the time of inspection by the MCC experts). Non-compliance to GMP guidelines shall lead to disqualification of the firm. (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-availability shall lead to disqualification of the section/s or firm).										Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. (Evaluated by the MCC experts at the time of inspection. Non-availability or non-functionality of the HVAC system under testing and/or logs shall lead to disqualification of the section/s or firm).										Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection. Non-availability or non-functionality of the HVAC system under testing and/or logs shall lead to disqualification of the section/s or firm).										1. Bioavailability / Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website and / or 2. For biologics, bio-similarity studies shall be provided for award of marks in this parameter and / or 3. In cases where Raw materials are acquired from Local sources valid review (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid Certificate of Origin (COO) clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC 2. Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GDD) provided in volume 18, duly attested by the senior executive of the firm. Moreover, in case of products/quoted item having multiple APIs, the marks for GDD, CoA, API source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In case of Non-provision of matching GDD the marks for CoA will not be awarded. 3. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission. Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.										1. Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US - FDA / EMA / MHRA / TGA / PMDA/ Swiss Meds. or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form(s) of undertaking to accompany (GDD) provided in volume 18, duly attested by the senior executive of the firm. Moreover, in case of products/quoted item having multiple APIs, the marks for GDD, CoA, API source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In case of Non-provision of matching GDD the marks for CoA will not be awarded. 3. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT bid submission. Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.										Valid WHO prequalification and / or 2. Valid product registration in SRA country(ies) and / or 3. Valid free sale certificate issued by regulatory body of any SRA country(ies) Certificate on company's own letter head shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm).										Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Material (e.g., Aluminium Foil, PVC, Capable Shells, Plastics (HDPE, LDPE) or any other material used for the immediate container of the quoted items complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class I (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).										Stability studies of quoted items duly attested by the Q/C (exchange of the firm). For award of marks, the certificate of analysis must clearly mention: 1. Material (e.g., Aluminium Foil, PVC, Capable Shells, Plastics (HDPE, LDPE) or any other material used for the immediate container of the quoted items complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class I (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).										Availability of quoted items in Pakistan market as per recent most data of IMSQVIA. Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMSQVIA data is not applicable the bidder shall provide Tender Approvals not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or ICJ accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 01 Tender approvals- 01 marks 04 Tender approvals- 02 marks 08 Tender approvals- 03 marks 16 Tender approvals- 05 marks 18 or more Tender approvals- 05 marks Note: (Tender approval means award of contract(s) for the quoted product(s)) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/procuring agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.																			
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70																																																																																																																																										
70	Tramadol HCl	tg. 50 mg/ml,2ml	Tramadol	2	2	3	0	5	6	2	2	2	2	2	28	0	0	0	0	0	4	5	0	9	37																																																																																																																																										
217	Cefixime	Cap. 400 mg/54	Cefixon	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	0	0	14	42																																																																																																																																										
218	Cefixime	Dry Susp. 100 mg/5ml 30ml	Cefixon	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	0	0	0	10	38																																																																																																																																										
219	Cefixime	Dry Susp. 200 mg/5ml 30ml	Cefixon	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	0	0	0	10	38																																																																																																																																										
231	Ceftriaxone	tg. 1gm/5ml	Bactriphlin	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45																																																																																																																																										
238	Cephadrine	Cap. 500 mg	Rebsof	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																																																																																																										
241	Cephadrine	Dry Susp. 125mg / 5ml	Rebsof	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																																																																																																										
242	Cephadrine	Dry Susp. 250 mg / 5ml	Rebsof	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47																																																																																																																																										
735	Levetiracetam	tg. 500 mg/ml 5 ml	Le-Tast	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52																																																																																																																																										

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2025-26																				
S. No.	Name of Firm				Technical Evaluation Matrix															
	General Product Information				Factory Technical Evaluation Parameters										Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score
					Documents Based Factory Score						Evaluation visit Score									
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)		
	Ref. No. of item in MCC Formulary	Generic Name of Item	Sizes and specifications	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70
	967	Cotton (Surgical) Corded BPC	200 gm	Surgee Cotton	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	968	Cotton (Surgical) Corded BPC	100 gm	Surgee Cotton	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	969	Cotton Bandages (Surgical) B.P Type II	6.5 cm x 4 m	Surgee Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	970	Cotton Bandages (Surgical) B.P Type II	7.5 cm x 4m	Surgee Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	971	Cotton Bandages (Surgical) B.P Type II	10 cm x 4 m	Surgee Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	972	Cotton Bandages (Surgical) B.P Type II	15 cm x 4 m	Surgee Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	979	Crepe Bandages BPC	7.5cm x 4.5m	Surgee Crepe Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	980	Crepe Bandages BPC	10cm x 4.5m	Surgee Crepe Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	981	Crepe Bandages BPC	15cm x 4.5m	Surgee Crepe Bandage	3	3	3	4	5	3	6	6	6	6	45	0	10	0	10	55
	1076	Eye Pads sterile	6cm x 8cm	Surgee Optic	3	3	3	4	5	3	6	6	6	6	45	0	10	0	10	55
	1092	Gauze Cloth Roll packing	100 cm x 20 m	Surgee Absorbent Gauze	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	1093	Gauze Cloth Roll packing	100 cm x 40 m	Surgee Absorbent Gauze	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
	1173	Paraffin Gauze dressing (Tulle) with Chlorhexidine	10x10 cm	Surgee Tulle	3	3	3	4	5	3	The inspection team at the time of inspection observed that, 1. The Paraffin and Chlorhexidine area was observed to be locked with no internal lighting, and the ambient temperature and humidity recorded was 32.9°C and 65% respectively. This indicates a lack of environmental monitoring and control in a sensitive processing area 2. Upon request, no analytical test records or certificates of analysis (CoA) for active pharmaceutical ingredients (APIs) were provided to the inspection team, indicating non-compliance with documentation and traceability requirements as per GMP guidelines. 3. In the raw material storage area, no logbook or material movement record was maintained. Additionally, no APIs were present, and the area was found to be unattended, with no store in-charge or qualified pharmacist present at the time of inspection, violating basic GMP and accountability practices. Hence, the firm is NOT-RECOMMENDED for PARAFFIN/ CHLORHEXIDINE GAUZE (ALL TYPES / SIZES.				21	0	10	10	20	41

1206	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP/BP/BPC) Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	Blister pack 10x10cm, 8 ply	Surgee Gauze(St.)	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
1207	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP/BP/BPC) Among the three different monograph specifications only one (the best evaluated	Blister pack 15x15cm, 8 ply	Surgee Gauze(St.)	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
1208	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP/BP/BPC) Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	Blister pack 30x30cm, 4 ply	Surgee Gauze/Sponge	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65
1209	Sterile Gauze Dressing Pad (USP/BP/BPC), Among the three different monograph specifications only one (the best evaluated bid) shall be selected in the combined competition	Blister pack 10x10 cm, 8 ply	Surgee Gauze(St.)	3	3	3	4	5	3	6	6	6	6	45	0	10	10	20	65

Name of Firm				Relizon Pharma Lahore																																	
S. No.	Product General Information				Factory Technical Evaluation Parameters															Total Factory Evaluated Score	Product Evaluation Parameters										Total Product Evaluated Score	Total Technical Score					
					Documents Based Factory Score					Factory Evaluation Visit Score					Product Technical Parameters																						
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26											
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered) Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule B of DRAP), as evaluated at the time of inspection by the MCC expert/s). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm.	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the relevant section / firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US	Goods Declaration certificate of imported API of the quoted items, coupled with valid airway bill or Bill of Lading for the quoted item's, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item's, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material	Stability studies of quoted item's duly attested by the Q.C incharge of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve/ 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.	Availability of quoted item's in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve/ 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.															
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70											
1	8	Nitazoxanide	Susp. 100mg/5ml, 30ml		2	2	3	0	5	2	The inspection team at the time of inspection observed that, POOR ADHERANCE TO cGMP 1. Dispensed materials in the Raw Material Store (RMS) were not properly labeled, creating ambiguity regarding material identity, status, and traceability—violating GDP (Good Documentation Practices) and GMP principles. 2. The Batch Manufacturing Record (BMR) for Gabazone 30 mg capsules was processed without the mandatory review and signatures of the Quality Control (QC) and Quality Assurance (QA) Managers, indicating a serious lapse in batch release and quality oversight procedures. 3. Line clearance for Citrazone 10 mg tablets, Batch No. 252024, was conducted without documented approval from QA, violating standard GMP protocols for line clearance and batch changeover. 4. Standard Operating Procedures (SOPs) and logbooks were either not maintained or unavailable at several critical control points, reflecting serious deficiencies in documentation control and GMP compliance.															14	0	5	5	0	0	5	0	15	29		
2	50	Mefenamic Acid	Tab. 500 mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
3	60	Paracetamol	Tab. 500 mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
4	67	Paracetamol+Tramadol	Tab.325mg/37.5 mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
5	147	Fluconazole	Tab. / Cap. 50 mg		2	2	3	0	5	2																14	0	5	5	0	0	0	0	0	10	24	
6	148	Fluconazole	Tab. / Cap. 150 mg 1s		2	2	3	0	5	2																14	0	5	5	0	0	0	0	5	0	15	29
7	152	Itraconazole	Cap. 100 mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
8	164	Cetirizine	Tab. 10 mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
9	171	Montelukast	Tab. 10 mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
10	202	Azithromycin	Tab. / Cap. 250 mg 12s or less		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
11	203	Azithromycin	Tab. / Cap. 500 mg 6s		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
12	205	Azithromycin	Dry Susp. 200 mg/5ml 25ml or less		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
13	243	Ciprofloxacin	Tab. 250 mg 10s		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
14	244	Ciprofloxacin	Tab. 500 mg 10s		2	2	3	0	5	2																14	0	5	5	0	0	0	0	0	10	24	
15	277	Levofloxacin	Tab. 250 mg 10s		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
16	278	Levofloxacin	Tab. 500 mg 10s		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
17	281	Linezolid	Tab. 600mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
18	282	Linezolid	Suspension 100mg/5ml 60ml		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
19	288	Moxifloxacin	Tab. 400 mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
20	313	Artemether + Lumefantrine	Tab. 40 mg/240mg 8s		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
21	314	Artemether + Lumefantrine	Tab. 80 mg/480mg 6s		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
22	315	Artemether + Lumefantrine	Susp. 15 mg/ 90 mg/5ml 60ml		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
23	352	Osetamivir	Cap. 75mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
24	355	Tenofovir	Tab. 300 mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	
25	513	Domperidone	Tab. 10 mg		2	2	3	0	5	2																14	0	5	5	0	0	0	5	0	15	29	

26	517	Famotidine	Tab. 40 mg		2	2	3	0	5	2	Inspection. NON-FUNCTIONAL HVAC SYSTEM AND ENVIRONMENTAL CONTROL 6. The HVAC system in the capsule filling area was non-functional, with inadequate control over temperature and humidity. The ambient temperature was recorded at 31.1°C, which exceeds acceptable limits for a controlled manufacturing environment Based on the aforementioned findings, the inspection team recommends that the firm be classified as NOT RECOMMENDED	14	0	5	5	0	0	0	5	0	15	29
27	527	Omeprazole	Cap. 40 mg		2	2	3	0	5	2		14	0	5	5	0	0	5	0	15	29	
28	528	Esomeprazole	Cap. 40mg		2	2	3	0	5	2		14	0	5	5	0	0	5	0	15	29	
29	531	Pantoprazole	Tab. 20mg		2	2	3	0	5	2		14	0	0	0	0	0	5	0	5	19	
30	532	Pantoprazole	Tab. 40mg		2	2	3	0	5	2		14	0	0	0	0	0	5	0	5	19	
31	583	Sitagliptin + Metformin	Tab. 50 mg/500 mg		2	2	3	0	5	2		14	0	5	5	0	0	5	0	15	29	
32	584	Sitagliptin + Metformin	Tab. 50mg /1000 mg		2	2	3	0	5	2		14	0	5	5	0	0	5	0	15	29	
33	683	Febuxostat	Tab. 40 mg		2	2	3	0	5	2		14	0	0	0	0	0	0	0	0	14	
34	684	Febuxostat	Tab. 80 mg		2	2	3	0	5	2		14	0	0	0	0	0	0	0	0	14	
35	717	Duloxetine	Cap. 30 mg		2	2	3	0	5	2		14	0	5	5	0	0	5	0	15	29	
36	718	Duloxetine	Cap. 60 mg		2	2	3	0	5	2		14	0	5	5	0	0	5	0	15	29	
37	751	Pregabalin	Cap. 50 mg		2	2	3	0	5	2		14	0	5	5	0	0	5	0	15	29	
38	752	Pregabalin	Cap. 75mg		2	2	3	0	5	2		14	0	5	5	0	0	5	0	15	29	
39	753	Pregabalin	Cap. 150 mg		2	2	3	0	5	2		14	0	5	5	0	0	5	0	15	29	
40	769	Venlafaxine	Tab. 75 mg		2	2	3	0	5	2		14	0	5	5	0	0	5	0	15	29	
41	907	Ascorbic Acid	Tab. 500 mg		2	2	3	0	5	2	14	0	5	5	0	0	5	0	15	29		

GRC Decision
The GRC agreed with the findings and recommendations of the inspection report and disposed of the appeals in accordance with the said terms.

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																						
Name of the firm/Renacon Pharma Lahore					Technical Evaluation Matrix																	
S.No	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score								Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score													
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection). Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, completed with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC. (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration - (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications/ strength /dosage form.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.				
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70		
	651	Haemodialysis Concentrate	Part A- Solution, Part B- Powder With 34.45 g/L dextrose	Rencarb	3	5	5	6	5	5	5	5	39	5	5	0	0	10	20	59		
	652	Haemodialysis Concentrate	Part A- Solution, Part B- Powder With 36.46 g/L dextrose	Rencit	3	5	5	6	5	5	5	5	39	5	5	0	0	10	20	59		

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26																						
Name of Firm																						
S. No.	Product General Information				Technical Evaluation Matrix																	
					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation								
														Product Technical Parameters								
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
					Valid WHO (WHO) certificate of the facility where the product is manufactured issued by authorized body of the country of origin duly accredited with International Pharmaceutical Accreditation Forum (IAF) duly attested by senior executive of the firm	Valid WHO (WHO) certificate of the facility where the product is manufactured issued by authorized body of the country of origin duly accredited with International Pharmaceutical Accreditation Forum (IAF) duly attested by senior executive of the firm	Valid WHO (WHO) certificate of the facility where the product is manufactured issued by authorized body of the country of origin duly accredited with International Pharmaceutical Accreditation Forum (IAF) duly attested by senior executive of the firm	Valid accreditation of manufacturing unit or its relevant sections by the US FDA or WHO or official accreditation body not approved material and finished products in the case of IMA countries duly attested by senior executive of the firm	Valid calibration certificate for measuring instrument used in the product in the official daily against the master reference of the product	Availability of minimum 20% inventory of the total import of the product in the official daily against the master reference of the product	Adherence to Good storage practices (GSP) for storage of finished product	Adequate availability of qualified personnel of company & Pharmacist (a vice mandatory & relevant Human Resource)	Traceability: Biopreservation study conducted by WHO (WHO) duly attested along with the bid and study must be available on WHO Website and / or	Product Declaration certificate of imported finished product from the manufacturer as mentioned in the product declaration (D) provided in the product form, not older than 31 months in the certificate for submission of bids	Product Declaration certificate of imported finished product from the manufacturer as mentioned in the product declaration (D) provided in the product form, not older than 31 months in the certificate for submission of bids	Certificate of Analysis of finished product from the Principal Manufacturer as mentioned in the product declaration (D) provided in the product form, not older than 31 months in the certificate for submission of bids	Active Pharmaceutical Ingredient (API) source accreditation certificate issued by WHO (WHO) / IMA / MHRA / TGA / PMDA / Swiss Medic or Health Canada or by regulatory authority/body of IMA country (s)	Valid WHO prequalification and / or	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the product form, as supplied by the manufacturer of the material supplied with the product	Stability studies of product form duly attested by the IVC (in-house or the firm)	Availability of product form in Pakistan market in per cent most data of WHO/IVA Health not older than twelve (12) months	
					Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided		Valid Calibration Certificate attested by Quality Head of the firm	Non availability of the IPI stock in the warehouse at the time of inspection of the importer shall lead to disqualification of the product	The physical inspection committee/ M.C. experts shall verify the compliance of the GSP as mentioned in the bid across various and various and compliance of the Drug Sales Policy Medical Device Rules Regulations issued by the IMA/	It certified by the senior executive of the firm & evaluated / confirmed by M.C. experts at the time of inspection as non-compliance in this parameter shall lead to disqualification of the firm.		In case of pre-bid through third party inspection a valid certificate shall be submitted between the principal manufacturer and the importer for the product to be submitted with the firm offering the product to Govt. MCC	In case of pre-bid through third party inspection a valid certificate shall be submitted between the principal manufacturer and the importer for the product to be submitted with the firm offering the product to Govt. MCC	In case of pre-bid through third party inspection a valid certificate shall be submitted between the principal manufacturer and the importer for the product to be submitted with the firm offering the product to Govt. MCC	In case of pre-bid through third party inspection a valid certificate shall be submitted between the principal manufacturer and the importer for the product to be submitted with the firm offering the product to Govt. MCC	In case of pre-bid through third party inspection a valid certificate shall be submitted between the principal manufacturer and the importer for the product to be submitted with the firm offering the product to Govt. MCC	In case of pre-bid through third party inspection a valid certificate shall be submitted between the principal manufacturer and the importer for the product to be submitted with the firm offering the product to Govt. MCC	In case of pre-bid through third party inspection a valid certificate shall be submitted between the principal manufacturer and the importer for the product to be submitted with the firm offering the product to Govt. MCC	In case of pre-bid through third party inspection a valid certificate shall be submitted between the principal manufacturer and the importer for the product to be submitted with the firm offering the product to Govt. MCC	
	Ref. No. of Item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40
Roche/Boringer Germany	370	Epoetin β	5000 IU PFS	Rocormon 5000 PFS	2	2	2	5	5	4	5	5	30	5	5	5	5	2	4	0	5	26
Hoffman La Roche/Roche USA/Germ	418	Rituximab	500 mg/50ml Vial	Rituxo 500mg/50ml Vial	2	2	2	5	5	4	5	5	30	5	5	5	5	4	4	0	5	33

Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																							
Name of the firm					Sadqain Rawalpindi.																		
					Technical Evaluation Matrix																		
					Principal's and Importer's Evaluation Parameters						Product Technical Evaluation									Product Evaluated Score	Total Technical Score		
Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score																	
1		2		3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19			
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item		Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical			
						3	5	5	5	6	6	30	5	5	5	3	6	16	40	70			
InterSurgica UK	1	931	Bacterial filter,HME Filter and Vial filter (HCV, HBS+ HHV etc.)			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	2	932	Bain Circuit Adult			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	3	933	Bain Circuit Peads			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	4	1056	Disposable sterile catheter mount			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	5	1134	Laryngeal Mask			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	6	1145	Nasal Oxygen Cannula (Neonatal)			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	7	1146	Nasal Oxygen Cannula (Pediatric)			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	8	1147	Nasal Oxygen Cannula (Adult)			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	9	1148	Nebulizer mask with chamber and tubing peads			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	10	1149	Nebulizer mask with chamber and tubing (Adult)			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	11	1158	Non-rebreather mask (Adult)			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	12	1159	Non-rebreather mask (Pediatric)			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	13	1164	Oxygen Mask (Adult)			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	14	1165	Oxygen Mask (Pediatric)			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	15	1166	Oropharyngeal Airway size 0			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	16	1167	Oropharyngeal Airway size 1			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	17	1168	Oropharyngeal Airway size 2			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	18	1169	Oropharyngeal Airway size 3			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	19	1170	Oropharyngeal Airway size 4			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	20	1171	Oropharyngeal Airway size 5			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	21	1282	Ventilator Circuit			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			
InterSurgica UK	22	1283	Venturi Oxygen Mask with different oxygen concentration venturi valve			3	5	5	5	6	6	30	5	5	0	2	2	16	30	60			

SAFE PHARMA KARACHI																																
Name of Firm				Technical Evaluation Matrix																Total Product Evaluated Score		Total Technical Score										
S.No.	Product General Information				Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Evaluation Parameters																
	1	2	3	4	5	6	7	8	9	10	11	12	13	14		15	16	17	18	19	20	21	22	23	24	25	26					
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/RQVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/RQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th position 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment & instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificate issued by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the registered firm for the last year i.e. FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: (Evaluated at the time of inspection by the MCC experts, as non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process material, Finished good storage (as in Schedule B of DRAP) as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, (as in Schedule B of DRAP) in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. (Certified by the senior executive of the firm & evaluated by the MCC experts at the time of inspection). Non-availability of the time of inspection of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the relevant section / firm.	33	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website).	Goods Declaration certificate of imported API of the quoted item's from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item's, not older than 24 months from the cutoff date for submission of bids.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (API) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs).	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item's, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks	Stability studies of quoted item's duly attested by the Q.C. incharge of the firm)	Availability of quoted item's in Pakistani market as per recent most data of IMS/RQVIA Health not older than twelve (12) months.	1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks								
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2		5	5	5	5	3	4	5	5	37	70						
1	2	Metronidazole	Tablet 400mg	Pasigel	2	2	3	0	5	4	The firm was inspected as per technical evaluation criteria and the inspection team observed the following: Non Adherence to Good Storage Practices (GSP): 1. In the raw material store, there was no segregation between active and inactive materials, and a dispensed batch was placed in the RMS in such a manner that it was not identifiable as a dispensed batch. Furthermore, there was no dedicated area for the storage of dispensed batches. This deficiency may potentially lead to serious errors, including the dispensing of incorrect materials in production batches. 2. There was no rejected area in the RMS. Poor Good Laboratory Practices (GLP) & Non compliance to current Good Manufacturing Practice (cGMP): 3. There were no primary reference standards in the quality control lab and most of the internal working standards were also expired. 4. During inspection, no production was observed in any section (except packaging). Machinery was covered with plastic sheets without documented cleaning or maintenance, posing risks of dust accumulation, microbial contamination, and equipment damage. 5. The entire unit was severely congested, having significant space constraints. Notably, the microbiology section was accommodated within the QC Lab. 6. The epoxy floor was broken in multiple areas facilitating the accumulation of dust and dirt. In view of the above, the firm is NOT-RECOMMENDED.										16	0	5	5	5	0	0	4	5	0	0	16
2	4	Metronidazole	Suspension 200mg/5ml	Pasigel	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
3	41	Diclofenac Sodium	Injection 75mg/2ml	Voltec	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
4	42	Diclofenac Sodium	Tablet 50mg	Voltec	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
5	45	Ibuprofen	Tablet 400mg	Ocedin	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
6	47	Ibuprofen	Suspension 100mg/5ml	Ocedin	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
7	49	Mefenamic Acid	Tablet 500mg	Ponsie	2	2	3	0	5	4	16	0	5	5	0	0	4	5	1	20	36											
8	50	Mefenamic Acid	Tablet 500mg	Ponsie Forte	2	2	3	0	5	4	16	0	5	5	0	0	4	5	1	20	36											
9	51	Mefenamic Acid	Suspension 50mg/ml	Ponsie	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
10	60	Paracetamol	Tablet 500mg	Cepol	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
11	61	Paracetamol	Suspension 100mg/5ml	Cepol	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
12	62	Paracetamol	Tablet 400mg + 35mg	Cepol 6 Plus	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
13	66	Acetaminophen + Orphenadrine Citrate	Tablet 400mg + 35mg	Pungesic	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
14	69	Tramadol HCl	Injection 100mg/2ml	Ultrame	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
15	70	Tramadol HCl + Acetaminophan	Tablet 37.5mg + 325mg	Ultrame Plus	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
16	163	Cetirizine	Tablet 10mg	Ertizine	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
17	164	Cetirizine	Syrup 5mg/5ml	Ertizine	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
18	168	Levocetirizine Dihydrochloride	Tablet 5mg	Citlox	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
19	216	Cefixime	Capsule 400mg	Planax	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
20	217	Cefixime	Suspension 100mg/5ml	Planax	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
21	218	Cefixime	Suspension 100mg/5ml	Planax DS	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
22	227	Cefazidime	Injection 500mg	Safedime	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
23	229	Ceftriaxone Sodium	Injection 500mg	Safe-Trazone	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	15	31											
24	230	Ceftriaxone Sodium	Injection 1000mg	Safe-Trazone	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	15	31											
25	231	Ceftriaxone Sodium	Injection 2000mg	Safe-Trazone	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	15	31											
26	255	Colistimethate Sodium	Injection 1 Million IU	Colybid	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
27	276	Levofloxacin	Tablet 500mg	Levosale	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
28	277	Levofloxacin	Tablet 500mg	Levosale	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
29	311	Artemether	Injection 80mg/ml	Artemate	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
30	312	Artemether + Lumefantrine	Tablet 40/240	Artemate Plus	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
31	313	Artemether + Lumefantrine	Tablet 80/480	Artemate	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
32	315	Artesunate	Injection 60mg	Artemac	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	15	31											
33	316	Artesunate	Injection 120mg	Artemac	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	15	31											
34	386	Iron (III) hydroxide Sucrose	Injection 100mg/5ml	Vitoham	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
35	509	Dimenhydrinate	Syrup 12.5mg/4ml	Dramine	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
36	510	Dimenhydrinate	Injection 50mg/ml	Dramine	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
37	515	Drotaverine	Injection 40mg/2ml	Rotavin	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
38	525	Ompoxazole	Injection 40mg	Zolpin	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
39	528	Ondansetron Hydrochloride Dihydrate eq. to Ondansetron	Tablet 8mg	Tiroden	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
40	529	Ondansetron Hydrochloride Dihydrate eq. to Ondansetron	Injection 8mg/4ml	Tiroden	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
41	545	Dexamethasone Sodium Phosphate	Injection 4mg/ml	Ocedin	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
42	554	Glimipride	Tablet 1mg	Dibilo	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
43	555	Glimipride	Tablet 2mg	Dibilo	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
44	556	Glimipride	Tablet 3mg	Dibilo	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
45	557	Glimipride	Tablet 4mg	Dibilo	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
46	582	Sitagliptin (as Phosphate Monohydrate) + Metformin Hydrochloride	Tablet 50/500mg	Jangulip-M	2	2	3	0	5	4	16	0	0	0	0	0	4	5	0	9	25											
47	583	Sitagliptin (as Phosphate Monohydrate) + Metformin Hydrochloride	Tablet 50/1000mg	Jangulip-M	2	2	3	0	5	4	16	0	0	0	0	0	4	5	0	9	25											
48	721	Levetiracetam	Tablet 500mg	Torleva	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
49	732	Levetiracetam	Tablet 1000mg	Torleva	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											
50	733	Levetiracetam	Injection 500mg/5ml	Torleva	2	2	3	0	5	4	16	0	5	5	0	0	4	5	0	19	35											

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																				
S. No.	Name of Firm				SAMI Pharmaceuticals, Karachi																															
	Product General Information				Factory Technical Evaluation Parameters															Total Factory Evaluated Score	Technical Evaluation Matrix										Product Evaluation Parameters				Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score					Factory Evaluation Visit Score											Product Technical Parameters															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26										
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest DMS/MSQVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by DMS/MSQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Weighing, Assay Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. Valid Calibration Certificates attested by Quality head of the firm.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of more than PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted item and adherence to good laboratory practices (GLP) in all labs - Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP.	Raw material in-process and finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, as in Schedule-B of DRAP (as evaluated at the time of inspection by the MCC experts).	Non-compliance to cGMP guidelines shall lead to disqualification of the firm.	Non-adherence to cGMP guidelines shall lead to disqualification of the firm.	Non-availability of the firm & evaluated by the MCC experts at the time of inspection. Non-availability of the firm & evaluated by the MCC experts at the time of inspection. Non-availability of the firm & evaluated by the MCC experts at the time of inspection.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs (As evaluated by the MCC experts at the time of inspection).	Disavailability/ Inequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or	Goods Declaration certificate of the quoted items from Pakistan Customs, coupled with valid away bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids.	In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered.	In case of Large volume parenteral i.e. greater than 10ml up to 5L, product validation report (as per WHO/US-FDA/ASIP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GCD) provided in column 18, duly attested by the senior executive of the firm.	In case of Non-provision of matching GCD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Meds or Health Canada or by regulatory authority body of SRA's country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to Import Drugs).	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase.	For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium foil, PVC, Capsule Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/ Syringettes must be USP Type 2 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).	Stability studies of quoted items duly attested by the Q.C. in-charge of the firm	Availability of quoted items in Pakistan market as per recent most data of DMS/MSQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where DMS/MSQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or JCI accredited private hospitals of Pakistan. Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specification / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.							
KMC No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70											
36	Acetofenone 100mg Tablets	Tab. 100mg	Alkeris	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	2	21	54											
48	Acetaminophen-Tetracycline 30mg/5ml Injection	Inj. 30mg/5ml	Tekac	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53											
52	Meloxicam 15mg Tablets	Tab. 15mg	Melor	2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	4	5	1	10	43												
53	Meloxicam 7.5mg Tablets	Tab. 7.5mg	Melor	2	2	3	5	5	6	2	2	2	2	2	33	0	0	0	0	4	5	1	10	43												
101	Myophenolac Medical Tablets 500mg	Tab. 500mg	Icofate-M	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53											
105	Flunitrazepam 1mg Capsules	Cap. 1mg	Arillo	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52											
106	Flunitrazepam 0.5mg Capsules	Cap. 0.5mg	Arillo	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	52											
161	Bupropione Dihydrochloride 8mg Tablets	Tab. 8mg	Enier	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	2	21	54												
162	Bupropione Dihydrochloride 16mg Tablets	Tab. 16mg	Enier	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	2	21	54												
175	Amikacin Sulphate 25mg Injection	Inj. 25mg	Grasill	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	5	29	62											
176	Amikacin Sulphate 50mg Injection	Inj. 50mg	Grasill	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	5	0	4	5	5	29	62											
204	Azithromycin 500mg Injection	Inj. 500mg	Azitma	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	1	20	53											
305	Rifeximin 550mg Tablets	Tab. 550mg	Nikaf	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
396	Bromazepam 10mg Tablets	Tab. 10mg	Ritban	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
397	Bromazepam 15mg Tablets	Tab. 15mg	Ritban	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
397	Bromazepam 20mg Tablets	Tab. 20mg	Ritban	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
400	Fluoxeticine Acid 500mg/5ml Injection	Inj. 500mg/5ml	Brino	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
419	Bisoprolol Fumante 2.5mg Tablets	Tab. 2.5mg	Actim	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
420	Bisoprolol Fumante 5mg Tablets	Tab. 5mg	Actim	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
421	Bisoprolol Fumante 10mg Tablets	Tab. 10mg	Actim	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
544	Clomiphene Citrate 50mg Tablets	Tab. 50mg	Samclom	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
549	Empagliflozin Tablets 10mg	Tab. 10mg	Empoli	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
550	Empagliflozin Tablets 25mg	Tab. 25mg	Empoli	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	1	20	53												
681	Efedronate 40mg Tablets	Tab. 40mg	Urigo	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	2	21	54												
682	Efedronate 80mg Tablets	Tab. 80mg	Urigo	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	2	21	54												
796	Doxacycline 400mg Tablets	Tab. 400mg	Fyloed	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	4	5	2	21	54												

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
S. No.	Name of Firm				Sante Pharma Karachi																							
	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score						Factory Evaluation Visit Score						Product Evaluation Parameters											
					Product Technical Parameters																							
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26		
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	Valid ISO	Valid ISO	Valid ISO 9001	Latest BSE/VITA ranking of the leading manufacturer firm (by value) in Pakistan	Valid calibration	Valid documents of the Federal Board of Revenue (FBR) showing the	Availability of calibrated equipment for	Raw material In-Processance In	Adherence to	Adequate availability of	Availability of Functional and	Biocompatibility/ Biocompatibility study conducted by WHO	Goods Declaration certificate of imported API of the	Certificate of	Active Pharmaceutical Ingredients (APIs) source	Valid WHO prequalification	Valid Certificate of Analysis of the Type / class of material used for the	Stability studies of	Availability of quality system in Pakistan market in past recent month data of						
01	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70			
02	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
03	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
04	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
05	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
06	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
07	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
08	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
09	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
10	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
11	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
12	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
13	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
14	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
15	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
16	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
17	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
18	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
19	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
20	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
21	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
22	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
23	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
24	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
25	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			
26	Trasolololone 0.1% eye drops	Tablet - 40mg	Trasolololone 0.1% eye drops	2	2	3	5	5	6	2	2	2	2	2	33	0	5	5	0	0	4	5	0	19	50			

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																											
Name of Firm				SCHAZOO PHARMACEUTICALS LABORATORIES PVT. LTD.																							
S. No.	Product General Information				Factory Technical Evaluation Parameters																Technical Evaluation Matrix					Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Factory Evaluation Visit Score				Total Factory Evaluated Score	Product Evaluation Parameters													
	1	2	3	4	5	6	7	8	9	10	11	12		13	14	15	16	17	18	19	20	21	22	23	24	25	26
Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Function as in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC expert/s as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, in-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s).	Non-adherence to GSP shall lead to disqualification of the firm.	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to Disqualification of the section/s or firm).	Availability of functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section/ firm.	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available (on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US/DA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid arrival bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importer a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, API source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / USFDA/ EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for license to import Drugs). Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies)	1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium foil, PVC, Capsule Shell, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted products). 3. Type of Glass material for Oral Syringe/ Suspensions must be USP Type 3 or better (Non-	Stability studies of quoted items duly attested by the Q/C (incharge of the firm).	Availability of quoted items in Pakistani market as per recent most data of IMS/QVIA. Health not older than twelve (12) months: 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals-01 mark 04 Tender approvals-02 marks			
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70	
101	Mycophenolate Mofetil	Tab. / Cap. 500 mg	Veto M	0	0	0	2	5	6	2	2	2	2	2	2		0	0	0	0	0	5	0	5	5		
103	Mycophenolate Sodium	Tab. / Cap. 360 mg	Veto S	0	0	0	2	5	6	2	2	2	2	2	2	23	0	0	0	0	0	5	0	5	28		
105	Tacrolimus	Tab./Cap. 1mg	Tacmas Cap	0	0	0	2	5	6	2	2	2	2	2	2	23	0	0	0	0	0	5	0	5	28		
311	Artemether	Inj. 80 mg/ml 1ml	Artemex Inj	0	0	0	2	5	6	2	2	2	2	2	2	23	0	0	0	0	0	0	0	0	0	23	
312	Artemether + Lumefantrine	Tab. 40 mg/240mg 8s	Artemex LDS	0	0	0	2	5	6	2	2	2	2	2	2	23	0	0	0	0	0	0	0	0	0	23	
314	Artemether + Lumefantrine	Tab. 80 mg/480mg 6s	Artemex L Forte	0	0	0	2	5	6	2	2	2	2	2	2		0	0	0	0	0	5	0	5	5		
383	Iron Hydroxide poly maltose complex + Folic acid	Tab. 100 mg	Hemifere	0	0	0	2	5	6	2	2	2	2	2	2	23	0	0	0	0	0	5	0	5	28		
529	Ondansetron	Tab. 8 mg	Sharon	0	0	0	2	5	6	2	2	2	2	2	2	23	0	0	0	0	0	5	0	5	28		
764	Topiramate	Tab. 50 mg	Tomax	0	0	0	2	5	6	2	2	2	2	2	2	23	0	0	0	0	0	5	0	5	28		
829	Diclofenac Sodium	Eye Drops 0.1% w/v	Diclomin	0	0	0	2	5	6	2	2	2	2	2	2	23	0	0	0	0	0	5	0	5	28		
830	Dorzolamide + Timokol	Eye Drops 2 + 0.5% 5ml	Glazol T	0	0	0	2	5	6	2	2	2	2	2	2		0	0	0	0	0	5	0	5	5		
833	Fluorometholone + Neomycin	Eye Drops 0.1%+0.5% 5ml	Florom N	0	0	0	2	5	6	2	2	2	2	2	2		0	0	0	0	0	5	0	5	5		
835	Latanoprost	Eye Drops 0.05%, 2.5ml	Latep	0	0	0	2	5	6	2	2	2	2	2	2		0	0	0	0	0	5	0	5	5		
837	Moxifloxacin	Eye Drops 0.5% w/v, 5ml	Moxidin	0	0	0	2	5	6	2	2	2	2	2	2		0	0	0	0	0	5	0	5	5		
849	Tobramycin	Eye Drops 0.3% w/v, 5ml	Tobra	0	0	0	2	5	6	2	2	2	2	2	2		0	0	0	0	0	5	0	5	5		
850	Tobramycin + Dexamethasone	Eye Drops 0.3% + 0.1% w/v 5 ml	Tobra D	0	0	0	2	5	6	2	2	2	2	2	2		0	0	0	0	0	5	0	5	5		

GRC Decision

The GRC agreed with the findings of scrutiny committee and the firm is not recommended for not providing the mandatory valid cGMP certificate in the technical bid and disposed of the appeals in accordance with the said terms.

Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																							
Name of the firm						Searle Medical Devices Karachi																	
S. No.	Product General Parameter				Technical Evaluation Matrix																		
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation										Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20				
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for Co.A will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only. (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Physical examination of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.							
		Ref. No. of	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70			
Abu Dhabi Medical Devices	3	1019	Disposable Insulin Syringe Ordinary sterile	30 G / 31 G, 1ml	Medeco	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Abu Dhabi Medical Devices	7	1116	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G	Medeco	3	5	0	5	5	6	24	5	5	0	2	DTL Substandard	10	22	46			
Abu Dhabi Medical Devices	8	1117	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G	Medeco	3	5	0	5	5	6	24	5	0	0	2	DTL Substandard	10	17	41			
Abu Dhabi Medical Devices	9	1118	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G	Medeco	3	5	0	5	5	6	24	5	5	0	2	10	10	32	56			
Abu Dhabi Medical Devices	10	1119	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G	Medeco	3	5	0	5	5	6	24	5	0	0	2	10	10	27	51			
Abu Dhabi Medical Devices	11	1120	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G	Medeco	3	5	0	5	5	6	24	5	5	0	2	DTL Substandard	10	22	46			
Abu Dhabi Medical Devices	12	1121	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G	Medeco	3	5	0	5	5	6	24	5	0	0	2	DTL Substandard	10	17	41			

Abu Dhabi Medical Devices	13	1122	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G	Medeco	3	5	0	5	5	6	24	5	0	0	2	DTL Substandard	10	17	41
---------------------------	----	------	---	-----	--------	---	---	---	---	---	---	----	---	---	---	---	-----------------	----	----	----

[illegible]

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																									
				Name of the firm		SEHAT MEDICAL DEVICES																			
S.No	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	Technical Evaluation Matrix											
					Documents Based Factory Score				Evaluation Visit Score					Product technical Evaluation Parameters										Product Evaluated Score	Total Technical Score
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21					
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC. (Certificate Duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 2 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.						
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size & Guage of Medical Device	Trade Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70				
1	1020	Disposable Syringe Ordinary (Blister packing) sterile	1CC	SMD	3	5	5	2	GRC Decision:The firm is not recommended due to non fullfilment of mandatory document under the bid form-1 (7)(iii) of the approved BSDs, MCC FY 2025-26.				15	5	5	0	0	10	10	20	35				
2	1016	Disposable Auto Disable Syringe (Blister packing) sterile	3CC	SMD	3	5	5	2					15	5	5	0	0	10	10	20	35				
3	1017	Disposable Auto Disable Syringe (Blister packing) sterile	5CC	SMD	3	5	5	2					15	5	5	0	0	10	10	20	35				
4	1021	Disposable Syringe Ordinary (Blister packing) sterile	10CC	SMD	3	5	5	2					15	5	5	0	0	10	10	20	35				
5	1019	Disposable Insulin Syringe Ordinary sterile	Insulin 1CC	SMD	3	5	5	2					15	5	5	0	0	10	10	20	35				
6	1022	Disposable Syringe Ordinary (Blister packing) sterile	20CC	SMD	3	5	5	2					15	5	5	0	0	10	10	20	35				
7	1112	I/V fluid administration set	sterile and pyrogen free, minimum 150cm tube length, blister pack	SMD	3	5	5	2					15	5	5	0	0	10	10	20	35				
8	1113	I/V fluid administration set with additional "Y" injection port	minimum 150cm length tubing, latex, and pyrogen free, blister pack	SMD	3	5	5	2					15	5	5	0	0	10	10	20	35				

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																			
Name of Firm				SERAPH PHARMA, ISLAMABAD																															
S. No.	Product General Information				Technical Evaluation Matrix																Product Evaluation Parameters					Total Product Evaluated Score	Total Technical Score								
					Factory Technical Evaluation Parameters										Total Factory Evaluated Score		Product Technical Parameters																		
					Documents Based Factory Score					Factory Evaluation Visit Score							Product Technical Parameters																		
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26									
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMSI/QVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered).	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest.	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP)	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated by the MCC experts at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection).		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter.	Goods Declaration certificate of imported API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs (country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs).	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks	Valid Certificate of Analysis of the Type / class of material used (the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminum Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of a Pharmaceutical grade.	Stability studies of quoted items duly attested by the Q.C. incharge of the firm).	Availability of quoted items in Pakistan market as per recent most data of IMSI/QVIA Health not older than twelve (12) months. 1-10% market share – 1 mark 11-30% market share – 2 marks 31-50% market share – 3 marks 50% and above market share – 5 marks For items specifically used in institutions where IMSI/QVIA data is not applicable, the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan.											
					Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMSI/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) Ranking between 41-100 positions 3 marks.	Maximum 6 marks shall be awarded in the following manner: (Valid Calibration Certificates attested by Quality head of the firm).	Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior	(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).						Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, (as per WHO/US	In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importer a valid bill/trail DRAP clearance NOC between the principal manufacturer and the importer firm shall be			Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the	Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Note: Valid Certificates for the same brand shall												
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70									
	15	Dexamethomidine	Inj. 0.1mg/ml, 2ml	Dexmeda	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	4	5	0	19	28									
	48	Ketorolac	Inj. 30 mg/ml 1ml	Clostat 30mg/ml Inj	0	0	0	0	0	5	4	9	9	9	9	9	9	5	5	0	0	4	5	0	19	28									
	67	Paracetamol+ Tramadol	Ovsodol Plus	Ovsodol Plus	0	0	0	0	0	5	4	9	9	9	9	9	9	0	0	0	0	0	5	0	5	14									
	70	Tramadol HCl	Inj. 50 mg/ml 2ml	Ovsodol 100mg/2ml Injection	0	0	0	0	5	4	9	9	9	9	9	9	9	0	0	0	0	0	5	0	5	14									
	95	Leflunomide	Tab. 20 mg	Leflomid Tab 20mg	0	0	0	0	5	4	9	9	9	9	9	9	9	0	0	0	0	0	5	0	5	14									
	155	Miconazole	Oral Gel 2%	Acturin Gel 2% w/w	0	0	0	0	5	4	9	9	9	9	9	9	9	0	5	0	0	0	5	0	15	24									
	161	Betahistine	Tab. 8 mg	Iugo Tab 8mg	0	0	0	0	5	4	9	9	9	9	9	9	9	0	0	0	0	0	5	0	5	14									
	162	Betahistine	Tab. 16 mg	Iugo Tab 16mg	0	0	0	0	5	4	9	9	9	9	9	9	9	0	0	0	0	0	5	0	5	14									
	169	Levocetirizine	Tab. 5 mg 10s	Levosor 5mg Tablet	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	171	Montelukast	Tab. 10 mg	Zarim Tab 10mg	0	0	0	0	5	4	9	9	9	9	9	9	9	0	0	0	0	0	5	0	5	14									
	172	Montelukast	Tab. 5mg	Zarim Tab 5mg	0	0	0	0	5	4	9	9	9	9	9	9	9	0	0	0	0	0	5	0	5	14									
	202	Azithromycin	Tab. 250 mg	Azitem Tab 250mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	10	19									
	203	Azithromycin	Oral Suspension	Azitem Tab 500mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	10	19									
	215	Cefixime	Inj. 500mg/Vial	Cerpinje Injection IM/IV 500mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	17	26									
	216	Cefixime	Inj. 1 gm/vial	Cerpinje Injection IM/IV 1gm	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	2	5	0	26									
	217	Cefixime	Cap. 400 mg 5s	Trispan Cap 400mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	218	Cefixime	Oral Suspension	Trispan Oral Dry Suspension 100mg/5ml	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	219	Cefixime	Oral Suspension	Trispan Oral Dry Suspension 200mg/5ml	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	220	Cefoperazone + Sulbactam	Inj. 1gm/Vial	Cerbac Injection 500g/500mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	17	26									
	221	Cefoperazone + Sulbactam	Inj. 2 gm/Vial	Cerbac Inj 1000mg/1000mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	17	26									
	226	Cefpodoxime	Oral Suspension	Cefipod DS 40mg/5ml Dry Suspension	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	228	Cefazidime	Inj. 500 mg/Vial	Certum Injection 500mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	229	Cefazidime	Inj. 1gm/Vial	Certum Injection 1gm	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	2	5	0	17	26								
	230	Ceftriaxone	Inj. 500 mg/Vial	Droncef Injection IM 500mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	2	5	0	12	21								
	231	Ceftriaxone	Inj. 1gm/Vial	Droncef Injection IV 1g	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	2	5	0	21	21								
	232	Ceftriaxone	Inj. 2 gm Vial	Droncef Injection IV 2g	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	2	5	0	21	21								
	243	Ciprofloxacin	Tab. 250 mg 10s	Ciptec Tab 250mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	244	Ciprofloxacin	Tab. 500 mg 10s	Ciptec Tab 500mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	277	Levodopa	Tab. 250 mg 10s	Lexus Tab 250mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	278	Levodopa	Tab. 500 mg 10s	Lexus Tab 500mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	281	Limezolid	Tab. 600mg	Lizobest 600mg Tablet	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	288	Moxifloxacin	Tab. 400 mg	Moxer Tab 400mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	387	Iron Sucrose	Inj. 20 mg/ml 5 ml	Serosec-IV Injection	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	14	23									
	414	Amlodipine + Valsartan	Tab. 5mg+80 mg	AmVal Tab 5mg/80mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	5	14									
	415	Amlodipine + Valsartan	Tab. 5mg+160 mg	AmVal Tab 5mg/160mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	5	14									
	416	Amlodipine + Valsartan	Tab. 5mg+320 mg	AmVal Tab 5mg/320mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	5	14									
	461	Losartan + Hydrochlorothiazide	Tab. 50 mg	Czarlan Plus Tab 50mg + 12.5mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	5	14									
	463	Losartan Potassium	Tab. 50 mg	Czarlan	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	5	14									
	482	Rosuvastatin	Tab. 10 mg	Roscard Tab 10mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	526	Omeprazole	Inj. 40 mg / Vial	Meraz Cap 40mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	17	26									
	528	Esomeprazole	Cap. 40mg	Empiro Cap 40mg	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	532	Pantoprazole	Tab. 40mg	Cunreps	0	0	0	0	5	4	9	9	9	9	9	9	9	5	5	0	0	0	5	0	15	24									
	583	Staglitpin + Metformin	Inj. 500 mg/500mg	Xtaglip Plus Tab 50mg/500mg	0	0	0	0	5	4																									

				Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																
Name of the firm				SHAAD TRADERS, Peshawar																
				Technical Evaluation Matrix																
				Principal's and Importer's Evaluation Parameters									Product Technical Evaluation						Product Evaluated Score	Total Technical Score
				Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	
					Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical	
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	6	6	30	5	5	5	3	6	16	40	70	
	495	Male Latex Condom		Mix Fun	3	5	0	5	6	6	25	5	5	0	1	2	16	29	54	
	1053	Disposable Non-sterile Nitrile Examination Gloves (Powder Free)		SHAAD Gloves	0	5	0	5	6	6	22	5	5	0	0	0	16	26	48	

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																																																																															
Product General Information				Shazeb Pharmaceuticals, Lahore																																																																											
				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix																																																															
																Product Evaluation Parameters										Total Product Evaluated Score	Total Technical Score																																																				
Documents Based Factory Score				Factory Evaluation Visit Score											Product Technical Parameters																																																																
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26																																																						
Valid ISO 18001:2001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided				Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided				Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided				Latest IMS/QVIA ranking of the leading manufacturer firm by value in Pakistan. (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.				Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).				Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)				Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in labs - Functional Stability Chamber (Both Accelerated and Real Time) in Schedule H of DRAP) (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).				Raw material, in-process and finished goods guidelines, range (as in Schedule H of DRAP) as evaluated at the time of inspection by the MCC experts (s).				Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm.				Non-adherence to GSP shall lead to disqualification of the section/s or firm.				(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).				Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section/ firm.				Biowallability/ Bioequivalence study conducted by WHO. Audited Labs must be attached along with the bid and study must be available on WHO Website) For biologicals, bio-similarity studies shall be provided for award of marks in this parameter and / or Biowaver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. Proof of inventor / innovative products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.				Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid survey bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/bill/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC				Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/Id submission. Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.				Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO /US-FDA /EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA(s) country (ies) coupled with Form 3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only when these documents are submitted for all API/component of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/Id submission. Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.				Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 3 marks. Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.				Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/no of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium foil, PVC, Capable Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables: a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).				Stability studies of the quoted items duly attested by the Q.C. (exchange of the firm) For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specification/ strength/ dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.				Availability of quoted items in Pakistan market as per recent most data of IMS/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specification/ strength/ dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.			

SHWAAAN, Rawal Islamabad																																		
Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix																		
																Product Evaluation Parameters																		
				Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters																		
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26									
				Valid ISO 18001 (4500) certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC/ accredited body duly attested by senior executive of the firm)	Latest IMS/RVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered).	Valid calibration certificate for equipment / instruments used in the factory for Measuring, Weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year (i.e. FY 2023-24) or latest.	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs - Functional Stability Chamber (cloth Accelerated and Real Time) in Schedule II of DRAP)	Raw material, In-process and Finished good storage (as in Schedule II of DRAP) as evaluated at the time of the quoted inspection by the MCC experts)	Adherence to cGMP guidelines, for in-Schedule-II of DRAP, as mentioned in schedule-II of DRAP	Adequate availability of qualified & relevant Human Resource and equipment, testing, logs.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs.		Bio-availability/ Bioequivalence study conducted by WHO Assayed Labs must be attached along with the bid and study must be available on WHO Website)	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid survey bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GCD) provided in column 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (API) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medics or Health Canada/ regulatory authority body of SRA's country (ies) coupled with Form 3 (form of undertaking to accompany an application for License to import Drugs).	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase:	Stability studies of quoted items duly attested by the Q.C. incharge of the firm)	Availability of quoted items in Pakistan market as per recent most data of IMS/RVIA Health not older than twelve (12) months.											
				Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firm having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firm having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firm having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firm having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	(Valid Calibration Certificates attested by Quality head of the firm).	Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-II shall lead to disqualification of the firm).	Non-compliance with cGMP guidelines shall lead to disqualification of the firm.	Non-adherence to MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s of firm).	Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section of firm.			In case where Raw materials are acquired from Local source valid invoice (s) not older than 24 months shall be considered. In case of Large volume parenteral (i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovative products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	In case of purchases through third party importers a valid trail/bill/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only, if it was issued within the last five (05) years from the date of NIT/bid submission.	In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only, if it was issued within the last five (05) years from the date of NIT/bid submission.	Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminum Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is of Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP Class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringe/ ampoules must be USP Type 1 or better (Non-compliance or non-provision of Cxk of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded b. For USP Type 2 Glass 2 marks will be awarded c. For products where USP Type 2 glass is used or where the Cxk of Glass material is not provided shall lead to disqualification of the item (s). Document duly attested by the Senior executive of the firm)	For items specifically used in institutions where IMS/RVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specification / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.												
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	4	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70									
42	Diclofenac Sodium enteric coated	Tab. 50 mg		0	2	3	0	5	2	The inspection team during inspection made following observations; ➔ General 1. In raw material store, separate and dedicate area for quarantine was not present which is against the good storage and good manufacturing practices.. 2. Approved sections were four while pharmacists employed were four which indicates non availability of adequate qualified staff. ➔ Cephalosporin Area 1. In RMS released labels were not affixed to all raw material containers required for identification purposes under good storage practices. 2. Dispensing booth was not present in dispensing area which is required for carrying out dispensing of materials in a control environment in order to protect cross contamination. ➔ Quality Control 1. FTIR was not available which is mandatory instrument for qualitative testing of the quoted items. 2. Karl Fischer titration apparatus was out of order which is required for the compendial testing of raw materials of the quoted items. 3. No primary reference standards were present for carrying out standardization and testing of raw materials of the quoted items. 4. Muffle furnace was not in working condition while residue on ignition and sulphated ash tests were performed. (Sulphated ash test for Venlafixine raw material was carried out on 10-04-2025), which indicates that the testing record is not authentic. 5. In Microbiology section the personnel and material entry was same and transfer window with UV light required for transfer of materials in sterility room was not present thereby compromising strict area control required for carrying out sterility testing. Since the above observations are not in accordance with criteria laid down for the evaluation of physical inspection of the firm and good manufacturing practices, good storage practices and good laboratory practices, therefore, the firm is NOT RECOMMENDED for the award of marks as specified for physical inspection in the relevant pro-forma.												12	0	0	0	0	0	0	0	0	0	0	0	12
52	Meloxicam	Tab. 15 mg		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12									
53	Meloxicam	Tab. 7.5 mg		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12									
164	Ceftriaxone	Tab. 10 mg		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12									
169	Levomefexazine	Tab. 5 mg 10s		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12									
170	Lorazepam	Tab. 10 mg 10s		0	2	3	0	5	2	12	0	0	3	5	0	0	5	5	0	5	0	5	0	15	27									
171	Montelukast	Tab. 10 mg		0	2	3	0	5	2	12	0	0	5	5	0	0	5	5	0	5	0	5	0	15	27									
172	Montelukast	Tab. 5 mg		0	2	3	0	5	2	12	0	0	5	5	0	0	0	0	0	0	0	0	10	22										
202	Azithromycin	Tab. / Cap. 250 mg 12s or less		0	2	3	0	5	2	12	0	0	0	0	0	0	0	5	0	0	5	0	5	0	17									
203	Azithromycin	Tab. / Cap. 500 mg 6s		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	12										
211	Cefaclor	Susp. 125mg/ 5ml 60 ml		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	12										
212	Cefaclor	Susp. 250 mg /5ml 60 ml		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	12										
214	Cefepime	Inf. 500mg/Vial		0	2	3	0	5	2	12	0	0	5	5	0	0	5	5	0	10	0	0	0	15	27									
216	Cefepime	Inf. 1 gm/Vial		0	2	3	0	5	2	12	0	0	5	5	0	0	0	0	0	10	0	0	0	15	27									
217	Cefixime	Cap. 400 mg 5s		0	2	3	0	5	2	12	0	0	5	5	0	0	0	0	0	10	0	0	0	15	27									
218	Cefixime	Dry Susp. 100 mg/ml 30ml		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
219	Cefixime	Dry Susp. 200 mg/ml 30ml		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
220	Cefoperazone + Sulbactam	Inf. 1gm/Vial		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
221	Cefoperazone + Sulbactam	Inf. 2 gm/Vial		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
222	Cefotaxime Sodium	Inf. 250 mg/Vial		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
223	Cefotaxime Sodium	Inf. 500 mg/Vial		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
224	Cefotaxime Sodium	Inf. 1gm/Vial		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
225	Cefepodostine	Tab. 100 mg		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	12										
226	Cefepodostine	Dry Susp. 40 mg/5ml 50 ml		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	12										
230	Ceftriaxone	Inf. 500 mg/Vial		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
231	Ceftriaxone	Inf. 1gm/Vial		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
237	Ceftriaxone	Cap. 250 mg		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
238	Ceftriaxone	Inf. 500 mg / Vial		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
241	Ceftriaxone	Dry Susp. 125mg / 5ml		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	10	0	0	0	10	22									
242	Ceftriaxone	Dry Susp. 250 mg / 5ml		0	2	3	0	5	2	12	0	0	5	5	0	0	0	0	0	10	0	0	0	10	22									
243	Ciprofloxacin	Tab. 250 mg 10s		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
244	Ciprofloxacin	Tab. 500 mg 10s		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
247	Clarithromycin	Tab. 250 mg 10s		0	2	3	0	5	2	12	0	0	0	0	0	0	5	0	0	5	0	0	0	5	17									
248	Clarithromycin	Tab. 500 mg 10s		0	2	3	0	5	2	12	0	0	0	0	0	0	5	0	0	5	0	0	0	5	17									
277	Levofloxacin	Tab. 250 mg 10s		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	10	22									
278	Levofloxacin	Tab. 500 mg 10s		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	10	22									
415	Amiodipine + Valartum	Tab. 5mg+160 mg		0	2	3	0	5	2	12	0	0	5	5	0	0	0	0	0	10	0	0	0	10	22									
416	Amiodipine + Valartum	Tab. 10mg+160 mg		0	2	3	0	5	2	12	0	0	5	5	0	0	0	0	0	10	0	0	0	10	22									
517	Famotidine	Tab. 40 mg		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	15	0	0	0	15	27									
527	Omeprazole	Cap. 40 mg		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	5	0	0	0	5	17									
528	Esomeprazole	Cap. 40mg		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	5	0	0	0	5	17										
723	Escitalopram	Tab. 10 mg		0	2	3	0	5	2	12	0	0	5	5	0	0	0	0	0	10	0	0	0	10	22									
724	Fluoxetine HCl	Cap. 20 mg		0	2	3	0	5	2	12	0	0	5	5	0	0	0	0	0	10	0	0	0	10	22									
758	Quetiapine	Tab. 300 mg		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	10	22									
759	Risperidone	Tab. 2mg		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	10	0	0	0	10	22									
760	Risperidone	Tab. 4 mg		0	2	3	0	5	2	12	0	0	5	5	0	0	5	0	0	10	0	0	0	10	22									
762	Nerualine	Tab. 300 mg		0	2	3	0	5	2	12	0	0	0	0	0	0	0	0	0	0	0	0	0	10	22									

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																					
Name of the firm					Silver surgical Karachi																
S.No	Product General Information				Technical Evaluation Matrix																
					Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters						Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score												
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	
	Ref. No. of item in	Generic Name of Item	Size & Guage of Medical Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid calibration	Valid documents of the	Adherence to Good	Adherence to Current	Availability of,	Adequate availability of		Goods Declaration	Certificate of Analysis	Tender Approvals (not	Valid WHO	Samples evaluation by	Physical examination of		
					3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
1	1016	Disposable Auto Disable Syringe (Blister packing) sterile	3 ml	Orange	3	5	5	2	3	3	2	2	20	0	0	0	0	10	0	10	30
2	1017	Disposable Auto Disable Syringe (Blister packing) sterile	5 ml	Orange	3	5	5	2	3	3	2	2	20	0	0	0	0	10	0	10	30
3	1112	I/V Fluid administration set	Sterile and pyrogen free, minimum 150cm tube length, blister pack	Orange	3	5	5	2	3	3	2	2	20	0	0	0	0	0	0	0	20
4	1116	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18 G	Green	3	5	5	2	3	3	2	2	20	0	0	0	0	DTL substandard	0	0	20
5	1117	I/V Cannula (Sterile having wings + injection port with heparin stopper in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18 G	Green	3	5	5	2	3	3	2	2	20	0	0	0	0	DTL substandard	0	0	20
6	1118	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20 G	Green	3	5	5	2	3	3	2	2	20	0	0	0	0	DTL substandard	0	0	20
7	1119	I/V Cannula (Sterile having wings + injection port with heparin stopper in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20 G	Green	3	5	5	2	3	3	2	2	20	0	0	0	0	DTL substandard	0	0	20
8	1120	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22 G	Green	3	5	5	2	3	3	2	2	20	0	0	0	0	DTL substandard	0	0	20
9	1121	I/V Cannula (Sterile having wings + injection port with heparin stopper in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22 G	Green	3	5	5	2	3	3	2	2	20	0	0	0	0	DTL substandard	0	0	20
10	1122	I/V Cannula (Sterile having wings + injection port with heparin stopper in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24 G	Green	3	5	5	2	3	3	2	2	20	0	0	0	0	DTL substandard	0	0	20
11	1123	I/V Cannula (Sterile having wings + with heparin stopper in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24 G	Green	3	5	5	2	3	3	2	2	20	0	0	0	0	DTL substandard	0	0	20

GRC Decision:

The quoted products of the firm are not recommended due to non fulfilment of mandatory bid form-1(6)(V), of the approved BSDs FY 2025-26.

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																				
Name of the firm					Silver Surgical Complex Karachi															
S.No	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	Technical Evaluation Matrix					Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score											
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70
1	1221	Stop Cock 3 way with Extension			3	0	5	2	5	5	5	5	30	5	5	0	0	10	20	50

GRC Decision:

1 The quoted products of the firm are not recommended due to non fulfillment of mandatory bid form-1(6)(V), of the approved BSDs FY 2025-26.

Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																						
Name of the firm					Sind Medical Store Karachi																	
S. No.	Product General Parameter				Technical Evaluation Matrix																	
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation									Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20			
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit of its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm). In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated	Adequate availability of qualified, (Presence of Category-A Pharmacists/ is / are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (\$10 K)/ US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.					
		Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70		
ASFANDYARAJAB No. 115 Nongxinhe Road,	1	1019	Disposable Insulin Syringe Ordinary sterile 1ml	1ml 30G	Yushou	3	5	0	5	5	6	24	0	5	0	0	10	10	25	49		
ASFANDYARAJAB No. 115 Nongxinhe Road,	2	1021	Disposable Syringe Ordinary (Blister packing) sterile 10ml	10ml	Yushou	3	5	0	5	5	6	24	0	5	0	0	10	10	25	49		
ASFANDYARAJAB No. 115 Nongxinhe Road,	4	1023	Disposable Syringe Ordinary (Blister packing) sterile 50ml	50ml	Yushou	3	5	0	5	5	6	24	0	5	0	0	10	10	25	49		
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	5	1300	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	4/0	DemeGUT	0	5	5	5	5	6	26	0	5	0	2	10	10	27	53		
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	6	1301	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	3/0	DemeGUT	0	5	5	5	5	6	26	0	5	0	2	10	10	27	53		
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	7	1302	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	2/0	DemeGUT	0	5	5	5	5	6	26	0	5	0	2	10	10	27	53		
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	8	1304	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	0	DemeGUT	0	5	5	5	5	6	26	0	0	0	2	10	10	22	48		
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	9	1306	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	1	DemeGUT	0	5	5	5	5	6	26	0	0	0	2	10	10	22	48		
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	10	1308	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	2	DemeGUT	0	5	5	5	5	6	26	0	5	0	2	10	10	27	53		
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	11	1317	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1	DemeSilk	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48		
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	12	1318	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1	DemeSilk	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48		
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	13	1320	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	2	DemeSilk	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48		

Corp., 14175 NW 60th Ave Miami Lakes,FL 33014.	14	1322	8mm, 1/4 circle spatulated needle, strand length 45cm	6/0	DemeCRYL	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 14175 NW 60th Ave Miami Lakes,FL 33014.	15	1324	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm	6/0	DemeCRYL	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 14175 NW 60th Ave Miami Lakes,FL 33014.	16	1325	11mm, 3/8 circle reverse cutting needle, Strand length 45 cm	5/0	DemeCRYL	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 14175 NW 60th Ave Miami Lakes,FL 33014.	17	1334	22mm, 1/2 circle round bodied taper point, strand length 70 cm	3/0	DemeCRYL	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 14175 NW 60th Ave Miami Lakes,FL 33014.	18	1335	26mm, 1/2 circle round bodied taper point, Strand length 70 cm	3/0	DemeCRYL	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 14175 NW 60th Ave Miami Lakes,FL 33014.	19	1336	26mm, 1/2 circle round bodied taper point, strand length 70 cm	2/0	DemeCRYL	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 14175 NW 60th Ave Miami Lakes,FL 33014.	20	1337	31mm, 1/2 circle round bodied taper point, Strand length 70 cm	2/0	DemeCRYL	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 14175 NW 60th Ave Miami Lakes,FL 33014.	21	1341	40mm, 1/2 circle round bodied taper point, strand length 90 cm	0	DemeCRYL	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 14175 NW 60th Ave Miami Lakes,FL 33014.	22	1342	40mm, 1/2 circle round bodied taper point, strand length 70 cm	1	DemeCRYL	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	23	1347	17mm, 1/2 circle round bodied needle, Strand length 75cm	4/0	Deme SORB	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	24	1350	25mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0	Deme SORB	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	25	1351	30mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0	Deme SORB	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	26	1352	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	0	Deme SORB	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	27	1353	30mm, 1/2 circle round bodied taper point needle, strand length 75 cm	1	Deme SORB	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	28	1354	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	1	Deme SORB	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	29	1355	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	2	Deme SORB	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	30	1364	13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	6/0	DemeLENE	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	31	1368	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	4/0	DemeLENE	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	33	1369	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	4/0	DemeLENE	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	35	1371	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	3/0	DemeLENE	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	36	1372	30 mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	3/0	DemeLENE	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	37	1373	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0	DemeLENE	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43

Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	38	1374	26mm, 3/8 circle reverse cutting needle, strand length 45cm	2/0	DemeLENE	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	39	1375	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	2/0	DemeLENE	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	40	1376	26mm, 1/2 circle round bodied taper cut double armed needle, strand length 75cm	2/0	DemeLENE	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	41	1377	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0	DemeLENE	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	43	1379	60mm, straight cutting needle, strand length 75cm	2/0	DemeLENE	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	44	1380	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	0	DemeLENE	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	45	1381	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1	DemeLENE	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	46	1382	6.5mm, 3/8 circle micro-point spatula double needle, strand length 30cm	10/0	DemeLON	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	47	1385	17mm, 1/2 circle round bodied taper cut double needle, strand length 75cm	2/0	DemeBOND	0	5	0	5	5	6	21	0	5	0	2	10	10	27	48
Corp., 5980 Miami Lakes Drive, Miami Lakes, FL USA	49	1387	26mm, 1/2 circle round bodied taper point double needle, strand length 90cm	2/0	DemeBOND	0	5	0	5	5	6	21	0	0	0	2	10	10	22	43

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26														
Name of the firm					Sind Medical store Karachi														
					Technical Evaluation Matrix														
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
					Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of minimum	Adherence to Good	Adequate availability of		Goods Declaration certificate of imported	Certificate of Analysis	Tender Approvals (not older than twelve 12 months)	Valid WHO prequalification	CE mark/Quality assurance certificate/Quality	Physical examination	Evaluated	Technical
S. No.	Ref. No. of Item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	6	6	30	5	5	5	3	6	16	40	70
1	1416	Polypropylene	30cm x 30cm	Demelene MESH	0	5	0	5	6	6	22	5	0	0	0	2	16	23	45
2	1417	Polypropylene	15cm x 15cm	Demelene MESH	0	5	0	5	6	6	22	0	0	0	0	2	16	18	40
3	1419	Polypropylene	6cm x 11cm	Demelene MESH	0	5	0	5	6	6	22	5	0	0	0	2	16	23	45

	110	Zalcidronic Acid.....10mg / 4 mg / 6ml	EDONAX INJECTION	2	2	3	4	5	4	2	2	2	2	2	20	0	0	0	0	0	0	5	2	7	37
--	-----	--	---------------------	---	---	---	---	---	---	---	---	---	---	---	----	---	---	---	---	---	---	---	---	---	----

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2025-26																								
	Name of Firm				SOS TECHNOLOGIES, MULTAN																			
S. No.	General Product Information				Factory Technical Evaluation Parameters										Technical Evaluation Matrix				Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score
					Documents Based Factory Score					Evaluation visit Score														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20				
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP (Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. (Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) (To be evaluated by the MCC experts at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).	15	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)						
	Ref. No. of item in MCC Formulary	Generic Name of Item	Sizes and specifications	Trade Name	3	3	3	4	5	3	6	6	6	6	45	5	10	10	25	70				
	967	Cotton (Surgical) Corded BPC 200 Gm	AB Absorbent Cotton Roll (BPC) 200 Grams		3	3	3	4	5	0	6	6	6	6	42	0	0	DTL Substandard	0	42				
	968	Cotton (Surgical) Corded BPC 100 Gm	AB Absorbent Cotton Roll (BPC) 100 Grams		3	3	3	4	5	0	6	6	6	6	42	0	10	10	20	62				
	1092	Gauze Cloth Roll packing 100 cm x 20 m	AB Absorbent Gauze B.P.C Roll 100cm x 20 meters		3	3	3	4	5	0	6	6	6	6	42	0	10	10	20	62				
	1093	Gauze Cloth Roll packing 100 cm x 40 m	AB Absorbent Gauze B.P.C Roll 100cm x 40 meters		3	3	3	4	5	0	6	6	6	6	42	0	0	DTL Substandard	0	42				

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
Name of Firm				Stallion Pharmaceutical (Pvt) Ltd Lahore																								
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score
																	Product Evaluation Parameters											
					Documents Based Factory Score										Factory Evaluation Visit Score													
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15		16	17	18	19	20	21	22	23	24	25		
				Valid ISO 18001 (4500) certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest BMS/QVIA ranking of the leading manufacturer firm (by value) in Pakistan (12 months to date ranking will be considered).	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Weighing, Assay / Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest.	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs - Functional Stability Chamber (Both Accelerated and Real Time) as in Schedule B of DRAP.	Raw material, In-process and Finished good storage (as in Schedule B of DRAP), in area / section of the quoted product (i).	Adherence to cGMP guidelines, as per the requirements mentioned in schedule-B of DRAP.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP.	Availability of Functional and validated IVAC, with all relevant equipment, testing, logs.	(As evaluated by the MCC reports at the time of inspection).	Bio-warmer certificate from an accredited lab of SRA countries (stringent Regulatory Authorities)	In cases where Raw materials are acquired from Local sources valid sources (i.e. not older than 24 months shall be considered).	In case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIComponents of the quoted products.	However, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIComponents of the quoted products.	Valid WHO prequalification and / or	Valid product registration in SRA country(ies) and / or	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item's, as issued by the manufacturer of the material coupled with invoice proof of purchase.	Stability studies of quoted item's duly attested by the QC (in-house or 3rd firm)	Availability of quoted item's in Pakistan market as per recent most data of BMS/QVIA Health not older than twelve (12) months.				
				Online verification link shall be provided	Online verification link shall be provided	Online verification link shall be provided	1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.	1. Firm having (12-Month) Ranking between 21-40th positions 4 marks.	1. Firm having (12-Month) Ranking between 41st to 60th positions shall be awarded 3 marks.	Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks.	Financial turnover of more than PKR 1000 million - 6 marks.	Non-conformance to cGMP guidelines shall lead to disqualification of the vendor's bid.	Non-availability of the time of inspection or non-availability of the IVAC system and/or testing and/or logs, shall lead to disqualification of the vendor's bid.	Non-availability of the time of inspection or non-availability of the IVAC system and/or testing and/or logs, shall lead to disqualification of the vendor's bid.														
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	3	3	4	5	37	70				
180	Cap. Amoxicillin	250mg	Stamox Capsule 250mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	3	18	50			
181	Cap. Amoxicillin	500mg	Stamox Capsule 500mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	3	18	50			
182	Dry Susp. Amoxicillin	125 mg /5ml	Stamox Dry Powder Suspension 125mg (60ml)	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	3	22	54			
183	Dry Susp. Amoxicillin	125 mg /5ml	Stamox Dry Powder Suspension 125mg (90ml)	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	3	22	54			
184	Inj. Amoxicillin	500 mg/Vial	Stamox 500 mg Dry Powder Injection	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	2	5	3	20	52			
185	Dry Susp. Amoxicillin	250mg /5ml	Stamox Dry Powder Suspension 250mg (60ml)	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	3	22	54			
186	Dry Susp. Amoxicillin	250 mg /5ml	Stamox Dry Powder Suspension 250mg (90ml)	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	3	22	54			
187	Tab. Amoxicillin + Clavulanic Acid	250mg/ 125mg (175mg)	Stamoxin Tablet 275mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	15	47			
188	Tab. Amoxicillin + Clavulanic Acid	500mg/ 125mg (625mg)	Stamoxin Tablet 625mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	18	50			
189	Tab. Amoxicillin + Clavulanic Acid	875mg/ 125mg (1gm)	Stamoxin Tablet 1gm	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	0	5	0	18	50			
190	Dry Susp. Amoxicillin + Clavulanic Acid	125 mg +31.5mg/5ml	Stamoxin Dry Powder Suspension 156.25mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	3	22	54			
192	Dry Susp. Amoxicillin + Clavulanic Acid	250 mg +62.5mg/5ml	Stamoxin DS Dry Powder Suspension 312.5mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	3	22	54			
193	Inj. Amoxicillin + Clavulanic Acid	500 mg + 100mg/Vial	Stamoxin Dry Powder Injection 600mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	2	5	0	20	52			
194	Inj. Amoxicillin + Clavulanic Acid	1gm/200mg/Vial	Stamoxin Dry Powder Injection 1.2 gm	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	2	5	0	17	49			
196	Inj. Ampicillin	500 mg/Vial	Ampisil Injection 500mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	2	5	0	17	49			
200	Inj. Ampicillin + Cloxacillin	250 mg + 250mg/Vial	Staxone Injection 500mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	2	5	0	17	49			
268	Cap. Flucloxacillin + Amoxicillin	250 mg + 250mg	Fluxal Capsule 500mg	2	2	3	4	5	6	2	2	2	2	2	32	0	0	0	0	0	4	5	0	9	41			
273	Inj. Imipenem + Cilastatin	500 mg+500mg / Vial	Primoxin Injection 500mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	5	0	2	5	0	22	54			
285	Inj. Meropenem	500 mg/Vial	Merostin 500mg Dry Powder Injection	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	5	0	2	5	0	25	57			
286	Inj. Meropenem	1gm /Vial	Merostin 1gm Dry Powder Injection	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	5	0	2	5	0	25	57			
292	Inj. Piperacillin + Tazobactam	2 gm+0.25gm / 2.5gm/Vial	Talzon 2.25gm Dry Powder Injection	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	2	5	0	19	51			
293	Inj. Piperacillin + Tazobactam	4 gm+2 g /4.5gm/Vial	Talzon 4.5gm Dry Powder Injection	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	21	53			

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26

[illegible]

					Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26														
Name of the firm					SUDAIS ASSOCIATES, PSHAWAR														
S. No.	Product General Parameter				Technical Evaluation Matrix														
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
	Ref. No. of item in	Generic Name of	Size, Gauge, etc. of	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of	Adherence to Good	Adequate availability of		Goods Declaration	Certificate of Analysis	Tender Approvals (not	CE mark/ Quality	Samples evaluation by	Physical examination of		
					3	5	5	5	5	6	29	5	5	5	6	10	10	41	70
Verifine, China	1019	Disposable Insulin Syringe Ordinary sterile	30G		3	5	0	5	5	6	24	5	5	0	2	10	10	32	56
Winset, China	1113	I/V fluid administration set with additional “Y” injection port	minimum 150cm length tubing, latex, and pyrogen free, blister		0	5	0	5	5	6	21	5	5	0	2	10	10	32	53
		GRC Decision:	The quoted item at formulary No: 1113 is not recommended due to non full filment of mandatory DRAP registration under bid form-1 (8)(ii), bid form-3 and bid form-5 of the approved BSDs FY 2025-26.																

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26																		
Name of the firm					SUDAIS ASSOCIATE, PESHAWAR																		
					Technical Evaluation Matrix																		
					Principal's and Importer's Evaluation Parameters										Product Technical Evaluation						Product Evaluated Score	Total Technical Score	
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score												
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19				
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of	Adherence to Good	Adequate availability of		Goods Declaration	Certificate of Analysis	Tender Approvals (not	Valid WHO	CE mark/Quality	Physical examination of	Product Technical Score	Total Technical Score				
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70				
	Lifecare, China	964	Colostomy bags (Set comprising bag, adhesive ring, and clamp)		0	5	0	5	6	6	22	5	5	0	0	2	16	28	50				
	Wellex, Egypt	982	CVP LINE Single lumen	14Gx20cm	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50				
	Wellex, Egypt	982	CVP LINE Single lumen	16Gx20cm	0	5	0	5	6	6	22	0	0	0	0	2	16	18	40				
	Wellex, Egypt	984	CVP line (Triple Lumen)	7F x 16cm	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50				
	Wellex, Egypt	990	Dialysis Catheter (Double Lumen)	12FR x 15cm straight	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50				
	Dr. Japan, Japan	1041	Disposable Sterile Spinal Needle-	23 G	0	0	0	5	6	6	17	0	0	0	0	2	16	18	35				
	Dr. Japan, Japan	1042	Disposable Sterile Spinal Needle-	25 G	0	0	0	5	6	6	17	0	0	0	0	2	16	18	35				
	Medstream, China	1126	Infusion Chamber (Burette Type) Sterile, Disposable	100ml	0	0	0	5	6	6	17	5	5	0	0	2	16	28	45				
	Wellex, Egypt	1129	JJ Stent	6Fr	Ureteral stent	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50			
	Wellex, Egypt	1130	JJ Stent	4.7 FR	0	5	0	5	6	6	22	5	5	0	0	2	16	28	50				
	MDK, China	1220	Ostomy Paste		0	5	0	5	6	6	22	5	5	0	0	2	16	28	50				
	Stay Dry, China	1279	Urine Bag with T- valve	2000ml	0	5	0	5	6	6	22	5	0	0	0	2	16	23	45				
		GRC Decision:		The quoted item at formulary No: 964, 1126, 1220 and 1279 are not recommended due to non full filment of mandatory DRAP registration under bid form-1 (8)(ii), bid form-3 and bid form-5 of the approved BSDs FY 2025-26.																			

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																												
S. No.	Name of Firm				Unisa Pharmaceuticals Pvt Limited, Peshawar																							
	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score						Factory Evaluation Visit Score						Product Evaluation Parameters											
					5	6	7	8	9	10	11	12	13	14	15		16	17	18	19	20	21	22	23	24	25		
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan. (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) Ranking between 41-60th positions 3 marks.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm)	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time) as per Schedule B of DRAP. (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert's).	Adherence to cGMP guidelines, (as in Schedule-B of DRAP) as per the requirements mentioned in schedule-B of DRAP. Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm)	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid away bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / TGA / PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syringa/ Suppositories must be USP Type 2 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of	Stability studies of quoted items duly attested by the Q.C (in charge of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks	Availability of quoted items in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and / or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks						
	Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70		
1	4	Metronidazole	Inf. 500mg, 100 ml	Unisol	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
2	64	Paracetamol	Inf.1000 mg 100ml	Unisol-Para	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
3	245	Ciprofloxacin	Inf. 400 mg/100ml 100 ml	Uniciprox	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
4	276	Levofloxacin	Inf. 5 mg/ml 100 ml	Unilevoflox	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
5	638	Dextrose	IV Inf. 0.1 500ml	Unisol - 10%	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
6	639	Dextrose	IV Inf. 0.1 1000ml	Unisol - 10%	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52		
7	640	Dextrose	IV Inf. 5% 100ml	Unisol - 5%	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
8	641	Dextrose	IV Inf. 0.05 500ml	Unisol - 5%	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52		
9	642	Dextrose	IV Inf. 0.05 1000ml	Unisol - 5%	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52		
10	643	Dextrose + Sodium Chloride	IV Inf. 5% + 0.45% 500ml	Unisol - DS 1/2	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52		
11	644	Dextrose + Sodium Chloride	IV Inf. 5% + 0.9% 500ml	Unisol - DS	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52		
12	645	Dextrose + Sodium Chloride	IV Inf. 5% + 0.9% 1000ml	Unisol - DS	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52		
13	655	Mannitol	IV Inf. 0.2 500 ml	Unilevic-20	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
14	656	Normal Saline	IV Inf. 0.9% 100 ml	Unisol - NS	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52		
15	657	Normal Saline	IV Inf. 0.9% 500 ml	Unisol - NS	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57		
16	659	Normal Saline	IV Inf. 0.009 1000 ml	Unisol - NS	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	5	0	4	5	0	29	57		
17	666	Unisol-Lactate + Dextrose 5%	IV Inf. 500 ml	Unisol - RLD	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52		
18	667	Unisol-Lactate + Dextrose 5%	IV Inf. 1000 ml	Unisol - RLD	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52		
19	668	Ringer's Lactate Soln.	IV Inf. 500 ml	Unisol - RL	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52		
20	669	Ringer's Lactate Soln.	IV Inf. 1000 ml	Unisol - RL	2	2	3	0	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52		

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																						
Product General Information					Technical Evaluation Matrix																	
					Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters							Product Evaluated Score	Total Technical Score
S.No	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s)	Valid WHO prequalification and / or valid product registration in SRA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Samples evaluation by DTL. (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.			
	NO. OF item in MCC Formu	Generic Name of Item	Size & Guage of Medical Device	Trade Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70	
1	1016	Disposable Auto Disable Syringe (Blister Packing) Sterile 3mL	3ml	UNILOCK 3mL Syringes	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57	
2	1017	Disposable Auto Disable Syringe (Blister Packing) Sterile 5mL	5ml	UNILOCK 5mL Syringes	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57	
3	1019	Disposable Insulin Syringe Ordinary Sterile	1ml	UNILIN-1	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57	
4	1020	Disposable Syringe Ordinary Blister Pack Sterile		UNIJECT 1mL/cc syringes	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57	
5	1021	Disposable Syringe Ordinary (Blister Packing) Sterile 10mL		UNIJECT 10mL Syringes	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57	
6	1022	Disposable Syringe Ordinary (Blister Packing) Sterile 20mL		UNIJECT 20mL Syringes	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57	
7	1112	IV fluid administration Set, Sterile and pyrogen free, minimum 150cm tube length, blister pack		UNISSET	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57	
8	1113	IV fluid administration Set with additional "Y" injection port, Sterile, minimum 150cm length tubing, latex and pyrogen free, blister pack		UNISSET (WITH Y-PORT)	3	5	5	4	3	3	2	2	27	5	5	0	0	10	10	30	57	

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																						
Name of the firm					UNISA PVT LTD																	
S.No	Product General Information				Technical Evaluation Matrix																	
					Factory Technical Evaluation Parameter								Factory Evaluated Score								Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score													
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.					
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70		
1	965	Cord Clamp			0	0	0	4					4			0	0	0	0	4		

Observation
cGMP does not cover the manufacture of Cord clamp.

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																							
Name of the firm					UNIVERSAL MEDICAL DEVICES, Gadoon																		
S.No	Product General Information				Technical Evaluation Matrix																		
					Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters					Product Evaluated Score	Total Technical Score			
	Documents Based Factory Score				Evaluation Visit Score																		
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21			
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment/instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (As evaluated at the time of inspection by the MCC experts). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC experts at the time of inspection, Non-compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificate Duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength/ dosage form. Moreover, the approvals(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 2 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC experts. Rejection of the quoted item/s by the MCC experts shall lead to disqualification of the said item/s.				
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size & Gauge of Medical Device	Trade Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70		
	1016	Disposable Auto Disable Syringe (Blister Packing) Sterile 3ml	3ml	SKY Auto Disposable Syringe 3ml	3	5	5	0	3	3	2	2	23	5	5	0	0	10	10	30	53		
	1017	Disposable Auto Disable Syringe (Blister Packing) Sterile 5ml	5ml	SKY Auto Disposable Syringe 5ml	3	5	5	0	3	3	2	2	23	5	5	0	0	10	10	30	53		
	1020	Disposable Syringe Ordinary (Blister Packing) Sterile 1ml	1ml	SKY Disposable Syringe 1ml	3	5	5	0	3	3	2	2	23	5	5	0	0	10	10	30	53		
	1021	Disposable Syringe Ordinary (Blister Packing) Sterile 10ml	10ml	SKY Disposable Syringe 10ml	3	5	5	0	3	3	2	2	23	5	5	0	0	10	10	30	53		
	1022	Disposable Syringe Ordinary (Blister Packing) Sterile 20ml	20ml	SKY Disposable Syringe 20ml	3	5	5	0	3	3	2	2	23	5	5	0	0	10	10	30	53		
	1112	IV Fluid administration Sterile, and Pyrogen free minimum 150 cm tube length, blister pack		Sky IV Set (Specification: Hypodermic Needle (21Gx1.1.5") Tube Length: (150cm)	3	5	5	0	3	3	2	2	23	5	5	0	0	10	10	30	53		
	1113	IV Fluid administration set with additional "Y" injection portsterile, minimum 150cm length tubing, latex, and pyrogen free, blister pack		Sky IV Set with Y Connector (Specification: Hypodermic Needle (21G x 1.1.5") Tube Length:(150cm)	3	5	5	0	3	3	2	2	23	5	5	0	0	10	10	30	53		

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2025-26																					
Name of the firm					Universal Medical Devices																
S.No	Product General Information				Technical Evaluation Matrix																
					Factory Technical Evaluation Parameter								Factory Evaluated Score							Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score												
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20		
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. (to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of, Functional and validated HVAC, with all relevant equipment, testing and logs. (As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificates duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.			
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of	Trade Name	3	5	5	6	5	5	5	5	39	5	5	5	6	10	31	70	
1126	Infusion Chamber (Burette type) Sterile, Disposable 100ml	100ml	Sky IV Set with 100ml Burrete (Specifica tion tube Length: 150cm 100ml Drip Chamber		3	5	5	0	5	5	5	5	33	5	5	0	0	10	20	53	

Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																					
Name of the firm					USMANCO INTERNATIONAL, KARACHI																
S. No.	Product General Parameter				Technical Evaluation Matrix																
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation								Product Evaluated Score	Total Technical Score
	Principal Manufacturer Evaluation			Importer's Evaluation				Suppliers Technical Score													
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20			
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured issued by authorized body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/regulatory bodies in the case of SRA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). Non availability of the 20% stock at the time of inspection at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.	Adequate availability of qualified, (Presence of Category-A Pharmacist/s (are mandatory), & relevant Human Resource (Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC. (Certificate duly attested by senior executive of the firm)	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only (verification Link shall be provided) and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US FDA (510 K) / US free sale certificate of the quoted products, The document submitted in the technical bid of the quoted items for award of marks shall have the same brand name mentioned in all the above certificate/s. 02 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable. Online verification link shall be provided. (copies of relevant certificates duly attested by the senior executive of the firm)	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.						
	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70		
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	1116	I/V Cannula (Sterile Having Wings + Injection Port in Sterilized Blister Packing The Cannula Should be Radio-Opaque, as well as Latex, Pyrogen and PVC Free) 18G	18G	B. Cat 2 I.V. Cannula	3	5	0	5	5	6	24	5	5	0	0	10	Not Recommended	20	44		
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	1117	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 18G	18G	B. Cat2 IV Cannula	3	5	0	5	5	6	24	5	5	0	0	DTL Substandard	Not Recommended	10	34		
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	1118	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 20G	20G	B. Cat 2 I.V. Cannula	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54		
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	1119	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 20G	20G	B. Cat2 IV Cannula	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54		
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	1120	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 22G	22G	B. Cat 2 I.V. Cannula	3	5	0	5	5	6	24	5	5	0	0	DTL Substandard	10	20	44		
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	1121	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 22G	22G	B. Cat2 IV Cannula	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54		
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	1122	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 24G	24G	B. Cat 2 I.V. Cannula	3	5	0	5	5	6	24	5	5	0	0	DTL Substandard	10	20	44		
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	1123	I.V Cannula (Sterile having wings with heparin stopper inside sterilized blister packing. The cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 24G	24G	B-Cat IV Cannula	3	5	0	5	5	6	24	5	5	0	0	DTL Substandard	10	20	44		
Jiangxi Sanxin Medtec Co. Ltd. China	1016	Disposable Auto Disable Syringe (Blister packing) sterile 3ml	3ml	Yi Xin	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54		
Jiangxi Sanxin Medtec Co. Ltd. China	1017	Disposable Auto Disable Syringe (Blister packing) sterile 5ml	5ml	Yi Xin	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54		

Jiangxi Sanxin Medtec Co. Ltd. China	1021	Disposable Syringe Ordinary (Blister packing) sterile 10ml	10ml	UCI Disposable Syringe	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54
Jiangxi Sanxin Medtec Co. Ltd. China	1022	Disposable Syringe Ordinary (Blister packing) sterile 20ml	20ml	UCI Disposable Syringe	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54
Jiangxi Sanxin Medtec Co. Ltd. China	1023	Disposable Syringe Ordinary (Blister packing) sterile 50ml	50ml	UCI Disposable Syringe	3	5	0	5	5	6	24	5	5	0	0	10	10	30	54

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26														
Name of the firm					USMANCO INTERNATIONAL, KARACHI														
					Technical Evaluation Matrix														
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
					Valid ISO 14001 certificate of the	Valid ISO 13485 certificate of the	Valid accreditation of	Availability of minimum 20%	Adherence to Good Storage	Adequate availability of		Goods	Certificate of	Tender Approvals	Valid WHO	CE mark/Quality	Physical	Product Evaluated Score	Product Technical Score
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	3	5	5	5	6	6	30	5	5	5	3	6	16	40	70
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	960	Chest Drainage Bottle with Tubing		Thoracic Drainage System	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	961	Chest Tube (with trocar) Different Size		Thoracic Catheter With Trocar	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53
Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	962	Chest Tube (without trocar) Different Size		Thoracic Catheter Without Trocar	3	5	0	5	6	6	25	5	5	0	0	2	16	28	53
Chilecom Medical Devices Co. Ltd. China	993	Disposable Endotracheal Tube without cuff 2.5mm		Endosoft	0	5	0	5	6	6	22	5	5	0	0	0	16	26	48
Chilecom Medical Devices Co. Ltd. China	994	Disposable Endotracheal Tube without cuff 3.0mm		Endosoft	0	5	0	5	6	6	22	5	5	0	0	0	16	26	48
Chilecom Medical Devices Co. Ltd. China	995	Disposable Endotracheal Tube without cuff 3.5mm		Endosoft	0	5	0	5	6	6	22	5	5	0	0	0	16	26	48

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposables and Sutures for Government MCC 2025-26																									
				Name of the firm																					
				VIKOR HEALTHCARE																					
S.No	Product General Information				Factory Technical Evaluation Parameter												Factory Evaluated Score	Product technical Evaluation Parameters						Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score																
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21				
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). Online verification link shall be provided.	Valid calibration certificates for equipment/instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. (As evaluated at the time of inspection by the MCC experts). Non adherence to GSP shall lead to disqualification of the firm.	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. (to be evaluated by the MCC experts at the time of inspection. Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)	Availability of Functional and validated HVAC, with all relevant equipment, testing, and logs. (As evaluated by the MCC experts at the time of inspection).	Adequate availability of qualified & relevant Human Resources as per the requirement laid down in DRAP regulations. (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.	Goods Declaration certificate of imported raw material of the quoted items from Pakistan Customs, complied with valid away bill or Bill of Lading for the quoted items, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid invoice/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC (Certificate Duly attested by Senior Executive of the firm)	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque	Valid WHO prequalification and / or valid product registration in SRA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. 2 marks for each certification, up to a maximum of 06 marks. Certificates on company's own letter heads shall not be acceptable.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products) Physical examination of the quoted items by the MCC experts. Rejection of the quoted items by the MCC experts shall lead to disqualification of the said items.								
	Ref. No. of Item in MCC Formulary	Generic Name of Item	Size & Gauge of Medical Device	Trade Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70				
1	1300	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 4/OM2 20mm, 1/2 circle round bodied premium taper point 76 cm. (Dz Pack)	SURGLINE Surgikut Chromic (CT224)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
2	1301	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 3/OM3, 20mm, 1/2 circle round bodied premium taper point 76 cm. (Dz Pack)	SURGLINE Surgikut Chromic (CT214)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
3	1302	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 2/OM3.5, 30mm 1/2 circle round bodied premium taper point 76cm. (Dz Pack)	SURGLINE Surgikut Chromic (CT220)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
4	1303	26mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 2/OM3.5, 26mm, 1/2 circle round bodied premium taper point 76cm. (Dz Pack)	SURGLINE Surgikut Chromic (CT221)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
5	1304	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size OM4, 40mm, 1/2 circle heavy round bodied premium taper point 76cm. (Dz Pack)	SURGLINE Surgikut Chromic (CTH205)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
6	1305	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 3M5, 40mm, 1/2 circle round bodied premium taper point 76cm. (Dz Pack)	SURGLINESurgikut Chromic (CT205)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
7	1308	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 2M6, 40mm 1/2 Circle heavy Round Bodied Premium Taperpoint 76cm. (Dz Pack)	SURGLINESurgikut Chromic (CTH201)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
8	1309	17mm, 1/8 circle round bodied taper point needle, strand length 75cm	Silk Braided Size 4/OM1.5, 16mm, 1/2 circle round bodied premium taper point 76cm. (Dz Pack) (Since needle length with small variation doesnot impact in surgery so, we quoted our code with needle length nearest to the required length in tender specs)	Non formulary	3	5	5	2	3	3	2	2	25	5	5	0	0	0	0	10	35				
9	1310	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 3/OM2, 30mm 1/2 circle round bodied premium taper point 76cm. (Dz Pack)	SURGLINE Silk Braided (ST209)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
10	1311	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 3/OM2, 26 mm 1/2 circle round bodied premium taper point 76cm. (Dz Pack)	SURGLINE Silk Braided(ST210)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
11	1312	26mm, 3/8 circle conventional cutting needle, Strand length 45 cm	Silk Braided Size 3/OM2, 26mm 3/8 circle triangular body inside cutting 45cm. (Dz Pack)	SURGLINE Silk Braided (SI301)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
12	1314	31mm, 1/8 circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 2/OM2, 30mm, 1/2 circle round bodied premium taper point 76cm. (Dz Pack) (Since needle length with small variation doesnot impact in surgery so, we quoted our code with needle length nearest to the required length in tender specs)	Non formulary	3	5	5	2	3	3	2	2	25	5	5	0	0	0	0	10	35				
13	1315	26mm, 1/8 circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 2/OM2, 26mm, 1/2 circle round bodied premium taper point 76cm. (Dz Pack)	SURGLINE Silk Braided (ST207)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
14	1316	31mm, 1/8 circle round bodied needle, Strand length 75cm	Silk Braided Size OM3.5, 30mm, 1/2 circle round bodied premium taper point 76cm. (Dz Pack) (Since needle length with small variation doesnot impact in surgery so, we quoted our code with needle length nearest to the required length in tender specs)	Non formulary	3	5	5	2	3	3	2	2	25	5	5	0	0	0	0	10	35				
15	1318	30mm, 1/8 circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 3M4, 30mm, 1/2 circle heavy round bodied premium taper point 76cm. (Dz Pack)	SURGLINE Silk Braided(STH202)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
16	1320	40mm, 1/8 circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 2M5, 40mm, 1/2 circle heavy round bodied premium taper point 76cm. (Dz Pack)	SURGLINE Silk Braided (STH201)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
17	1368	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	Polypropylene Blue Monofilament, Size 4/OM1.5, 16mm, 3/8 circle, triangular bodied conventional cutting needle taper point , 45cm. (Dz Pack)	SURGLINE Surgilene (NX308)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
18	1369	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	Polypropylene Blue Monofilament, Size 4/OM1.5, 26mm, 1/2 circle double round bodied taper point needle, 90cm. (Dz Pack)	SURGLINE Surgilene (NTD206)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				
19	1371	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	Polypropylene Blue Monofilament, Size 3/OM2, 26mm 1/2 circle double round bodied taper point needle, 90cm. (Dz Pack)	Surgiline Surgilene (NTD203)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55				

20	1372	30mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	Polypropylene Blue Monofilament, Size 3/0M2, 30mm, 1/2 circle double round bodied taper point needle, 90cm. (Dz Pack)	SURGLINE Surgilene (NTD202)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55
21	1373	26mm, 1/2 circle round bodied taper point needle, strand length 75 cm	Polypropylene Blue Monofilament, Size 2/0M3, 26mm, 1/2 circle round bodied taper point needle, 75cm. (Dz Pack)	SURGLINE Surgilene (NT206)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55
22	1374	26mm, 3/8 circle reverse cutting needle, strand length 45cm	Polypropylene Blue Monofilament, Size 2/0M3, 26mm, 3/8 circle, triangular bodied reverse cutting needle, 45cm. (Dz Pack)	SURGLINE Surgilene (NR302)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55
23	1377	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	Polypropylene Blue Monofilament, Size 2/0M3, 30mm, 1/2 circle round bodied taper point needle, 75cm. (Dz Pack)	SURGLINE Surgilene (NT205)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55
24	1379	60mm, straight cutting needle, strand length 75cm	Polypropylene Blue Monofilament, Size 2/0M3, 60mm, triangular bodied straight cutting needle 75cm. (Dz Pack)	SURGLINE Surgilene (NS002)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55
25	1380	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	Polypropylene Blue Monofilament, Size 0M3.5, 40mm, 1/2 circle round bodied taper point needle, 75cm. (Dz Pack)	SURGLINE Surgilene (NT204)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55
26	1381	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	Polypropylene Blue Monofilament, Size 1M4, 40mm, 1/2 circle round bodied taper point needle, 75cm. (Dz Pack)	SURGLINE Surgilene (NT202)	3	5	5	2	3	3	2	2	25	5	5	0	0	10	10	30	55

[illegible]

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																													
Name of Firm				WIMTS PHARMACEUTICALS LAHORE																									
S. No.	Product General Information				Factory Technical Evaluation Parameters																Product Evaluation Parameters							Total Product Evaluation Score	Total Technical Score
					Documents Based Factory Score								Factory Evaluation Visit Score								Product Technical Parameters								
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24					
					Valid DPO 100% (DPO verification of facility, where the facility where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm))	Valid DPO 100% (DPO verification of facility, where the facility where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm))	Valid DPO 100% (DPO verification of facility, where the facility where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm))	Valid DPO 100% (DPO verification of facility, where the facility where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm))	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)				
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)					
					Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by the facility, where the product is manufactured, issued by PSCA awarded body (also awarded by state executive of the firm)	Valid certificate submitted by					

					Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2025-26															
Name of the firm					Wirha & Co, Rawalpindi															
					Technical Evaluation Matrix															
					Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							Product Evaluated Score	Total Technical Score
					Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	
S. No.	Ref. No. of item in MCC Formulary	Generic Name of Item	Size, Gauge, etc. of Device	Trade Name	Valid ISO 14001	Valid ISO 13485	Valid accreditation of	Availability of	Adherence to Good	Adequate availability of		Goods Declaration	Certificate of Analysis	Tender Approvals (not	Valid WHO	CE mark/Quality	Physical examination of	Product Compliance Score	Total Technical Score	
					3	5	5	5	6	6	30	5	5	5	3	6	16	40	70	
	938	Blood Bags (CPDA-1)	Single, 500 ml	Sozhou Laishi	3	5	0	All mandatory documents of the quoted items in original were checked and the warehouse was inspected by the inspection team for evaluation of adherence to the required criteria of physical inspection for importer given under SBD (Standard Bidding Document), subsequent to which following observations were noted; SOZHOU LAISHI CHINA 1. Original Embassy attested FSC was not present. 2. Original embassy attested EC certificate was not present. 3. Drug Sale License was not obtained by the bidder rather Form-4 (Import Establishment) under Medical Devices Rules, 2017, was available. 4. Qualified person on Form-4 Mr. Nawshad Ali was not present at the time of inspection. Based on the above observations the firm is NOT RECOMMENDED for the award of marks as specified for physical inspection in the relevant pro-forma for items of SOZHOU LAISHI CHINA.				8	0	0	0	1	2	16	19	27
	939	Blood Bags (CPDA-1)	Single, 250 ml	Sozhou Laishi	3	5	0					8	0	0	0	1	2	16	19	27
	940	Blood Bags (CPDA-1)	Double 500ml	Sozhou Laishi	3	5	0					8	0	0	0	1	2	16	19	27
	941	Blood Bags (CPDA-1)	Double 250ml	Sozhou Laishi	3	5	0					8	0	0	0	1	2	16	19	27
	943	Blood Bags (CPDA-1)	Triple 500ml	Sozhou Laishi	3	5	0					8	5	5	0	1	2	16	29	37
	943	Blood Bags (CPDA-1)	Triple 250ml	Sozhou Laishi	3	5	0					8	0	0	0	1	2	16	19	27

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																										
Name of Firm				ZAFPA Pharmaceuticals, KARACHI																						
S. No.	Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix									
					Documents Based Factory Score					Factory Evaluation Visit Score							Product Evaluation Parameters									
																	Product Technical Parameters									
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Latest IMSR/QVIA ranking of the leading manufacturer firm (y value) in Pakistan. (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMSR/QVIA, in the following manner: 1. Firms having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificate for equipment / instruments used in the quoted product. Missing, weightless Asset/ Analyser of raw material, in-process material and finished products for the quoted manufacturing of the product.	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or last.	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (both Accelerated and Real Time) in process of DRAP.	Raw material, in-process and finished goods storage (as in schedule-B of DRAP) as evaluated at the time of inspection by the MCC experts.	Non-compliance to GMP guidelines, Non-adherence to GSP shall lead to disqualification of the firm.	Non-compliance to GMP guidelines, Non-adherence to GSP shall lead to disqualification of the firm.	Non-availability or non-functionality of the HVAC system and/or logs, shall lead to disqualification of the section or firm.	Availability of functional and validated IPV-C with all relevant equipment, using logs, (As evaluated by the MCC experts at the time of inspection).	Bioavailability/Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO (Public Website) and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-similar certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities).	Good Declaration certificate of imported APIs at the quoted items from Pakistan Customs, coupled with valid away bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GDI) provided in column 18, duly attested by the senior executive of the firm.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / USFDA / EMA / MHRA / TGA / PMDA / Swiss-Medic or Health Canada or by regulatory authority/body of SRA country (not coupled with Form 3 (Form of undertaking to accompany GDI) provided in column 18, duly attested by the senior executive of the firm).	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 10 Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items, as issued by the manufacturer of the material coupled with invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium foil, PVC, Capsule shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmaceutical standards, or most clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material (e.g. Liquid ampoules must be USP class 1 Type 1 or better (Non-compliance or non-precision of CoA of glass material shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral vials/ Suspension must be USP Type 1 or better (Non-compliance or non-precision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 1 glass is used as where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).	Stability studies of quoted items duly attested by the Q/C (incharge of the firm).	Availability of quoted items in Pakistan market as per recent most date of IMSR/QVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMSR/QVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12) months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 82 Tender approvals- 01 mark 84 Tender approvals- 02 marks 86 Tender approvals- 03 marks 88 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approvals shall be duly attested by the concerned procuring entity and accompanied with purchase orders, delivery challans, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transactions against the cheque received shall also be submitted with each purchase order.			
Ref. No. of item	Generic Name of Rem	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70	
2	Motifenadate	Tab. 400mg	Motifen400mg	2	2	3		3	5	6	2	2	2	2	2	31	0	5	5		0	0	5	0	15	46
3	Motifenadate	Susp 200 mg/5ml	Motifen4 200mg/5ml	2	2	3		3	5	6	2	2	2	2	2	31	0	5	5		0	0	5	0	15	46
36	Acetofenac	Tab 500 mg	Acetofen500mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
41	Diclofenac Sodium	Inj 75 mg/ml	Diclofen75mg/ml	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50
48	Ketorolac	Inj 30 mg/ml	Ketorolac30mg/ml	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50
60	Paracetamol	Tab 500 mg	Paracetamol500mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
61	Paracetamol	Susp 120 mg/5 ml	Para 4 Kids 120mg/5ml	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
62	Paracetamol	Susp 250 mg/5 ml	Para 6 + 250mg/5ml	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
67	Paracetamol+Tramadol	Tab 37.50/325 mg	Zarminoa Tab 37.50/325	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	10	41
70	Tramadol	Inj 100 mg/2 ml	Tradol 100mg/2ml	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50
168	Levetiracetam Dihydrochloride	Syp 2.5 mg/ml	Levetof 2.5mg/ml	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
170	Loratadine	Tab 10 mg	Zorat10mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
171	Montelukast	Tab 10 mg	Monteaa10mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
172	Montelukast	Tab 5 mg	Monteaa5mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
177	Amikacin Sulphate	100 mg Inj	Amikacin 100mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50
178	Amikacin Sulphate	250 mg Inj	Amikacin 250mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50
179	Amikacin Sulphate	500 mg Inj	Amikacin 500mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	19	50
180	Amoxicillin	Cap 250 mg	Zoxicilin 250mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
181	Amoxicillin	Cap 500 mg	Zoxicilin 500mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
182	Amoxicillin	Susp 125 mg	Zoxicilin 125mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
184	Amoxicillin	Inj 500 mg	Zoxicilin 500mg + WF1	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
185	Amoxicillin	Susp 250 mg/5 ml	Zoxicilin 250mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
188	Amoxicillin + Clavulanic Acid	Tab 625 mg	Zamoclav625mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
190	Amoxicillin + Clavulanic Acid	Dry Susp 156.25 mg	Zamoclav 156.25mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
192	Amoxicillin + Clavulanic Acid	Dry Susp 312.50 mg	Zamoclav 312.50mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
193	Amoxicillin + Clavulanic Acid	Inj 600 mg	Zamoclav 600mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
194	Amoxicillin + Clavulanic Acid	Inj 1.2 gm	Zamoclav 1.2gm	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	5	36
195	Amoxicillin	Inj 250 mg	Zamocillin 250mg + WF1	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	5	36
196	Amoxicillin	Inj 500 mg	Zamocillin 500mg + WF1	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	5	36
197	Amoxicillin	Inj 1 gm	Zamocillin 1gm + WF1	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	5	36
199	Amoxicillin + Cloxacillin	Inj 250 mg	Zamoclox 250mg + WF1	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	5	36
200	Amoxicillin + Cloxacillin	Inj 500 mg	Zamoclox 500mg + WF1	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	5	36
202	Aspirin	Cap 250 mg	Zafanax 250mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
213	Cefazoline	Inj 500 mg	Zafacilin 500mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	4	35
214	Cefazoline	Inj 1 gm	Zafacilin 1gm	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	4	5	0	9	40
215	Cefixime	Inj 500 mg	Dimox4 500mg + WF1	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	5	36
216	Cefixime	Inj 1gm	Dimox4 1gm + WF1	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	5	36
217	Cefixime	Cap 400 mg	Ceforal3 400mg	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
218	Cefixime	Susp 100 mg/ml	Ceforal3 100mg/5ml	2	2	3		5	5	6	2	2	2	2	2	31	0	5	5	0	0	0	5	0	15	46
220	Cefoperazone + Sulbactam	Inj 1 gm	Suloftra 1gm	2	2	3		5	5	6																

	384	Iron III Hydroxide Polymaltose	Syp 50 mg/5ml	Iroaf 50mg/5ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		0		10	41
	387	Iron Succrose	100 mg liq	Irofi 100mg/5ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		4		5		19	50
	388	Micobalamin	100 mg liq	Flcobal 100mcg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		4		5		19	50
	400	Tranexamic Acid	liq 250 mg	Zakrane 250mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		4		0		14	45
	401	Tranexamic Acid	liq 500 mg	Flextran 500mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		4		5		19	50
	412	Amelodipine Besylate 5mg	Tab 5 mg	Zanilo Tab 5 mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	414	Amelodipine + Valiartan	Tab 5mg/80 mg	Zodip-V 5mg/80mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	415	Amelodipine + Valiartan	Tab 5mg/160 mg	Zodip-V 5mg/160mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	416	Amelodipine + Valiartan	Tab 10 mg/160 mg	Zodip-V 10mg/160mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	417	Amelodipine+Valiartan + Hydrochlorothiazide	Tab 10/160/12.5 mg	Zodip-V Plus10/160/12.5mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	418	Atenolol	Tab 50 mg	Zafol 50mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	419	Atenolol	Tab 100 mg	Atenolol 100mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	428	Captopril	Tab 25 mg	Acetopril25mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	432	Clopidogrel	Tab 75 mg	Pluagag 75mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	448	Hydralazine	liq 20 mg/ml	Hydralazine 20mg/ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		4		5		19	50
	449	Hydralazine	Tab 25 mg	Hydralazine25mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	451	Hydrochlorothiazide	Tab 25 mg	Diazu25mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	456	Isoxanthol-5 Mononitrate	Tab 20 mg	Sorlimon20mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	458	Labetalol HCl USP	liq 10 mg/10 ml	Labetalol 50 mg/10 ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		4		5		19	50
	459	Lisinopril	Tab 5 mg	Lisina5mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		0	0		0		0		0		5		5	36
	463	Losartan Potassium	Tab 50 mg	Zosartan K50mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	473	Nifedipine	Tab 30 mg	Nifedil XL30mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	493	Levonorgestrel + Ethinyl Estradiol	28 F tab	Familia 28F	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		10	41
	494	Methoxyprogesterone	150mg/ml	Familia 150mg/ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	501	Multicassone Propionate Microencapsulated BP	Spray 0.5 mg	Rufaz Nasal spray 0.05%	2	2	3		3		5		6		2	2	2	2	2	2	31		0		0	0		0		0		0		5		5	36
	504	Sodium Chloride	0.65%	Xynoline Saline 0.65%	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	505	Xylometazoline	Nasal Drops	Xynoline Nasal Drops (C.F.)	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	506	Xylometazoline	Nasal spray	Xynoline Nasal Spray (Adult)	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	517	Famotidine	Tab 40 mg	Famotaz40mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	523	Loperamide	2 mg Cap	Floramax 2mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	527	Esomeprazole	Cap 40 mg	Zilnes Cap 40 mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	542	Zinc Sulfate Monohydrate USP	Tab 30 mg	Znclg20mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	543	Zinc Sulphate	Syp 30 mg/5 ml	Znc 2 Zinc 20mg/5ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		10	41
	545	Clemastine Chlorate BP	50 mg Tab	Gynden Tab 50 mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	549	Dihydroergotone	Tab 10 mg	Dihygetal5mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	554	Gliclazide	Tab 80 mg	Zaciazide80mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		10	41
	563	Hydrocortisone Sodium Succinate	liq 100 mg/2 ml	Hydro Sol Suc 100mg + WF1	2	2	3		3		5		6		2	2	2	2	2	2	31		0	Not Recommended due to non fulfillment of technical evaluation criterion No: 22 (4)C					0		4		5		9	40	
	564	Hydrocortisone Sodium Succinate	liq 250 mg	Hydro Sol Suc 250mg + WF1	2	2	3		3		5		6		2	2	2	2	2	2	31		0						0		4		5		9	40	
	576	Misoprostol	Tab 200 mcg	S.T. Momi200mcg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	587	Triamcinolone	liq 40 mg/ml	Lonicort 40mg/ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		4		5		19	50
	653	Magnesium	liq 500 mg/ml 2ml	Magnesium Solp 500mg/ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		4		5		19	50
	654	Magnesium	liq 500 mg/ml 10ml	Magnesium Solp 500mg/ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		10	41
	665	Proxolium Chloride	Tab 500 mg	Nex-5500mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	687	Bandrolic Acid	Tab 150 mg	Bondaf150mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	724	Phenmetine	Cap 30 mg	Ziwatf 20mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	729	Mirtazapine	Tab 15 mg	Mirtazep15mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	806	Acetofen	1 mg Tab	Aschhoffent5mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	807	Acetofen	1 mg/ml syp	Aschhoffen 1mg/5ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	808	Salbutamol	Tab 2 mg	Zafholin2mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	809	Salbutamol	Tab 4 mg	Zafholin4mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	810	Salbutamol	Syp 2 mg/5 ml	Zafholin 2mg/5ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	811	Salbutamol	Solus mg/ml	Zafholin Solution 5mg/ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	814	Terbutaline	Tab 2.5 mg	Teamic2.5mg	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5		0		0		0		5		15	46
	815	Terbutaline	Syp 0.3 mg/ml	Teamic 0.3mg/ml	2	2	3		3		5		6		2	2	2	2	2	2	31		0		5	5											

Name of Firm				GLITZ PHARMA, ISLAMABAD																																	
S. No.	Product General Information				Factory Technical Evaluation Parameters																Total Factory Evaluated Score	Technical Evaluation Matrix										Product Evaluation Parameters				Total Product Evaluation Score	Total Technical Score
					Documents Based Factory Score					Factory Evaluation Visit Score												Product Technical Parameters															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26											
					Valid ISO 18001-ISO9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/QVIA ranking of the leading manufacturer firms (by value) in Pakistan Marks shall be awarded up to top 100 firms in Pakistan as ranked by value by IMS/QVIA, in the following manner: 1. Firms having (12-Month) Ranking below top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21st-40th positions shall be awarded 4 marks. 3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, Weighing, Analyzing or Raw material, in-process materials and finished products for the manufacturing of the products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR. 100 to 500 million - 2 marks; Financial turnover of more than PKR. 500 million and upto 1000 million - 4 marks; Financial turnover of more than PKR. 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (G.L.P.) at all labs + Functional Stability Chamber (both Accelerated and Real Time) in Schedule B of DRAP) (Evaluated at the time of inspection by the M.C.C experts, no non-availability or non-functioning of stability chambers under test will lead to disqualification of the firm).	Raw material:- In-process and Finished goods storage (as in Schedule-B of DRAP), are evaluated at the time of inspection by the MCC experts). Non-adherence to GMP guidelines shall lead to disqualification of the firm.	Adherence to cGMP guidelines, Issued by relevant authorities, in accordance with the requirements mentioned in schedule-I of DRAP. (Certified by the senior executive of the firm & evaluated by M.C.C experts at the time of inspection, Non-availability shall lead to disqualification of the section/firm).	Adequate availability of qualified & solvent trained Resource as per requirement mentioned in schedule-II of DRAP. (Certified by the senior executive of the firm & evaluated by M.C.C experts at the time of inspection, Non-availability shall lead to disqualification of the section/firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, etc. (Ascertained by the MCC experts at the time of inspection).	Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to disqualification of the relevant section /firm.	Bio-stability/Biosimilarity study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and /or For biologics, bio-similarity studies shall be provided for award of marks in this parameter and /or In case of Large volume potential i.e., greater than 100mg up to 5L, product validation report as per WHO/USFDA/SPP guidelinses) shall be submitted and /or Proof of inventor's innovative products from relevant body shall be provided where the firm claims that the bioprevalence / bio-similarity is applicable. Proof on company's own letter head shall not be acceptable.	Good Declaration/certificate of imported APIs of the quoted item(s) from Pakistan Customs, coupled with valid waybill or Bill of Lading for the quoted item(s), not older than 24 months from the cut-off date for submissions of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid bill/invoice/NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API From the Principal Manufacturer as mentioned in the goods declaration (GITD) provided in column 18, duly attested by the senior executive of the firm. In case of non-provision of matching GITD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (API)s source accreditation certificate issued by WHO / US-FDA / EMA / MHFA / ICA/PMDA Swiss Medico or Health Canada or regulatory authority/body of SRA As country (ies) coupled with Form 3 form of undertaking to accompany application for License to Import Drugs). Moreover, in case of prequalified/quotaed items having multiple APIs, the marks for GITD, CoA, APIs source accreditation will be awarded only where these documents are submitted for all API/component(s) of the quoted product. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NCT bid submission.	Valid WHO prequalification and /or Valid product registration in SRA country(ies) and /or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of three marks. Copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificate for same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item(s), as issued by the manufacturer of the material coupled with invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium foil, PVC, Canine Sheet, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with USA, European, British, Japanese pharmaceutical standards, or must clearly mention that the material is compliant with USP Class II glass material for liquid ampoules must be USP Class I (Non-compliance shall lead to disqualification of the quoted product); 2. Type of Glass material for Oral Storage Suspension must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product); 4. For Dry Powder Injectables: a. For USP Type 1 glass ampoules will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 2 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Documents duly attested by the Senior executive of the firm).	Stability studies of quoted item(s) duly attested by the Q/C exchange of the firm) 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks (For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or JCII accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals= 03 marks 04 Tender approvals= 04 marks 08 Tender approvals= 05 marks 10 or more Tender approvals= 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted item(s) in Pakistan market as per recent most data of IMS/QVIA Health not older than twelve (12) months 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks (For items specifically used in institutions where IMS/QVIA data is not applicable the bidder shall provide Tender Approvals not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or JCII accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals= 03 marks 04 Tender approvals= 04 marks 08 Tender approvals= 05 marks 10 or more Tender approvals= 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.													
Ref. No. of Item	Generic Name of Items	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	5	37	70											
47	Ibuprofen	Susp. 100 mg/Stal	Gilifex	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
48	Fenitroline	Tab. 5mg	Rileston	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
49	Hydroxyurea	Cap. 500-mg	Hydrosora	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
105	Tacrolimus	Tab. Cap. 1mg	Azagraf	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	9	35											
106	Tacrolimus	Tab./Cap. 0.5 mg	Azagraf	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	9	35											
121	Deferasirox	Tab. 250mg	Desiron	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
124	Deferasirox	Tab. 500mg	Desiron	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
143	Clotrimazole	Vaginal tablet with applicator 500mg	Wormick-1	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
144	Clotrimazole	Vaginal Cream with applicator 1%	Wormick	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
167	Chlorpheniramine Maleate	Syp. 2 mg/ 5 ml	Clomin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
169	Levetocitrazine	Tab. 5 mg	Zecost	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
171	Montelukast	Tab. 10 mg	Mac-10	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	9	35											
243	Ciprofloxacin	Tab. 250 mg	Giliox	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
244	Ciprofloxacin	Tab. 500 mg	Giliox	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	19	45											
277	Levetofloxacin	Tab. 250 mg	Levoz	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
278	Levetofloxacin	Tab. 500 mg	Levoz	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
288	Moxifloxacin	Tab. 400 mg	Mogiz	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	9	35											
383	Iron Hydroxide poly maltose complex	Tab. 100 mg	Gloft	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	9	35											
384	Iron Hydroxide poly maltose complex	Syp. 50 mg/5ml	Gloft	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	9	35											
429	Carvedilol	Tab. 6.25 mg	Vedgit	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
430	Carvedilol	Tab. 12.5 mg	Vedgit	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
431	Carvedilol	Tab. 25 mg	Vedgit	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
441	Paracetamol	Tab. 40 mg	G-mide	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
482	Rosuvastatin	Tab. 10 mg	Rosur	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
514	Doxepinhydrochloride	Susp. 5 mg/5ml	Doxim-D	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	9	35											
517	Fenitroline	Tab. 40 mg	Ezlin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
527	Obetopazole	Cap. 40 mg	Obimig	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
528	Esomeprazole	Cap. 40mg	Egze	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	9	35											
543	Zinc Sulphate	Syp. 20 mg/5ml	Ziglit	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
647	Flavored Oral Rehydration Salt (Low Osmolality)	Sachet Sodium Chloride Sachet (2.6 g/L) Glucose Anhydrous (13.5 g/L), Potassium Chloride (1.5 g/L), Trisodium citrate (2.9 g/L)	Oxagil	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	5	31											
700	Aripiprazole	Tab. 15 mg	Arigat	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
704	Chlorthalidone	Tab. 10 mg	Glipam	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
711	Chlorzine	Tab. 25mg	Glipis	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	9	35											
712	Chlorzine	Tab. 100 mg	Glipis	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	0	9	35											
717	Duloxetine	Cap. 30 mg	Duphree	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
718	Duloxetine	Cap. 60 mg	Duphree	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
723	Bivalirudin	Tab. 10 mg	Eglin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
724	Fluoxetine HCl	Cap. 20 mg	Gidrety	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
731	Flamoprine	Tab. 50 mg	Flamopil	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
733	Levetiracetam	Tab. 250 mg	Setam	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	14	40											
734	Levetiracetam	Tab. 500mg	Setam	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	14	40											
739	Mirtazapine	Tab. 15mg	Mitaz	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
740	Olanzapine	Tab. 5mg	O-Zip	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
741	Olanzapine	Tab. 10 mg	O-Zip	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
751	Pregabalin	Cap. 50 mg	P-Gab	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
752	Pregabalin	Cap. 75mg	P-Gab	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
753	Pregabalin	Cap. 150 mg	P-Gab	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
756	Procydine HCl	Tab. 5mg	Procye	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
758	Quetiapine	Tab. 100 mg	Quita	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
759	Risperidone	Tab. 2mg	Raze	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
760	Risperidone	Tab. 4 mg	Raze	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	0	19	45											
763	Sodium Valproate	Syp. 250 mg/5ml	Valproo	2	2	3	0	5</																													

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injctable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																													
Name of Firm				Shaigan Pharma, Rawalpindi																									
S. No.	Product General Information				Factory Technical Evaluation Parameters												Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score								Factory Evaluation Visit Score					Product Evaluation Parameters											
																		Product Technical Parameters											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26			
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Online verification link shall be provided	Latest DMS/RVIA ranking of the leading manufacturer firm (by value) in Pakistan - (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by DMS/RVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firm having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firm having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks. 4. Firm having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks. 5. Firm having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 at latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) as evaluated at the time of inspection by the MCC experts). (Evaluated at the time of inspection by the MCC experts, as non-availability of non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, in-process and Finished goods storage (as in Schedule II of DRAP) as evaluated at the time of inspection by the MCC experts). Non-compliance in cGMP guidelines shall lead to disqualification of the firm. Non-adherence to GSP shall lead to disqualification of the section/s of the firm.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-II of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to disqualification of the relevant section / firm.	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs (As evaluated by the MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to disqualification of the relevant section / firm.	Bioavailability / Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologics, bio-similarity studies shall be provided for award of marks in this parameter and / or Bio-waiver certificate from an accredited lab of SRA countries (stringent Regulatory Authorities) In case of Large volume parenteral (i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted items from Pakistan Customs, coupled with valid away bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid FullLink-DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 11, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Active Pharmaceutical Ingredient(s) (API)s source accreditation certificate issued by WHO / US- FDA / EMA / MHRA / TGA / PMDA / Swiss Meds. or Health Canada or by regulatory authority/body of SRA country (ies) coupled with Form-1 (form of undertaking to accompany (GD) provided in column 11, duly attested by the senior executive of the firm). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only when these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) Note: Valid Certificate for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted items), as issued by the manufacturer of the material coupled with Invoice/proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium foil, PVC, Capable Sheets, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted items complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral-Syringe Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 2 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). (Document duly attested by the Senior executive of the firm).	Stability studies of quoted items duly attested by the Q/C incharge of the firm) 1-10% market share = 1 mark 11-50% market share = 2 marks 51-95% market share = 3 marks 95% and above market share = 5 marks (For items specifically used in institutions where DMS/RVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 03 marks 04 Tender approvals- 02 marks 05 Tender approvals- 03 marks 06 Tender approvals- 04 marks 07 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Availability of quoted items in Pakistan market as per recent most data of DMS/RVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-50% market share = 2 marks 51-95% market share = 3 marks 95% and above market share = 5 marks (For items specifically used in institutions where DMS/RVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve (12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 03 marks 04 Tender approvals- 02 marks 05 Tender approvals- 03 marks 06 Tender approvals- 04 marks 07 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.						
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	5	37	70			
52	Meloxicam	Tab. 15mg	Mils	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
53	Meloxicam	Tab. 7.5mg	Mils	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
152	Ibuprofen	Cap. 300mg	Sporax	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
179	Amlodine	tbl. 500mg	Glylim-500mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	1	20	52				
216	Cefepime Hydrochloride	tbl. 3gm	Cepime-1000mg	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
219	Cefepime	Susp. 200mg/5ml	Ruvain DS	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
218	Cefepime	Susp. 100mg/5ml	Ruvain 100	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
217	Cefepime	Cap. 400mg	Ruvain 400	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
220	Cefoperazone Sodium	tbl. 3gm	Daizone Plus	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
221	Cefoperazone Sodium	tbl. 2gm	Daizone Plus	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
224	Cefotaxime Sodium	tbl. 3gm	Clear-3000	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
231	Ceftriaxime Sodium	tbl. 3gm	Calix	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
387	Iron Sucrose	tbl. 300mg/5ml	Iron	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
402	Warfarin Sodium	Tab. 5mg	Warfin	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	5	24	56				
403	Warfarin Sodium	Tab. 2.5mg	Warfin	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	5	24	56				
404	Warfarin Sodium	Tab. 5mg	Warfin	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	5	24	56				
414	Ambidipine Besylate + Valartan	Tab. 5/80mg	Diasar	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
415	Ambidipine Besylate + Valartan	Tab. 5/160mg	Diasar	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
416	Ambidipine Besylate + Valartan	Tab. 10/160mg	Diasar	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
517	Famotidine	Tab. 40mg	Famot	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
526	Omeprazole Sodium	tbl. 40mg	Vylser	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	1	20	52				
556	Glibenclamide	Tab. 3mg	Glibem-2	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
583	Stagglefiner Metformin	Tab. 50/100mg	Admof 50/100	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
584	Stagglefiner Metformin	Tab. 50/100mg	Admof 50/100	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
789	Pigabalin	Cap. 75mg	Pigabon	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	1	20	52				
837	Moxifloxacin	Eye Drops	Mioxon	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
850	Tolaramycin/Dexamethasone	Eye Drops	Mydex	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	0	19	51				
868	Fusidic Acid	Cream, 2% 15gm	Fudic	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	5	0	4	5	1	25	57				
869	Fusidic Acid	Oint. 2% 15gm	Fudic	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	5	0	4	5	1	25	57				
883	Phenmethrin 5%	Lotion, 60ml	Skab	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	1	20	52				
884	Phenmethrin 5%	Cream, 5% 30gm	Skab	2	2	3	4	5	6	2	2	2	2	2	32	0	5	5	0	0	4	5	1	20	52				

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2025-26																											
Name of Firm					WILSHIRE, LAHORE																						
S. No.	Product General Information				Technical Evaluation Matrix																Product Evaluation Parameters				Total Product Evaluated Score	Total Technical Score	
					Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Technical Parameters											
					Documents Based Factory Score					Factory Evaluation Visit Score						Product Technical Parameters											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) Online verification link shall be provided	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . (12 months to date ranking will be considered). Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: 1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having (12-Month) Ranking between 21-40th positions 4 marks. 3. Firms having (12-Month) Ranking between 41-60th positions 3 marks.	Valid calibration certificate for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. (Valid Calibration Certificates attested by Quality head of the firm).	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e. FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior Executive of the firm).	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) (Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert's)	Adherence to cGMP guidelines, (as in Schedule-B of DRAP) of quoted product (s).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP (Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection. Non-availability shall lead to disqualification of the section/s or firm).	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. (As evaluated by the MCC experts at the time of inspection). Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm) (Non-availability of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e. greater than 100ml up to 5L, product validation report (as per WHO/US			Goods Declaration certificate of Imported API of the quoted item(s) from Pakistan Customs, coupled with valid inward bill or Bill of Lading for the quoted items, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. In case of purchases through third party importers a valid trail/link/DRAAP clearance NOC from the principal manufacturer and the importer firm shall be provided.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. In case of Non-provision of matching GD the marks for CoA will not be awarded.	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MIRA/ TGA/ PMDA/ Swiss Medic or by regulatory authority/body of SRA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA country(ies) with Form-3 (form of undertaking to accompany an application for License to import Drugs). 1 mark for each certification, up to a maximum of 03 marks. Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice-proof of purchase. For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. Note: Valid Certificates for the same brand shall be provided.	Stability studies of quoted items duly attested by the Q.C. incharge of the firm).	Availability of quoted items in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan.		
Ref. No. of Item	Generic Name of Item	Dosage Form with Strength	Trade Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70		
217	Cefixime	Cap. 400mg	SECURE	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
352	Oseltamivir	Cap. 75mg	PRONTO	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	24	52		
527	Omeprazole	Cap. 40mg	BENZIM	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
528	Esomeprazole Magnesium	Cap. 40mg	ZUNE-40	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
695	Tamsulosin	Cap. 0.4mg	MAXRON	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
752	Pregabalin	Cap. 75mg	XAAR	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
41	Diclofenac Sodium	Inj. 75mg/3ml	ZWITTER	2	2	3	0	5	6	2	2	2	2	2	28	0	older than 2 years	0	0	0	4	5	0	9	37		
220	Cefoperazone+Sulbactam	Inj. 1gm	ELEVA	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	older than 5 years	0	2	5	0	17	45		
221	Cefoperazone+Sulbactam	Inj. 2gm	ELEVA	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	older than 5 years	0	2	5	0	17	45		
230	Ceftriaxone	Inj. 500mg	TRIAx	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45		
231	Ceftriaxone	Inj. 1gm	TRIAx	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45		
232	Ceftriaxone	Inj. 2gm	TRIAx	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45		
245	Ciprofloxacin	Inj. 200mg/100ml	QUASH	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45		
256	Colistimethate Sodium	Inj. 2MIU	LISCOWIL 2MIU	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45		
257	Colistimethate Sodium	Inj. 1MIU	LISCOWIL 1MIU	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45		
284	Linezolid	Inj. 600mg/300ml	VOLINZA	2	2	3	0	5	6	2	2	2	2	2	28	0	Not attached	0	0	0	2	5	0	7	35		
289	Moxifloxacin	Inj. 400mg/250ml	PALZIC	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45		
308	Vancomycin Hydrochloride	Inj. 500mg	ZALPAX	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	older than 5 years	0	2	5	0	17	45		
309	Vancomycin Hydrochloride	Inj. 1gm	ZALPAX	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	older than 5 years	0	2	5	0	17	45		
388	Mecobalamin	Inj. 500mcg	XYSTER	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
401	Tranexamic Acid	Inj. 500mg/5ml	XAVENE	2	2	3	0	5	6	2	2	2	2	2	28	0	older than 2 years	0	0	0	4	5	0	9	37		
526	Omeprazole	Inj. 40mg	BENZIM	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45		
716	Diazepam	Inj. 10mg/2ml	RELAX	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
205	Azithromycin	Susp. 200mg/5ml 15ml	ZEECIN	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
218	Cefixime	Susp. 100mg/5ml 30ml	SECURE	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
219	Cefixime	Susp. 200mg/5ml 30ml	SECURE	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
250	Clarithromycin	Susp. 125mg/5ml 60ml	RANKER	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
52	Meloxicam	Tab. 15mg	M.COM	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
53	Meloxicam	Tab. 7.5mg	M.COM	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
66	Orphenadrine Citrate+Paracetamol	Tab. 35mg/450mg	MEDIGESIC	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
67	Tramadol+Paracetamol	Tab. 37.5mg/325mg	ZULTRACET	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
171	Montelukast	Tab. 10mg	TAIR	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	older than 5 years	0	4	5	0	19	47		
202	Azithromycin	Tab. 250mg	ZEECIN	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	older than 5 years	0	4	5	0	19	47		
203	Azithromycin	Tab. 500mg	ZEECIN	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	older than 5 years	0	4	5	0	19	47		
243	Ciprofloxacin	Tab. 250mg	QUASH	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
244	Ciprofloxacin	Tab. 500mg	QUASH	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
247	Clarithromycin	Tab. 250mg	RANKER	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
248	Clarithromycin	Tab. 500mg	RANKER	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
281	Linezolid	Tab. 600mg	VOLINZA	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
288	Moxifloxacin	Tab. 400mg	PALZIC	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
412	Amlodipine Besylate	Tab. 5mg	CAPRINZA	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52		
413	Amlodipine Besylate	Tab. 10mg	CAPRINZA	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52		
429	Carvedilol	Tab. 6.25mg	OTELLO	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		
430	Carvedilol	Tab. 12.5mg	OTELLO	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47		

	432	Clopidogrel Bisulphate	Tab. 75mg	FLEXIFLOW	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	482	Rosuvastatin Calcium	Tab. 10mg	QAZZO	2	2	3	0	5	6	2	2	2	2	2	28	0	older than 2 years	0	0	0	4	5	0	9	37
	550	Empagliflozin	Tab. 10mg	JEMVESTA	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52
	551	Empagliflozin	Tab. 25mg	JEMVESTA	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	0	24	52
	555	Glimepiride	Tab. 1mg	GLYSET	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	556	Glimepiride	Tab. 2mg	GLYSET	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	557	Glimepiride	Tab. 3mg	GLYSET	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	558	Glimepiride	Tab. 4mg	GLYSET	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	583	Sitagliptin+ Metformin	Tab. 50mg/500mg	QOSMET	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	584	Sitagliptin+ Metformin	Tab. 50mg/1000mg	QOSMET	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	19	47
	723	Escitalopram	Tab. 10mg	CHEER UP	2	2	3	0	5	6	2	2	2	2	2	28	0	5	Not attached	0	0	4	5	0	14	42